text string | url string | crawl_date timestamp[ms] | label int64 | id string |
|---|---|---|---|---|
BEIJING, July 31, 2023 /PRNewswire/ -- SANY Group ("SANY") has announced the 2023 employee stock ownership plan (ESOP). This is the fourth consecutive year that SANY has launched the ESOP, which gives employees an opportunity to own shares in the company through the setting up of incentive funds. The 2023 ESOP has set up a fund size of around 590 million yuan (USD 82 million) with a share repurchase price planned at 16.13 yuan per share (USD 2.24). The capital will be from the incentive funds accrued following relevant provisions of the group.
SANY has always focused on improving employee benefits and adhering to the principle of "growing together, pursuing common development, and sharing achievements." By establishing a comprehensive incentive and restraining mechanism, it aims to inspire employees' enthusiasm and creativity and align the interests of shareholders, the listed company, and individuals. This encourages all parties to join efforts to boost SANY's long-term development.
SANY's annual ESOP aims to share the fruits of the group's achievements with employees. The number of employees awarded with stock ownership incentives is growing annually, and the proportion of mid-level and key position employees is increasing year by year:
- 2020: SANY awarded 8.31 million shares to 2,264 employees, 71.52 percent were employees in mid-level management, key positions, and core business (technical) positions.
- 2021: SANY awarded 7.54 million shares to 4,205 employees, 91.33 percent were employees in mid-level management, key positions, and core business (technical) positions.
- 2022: SANY awarded 20.5 million shares to 6,996 employees, 94.26 percent were employees in mid-level management, key positions, and core business (technical) positions.
- 2023: SANY is awarding 36.62 million shares to 7,131 employees, 95.69 percent were employees in mid-level management, key positions, and core business (technical) positions.
The source of shares for the 2023 ESOP is the shares that have already been repurchased by SANY's special account. It does not exceed 36.62 million shares in total and is within one percent of SANY's current total capital stock.
In the meantime, SANY Renewable Energy (SH688349) released an announcement relating to exercising of the second exercise period of the 2020 stock option incentive plan, with 16.0368 million granted options to be exercised, with a three-year restricted period. The subsidiary is committed to becoming a global leader of clean energy equipment and services, and contributing to reaching the goals of carbon peaking and carbon neutrality.
View original content to download multimedia:
SOURCE SANY Group | https://www.wbay.com/prnewswire/2023/07/31/sany-announces-2023-employee-stock-ownership-plan/ | 2023-07-31T12:33:57 | 0 | https://www.wbay.com/prnewswire/2023/07/31/sany-announces-2023-employee-stock-ownership-plan/ |
ALHAMBRA, Calif., July 31, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced an agreement to partner with IntraCare, an operator of a value-based primary care provider network and primary care clinics located predominantly in Texas with a growing presence in Oklahoma.
Headquartered in the Dallas-Fort Worth metropolitan area of Texas, IntraCare is aligned with over 425 providers managing the care of over 40,000 members. Like ApolloMed, IntraCare is on a mission to build a thriving healthcare ecosystem that promotes successful, independent physicians, strengthens the patient-physician relationship, and improves patient satisfaction and healthcare outcomes through quality, compassionate coordinated care.
ApolloMed's partnership with IntraCare is poised to accelerate access to high-quality, value-based care for seniors in three areas. First, ApolloMed's ACO will partner with IntraCare's primary care providers as part of the ACO REACH program, an attribution-based risk-bearing model designed to advance health equity and bring the benefits of accountable care to Medicare beneficiaries in underserved communities. In addition, ApolloMed will deploy its value-based care platform as the exclusive care enablement partner for IntraCare providers participating in the ACO REACH program. Finally, to further IntraCare's mission and growth, ApolloMed will lend IntraCare a $25 million senior secured convertible promissory note maturing in 2028. Guggenheim Securities, LLC acted as financial advisor to IntraCare in connection with the transactions.
Brandon Sim, Co-CEO of ApolloMed, stated, "We have admired IntraCare's demonstrated track record of successfully empowering local independent primary care practices in Texas and Oklahoma, a strategy which is aligned with and complementary to our success in our core markets. With this partnership, we are excited to build upon IntraCare's momentum and partner with their providers in our ACO, continuing to scale our Care Partners business. We also look forward to bringing our Care Enablement platform to these providers and will work closely with IntraCare's leadership team in continuing to expand upon their historical success while exploring additional avenues for collaboration down the road."
Anwar Kazi, CEO of IntraCare, added, "We are thrilled to be partnering with ApolloMed, a company that is aligned with IntraCare in its mission of empowering providers in the successful delivery of value-based care. We believe that joining forces with ApolloMed will enable us to accelerate the growth of our business as we look to continue expanding our affiliate network and owned clinic footprint within our existing geographic presence in Texas and Oklahoma."
About Apollo Medical Holdings, Inc.
ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.
Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and entities participating in the Centers for Medicare & Medicaid Services Innovation Center (CMMI) innovation models. For more information, please visit www.apollomed.net.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the Company's operational focus and strategic growth plans and expectations regarding its ability to successfully partner with third parties. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the Securities and Exchange Commission ("SEC"), including without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC and any subsequent quarterly reports on Form 10-Q.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
(626) 943-6491
investors@apollomed.net
Carolyne Sohn, The Equity Group
(408) 538-4577
csohn@equityny.com
View original content to download multimedia:
SOURCE Apollo Medical Holdings, Inc. | https://www.kwch.com/prnewswire/2023/07/31/apollo-medical-holdings-inc-announces-partnership-with-intracare-advance-value-based-care-texas-oklahoma/ | 2023-07-31T12:34:01 | 0 | https://www.kwch.com/prnewswire/2023/07/31/apollo-medical-holdings-inc-announces-partnership-with-intracare-advance-value-based-care-texas-oklahoma/ |
BURLINGTON, Mass., July 31, 2023 /PRNewswire/ -- SEKISUI Diagnostics announces the launch of the OSOM COVID-19 Antigen Home Test to diagnose COVID-19 at home.
The OSOM COVID-19 Antigen Home Test is a lateral flow immunoassay device intended for the qualitative detection of nucleocapsid protein antigen from SARS-CoV-2 virus. As with other OSOM Rapid Tests, it is made in the USA and supported by a highly skilled technical support team of medical technologists/professionals.
"We are excited to be able to provide consumers with more tools to help diagnose COVID-19 in a fast, easy-to-use format that can be purchased over the counter. This supports our goal of bringing diagnostics to where they are needed most, which in this case is at home, so people do not have to travel to medical facilities and can treat or quarantine quickly", said Erica Blight, VP of Client Services, Clinical Research & Marketing.
SEKISUI Diagnostics is a well-known provider of many rapid testing solutions to the professional market through a portfolio of point-of-care tests under the OSOM and Acucy® brands. These simple, high performing tests have provided flexibility to healthcare professionals for decades and are now being brought to the home testing market.
"Our entrance into the home testing market is another way we are providing solutions to enhance life with science to improve the health of all people. We understand home testing is a valuable tool and becoming more accepted and necessary, especially when we are experiencing significant waves of respiratory infections as we have seen in previous seasons", said Bob Schruender, President & CEO.
About the OSOM® COVID-19 Antigen Home Test
This product has not been FDA cleared or approved but has been authorized by FDA under a conditional EUA. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens; and the conditional emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated, or authorization is revoked sooner.
About SEKISUI Diagnostics:
With over 40 years of experience, SEKISUI Diagnostics' mission is to provide intelligent solutions to enhance life with science and improve the health of all people. We supply innovative medical diagnostics globally to physicians, hospitals, laboratories and alternate testing locations.
Our product lines include clinical chemistry reagents, point-of-care tests, pre-analytic systems as well as enzymes and specialty biochemicals.
View original content to download multimedia:
SOURCE SEKISUI DIAGNOSTICS, LLC | https://www.wbay.com/prnewswire/2023/07/31/sekisui-diagnostics-announces-launch-osom-covid-19-antigen-home-test/ | 2023-07-31T12:34:04 | 1 | https://www.wbay.com/prnewswire/2023/07/31/sekisui-diagnostics-announces-launch-osom-covid-19-antigen-home-test/ |
HOUSTON, July 31, 2023 /PRNewswire/ -- AutomationEdge, a leading Hyperautomation platform has announced strategic partnership with eAlliance Corp, a cutting-edge Hyperautomation solutions provider.
The partnership will enable eAlliance Corp to provide AutomationEdge solutions such as CogniBot - a conversational AI platform, DocEdge - an intelligent document processing platform, Intelligent Service Desk Ticket Data Analysis, IT Process Automation (ITPA) and RPA. This collaboration will empower AutomationEdge and eAlliance Corp to help customers innovate with automation to move the needle on the top and bottom line.
AutomationEdge, along with its Hyperautomation platform, has also build the ready automation solutions across industries. It will help customers achieve faster Go-To-Market for automation projects with lower cost. It is empowering 250+ customers globally in Healthcare, Banking, Insurance, Financial Services and other industries.
For over 20 years, eAlliance Corp has been delivering technology solutions to businesses worldwide across industries. It has been a trusted advisor to its customer in innovation, strategy and execution of automation solutions. Through this partnership, eAlliance will be able to offer innovative business process automation solutions to customers focusing on key enterprise domains such as finance & accounting, customer service, procurement, human resources, cash applications and more.
About AutomationEdge
AutomationEdge is a leading Hyperautomation platform across the globe with end-to-end automation capabilities. With its platforms working together as one solution, it has enabled seamless process automation for global enterprises.
AutomationEdge has already delivered its innovative solutions to large multinational organizations like American Express, Smart Dubai Government, Wipro, AccentCare, Danone, University of Maryland Medical System, Aspen Pharmacare, Oman LNG, Mashreq Bank, HDFC Bank, and Genpact, to name a few.
For more details, contact sales or request a demo.
About eAlliance Corp
eAlliance Corp is a professional services firm with big company expertise and small company relationships, taking pride in agility and real-time responsiveness. eAlliance Corp is a trusted name in the Hyperautomation industry, offering comprehensive services and solutions to help businesses achieve their automation goals with ease. Founded in 2002 in Chicago, IL, staffed with resources in the US and India possessing vast experience and leadership in business and technology.
For more details, visit website.
For media inquiries, please contact:
Rahul Wandile
Media Relations – AutomationEdge
rahul.wandile@automationedge.com
www.automationedge.com
Follow AutomationEdge on: Twitter, Facebook, LinkedIn, and YouTube
View original content:
SOURCE AutomationEdge | https://www.kwch.com/prnewswire/2023/07/31/automationedge-ealliance-corp-announced-partnership-hyperautomation-solutions/ | 2023-07-31T12:34:07 | 1 | https://www.kwch.com/prnewswire/2023/07/31/automationedge-ealliance-corp-announced-partnership-hyperautomation-solutions/ |
ALHAMBRA, Calif., July 31, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced an agreement to partner with IntraCare, an operator of a value-based primary care provider network and primary care clinics located predominantly in Texas with a growing presence in Oklahoma.
Headquartered in the Dallas-Fort Worth metropolitan area of Texas, IntraCare is aligned with over 425 providers managing the care of over 40,000 members. Like ApolloMed, IntraCare is on a mission to build a thriving healthcare ecosystem that promotes successful, independent physicians, strengthens the patient-physician relationship, and improves patient satisfaction and healthcare outcomes through quality, compassionate coordinated care.
ApolloMed's partnership with IntraCare is poised to accelerate access to high-quality, value-based care for seniors in three areas. First, ApolloMed's ACO will partner with IntraCare's primary care providers as part of the ACO REACH program, an attribution-based risk-bearing model designed to advance health equity and bring the benefits of accountable care to Medicare beneficiaries in underserved communities. In addition, ApolloMed will deploy its value-based care platform as the exclusive care enablement partner for IntraCare providers participating in the ACO REACH program. Finally, to further IntraCare's mission and growth, ApolloMed will lend IntraCare a $25 million senior secured convertible promissory note maturing in 2028. Guggenheim Securities, LLC acted as financial advisor to IntraCare in connection with the transactions.
Brandon Sim, Co-CEO of ApolloMed, stated, "We have admired IntraCare's demonstrated track record of successfully empowering local independent primary care practices in Texas and Oklahoma, a strategy which is aligned with and complementary to our success in our core markets. With this partnership, we are excited to build upon IntraCare's momentum and partner with their providers in our ACO, continuing to scale our Care Partners business. We also look forward to bringing our Care Enablement platform to these providers and will work closely with IntraCare's leadership team in continuing to expand upon their historical success while exploring additional avenues for collaboration down the road."
Anwar Kazi, CEO of IntraCare, added, "We are thrilled to be partnering with ApolloMed, a company that is aligned with IntraCare in its mission of empowering providers in the successful delivery of value-based care. We believe that joining forces with ApolloMed will enable us to accelerate the growth of our business as we look to continue expanding our affiliate network and owned clinic footprint within our existing geographic presence in Texas and Oklahoma."
About Apollo Medical Holdings, Inc.
ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.
Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and entities participating in the Centers for Medicare & Medicaid Services Innovation Center (CMMI) innovation models. For more information, please visit www.apollomed.net.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the Company's operational focus and strategic growth plans and expectations regarding its ability to successfully partner with third parties. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the Securities and Exchange Commission ("SEC"), including without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC and any subsequent quarterly reports on Form 10-Q.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
(626) 943-6491
investors@apollomed.net
Carolyne Sohn, The Equity Group
(408) 538-4577
csohn@equityny.com
View original content to download multimedia:
SOURCE Apollo Medical Holdings, Inc. | https://www.kait8.com/prnewswire/2023/07/31/apollo-medical-holdings-inc-announces-partnership-with-intracare-advance-value-based-care-texas-oklahoma/ | 2023-07-31T12:34:07 | 0 | https://www.kait8.com/prnewswire/2023/07/31/apollo-medical-holdings-inc-announces-partnership-with-intracare-advance-value-based-care-texas-oklahoma/ |
SAN FRANCISCO, July 31, 2023 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential shareholder derivative claims on behalf of shareholders of Norfolk Southern Corporation (NYSE: NSC).
On February 3, 2023, a Norfolk Southern train derailed in East Palestine, Ohio, releasing toxins and other combustible liquids, which ultimately led to a controlled burn of toxic chemicals. The derailment prompted the evacuation of residents from the surrounding area. Upon returning to their homes, residents reported hazardous air quality and other health and environmental concerns.
On February 8, 2023, Ohio Governor Mike DeWine stated that Norfolk Southern "created the problem" and that it was "their liability" and "ought to pay for it." On February 21, 2023, the U.S. Environmental Protection Agency ordered Norfolk Southern to clean up the site, stating that it "will pay for cleaning up the mess they created and for the trauma they've inflicted on this community." The National Transportation Safety Board's preliminary report stated that the derailment was 100% preventable, and it later opened a special investigation into Norfolk Southern's safety practices because it had experienced five significant accidents since December 2021. On March 14, 2023, Ohio Attorney General Dave Yost filed a complaint against Norfolk Southern alleging a wide range of violations in connection with a series of Norfolk Southern train derailments. On March 16, 2023, purchasers of Norfolk Southern stock filed securities fraud class action claims against the company. On March 31, 2023, the U.S. Department of Justice sued Norfolk Southern seeking penalties and injunctive relief for the unlawful discharge of pollutants, oil, and hazardous substances under the Clean Water Act, and declaratory judgment for past and future costs under the Comprehensive Environmental Response, Compensation, and Liability Act.
The Schubert Firm is investigating potential wrongdoing by Norfolk Southern's officers and directors in connection with these allegations. Norfolk Southern previously recognized $387 million in expenses related to these matters, and on July 27, 2023 announced another $416 million charge, for a total of $803 million.
If you own Norfolk Southern stock and wish to obtain additional information about your legal rights, please contact us today or visit our website at
https://www.classactionlawyers.com/norfolk.
About Schubert Jonckheer & Kolbe LLP
Schubert Jonckheer & Kolbe represents shareholders, employees, and consumers in class actions against corporate defendants, as well as shareholders in derivative actions against their officers and directors. The firm is based in San Francisco, and with the help of co-counsel, litigates cases nationwide.
View original content:
SOURCE Schubert Jonckheer & Kolbe LLP | https://www.wbay.com/prnewswire/2023/07/31/shareholder-alert-norfolk-southern-corporation-nsc-officers-directors-face-shareholder-investigation-potential-wrongdoing-related-february-2023-east-palestine-train-derailment-which-has-resulted-803-million-charges/ | 2023-07-31T12:34:10 | 0 | https://www.wbay.com/prnewswire/2023/07/31/shareholder-alert-norfolk-southern-corporation-nsc-officers-directors-face-shareholder-investigation-potential-wrongdoing-related-february-2023-east-palestine-train-derailment-which-has-resulted-803-million-charges/ |
SAN JOSE, Calif., July 31, 2023 /PRNewswire/ -- Broadcom Inc. (NASDAQ: AVGO), a Delaware corporation headquartered in San Jose, CA, and a global technology leader that designs, develops and supplies semiconductor and infrastructure software solutions, today announced it will report its third quarter fiscal year 2023 financial results and business outlook on Thursday, August 31, 2023 after the close of the market. Broadcom's management will host a conference call at 2:00 p.m. Pacific Time on the same day to discuss these results and business outlook.
Date: Thursday, August 31, 2023
Time: 2:00 PM (PT); 5:00 PM (ET)
To Listen via Telephone: Preregistration is required by the conference call operator. Please preregister at https://register.vevent.com/register/BIab1222c9ed364122895c0b8a81ef898b. Upon registering, you will be emailed a link to the dial-in number and unique PIN.
To Listen via Internet: The conference call can be accessed live online in the Investors section of the Broadcom website at https://investors.broadcom.com.
Replay: An audio replay of the conference call can be accessed for one year through the Investors section of Broadcom's website at https://investors.broadcom.com.
About Broadcom Inc.
Broadcom Inc. (NASDAQ: AVGO), a Delaware corporation headquartered in San Jose, CA, is a global technology leader that designs, develops and supplies a broad range of semiconductor and infrastructure software solutions. Broadcom's category-leading product portfolio serves critical markets including data center, networking, enterprise software, broadband, wireless, storage and industrial. Our solutions include data center networking and storage, enterprise, mainframe and cyber security software focused on automation, monitoring and security, smartphone components, telecoms and factory automation. For more information, go to https://investors.broadcom.com.
Contact:
Broadcom Inc.
Ji Yoo
Investor Relations
408-433-8000
investor.relations@broadcom.com
(AVGO-Q)
View original content:
SOURCE Broadcom Inc. | https://www.kait8.com/prnewswire/2023/07/31/broadcom-inc-announce-third-quarter-fiscal-year-2023-financial-results-thursday-august-31-2023/ | 2023-07-31T12:34:14 | 0 | https://www.kait8.com/prnewswire/2023/07/31/broadcom-inc-announce-third-quarter-fiscal-year-2023-financial-results-thursday-august-31-2023/ |
Impact "much bigger than a single project"
WAYNESBORO, Ga., July 31, 2023 /PRNewswire/ -- Bechtel, the engineering, procurement, and construction company brought in to complete construction on new Units 3 and 4 at the Vogtle nuclear power plant in Georgia, today issued the following statement from Brendan Bechtel, Bechtel Chairman and CEO, marking the start of commercial operations for Unit 3:
"We are extremely proud of Bechtel's part in achieving this milestone. Our team has been 100 percent committed to Vogtle's completion since being brought in to finish the project.
"Today's start of commercial operations for Vogtle Unit 3 gives the Southeast a major new source of clean, reliable, carbon-free baseload energy. And, as the first new nuclear unit built in the U.S. in more than 30 years, it helps put America back on the map as a leader in the global nuclear industry.
"Bechtel has supported the design and construction of 150 nuclear plants worldwide. We know firsthand how Vogtle Units 3 and 4 go a long way in restoring America's muscle memory in nuclear construction, including the workforce and domestic supply chains required to build America's largest nuclear power plant. Vogtle Unit 3 comes online at a pivotal time when energy security concerns and the need to cut carbon emissions are driving growth in the world's nuclear fleet.
"Plant Vogtle will generate more carbon-free electricity yearly than any other energy facility currently operating in the country. Its completion reinforces that the United States is the responsible partner of choice for new nuclear energy around the world, and maintains U.S. interests in ensuring strong safety, security, and non-proliferation standards. This is why Vogtle's impact is much bigger than a single project.
"Thank you to the thousands of skilled craft professionals, union partners, engineers, project managers, procurement experts, suppliers, subcontractors, and everyone who made this day possible. And thank you to Georgia Power and Southern Nuclear for the opportunity to bring this project over the finish line. We look forward to doing the same with Unit 4 in the coming months."
Background
In 2017, Bechtel was brought in by Georgia Power and Southern Nuclear to take over construction of Vogtle Units 3 and 4, bringing extensive experience supporting the design and construction of 150 nuclear plants worldwide. Vogtle Units 3 and 4 are the first Westinghouse AP1000 units to ever be built in the U.S.
Bechtel has completed more than 76,000 megawatts of new nuclear generation capacity and has designed, built, or performed engineering and/or construction services on more than 80% of nuclear plants in the United States. Today, the company leads efforts in designing and constructing advanced nuclear plants, critical to global efforts to achieve net zero carbon emissions.
Bechtel partnered with North America's Building Trades Unions (NABTU) to build Plant Vogtle Units 3 and 4. At peak, Bechtel and NABTU had a combined 9,000 workers on site.
About Bechtel
Bechtel is a trusted engineering, construction, and project management partner to industry and government. Differentiated by the quality of our people and our relentless drive to deliver the most successful outcomes, we align our capabilities to our customers' objectives to create a lasting positive impact. Since 1898, we have helped customers complete more than 25,000 projects in 160 countries on all seven continents that have created jobs, grown economies, improved the resiliency of the world's infrastructure, increased access to energy, resources, and vital services, and made the world a safer, cleaner place.
Bechtel serves the Energy; Infrastructure; Manufacturing & Technology; Mining & Metals; and Nuclear, Security & Environmental markets. Our services span from initial planning and investment through start-up and operations. www.bechtel.com
Contact:
Amanda Meixel
ammeixel@bechtel.com
M: 1-706-360-5526
P: 1-703-429-6313
View original content to download multimedia:
SOURCE Bechtel | https://www.kwch.com/prnewswire/2023/07/31/bechtel-commercial-operations-vogtle-unit-3-is-an-important-milestone-us-nuclear-industry/ | 2023-07-31T12:34:14 | 0 | https://www.kwch.com/prnewswire/2023/07/31/bechtel-commercial-operations-vogtle-unit-3-is-an-important-milestone-us-nuclear-industry/ |
Carolinas’ Own Queen City News (WJZY), virtual channel 46, is a FOX-affiliated television station serving Charlotte, North Carolina, United States that is licensed to Belmont. The station is owned by Nexstar Media Group, as part of a duopoly with Rock Hill, South Carolina-licensed MyNetworkTV affiliate WMYT-TV.
The two stations share studios on Performance Road in unincorporated western Mecklenburg County and transmitter facilities in Dallas, North Carolina, along the Catawba River.
The station first signed on the air on March 9, 1987, originally operating as an independent station.
WJZY presently broadcasts more than 60 hours of locally produced newscasts each week (with 10 hours each weekday, four and a half hours on Saturdays, and six hours on Sundays).
In regards to the number of hours devoted to news programming, it is the highest local newscast output of any television station in the Charlotte market. | https://www.qcnews.com/about-us/ | 2023-07-31T12:34:15 | 1 | https://www.qcnews.com/about-us/ |
FREIT Board Committed to Protecting Value for All Stockholders
Highlights Kushner's Transaction Record with FREIT and Ongoing Litigation with Kushner
HACKENSACK, N.J., July 31, 2023 /PRNewswire/ -- First Real Estate Investment Trust of New Jersey, Inc. ("FREIT" or the "Company") (OTCM: FREVS) today announced that its Board of Directors has unanimously adopted a stockholder rights plan (the "Rights Plan") following evaluation and consultation with the Company's legal and financial advisors.
The Rights Plan is similar to plans adopted by other publicly traded companies incorporated in Maryland and is intended to protect the long-term interests of FREIT stockholders and to enable them to realize the full potential value of their investment. The Rights Plan has a three-year duration and the rights will be exercisable only if any person (or any persons acting as a group) acquires 10% or more of FREIT common stock. This ownership limitation better aligns FREIT with the ownership limitation of other REITs.
The Rights Plan does not preclude the Board from considering an offer that recognizes the full value of the Company. Rather, the Rights Plan will reduce the likelihood that any entity, person or group gains control of FREIT without paying an appropriate control premium. Importantly, the Rights Plan provides the Board with adequate time to fully assess its options following its receipt of an unsolicited, non-binding expression of interest from K Corp Acquisitions LLC, a Kushner company, to acquire FREIT.
While the Board will always evaluate credible proposals to maximize stockholder value, it is mindful that Charles Kushner has proven not to be a bona fide counterparty in a prior potential transaction with FREIT. As such, the Board believes any definitive agreement with Charles Kushner would carry significant, atypical closing and additional litigation risk.
The Rights Plan will benefit FREIT stockholders by providing the Company with enough time to pursue a final outcome in the previously announced ongoing litigation with Sinatra LLC, a Kushner company, related to Kushner's abandonment of a January 2020 definitive agreement to acquire certain of FREIT's assets. Following the outcome of the litigation, the Board will have greater flexibility to consider a value-maximizing transaction.
Additional Details of the Rights Plan
In connection with the adoption of the Rights Plan, the Board of Directors declared a dividend distribution of one preferred stock purchase right for each outstanding share of FREIT common stock to stockholders of record as of the close of business on August 11, 2023. Initially, these rights will not be exercisable and will trade with the shares of FREIT common stock.
The Rights Plan provides several recognized stockholder protections, such as the following:
- Under the Rights Plan, the rights generally will become exercisable if a person or group becomes an "acquiring person" by acquiring 10% or more of the common stock of FREIT (which includes stock subject to a derivative transaction or an acquired derivative security) or if a person commences a tender offer that could result in that person becoming an "acquiring person".
- If a person becomes an "acquiring person," each holder of a right (other than the acquiring person) would be entitled to purchase, at the then-current exercise price, such number of shares of common stock (or, subject to the terms of the Rights Plan, shares of preferred stock that are equivalent to shares of FREIT common stock) at a 50% discount. If FREIT is acquired in a merger or other business combination transaction after any such event, each holder of a right would then be entitled to purchase, at the then-current exercise price, shares of the acquiring company's common stock at a 50% discount. The Board, at its option, may exchange on a cashless basis, each right (other than rights owned by the acquiring person that have become null and void) in whole or in part, at an exchange ratio of one share of FREIT common stock per outstanding right, subject to adjustment.
- The Rights will expire in three years on July 31, 2026, unless the rights have been previously redeemed or exchanged by the Board of Directors in accordance with the terms of the Rights Plan.
Under the Rights Plan, any person, entity or group that currently owns more than the triggering percentage may continue to own its shares of FREIT common stock but may not acquire any additional shares of common stock, or form a group with another owner of FREIT common stock, without triggering the Rights Plan.
Additional details about the Rights Plan will be contained in a Current Report on Form 8-K to be filed by FREIT with the Securities and Exchange Commission.
Advisors
Goldman Sachs & Co. LLC is acting as financial advisor to FREIT and Goodwin Procter LLP and Miles & Stockbridge P.C. are acting as legal counsel.
About FREIT
First Real Estate Investment Trust of New Jersey, Inc. is a publicly traded (over-the-counter – symbol FREVS) REIT organized in 1961. Its portfolio of residential and commercial properties are located in New Jersey and New York, with the largest concentration in northern New Jersey. For more information, visit: www.freitnj.com.
Forward-Looking Statements
This Company release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These forward-looking statements can be identified by the use of words such as "expect," "plan," "will," "estimate," "project," "intend," "believe," "guidance," "approximately," "anticipate," "may," "should," "seek" or the negative of these words and phrases or similar words or phrases that are predictions of or indicate future events or trends and that do not relate to historical matters. You can also identify forward-looking statements by discussions of strategy, plans or intentions of management. These forward-looking statements are subject to known and unknown risks and uncertainties that you should not rely on as predictions of future events. Forward-looking statements depend on assumptions, data and/or methods which may be incorrect or imprecise and we may not be able to realize them. The following risks and uncertainties, among others, could cause actual results to differ materially from those currently anticipated due to a number of factors, which include, but are not limited to: industry and economic conditions; the Company's ability to satisfy the conditions to closing and complete the proposed transaction; the Company's dependence upon its external manager to conduct its business and achieve its investment objectives; unknown liabilities acquired in connection with acquired properties or interests in real estate-related entities; general risks affecting the real estate industry and local real estate markets (including, without limitation, the market value of the Company's properties, potential illiquidity of the Company's remaining real estate investments, condemnations, and potential damage from natural disasters); the financial performance of the Company's tenants; the impact of any financial, accounting, legal or regulatory issues or litigation that may affect the Trust and its major tenants; volatility and uncertainty in the financial markets, including potential fluctuations in the consumer price index; risks associated with the Company's failure to maintain status as a REIT under the Internal Revenue Code of 1986, as amended; and other additional risks discussed in the Company's annual report on Form 10-K for the fiscal year ended October 31, 2022. The Company expressly disclaims any responsibility to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Media & Investor Contact
Scott Bisang / Nick Lamplough / Jack Kelleher
Collected Strategies
FREIT-IR@collectedstrategies.com
View original content to download multimedia:
SOURCE First Real Estate Investment Trust of New Jersey | https://www.kait8.com/prnewswire/2023/07/31/first-real-estate-investment-trust-new-jersey-inc-adopts-stockholder-rights-plan/ | 2023-07-31T12:34:15 | 0 | https://www.kait8.com/prnewswire/2023/07/31/first-real-estate-investment-trust-new-jersey-inc-adopts-stockholder-rights-plan/ |
SHENZHEN, China, July 31, 2023 /PRNewswire/ -- AMIRO ("the Company"), a leading beauty and skincare technology brand, is thrilled to announce that its research facility, AMIRO LAB, has successfully obtained the Qualified Testing Location (QTL) certification after a comprehensive audit conducted by SGS.
SGS, a globally recognized testing, inspection and certification organization with thousands of branches and laboratories worldwide, introduced the QTL certification for laboratory witness testing. As an SGS-accredited testing location, AMIRO LAB will undergo witness testing by SGS during the certification process, ensuring the accuracy and reliability of the test data. This reduces the time required for companies to transport samples to SGS-designated laboratories for testing, thus effectively shortening the product testing cycle.
"As we receive the QTL certification for AMIRO LAB, it signifies a resounding acknowledgment of our research center's testing capabilities and management efficiency," Jason Chen, Quality Management Director, said. "This milestone propels us into a new phase of strategic cooperation with SGS. Looking ahead, we will forge closer ties in product testing, inspection, certification, and industry standard-setting to drive the high-quality and sustainable development of the skincare technology industry."
Widely recognized as a technology-driven and innovation-focused skincare enterprise, AMIRO has always prioritized research and development. From its inception, AMIRO has established its AMIRO LAB to focus on innovative applications of photonic and medical technologies in the beauty and skincare field. The center boasts a wide array of state-of-the-art equipment, facilitating effective quantitative evaluations.
In a bid to enhance its research and development capabilities, AMIRO has also actively engaged in collaborations between industry, academia, and research institutions, partnering with renowned universities to set up joint R&D centers. These collaborations have enabled AMIRO to advance fundamental research and create products that precisely cater to users' skincare needs.
One exemplary collaboration involves the establishment of the Smart Photonic Medical Technology Joint Research Center with Shanghai Jiao Tong University's School of Biomedical Engineering. This center explores the application and commercialization of photonic therapy in relevant fields. Additionally, the Company has also collaborated with Zhejiang University's School of Pharmacy that led the research on transdermal permeation technology combined with photonic energy. AMIRO has also worked with Sichuan University on a precise skin measurement and evaluation development platform, and with Chongqing University on skin photonic science to study anti-aging skincare solutions for consumers.
AMIRO's prominent position in the industry is further cemented by its active participation in establishing industry standards. The Company has taken an active role in standard-setting initiatives by leveraging its profound R&D capabilities. AMIRO has led the formulation of several industry group standards, including "Guidelines for Face Masks Used in Conjunction with RF Beauty Devices" and "Guidelines for Skincare Products Used in Conjunction with RF and Microcurrent Home Beauty Devices." Moreover, AMIRO has participated in the development of the national standard "Special Requirements for the Safety of Electrical Skin Beauty Devices" to help with the standardization of the industry.
The latest SGS' awarding of the QTL certification to AMIRO is a testament to the brand's advanced laboratory equipment and robust quality management system. This certification represents not only the assurance of product quality but signifies The Company's commitment to enhancing product certification efficiency and accelerating its product launch process to benefit more consumers.
Looking ahead, AMIRO remains committed to optimizing its quality management system as well as its product inspection and testing processes. The Company will continue to translate scientific research achievements into practical applications, delivering simple, safe, and effective products. AMIRO's ultimate goal is to offer precise and tailored skincare solutions for every individual, allowing consumers to experience the beauty of life to the fullest.
For more information about AMIRO and its range of facial devices, please visit their official website.
Or connect with them on social media:
Instagram: https://www.instagram.com/amiroglobal/
Facebook: https://www.facebook.com/AMIRO-Global-103502195623795/
YouTube: https://www.youtube.com/@amiroglobal/featured
About AMIRO
AMIRO, a beauty and skincare technology brand founded in 2015, has been delivering joy and harmony through its technologically advanced home beauty and personal care electronic products. With over 38 international design awards, AMIRO is your trusted skincare partner that offers portable, short-acting, and long-lasting solutions to improve skincare efficiency.
Upholding the idea of "Revitalize beauty through science", AMIRO's products are designed to be affordable, high-quality, and supported by clinical data. With a commitment to sustainability and innovation, AMIRO is dedicated to providing skincare solutions that make women of all ages feel confident and beautiful.
View original content to download multimedia:
SOURCE AMIRO | https://www.wbay.com/prnewswire/2023/07/31/skincare-tech-brand-amiro-receives-qtl-certification-sgs-strengthen-rampd-efforts/ | 2023-07-31T12:34:17 | 1 | https://www.wbay.com/prnewswire/2023/07/31/skincare-tech-brand-amiro-receives-qtl-certification-sgs-strengthen-rampd-efforts/ |
NEW YORK, July 31, 2023 /PRNewswire/ -- BGC Group, Inc. (Nasdaq: BGC) ("BGC"), a leading global brokerage and financial technology company, today announced the addition of a Weather Derivatives Team with the hire of Nicholas and Eric Ernst. Nicholas joins the firm as Managing Director, BGC Weather Derivatives while Eric joins as Weather Broker.
John Abularrage, Co-Global Head of Financial Services Brokerage, commented on today's announcement, "We are excited to welcome Nicholas and Eric to BGC. They bring with them almost three decades of invaluable experience in the weather derivatives and climate risk transfer space. With these new hires, BGC now operates the premier weather and climate derivatives desk in the industry."
Nicholas Ernst brings with him over 20 years of experience in the weather derivatives and risk transfer space. Prior to joining BGC, he served as Managing Director, Weather Markets at ICAP. Additionally, Nicholas spent time in similar roles at OTC Global and Evolutions Markets.
Before joining BGC, Eric Ernst served as a Weather Broker at ICAP. Prior to that, Eric held various roles at Choice Energy and spent three years in the renewable energy sector.
About BGC Group, Inc.
BGC Group, Inc. ("BGC") began trading on Nasdaq at the market opening on July 3, 2023, under the new ticker symbol "BGC", following the corporate conversion of its predecessor BGC Partners, Inc. (formerly Nasdaq: BGCP). BGC is a leading global brokerage and financial technology company. BGC, through its various affiliates, specializes in the brokerage of a broad range of products, including Fixed Income (Rates and Credit), Foreign Exchange, Equities, Energy and Commodities, Shipping, and Futures. BGC, through its various affiliates, also provides a wide variety of services, including trade execution, brokerage, clearing, trade compression, post-trade, information, and other back-office services to a broad range of financial and non-financial institutions. Through its brands, including Fenics®, FMX™, FMX Futures Exchange™, Fenics Markets Xchange™, Fenics Digital™, Fenics UST™, Fenics FX™, Fenics Repo™, Fenics Direct™, Fenics MID™, Fenics Market Data™, Fenics GO™, Fenics PortfolioMatch™, BGC®, BGC Trader™, kACE2™, and Lucera®, BGC offers financial technology solutions, market data, and analytics related to numerous financial instruments and markets. BGC, BGC Group, BGC Partners, BGC Trader, GFI, GFI Ginga, CreditMatch, Fenics, Fenics.com, FMX, Sunrise Brokers, Poten & Partners, RP Martin, kACE2, Capitalab, Swaptioniser, CBID, Caventor, LumeMarkets and Lucera are trademarks/service marks and/or registered trademarks/service marks of BGC and/or its affiliates.
BGC's customers include many of the world's largest banks, broker-dealers, investment banks, trading firms, hedge funds, governments, corporations, and investment firms. BGC's Class A common stock trades on the Nasdaq Global Select Market under the ticker symbol "BGC". BGC is led by Chairman of the Board and Chief Executive Officer Howard W. Lutnick. For more information, please visit http://www.bgcg.com. You can also follow BGC at https://twitter.com/bgcgroupinc, https://www.linkedin.com/company/bgc_group and/or http://ir.bgcg.com.
Discussion of Forward-Looking Statements about BGC
Statements in this document regarding BGC that are not historical facts are "forward-looking statements" that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the effects of the COVID-19 pandemic on the Company's business, results, financial position, liquidity and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, BGC undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see BGC's Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.
Media Contact:
Karen Laureano-Rikardsen
+1 212-829-4975
View original content to download multimedia:
SOURCE BGC Group, Inc. | https://www.kwch.com/prnewswire/2023/07/31/bgc-group-hires-nicholas-eric-ernst-launch-weather-derivatives-desk/ | 2023-07-31T12:34:21 | 1 | https://www.kwch.com/prnewswire/2023/07/31/bgc-group-hires-nicholas-eric-ernst-launch-weather-derivatives-desk/ |
For immediate concerns:
Telephone: 704-944-3300
Email: engineering@qcnews.com
For written WJZY FOX 46 Charlotte closed captioning complaints:
Randall Honeycutt, Chief Engineer
Telephone: 704-944-3317
Email: Randall.honeycutt@qcnews.com
WJZY-TV
3501 Performance Road
Charlotte, NC 28214 | https://www.qcnews.com/closed-captions/ | 2023-07-31T12:34:21 | 1 | https://www.qcnews.com/closed-captions/ |
IXL's teaching and learning platform will be used district wide to close knowledge gaps, improve academic achievement and provide equitable educational experiences
LEXINGTON, Ky., July 31, 2023 /PRNewswire/ -- IXL, the personalized learning platform used by more than 14 million students, has announced a new partnership with Fayette County Public Schools (FCPS) in Kentucky. As part of the collaboration, the state's second-largest K-12 school system will now use IXL's award-winning platform district-wide to boost academic achievement in math, English language arts, science, social studies and Spanish. IXL is used by nearly 40 percent of all K-12 students in Kentucky, accounting for more than 283,000 learners.
Fayette County Public Schools strives to provide a world-class education
and positive learning environment to more than 40,000 students from the Lexington area. FCPS began using IXL to support its special education and English language learner communities, and recently expanded its implementation district-wide after successfully piloting the platform.
The district highly values IXL Analytics because it provides educators with data that allows them to track student achievement across schools and identify any gaps in knowledge. This information can then be used to quickly intervene and provide students with the support they need to succeed.
FCPS also appreciates IXL's comprehensive curriculum and instructional resources because they give educators the flexibility to create personalized learning pathways for students. These pathways allow students to learn at their own pace and in their own way, which helps them grow independently. Additionally, IXL provides FCPS with custom math skill plans that are aligned to the district's scope and sequence, as well as test preparation for Kentucky's Summative Assessment. These plans reinforce standards-aligned instruction, which helps students master the concepts they need to know to succeed.
"IXL is an immersive learning tool that helps students master content at school, on-the-go and at home. Insights provided by IXL help teachers track growth and target recommendations for next steps, and research shows that students who use IXL perform better on state assessments," said Brooke Stinson, Director of Assessment, Fayette County Public Schools. "We are excited for this partnership and to provide this resource for all of our students."
"We are delighted to continue our partnership with Fayette County Public Schools. By using IXL's platform district-wide, educators will be able to more effectively track student progress, close achievement gaps and empower all students to reach their full potential," said Paul Mishkin, CEO of IXL Learning. "We are proud to be an important resource to our partners, and we look forward to working with FCPS' team so that all of its learners have even more opportunities to succeed."
Recover learning and boost achievement with IXL's award-winning platform
IXL gives school districts everything that they need to make a bigger positive impact on learning. The all-inclusive platform provides thousands of curriculum and instructional resources, actionable analytics and a state-of-the-art assessment suite. In addition to helping schools and students succeed academically, IXL can even uncover hidden obstacles to learning, develop students' intrinsic motivation to learn and more.
IXL's state-of-the-art assessment suite
IXL's assessment suite works in concert with its curriculum to give educators and students real-time insight into performance, pinpoint gaps in knowledge and provide specific next steps that help recover learning. IXL's adaptive assessment, the Real-Time Diagnostic, accurately measures students' grade-level proficiency and growth in key math and ELA strands, helping educators understand exactly what learners know and what they can do to improve. Additionally, IXL's universal screener flags at-risk students in as little as 20 minutes to help educators plan district-wide math interventions.
Comprehensive curriculum for deeper learning
Teachers use IXL's comprehensive curriculum to provide students with tailored support and ensure that they master essential concepts. More than 10,000 rigorous, mastery-based skills deeply engage students, build a strong foundation of knowledge and prepare learners for higher-level thinking. Based on students' previous work in the curriculum, IXL generates personalized recommendations in real time that guide learners to the skills that will help them grow the fastest. Additionally, IXL's skill plans simplify lesson planning by providing teachers with skills that match their state standards and textbooks. IXL also provides test preparation skill plans and personalized study plans for the SAT and ACT.
Instructional resources and classroom engagement tools
IXL's built-in instructional resources include nearly 2,400 math and English language arts video tutorials, corrective feedback, educational games for young learners and step-by-step lessons that support students when they're working independently. Classroom engagement tools, like Group Jams and Leaderboards, make classroom learning engaging and create collaborative learning opportunities.
Actionable analytics for districts, schools, classrooms and individual learners
IXL Analytics is an essential daily tool that allows teachers to easily identify trouble spots, monitor performance on skills, deliver data-driven instruction and use limited class time more effectively. Administrators can use IXL District Analytics and IXL School Analytics to track student progress and teacher engagement, enabling them to improve IXL's impact on their school or district.
About Fayette County Public Schools
Fayette County Public Schools serves over 40,000 students from the Lexington metro area, with the goal of providing a world-class education for every child. The mission of Fayette County Public Schools is to create a collaborative community that ensures all students achieve at high levels and graduate prepared to excel in a global society.
About IXL Learning
Currently used by 14 million students and in 95 of the top 100 U.S. school districts, IXL is an all-inclusive educational platform that provides a comprehensive PK-12 curriculum and instructional resources, actionable analytics and a state-of-the-art assessment suite. IXL's end-to-end teaching and learning solution supports personalized instruction in math, English language arts, science, social studies and Spanish. With more than 130 billion questions asked and answered around the world, IXL is helping schools and parents successfully boost student achievement. The IXL Learning family of products also includes Rosetta Stone, TPT, SpanishDictionary.com, inglés.com, Wyzant, Vocabulary.com, ABCya, Education.com and Emmersion. To learn more about IXL, visit www.ixl.com, facebook.com/IXL and twitter.com/IXLLearning.
Press Contact
Eric Bates
IXL Learning
press@ixl.com
View original content to download multimedia:
SOURCE IXL Learning | https://www.kait8.com/prnewswire/2023/07/31/ixl-fayette-county-public-schools-partner-boost-academic-achievement-personalize-learning-all-students/ | 2023-07-31T12:34:22 | 1 | https://www.kait8.com/prnewswire/2023/07/31/ixl-fayette-county-public-schools-partner-boost-academic-achievement-personalize-learning-all-students/ |
The Avocados From Mexico® Chocolate Dulce De Leche Cupcake will be available at Sprinkles bakeries nationwide for one week beginning July 31
DALLAS, July 31, 2023 /PRNewswire/ -- Talk about a perfect pairing! Avocados From Mexico®, the number one selling avocado brand in the U.S., is making National Avocado Day even better by partnering with renowned dessert bakery chain Sprinkles for a delicious collaboration – a limited-edition cupcake featuring fresh Mexican avocados.
The Avocados From Mexico® Chocolate Dulce De Leche Sprinkles cupcake is a delectable banana cupcake that's studded with pecans and generously filled with a soft dulce de leche core. And to top it all off? A zesty frosting that blends rich cream cheese and chocolate made with fresh Mexican avocados for a delightful, creamy finish.
"The new Avocados From Mexico Chocolate Dulce De Leche cupcake features the highest quality and best-tasting ingredients," said Sprinkles Vice President, Culinary, Charles Craig. "By blending fresh avocado and smooth cream cheese alongside the banana and dulce de leche cupcake, we were able to elevate all the ingredients resulting in a cupcake that is out-of-this world. We can't wait for fans to try it!"
Beginning on July 31, National Avocado Day, consumers can make their week better by enjoying Avocados From Mexico in cupcake form — available at Sprinkles nationwide through August 6.
"Avocados From Mexico make everything better, and we're so proud that our avocados will get to shine in a unique way on National Avocado Day," said Kelly Burke, Director of Brand Marketing at Avocados From Mexico. "Our brand is known for bringing the good times with great tasting avocados. We are excited to partner with a beloved brand like Sprinkles to spark good times in a new way with everyone's favorite sweet treat."
"Sprinkles Cupcakes has always taken an innovative approach to classic desserts, and this new collaboration with Avocados From Mexico is no exception," said Sprinkles CMO, Michelle Wong. "Avocados From Mexico was an obvious choice for their quality and taste, and we can't wait for our guests to discover our latest cupcake, starring this beloved fruit."
To learn more about Avocados From Mexico, visit https://avocadosfrommexico.com, Facebook (facebook.com/avocadosfrommexico), Instagram (@avocadosfrommexico) or Twitter (@AvosFromMexico). #MakeItBetter #AFMxSprinkles
About Avocados From Mexico
Avocados From Mexico is a wholly-owned subsidiary of the Mexican Hass Avocado Importers Association (MHAIA), formed for the purpose of advertising, promotion, public relations and research for all stakeholders of Avocados From Mexico. Under agreements, MHAIA and the Association of Avocado Exporting Producers & Packers of Mexico (APEAM) have combined resources to fund and manage Avocados From Mexico, with the intent to provide a focused, highly- effective and efficient marketing program in the United States. Avocados From Mexico is headquartered in Irving, Texas.
About Sprinkles
Sprinkles offers premium cupcakes, cakes and cookies that are baked fresh in small batches throughout the day and handcrafted with only the finest ingredients. Sprinkles opened its first bakery in Beverly Hills in 2005, drawing long lines of loyal cupcake fans and celebrity endorsements. Sprinkles prides themselves in being passionate innovators and since debuting the world's first Cupcake ATM, the brand has introduced layer cakes, cookies and brownies, launched a national shipping platform and has grown to over 70 bakeries and ATMs coast-to-coast. Sprinkles launched domestic and international franchising in 2022. For additional information on Sprinkles, follow @sprinklescupcakes on social and visit www.sprinkles.com.
CONTACT: Ana Ambrosi, aambrosi@avocadosfrommexico.com
View original content to download multimedia:
SOURCE Avocados From Mexico | https://www.wbay.com/prnewswire/2023/07/31/sweet-news-avocados-mexico-sprinkles-launch-limited-edition-cupcake-national-avocado-day/ | 2023-07-31T12:34:23 | 0 | https://www.wbay.com/prnewswire/2023/07/31/sweet-news-avocados-mexico-sprinkles-launch-limited-edition-cupcake-national-avocado-day/ |
Two Children Injured In St. Charles ATV Crash
July 31, 2023 12:30AM EDT
A seven-year-old boy received life-threatening injuries after a four wheeler crash last Friday.
Police say the boy and a ten-year-old girl were riding the ATV in the 600 block of West Spruce Street in Saint Charles when it crashed. Neither child was wearing a helmet. The kids were taken to Covenant Healthcare in Saginaw. Police say the boy is breathing with the assistance of a ventilator. The girl is in good condition. | https://www.wsgw.com/two-children-injured-in-st-charles-atv-crash/ | 2023-07-31T12:34:25 | 1 | https://www.wsgw.com/two-children-injured-in-st-charles-atv-crash/ |
- Cash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023
- Announced positive interim data from BHV-7000 EEG biomarker study demonstrating evidence of central nervous system (CNS) target engagement, confirming previously reported preclinical and clinical data, and highlighting the paradigm-changing potential of BHV-7000 in the treatment of epilepsy and mood disorders
- Brain penetrant TYK2/JAK1 inhibitor, BHV-8000, advanced into Phase 1 with projected therapeutic concentrations achieved and well-tolerated profile observed to date
- Advanced targeted extracellular protein degradation platform with potential to support numerous clinical candidates across a broad range of high unmet need indications
- Orphan drug designation (ODD) granted by the European Commission for taldefgrobep alfa a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA)
- Type A meeting planned with FDA regarding troriluzole program in Spinocerebellar Ataxia Type 3 (SCA3) and enrollment in Phase 3 obsessive compulsive disorder (OCD) trial expected to complete at end of 2023
NEW HAVEN, Conn., July 31, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, "In less than a year since our spin-off, the Biohaven team has driven strong and consistent progress across multiple drug development platforms. We were excited to recently report positive interim data from the ongoing EEG biomarker study of our lead Kv7 activator, BHV-7000. As expected, BHV-7000 demonstrated CNS activity consistent with what has been reported in EEG studies with other Kv7 channel activators in development that are clinically effective in treating epilepsy and with other approved anti-seizure medications. Importantly, BHV-7000 demonstrates CNS target engagement but is not associated with the typical CNS adverse events associated with other ASMs, like somnolence and fatigue. We look forward to completing the higher dose groups in this EEG study and initiating Phase 2/3 studies with our once daily, extended-release oral formulation later this year."
Dr. Coric continued, "We also shared a number of equally exciting announcements across our broader pipeline this quarter. We successfully administered the first three doses in the SAD portion of our ongoing SAD/MAD study evaluating BHV-8000, an oral, brain-penetrant, dual TYK2/JAK1 inhibitor. Potential therapeutic concentrations of BHV-8000 were achieved and BHV-8000 was well tolerated with only mild adverse events reported, reinforcing our plans to start a Phase 2 clinical trial with BHV-8000 in Parkinson's disease and potentially other neuroinflammatory diseases in 2024. In addition, we have advanced IND enabling preclinical studies and remain on track to submit an IND with our IgG degrader, BHV-1300, later this year. We also anticipate submitting an IND with our IgA degrader in 2024 as we continue to advance multiple clinical degrader candidates across a wide range of indications. We also shared key updates for our taldefgrobep alfa program (an anti-myostatin) with enrollment completion in our pivotal study in SMA and a planned Phase 2 trial initiation in obesity."
"Finally, I want to reaffirm Biohaven's commitment to the SCA3 patient community in spite of the recent disappointing regulatory decision by the FDA not to review our submitted NDA. Given the seriousness of SCA3 and consistent treatment benefits observed across multiple prespecified outcome measures, including an 80% delay in disease progression over the one-year study period with substantial risk reduction in falls, we believe that full consideration of all available data is warranted for this ultra-rare disease. Biohaven has built its foundation around our patient mission and we plan to continue to work with regulatory agencies to try to advance troriluzole for individuals suffering from SCA3."
Second Quarter 2023 and Recent Business Highlights
- Announced positive interim data from EEG biomarker study with BHV-7000 - In July 2023, the Company provided a preliminary data update from the ongoing electroencephalogram (EEG) biomarker study for the Kv7 Channel Activator platform. Preliminary Phase 1 data confirmed evidence of target engagement in the central nervous system for subjects with projected therapeutic concentrations of BHV-7000 (based on the EC50 from preclinical models), measured by changes from baseline in EEG spectral power that occurred after dosing. These pharmacodynamic (PD) effects were similar to those reported in the literature for anti-seizure medicines (ASMs), including Kv7 activators in development that are clinically effective in treating epilepsy. BHV-7000's PD effects were also differentiated from those reported for other Kv7 activators including, specifically, the absence of increases in EEG spectral power in frequency bands associated with drowsiness and somnolence. Results from the low-dose group validate the preclinical hypothesis, confirm the Phase 1 SAD/MAD clinical data, and provide strong support for Biohaven's plans to initiate pivotal studies with BHV-7000 in focal epilepsy and bipolar disorder in the second half of 2023. The preliminary data highlight BHV-7000's differentiation and potentially favorable clinical profile compared to other ASMs, and the Company expects to present the complete EEG results by the end of the year. Additionally, new pharmacokinetic data from multiple clinical formulations being studied has now confirmed a once daily extended-release oral formulation that will be used in the Phase 2/3 clinical programs.
- Successfully dosed three cohorts with single ascending doses of oral, brain penetrant, dual TYK2/JAK1 agent, BHV-8000 - In July 2023, the Company announced that it successfully dosed three cohorts in the SAD portion of an ongoing SAD/MAD Phase 1 study evaluating brain penetrant TYK2/JAK1 agent, BHV-8000 in healthy volunteers. The ongoing Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and PD of single and multiple ascending doses of BHV-8000 in healthy volunteers. Based on the preliminary data available, projected therapeutic concentrations of BHV-8000 were achieved, and BHV-8000 was well tolerated with only mild adverse events reported. These data provide support for further development of BHV-8000, and the Company anticipates beginning a Phase 2 clinical trial with BHV-8000 in Parkinson's disease and potentially other neuroinflammatory diseases in 2024. The Company had previously reported initiation of dosing with BHV-8000 in the Phase 1 study at Biohaven's R&D Day in May 2023.
- Reported on continued progress observed with Biohaven's first-in-class bispecific IgG degrader, BHV-1300, as compound advances to IND filing in 2H2023 - In July 2023, the Company shared an update on BHV-1300's highly competitive safety, manufacturable and PD profile. The Company is assembling a pipeline of partially de-risked, follow-on IgG degraders as well as antigen-specific degraders providing both optionality and a sustainable output of drug candidates for several years. An IND application for BHV-1300 is on track for submission in 2023 and an IND application for Biohaven's IgA degrader on track for submission in 2024
- Type A meeting planned to comprehensively address FDA's concerns in connection with Troriluzole program in SCA3 - In July 2023, the Company announced that the FDA informed Biohaven it would not review the recently submitted New Drug Application (NDA) for troriluzole for the treatment of spinocerebellar ataxia type 3 (SCA3), an ultra-rare, genetically-defined, neurodegenerative disease associated with progressive disability, frequent falls, loss of ambulation, speech and swallowing impairment, and premature death that is the most common SCA genotype worldwide. The FDA informed Biohaven it would not review the application given that the study's primary endpoint was not met and thus, would not permit a substantive review. Biohaven is committed to working closely with the FDA to bring troriluzole to people with SCA3 as quickly as possible given no therapy is currently approved for this ultra-rare genetic disorder. Biohaven plans to request a Type A meeting to comprehensively address FDA's concerns cited in the refusal to file letter.
- EMA orphan drug designation granted for taldefgrobep alfa for the treatment of SMA: - In July 2023, the Company announced that taldefgrobep alfa received orphan drug designation (ODD) from the European Commission for taldefgrobep for the treatment of SMA. Taldefgrobep previously received Fast-Track and ODD from the FDA. At Biohaven's R&D Day, the Company announced plans to complete randomization of approximately 180 patients in global SMA trial.
Upcoming Milestones:
Biohaven is progressing its product candidates through clinical programs in a number of common and rare disorders. The Company plans to reach significant pipeline milestones in the coming periods. Biohaven expects to:
- Announce Phase 1 EEG study results by year-end 2023: The Company expects to present complete results from its ongoing EEG study with BHV-7000 in healthy volunteers by the end of the year.
- Initiate Phase 2/3 studies with BHV-7000 in the second half of 2023: Biohaven expects to initiate pivotal trials in patients with focal epilepsy and bipolar disorder in the second half of 2023.
- Submit IND with BHV-1300, the Company's lead extracellular degrader: The Company expects to submit an IND with pan-IgG degrader BHV-1300 in the second half of 2023 and expects to initiate Phase 2 studies in 2024.
- Submit IND with selective Gd-IgA1 degrader: The Company expects to submit an IND with a Gd-IgA1 degrader indicated for IgA nephropathy in the first half of 2024.
- Initiate Phase 2 study with BHV-8000: The Company commenced Phase 1 studies with BHV-8000, an oral, brain-penetrant, dual TYK2/JAK1 inhibitor for neuroinflammatory disorders, in the first half of 2023 and expects to initiate a Phase 2 study in Parkinson's disease in 2024.
- Submit IND with BHV-2100 in chronic pain: The Company expects to submit an IND with BHV-2100, a selective TRPM3 antagonist in the Company's ion channel platform, in the second half of 2023.
- Complete enrollment in Phase 3 study of troriluzole in OCD in 2023: Two Phase 3 randomized, double-blind, placebo-controlled studies of troriluzole in OCD are expected to enroll up to 700 patients (in each trial) across nearly 200 global study sites. The Company anticipates completing enrollment in at least one Phase 3 trial by year-end 2023.
- Complete enrollment in Phase 3 clinical study of taldefgrobep alfa in SMA: The Company expects to complete enrollment in the study of taldefgrobep in SMA in the second half of 2023.
- Continue advancements across multiple neuroscience and immunoscience indications: The Company's preclinical pipeline includes a platform of bispecific degraders of extracellular proteins directed against IgG, IgA and other targets, TRPM3 and Kv7 family of ion channels, and other undisclosed targets, including those with disease-modifying potential.
Capital Position:
Cash, cash equivalents and marketable securities as of June 30, 2023 was $349.0 million, including $13.9 million of restricted cash, and excluding $40.4 million of cash payable to Biohaven Pharmaceutical Holding Company Ltd. (the Former Parent), compared to $467.9 million, including $2.5 million of restricted cash, and excluding $35.2 million of cash payable to the Former Parent, as of December 31, 20221.
Second Quarter 2023 Financial Highlights:
Research and Development (R&D) Expenses: R&D expenses, including non-cash share-based compensation costs, were $79.5 million for the three months ended June 30, 2023, compared to $177.1 million for the three months ended June 30, 2022. Non-cash share-based compensation expense was $2.5 million for the three months ended June 30, 2023, a decrease of $10.3 million as compared to the same period in 2022. Non-cash share-based compensation expense was higher in the second quarter of 2022 primarily because expense allocated from the Former Parent equity plan, prior to the spin-off, was based on equity awards with higher grant date fair values.
General and Administrative (G&A) Expenses: General and administrative expenses were $14.5 million for the three months ended June 30, 2023, compared to $20.0 million for the three months ended June 30, 2022. The decrease of $5.5 million was primarily due to decreased non-cash share-based compensation costs. Non-cash share-based compensation expense was $2.2 million for the three months ended June 30, 2023, a decrease of $5.8 million as compared to the same period in 2022. Non-cash share-based compensation expense was higher in the second quarter of 2022 primarily because expense allocated from the Former Parent equity plan, prior to the spin-off, was based on equity awards with higher grant date fair values.
Other Income (Expense), Net: Other income (expense), net was a net income of $5.8 million for the three months ended June 30, 2023, compared to net expense of $0.1 million for the three months ended June 30, 2022. The increase of $5.9 million was primarily due to an increase in net investment income and an increase of $1.7 million in other income related to our transition services provided to the Former Parent, which is largely non-recurring.
Net Loss: Biohaven reported a net loss for the three months ended June 30, 2023, of $90.3 million, or $1.32 per share, compared to $203.3 million, or $5.16 per share, for the same period in 2022. Non-GAAP adjusted net loss for the three months ended June 30, 2023 was $85.7 million, or $1.25 per share, compared to $182.5 million, or $4.63 per share for the same period in 2022. These non-GAAP adjusted net loss and non-GAAP adjusted net loss per share measures, more fully described below under "Non-GAAP Financial Measures," exclude non-cash share-based compensation charges. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below. For periods prior to Biohaven's spin-off from the Former Parent on October 3, 2022 (the "Spin-Off"), net loss per share and non-GAAP adjusted net loss per share were calculated based on the 39,375,944 common shares of Biohaven distributed to the Former Parent shareholders at the time of the distribution, including common shares issued in connection with the Former Parent share options that were settled on October 3, 2022 and common shares issued in connection with the Former Parent restricted share units that vested on October 3, 2022. The same number of shares is being utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off.
Non-GAAP Financial Measures
This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States (GAAP), and also certain non-GAAP financial measures. In particular, Biohaven has provided non-GAAP adjusted net loss and adjusted net loss per share, which are adjusted to exclude non-cash share-based compensation, which is substantially dependent on changes in the market price of common shares. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. However, Biohaven believes the presentation of non-GAAP adjusted net loss and adjusted net loss per share, when viewed in conjunction with GAAP results, provides investors with a more meaningful understanding of ongoing operating performance and can assist investors in comparing Biohaven's performance between periods.
In addition, these non-GAAP financial measures are among those indicators Biohaven uses as a basis for evaluating performance, and planning and forecasting future periods. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between these non-GAAP measures and the most directly comparable GAAP measures is provided later in this news release.
About Biohaven
Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases. Biohaven's experienced management team brings with it a track record of delivering new drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia. The company is advancing a pipeline of therapies for diseases, many of which have limited or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia, myostatin inhibition for neuromuscular diseases and metabolic disorders, and brain-penetrant TYK2/JAK1 inhibition for neuroinflammatory disorders. Biohaven's portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and targeted extracellular protein degradation platform technology (MoDE™) with potential application in neurological disorders, cancer, and autoimmune diseases.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates; the potential for Biohaven's product candidates to be first in class therapies; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this new release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
MoDEs is a trademark of Biohaven Therapeutics Ltd.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
+1 (312) 961-2502
View original content to download multimedia:
SOURCE Biohaven Ltd. | https://www.kwch.com/prnewswire/2023/07/31/biohaven-reports-second-quarter-2023-financial-results-recent-business-developments/ | 2023-07-31T12:34:27 | 1 | https://www.kwch.com/prnewswire/2023/07/31/biohaven-reports-second-quarter-2023-financial-results-recent-business-developments/ |
NORTH BRUNSWICK, N.J., July 31, 2023 /PRNewswire/ -- Smirta, a New Jersey-based digital health company committed to improving cancer patient care, is pleased to announce that OneOncology has selected Smirta as a preferred vendor to provide Smirta's OncoSmart® oncology infusion schedule optimization platform to the OneOncology network of physician practices. OneOncology is a national partnership created by independent community oncologists to strengthen oncology practices by helping them grow and deliver high-value cancer care services. The network includes more than 300 sites of care, empowering oncologists to learn from their peers and leverage their collective experience to address the pressures facing community oncology today and innovate for the future of cancer care delivery.
OncoSmart® is a data-driven digital transformation platform developed by Smirta, in close collaboration with Tennessee Oncology, that optimizes resources, increases capacity, and simplifies the complexities of cancer treatment clinic operations. OncoSmart®'s clinic management, optimization, nurse assignment, business intelligence, and resource management modules empower infusion centers to better manage critical clinical resources and deliver the best in cancer care.
"Understandably, every patient wants to be the first to get their infusion and every doctor wants to start their day early," said Jeff Patton, MD, CEO, OneOncology. "Consequently, we found our clinics contending with a tremendous, daily bottleneck through the afternoon. Smirta's OncoSmart® platform has been invaluable in establishing a superior scheduling process to smooth out the day and boost patient care by flattening the utilization curve so that the ratio of clinical staff to patients remains consistent and ramps more evenly throughout the day. We are thrilled to partner with Smirta and sponsor their technology, which will exponentially improve the standard of care and the scheduling metrics of cancer treatment clinics nationwide."
Stephen Schleicher M.D., Chief Medical Officer, Tennessee Oncology, a OneOncology partner practice, added: "The Smirta team are amazing to work with. They tailor their software to precisely what we need for our clinics and staff and have been incredibly responsive during the onboarding process. The software itself is very intuitive. Outside of the clinic level where it helps with treatment room capacity and nurse assignments, it also offers a system-wide look across the company, allowing us to see how all of our clinics are doing in terms of overtime, staffing, volume, and so on. Through Smirta and OncoSmart®, we really get to understand which clinics need help through a birds-eye view of how the company's doing from a patient experience and staff experience standpoint."
The A.I.-generated solutions provided by the OncoSmart® platform were created to support a diverse group of clinics with varying sizes and volume, as well as to optimize all service types including lab, MA, MD, treatment, and injections. OncoSmart® products have:
- reduced patient appointment delays and wait times
- unlocked infusion chair capacity
- reduced infusion treatments that extend beyond operating hours
- reduced overtime costs
- created a radically more balanced nurse load through schedule optimization
"Cancer care is inherently complex, with a confluence of problems manifesting most pronouncedly during peak times," said Ram Iyengar, Smirta, CEO. "Through our OncoSmart® platform, we can address and neutralize preventable bottlenecks, nursing attrition, and increased operational expenses while significantly improving patient satisfaction and quality of care. We are proud to partner with OneOncology in our combined mission to ensure the best possible treatment for cancer patients through enabling the most supportive, productive setting for all clinic staff."
Smitra has also already worked with another OneOncology partner practice, Piedmont Cancer Institute. The Atlanta-based cancer center's Chief Clinical Officer, Stephanie Braatz said: "The Smirta team has been so responsive and are very easy to work with. Their OncoSmart platform offers tools that streamline our infusion center operations, and their optimization tool has helped us effectively utilize our resources by balancing the patient load across different types of service.
"The business intelligence tool has identified bottlenecks, such as provider schedules, and has helped us find solutions to fix them. The nurse assignments tool has tremendously, and positively, affected the reduction of manual effort while showing us a view of the treatment room that we simply weren't able to see before. The entire team and suite of tools have added value," said Braatz.
About OneOncology
OneOncology was founded by community oncologists, for community oncologists, with the mission of improving the lives of everyone living with cancer. Its goal is to enable community oncology practices to remain independent and to improve patient access to care in their communities, all at a lower cost than in the hospital setting. OneOncology supports its platform of community oncology practices through group purchasing, operational optimization, practice growth, and clinical innovation. The network's 960 cancer care providers care for approximately 528,000 patients at more than 300 sites of care nationwide. To learn more, visit oneoncology.com or LinkedIn.
About Tennessee Oncology
Tennessee Oncology, PLLC is one of the nation's leading teams of cancer care specialists, nationally recognized for improving patient outcomes and driving quality of life innovation. In 2018 it created a partnership with OneOncology, a technology-powered, data-driven, alliance of America's foremost community oncologists. Its comprehensive range of cancer care services includes specialized oncology nursing care, laboratory services, pharmacy, outpatient chemotherapy, PET/CT services, palliative care, patient and family education, and financial support services. Founded in 1976, the practice's unique vision, introducing patient-driven care with a clinical trial focus, propelled Tennessee Oncology to lead one of the largest, physician-owned, community oncology practices in the country. Currently over 95 physicians in more than 30 locations share the privilege of serving adult cancer patients from South Central Kentucky through Middle Tennessee to Northwest Georgia. For a complete list of Physicians, locations, and services please visit: www.tnoncology.com
About Smirta
Smirta is a digital health company providing next-generation technology solutions to the healthcare industry. Its OncoSmart® suite of products are at the core of cancer treatment clinical operations optimizing millions of services annually.
View original content to download multimedia:
SOURCE Smirta; OneOncology | https://www.kait8.com/prnewswire/2023/07/31/oneoncology-selects-smirta-its-innovative-oncosmart-platform-enhance-operational-efficiencies/ | 2023-07-31T12:34:29 | 1 | https://www.kait8.com/prnewswire/2023/07/31/oneoncology-selects-smirta-its-innovative-oncosmart-platform-enhance-operational-efficiencies/ |
SHENZHEN, China, July 31, 2023 /PRNewswire/ -- Taoping Inc. (Nasdaq: TAOP, the "Company" or "Taoping"), today announced that the board of directors of the Company approved a one-for-ten reverse stock split of the Company's issued and outstanding ordinary shares, no par value (the "Ordinary Shares"). Beginning August 1, 2023, the Company's Ordinary Shares will be trading on a split-adjusted basis under the same symbol "TAOP" but with new CUSIP number, G8675V 127.
As a result of the share consolidation, each ten Ordinary Shares outstanding will automatically combine and convert to one issued and outstanding Ordinary Share without any action on the part of shareholders who hold their shares in brokerage accounts or "street name". Shareholders holding certificates of Ordinary Shares are expected to receive instructions from the Company's transfer agent, Transhare Corporation, regarding procedures for exchanging share certificates. All outstanding options, warrants and other rights to purchase the Company's Ordinary Shares will be adjusted proportionately as a result of the reverse stock split. No fractional shares will be issued as a result of the reverse stock split, and instead, all such fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share.
The reverse stock split is intended to increase the per share trading price of the Ordinary Shares to satisfy the $1.00 minimum bid price requirement for continued listing on the NASDAQ Stock Market. Following the reverse stock split the Company will have approximately 1.86 million Ordinary Shares issued and outstanding, exclusive of shares issuable under outstanding options and warrants. The reverse stock split will not affect the number of total authorized Ordinary Shares of the Company.
About Taoping Inc.
Taoping Inc. (Nasdaq: TAOP) has a long history of successfully leveraging technology in the development of innovative solutions to help customers in both the private and public sectors to more effectively communicate and market to their desired targets. The Company has built a far-reaching city partner ecosystem and comprehensive portfolio of high-value, high-traffic areas for its products, which are aligned together with Taoping's smart cloud platform, cloud services and solutions, new media and artificial intelligence. For more information about Taoping, please visit www.taop.com. You can also follow us via LinkedIn, Twitter or YouTube.
Safe Harbor Statement
This press release contains "forward-looking statements" that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, such as statements regarding our estimated future results of operations and financial position, our strategy and plans, and our objectives or goals, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. We have attempted to identify forward-looking statements by terminology including "anticipates," "believes," "can," "continue," "could," "estimates," "expects," "intends," "may," "plans," "potential," "predicts," "should," or "will" or the negative of these terms or other comparable terminology. Our actual results may differ materially or perhaps significantly from those discussed herein, or implied by, these forward-looking statements. There are a significant number of factors that could cause actual results to differ materially from statements made in this press release, including: our potential inability to achieve or sustain profitability or reasonably predict our future results due to our limited operating history of providing smart cloud services, the effects of the global Covid-19 pandemic, the emergence of additional competing technologies, changes in domestic and foreign laws, regulations and taxes, uncertainties related to China's legal system and economic, political and social events in China, the volatility of the securities markets; and other risks including, but not limited to, those that we discussed or referred to in the Company's disclosure documents filed with the U.S. Securities and Exchange Commission (the "SEC") available on the SEC's website at www.sec.gov, including the Company's most recent Annual Report on Form 20-F as well as in our other reports filed or furnished from time to time with the SEC. The forward-looking statements included in this press release are made as of the date of this press release and the Company undertakes no obligation to publicly update or revise any forward-looking statements, other than as required by applicable law.
View original content to download multimedia:
SOURCE Taoping Inc. | https://www.wbay.com/prnewswire/2023/07/31/taoping-announces-1-for-10-reverse-stock-split/ | 2023-07-31T12:34:30 | 0 | https://www.wbay.com/prnewswire/2023/07/31/taoping-announces-1-for-10-reverse-stock-split/ |
SAN FRANCISCO, July 31, 2023 /PRNewswire/ -- Today, Blitz Insurance, a specialty insurance carrier, partners with Ascend to modernize payment experiences for insurance brokers selling in specialty markets. With this partnership, Blitz Insurance will open new customer segments by offering both direct bill and premium financing into their payments workflow.
"When we looked into the market for a solution, Ascend was the right choice. Ascend meets our needs for a better payments experience for our partners while reducing everyone's operational expenses," said Brandon Murphy, Chief Distribution Officer of Blitz Insurance. "We will now have the ability to not only expand to direct bill and a premium finance option but also simplify the movement of money between us and our partners."
With Ascend, Blitz Insurance is now able to provide a direct bill in addition to their existing agency bill workflow - allowing brokers to decide what billing method works best for them. By utilizing Ascend, Blitz Insurance not only grows their footprint of appointed brokers but also gains administrative efficiency by automating what would otherwise have been a large operational undertaking.
Ascend automatically attributes incoming payments to policies in real time, speeding up the reconciliation process. By modernizing the payments experience and speeding up the reconciliation of incoming premiums, Blitz Insurance can offer a best-in-class experience to its brokers and agents.
"We find that across the insurance ecosystem - companies want to provide a seamless payment workflow for their customers and their teams," said Andrew Wynn, co-CEO of Ascend. "Ascend is built so brokers and carriers can offer this experience without shouldering the administrative resources and costs needed to support these operations."
About Ascend
Ascend is the first insurance payments platform that automates financial operations from collections and financing to carrier and commission payables. Founded by two-time insurtech entrepreneurs Andrew Wynn and Praveen Chekuri, Ascend helps insurance brokers, MGAs, and carriers improve their bottom lines by eliminating expensive and labor-intensive payment workflows. To learn more, please visit LinkedIn, Twitter or check out https://www.useascend.com/.
About Blitz Insurance
Blitz is a tech-driven insurer revolutionizing the $60B specialty market catering to SME segment. By leveraging industry knowledge and cutting-edge technology, we deliver a simpler, smarter, and faster coverage experience.
The company is led by a veteran team of insurance and technology experts and has been funded with $25M from its founder & CEO, a Forbes-listed serial entrepreneur in the real estate and insurance industries.
Contact:
Mike Nguyen
press@useascend.com
View original content to download multimedia:
SOURCE Ascend | https://www.kwch.com/prnewswire/2023/07/31/blitz-insurance-partners-with-ascend-expand-payment-financing-offerings/ | 2023-07-31T12:34:34 | 0 | https://www.kwch.com/prnewswire/2023/07/31/blitz-insurance-partners-with-ascend-expand-payment-financing-offerings/ |
SHENZHEN, China, July 31, 2023 /PRNewswire/ -- AMIRO ("the Company"), a leading beauty and skincare technology brand, is thrilled to announce that its research facility, AMIRO LAB, has successfully obtained the Qualified Testing Location (QTL) certification after a comprehensive audit conducted by SGS.
SGS, a globally recognized testing, inspection and certification organization with thousands of branches and laboratories worldwide, introduced the QTL certification for laboratory witness testing. As an SGS-accredited testing location, AMIRO LAB will undergo witness testing by SGS during the certification process, ensuring the accuracy and reliability of the test data. This reduces the time required for companies to transport samples to SGS-designated laboratories for testing, thus effectively shortening the product testing cycle.
"As we receive the QTL certification for AMIRO LAB, it signifies a resounding acknowledgment of our research center's testing capabilities and management efficiency," Jason Chen, Quality Management Director, said. "This milestone propels us into a new phase of strategic cooperation with SGS. Looking ahead, we will forge closer ties in product testing, inspection, certification, and industry standard-setting to drive the high-quality and sustainable development of the skincare technology industry."
Widely recognized as a technology-driven and innovation-focused skincare enterprise, AMIRO has always prioritized research and development. From its inception, AMIRO has established its AMIRO LAB to focus on innovative applications of photonic and medical technologies in the beauty and skincare field. The center boasts a wide array of state-of-the-art equipment, facilitating effective quantitative evaluations.
In a bid to enhance its research and development capabilities, AMIRO has also actively engaged in collaborations between industry, academia, and research institutions, partnering with renowned universities to set up joint R&D centers. These collaborations have enabled AMIRO to advance fundamental research and create products that precisely cater to users' skincare needs.
One exemplary collaboration involves the establishment of the Smart Photonic Medical Technology Joint Research Center with Shanghai Jiao Tong University's School of Biomedical Engineering. This center explores the application and commercialization of photonic therapy in relevant fields. Additionally, the Company has also collaborated with Zhejiang University's School of Pharmacy that led the research on transdermal permeation technology combined with photonic energy. AMIRO has also worked with Sichuan University on a precise skin measurement and evaluation development platform, and with Chongqing University on skin photonic science to study anti-aging skincare solutions for consumers.
AMIRO's prominent position in the industry is further cemented by its active participation in establishing industry standards. The Company has taken an active role in standard-setting initiatives by leveraging its profound R&D capabilities. AMIRO has led the formulation of several industry group standards, including "Guidelines for Face Masks Used in Conjunction with RF Beauty Devices" and "Guidelines for Skincare Products Used in Conjunction with RF and Microcurrent Home Beauty Devices." Moreover, AMIRO has participated in the development of the national standard "Special Requirements for the Safety of Electrical Skin Beauty Devices" to help with the standardization of the industry.
The latest SGS' awarding of the QTL certification to AMIRO is a testament to the brand's advanced laboratory equipment and robust quality management system. This certification represents not only the assurance of product quality but signifies The Company's commitment to enhancing product certification efficiency and accelerating its product launch process to benefit more consumers.
Looking ahead, AMIRO remains committed to optimizing its quality management system as well as its product inspection and testing processes. The Company will continue to translate scientific research achievements into practical applications, delivering simple, safe, and effective products. AMIRO's ultimate goal is to offer precise and tailored skincare solutions for every individual, allowing consumers to experience the beauty of life to the fullest.
For more information about AMIRO and its range of facial devices, please visit their official website.
Or connect with them on social media:
Instagram: https://www.instagram.com/amiroglobal/
Facebook: https://www.facebook.com/AMIRO-Global-103502195623795/
YouTube: https://www.youtube.com/@amiroglobal/featured
About AMIRO
AMIRO, a beauty and skincare technology brand founded in 2015, has been delivering joy and harmony through its technologically advanced home beauty and personal care electronic products. With over 38 international design awards, AMIRO is your trusted skincare partner that offers portable, short-acting, and long-lasting solutions to improve skincare efficiency.
Upholding the idea of "Revitalize beauty through science", AMIRO's products are designed to be affordable, high-quality, and supported by clinical data. With a commitment to sustainability and innovation, AMIRO is dedicated to providing skincare solutions that make women of all ages feel confident and beautiful.
View original content to download multimedia:
SOURCE AMIRO | https://www.kait8.com/prnewswire/2023/07/31/skincare-tech-brand-amiro-receives-qtl-certification-sgs-strengthen-rampd-efforts/ | 2023-07-31T12:34:35 | 1 | https://www.kait8.com/prnewswire/2023/07/31/skincare-tech-brand-amiro-receives-qtl-certification-sgs-strengthen-rampd-efforts/ |
New dispensary delivers on brand promise of product quality and variety with convenient locations
TALLAHASSEE, Fla., July 31, 2023 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, announced the relocation of a medical dispensary in Kissimmee, Fla. located at 2647 E. Irlo Bronson Memorial Hwy. The dispensary will be open 9AM – 8:30PM Monday through Saturday and 11AM – 8PM on Sunday.
"Trulieve is committed to offering our Florida patients a broad selection of convenient locations and top-quality products to choose from, while also providing for best-in-class customer service," said Trulieve's Chief Executive Officer Kim Rivers. "This new location delivers on that commitment and we will continue to seek new opportunities to better serve this community."
Trulieve invites the Kissimmee community to join in celebrating this new dispensary on Friday, August 4 with partner giveaways, music, food trucks, specials discounts and more, starting at 9 AM. Trulieve also offers statewide home delivery, convenient online ordering and in-store pickup. As always, all first-time guests are eligible for a 60% new customer discount at any Florida-based location.
Designed to meet every patient's needs, our portfolio of in-house brands includes Alchemy, Co2lors, Cultivar Collection, Modern Flower, Momenta, Muse, Roll One, Sweet Talk and Trekkers. Customers also have access to beloved brands such as Alien Labs, Bhang, Binske, Black Tuna, Blue River, Connected Cannabis, DeLisioso, Khalifa Kush, Love's Oven, Miami Mango, Old Hippie Stash, O.Pen, Seed Junky and Sunshine Cannabis, all available exclusively at Trulieve in Florida.
For more information, or to learn how to become a registered patient, please visit Trulieve.com and connect on Facebook, Instagram or Twitter.
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established hubs in the Northeast, Southeast, and Southwest, anchored by leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.
Facebook: @Trulieve
Instagram: @Trulieve_
Twitter: @Trulieve
Investor Contact
Christine Hersey, Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Teresa Coulter, VancoreJones Communications
+1 (407) 808-6139
TCoulter@vancorejones.com
View original content to download multimedia:
SOURCE Trulieve Cannabis Corp. | https://www.kait8.com/prnewswire/2023/07/31/trulieve-opening-relocated-medical-marijuana-dispensary-kissimmee-florida/ | 2023-07-31T12:34:35 | 0 | https://www.kait8.com/prnewswire/2023/07/31/trulieve-opening-relocated-medical-marijuana-dispensary-kissimmee-florida/ |
CLEVELAND, July 31, 2023 /PRNewswire/ -- TransDigm Group Incorporated (NYSE: TDG) today said it will report fiscal 2023 third quarter earnings before the market opens on Tuesday, August 8, 2023.
A conference call will follow at 11:00 a.m., Eastern Time. To join the call telephonically, please register for the call here. Once registered, participants will receive the dial-in information and a unique pin to access the call. A live audio webcast of the call can also be accessed online at http://www.transdigm.com.
The webcast will be archived on the website and available for replay later that day.
About TransDigm Group
TransDigm Group, through its wholly-owned subsidiaries, is a leading global designer, producer and supplier of highly engineered aircraft components for use on nearly all commercial and military aircraft in service today. Major product offerings, substantially all of which are ultimately provided to end-users in the aerospace industry, include mechanical/electro-mechanical actuators and controls, ignition systems and engine technology, specialized pumps and valves, power conditioning devices, specialized AC/DC electric motors and generators, batteries and chargers, engineered latching and locking devices, engineered rods, engineered connectors and elastomer sealing solutions, databus and power controls, cockpit security components and systems, specialized and advanced cockpit displays, engineered audio, radio and antenna systems, specialized lavatory components, seat belts and safety restraints, engineered and customized interior surfaces and related components, advanced sensor products, switches and relay panels, thermal protection and insulation, lighting and control technology, parachutes, high performance hoists, winches and lifting devices, cargo loading, handling and delivery systems and specialized flight, wind tunnel and jet engine testing services and equipment.
View original content to download multimedia:
SOURCE TransDigm Group Inc. | https://www.wbay.com/prnewswire/2023/07/31/transdigm-third-quarter-earnings-report-conference-call-set-tuesday-august-8-2023/ | 2023-07-31T12:34:37 | 0 | https://www.wbay.com/prnewswire/2023/07/31/transdigm-third-quarter-earnings-report-conference-call-set-tuesday-august-8-2023/ |
BEIJING, July 31, 2023 /PRNewswire/ -- 36Kr Holdings Inc. ("36Kr" or the "Company") (NASDAQ: KRKR), a prominent brand and a pioneering platform dedicated to serving New Economy participants in China, today announced the launch of its 36Kr Media Lab in Silicon Valley, an initiative to embrace the large language models (LLM) revolution taking place in the content creation industry and optimize the application of artificial intelligence (AI) for the new economy sector.
36Kr Silicon Valley Media Lab's first project leveraging LLM, "Empty Office," will experimentally explore scenarios where AI can think and work as humans, enhancing content production efficiency and reducing costs. Through "Empty Office," 36Kr is also building innovative media solutions that will transform traditional video, graphic and text communications into avant-garde dialogues between customized AI characters and audiences. These network-based dialogues will be naturally and seamlessly driven by real-time data generation, and available anytime, anywhere.
At the same time, 36Kr Silicon Valley Media Lab continues to focus on tailoring its LLM to the new economy sector. By utilizing dedicated financial and business datasets, including enterprises' financial results, news, market dynamics and knowledge repositories, among other resources, to train its LLM to thoroughly understand and analyze business information, 36Kr has developed a model that keenly grasps the business nuances to generate accurate analysis and interpretation. 36Kr Silicon Valley Media Lab constantly maintains its database, serving as the reference foundation to ensure that its fact-based model produces rigorous and up-to-date business and financial analysis.
Furthermore, 36Kr's professionally-training, fine-tuning capability enables its LLM-empowered "Empty Office" to quickly and efficiently create informative content for the new economy sector. For instance, in the case of a business event, such as a new product launch, an AI agent can instantly extract relevant data from the database, automatically perform a comprehensive analysis, and issue reports within just seconds. This top-speed response gives 36Kr's business and financial-focused media platform an unrivaled edge.
Mr. Dagang Feng, Co-chairman and CEO of 36Kr, commented, "The launch of 36Kr Silicon Valley Media Lab is a testament to our AI technology acumen and vision as well as our commitment to extending media's boundaries. By integrating pioneering AI technology into content creation, 36Kr will constantly elevate the efficiency and quality of content production alongside the rapid advancement of the LLM, fostering a superior content ecosystem encompassing business, finance and technology, further turbocharging the evolution of the New Economy. As we adopt and develop more AI tools amid the technology's rapid advancement, we are strategically positioning the Company to break new ground and ultimately drive long-term growth for our business."
About 36Kr Holdings Inc.
36Kr Holdings Inc. is a prominent brand and a pioneering platform dedicated to serving New Economy participants in China with the mission of empowering New Economy participants to achieve more. The Company started its business with high-quality New Economy-focused content offerings, covering a variety of industries in China's New Economy with diverse distribution channels. Leveraging traffic brought by high-quality content, the Company has expanded its offerings to business services, including online advertising services, enterprise value-added services, and subscription services, to address the evolving needs of New Economy companies and upgrading needs of traditional companies. The Company is supported by a comprehensive database and strong data analytics capabilities. Through diverse service offerings and significant brand influence, the Company is well-positioned to continuously capture the high growth potential of China's New Economy.
For more information, please visit: http://ir.36kr.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's goal and strategies; the Company's future business development, results of operations and financial condition; relevant government policies and regulations relating to our business and industry; the Company's expectations regarding the use of proceeds from this offering; the Company's expectations regarding demand for, and market acceptance of, its services; the Company's ability to maintain and enhance its brand; the Company's ability to provide high-quality content in a timely manner to attract and retain users; the Company's ability to retain and hire quality in-house writers and editors; the Company's ability to maintain cooperation with third-party professional content providers; the Company's ability to maintain relationships with third-party platforms; general economic and business conditions in China; possible disruptions in commercial activities caused by natural or human-induced disasters; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
For investor and media inquiries, please contact:
In China:
36Kr Holdings Inc.
Investor Relations
Tel: +86 (10) 8965-0708
E-mail: ir@36kr.com
The Piacente Group, Inc.
Jenny Cai
Tel: +86 (10) 6508-0677
E-mail: 36Kr@tpg-ir.com
In the United States:
The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
E-mail: 36Kr@tpg-ir.com
View original content:
SOURCE 36Kr Holdings Inc. | https://www.wafb.com/prnewswire/2023/07/31/36kr-launches-silicon-valley-media-lab-empower-content-ecosystem-with-llm-based-ai-technology/ | 2023-07-31T12:34:37 | 0 | https://www.wafb.com/prnewswire/2023/07/31/36kr-launches-silicon-valley-media-lab-empower-content-ecosystem-with-llm-based-ai-technology/ |
SAN JOSE, Calif., July 31, 2023 /PRNewswire/ -- Broadcom Inc. (NASDAQ: AVGO), a Delaware corporation headquartered in San Jose, CA, and a global technology leader that designs, develops and supplies semiconductor and infrastructure software solutions, today announced it will report its third quarter fiscal year 2023 financial results and business outlook on Thursday, August 31, 2023 after the close of the market. Broadcom's management will host a conference call at 2:00 p.m. Pacific Time on the same day to discuss these results and business outlook.
Date: Thursday, August 31, 2023
Time: 2:00 PM (PT); 5:00 PM (ET)
To Listen via Telephone: Preregistration is required by the conference call operator. Please preregister at https://register.vevent.com/register/BIab1222c9ed364122895c0b8a81ef898b. Upon registering, you will be emailed a link to the dial-in number and unique PIN.
To Listen via Internet: The conference call can be accessed live online in the Investors section of the Broadcom website at https://investors.broadcom.com.
Replay: An audio replay of the conference call can be accessed for one year through the Investors section of Broadcom's website at https://investors.broadcom.com.
About Broadcom Inc.
Broadcom Inc. (NASDAQ: AVGO), a Delaware corporation headquartered in San Jose, CA, is a global technology leader that designs, develops and supplies a broad range of semiconductor and infrastructure software solutions. Broadcom's category-leading product portfolio serves critical markets including data center, networking, enterprise software, broadband, wireless, storage and industrial. Our solutions include data center networking and storage, enterprise, mainframe and cyber security software focused on automation, monitoring and security, smartphone components, telecoms and factory automation. For more information, go to https://investors.broadcom.com.
Contact:
Broadcom Inc.
Ji Yoo
Investor Relations
408-433-8000
investor.relations@broadcom.com
(AVGO-Q)
View original content:
SOURCE Broadcom Inc. | https://www.kwch.com/prnewswire/2023/07/31/broadcom-inc-announce-third-quarter-fiscal-year-2023-financial-results-thursday-august-31-2023/ | 2023-07-31T12:34:40 | 1 | https://www.kwch.com/prnewswire/2023/07/31/broadcom-inc-announce-third-quarter-fiscal-year-2023-financial-results-thursday-august-31-2023/ |
GUANGZHOU, China, July 31, 2023 /PRNewswire/ -- Against the backdrop of sustainable development around the globe, excellent ESG (environmental, social and governance) performance is a new measure for the quality and sustainable prospect of an enterprise. In the future, driven by the "dual carbon" strategic goal, ESG indicators will be new focus for domestic consumer goods companies.
Recently, the fast-growing beauty group YSG released its Environmental, Social and Governance Report of 2022 (hereinafter referred to as the ESG Report). This is the second consecutive year for the Company to release the ESG Report, which thoroughly demonstrates the actions and achievements of YSG in practicing the ESG framework in multiple dimensions in the past year.
YSG's good ESG performance has won the recognition of an authoritative third party institute— in December 2022, the world's largest index company, Morgan Stanley Capital International, MSCI, upgraded the rating of YSG to A, which is an internationally recognized leading level. The rating report shows that YSG is an industry leader in the management of packaging materials and wastes, and is committed to reducing the impact of packaging materials through green packaging, lightweight packaging and recycling, etc.
Expanding "Carbon Footprint" Assessment Category, Embarking on Sustainable Path of Beauty Products
Under the guidance of "dual carbon" national strategy, the beauty industry is actively participating in sustainable development and green growth. Domestic beauty enterprises rise to implement the ESG goals. With the long-term vision of "health and beauty explorer in the era of new technology", YSG has been adhering to low-carbon development, and has always been practicing its commitment to environmental friendliness.
Following Perfect Diary's core product "Rouge Intense Velet Slim Lipstick" launched in 2021, YSG has continued to expand the scope of categories covered by carbon footprint verification. The ESG report shows that in 2022, the Company conducted carbon footprint assessment on Perfect Diary's ace products, "Weightless Velvet Lip Stain" and "Translucent Blurring Loose Powder (Anti-dullness Version)". Through this process, YSG can ascertain the carbon emissions of products in the whole life cycle, identify the potential for emission reduction at each stage, and continue to upgrade its products in the future to reduce the impact on the environment.
In addition, YSG also focuses on issues such as suppliers' carbon emissions and energy management in order to realize low-carbon and sustainable development of the entire supply chain. The Company encourages suppliers to take the initiative to meet the challenge of carbon emission reduction and to seize the opportunity to set feasible and challenging carbon emission reduction goals, so as to work together with YSG to continuously reduce the total amount of carbon emissions of the supply chain. By the end of 2022, all seven core suppliers of YSG have implemented carbon emission management.
At the same time, the consumption of packaging materials, possible pollutions and other issues have drawn more concern; plastic reduction, lightweight packaging, recycling has become the direction advocated by the government and expected by consumers. In 2022, Yatsen's brands, including Perfect Diary, Pink Bear, and Little Ondine, adjusted the weight and size of their product cartons, switched from offset-printed cardboard boxes to watermarked ones, and adopted eco-friendly kraft paper materials, reducing paper consumption by 25%;at the same time, plastic films have been removed for all paper boxes, further reducing the use of plastic packaging materials. Galénic's plastic packaging in China is 100% replaced by degradable bio-based paper plastics. EVE LOM's product packaging achieved 100% recyclability (obtaining The Green Dot logo).
Committed to Scientific Research and Innovation, Laying Solid Foundation for Brand R&D
In the past year, the cosmetic industry has been speeding into the era of detailed brand building with quality as the focus, and the attention paid to R&D by domestic beauty brands has risen significantly, as the beauty industry has entered a new stage of competing for "internal strength". According to the ESG report, YSG attaches great importance to product innovation and R&D, and has invested RMB 127 million in R&D in 2022, accounting for 3.4% of its total revenue. The R&D expense ratio continues to rank among the top in the world.
With the support of the Open Lab R&D system, YSG has formed cooperation with many renowned research institutions, universities and colleges and hospitals home and abroad, identifying, studying and transferring for commercial applications worldwide— all for quality beauty products. Multiple types of achievements of technology-supported cosmetics have been made. Perfect Diary cooperated with the Key Laboratory of Molecular Nanostructure and Nanotechnology of Chinese Academy of Sciences and developed the SmartLOCK, which is used in the Translucent Blurring Loose Powder for its high efficiency in keeping look fresh with antioxidant capacity.
What is more noteworthy is that YSG understands that R&D innovation is the way to long-term development of an enterprise, drives category innovation, which in turn brings R&D breakthrough. In 2022 June, YSG R&D Center officially obtained the Laboratory Accreditation Certificate issued by China National Accreditation Service for Conformity Assessment (CNAS), which marks that the Center's product testing capabilities, equipment and devices have reached national approved standards. In November of the same year, the Company established the Sun Yat-sen University-Yatsen Group (YSG) Skin Health Precise Research Joint Laboratory,which has now built two major platforms, namely, the Chinese Skin Aging Research Platform for Chinese and the Bio-Fermentation Research Platform of Sun Yat-sen University.
Shouldering Public Welfare, Setting Benchmark for Sustainable Development
As young listed beauty enterprise, YSG spares no effort on public welfare while promoting its own development, deepening its enterprise and brand value. The Company explores actively the new path of beauty, aiming to discover female beauty, guard natural beauty and pass on the beauty of goodwill. The on-going "Create a beautiful life" and other training programs have witnessed YSG's endeavour in public welfare.
Since the establishment of the Company, YSG has been committed to involving more people to enjoy beauty as part of its corporate social responsibility practice. In 2020, YSG, with the goal of "helping women to discover and create beauty", joined hands with the China Women's Development Foundation to launch "Creating a beautiful life" public welfare training program. A total of RMB 2 million has been invested in the program in three years. As of March 2023, 5 training sessions have been completed, empowering 202 women to start their own business/employment in the field of beauty through the learning of beauty skills, quality enhancement, in-person visits and practice, industry exchanges, and mentor support.
At the same time, the Company is also expanding the depth and breadth of public welfare practices, actively contributing to social welfare such as education and research, child care, rural revitalization, public welfare for the disabled, shouldering a sense of social responsibility and mission, insisting on giving back real benefits to the society, and spreading the beauty of goodwill even farther.
Promoting high-quality development is the core in YSG's transformation process and the fundamental guideline for the Company's ESG practices. Mr. Huang Jinfeng, Founder, Chairman and CEO of YSG, said, "2022 is a year for YSG to deepen its transformation and reform in a comprehensive manner. Good ESG governance is an important driving force to promote the sustainable development of enterprises. In the future, YSG will focus on three aspects of optimization: continue to give full play to the value of ESG to create new momentum for development; continue to improve the green management to create sustainable products; and promote more public welfare programs to give full play to their own strengths and social influence, and actively give back to the society."
On the road of sustainable and high-quality development, YSG will continue to enhance its professional ability, improve itself through reformation, apply new technology and new thinking to the field of beauty, drive product upgrading with innovation, provide high-quality and innovative products to global consumers, and bring new vitality and confidence to the beauty industry.
View original content to download multimedia:
SOURCE Yatsen Global | https://www.kait8.com/prnewswire/2023/07/31/ysg-releases-its-second-esg-report-setting-benchmark-industry/ | 2023-07-31T12:34:42 | 0 | https://www.kait8.com/prnewswire/2023/07/31/ysg-releases-its-second-esg-report-setting-benchmark-industry/ |
ALHAMBRA, Calif., July 31, 2023 /PRNewswire/ -- Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: AMEH), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced an agreement to partner with IntraCare, an operator of a value-based primary care provider network and primary care clinics located predominantly in Texas with a growing presence in Oklahoma.
Headquartered in the Dallas-Fort Worth metropolitan area of Texas, IntraCare is aligned with over 425 providers managing the care of over 40,000 members. Like ApolloMed, IntraCare is on a mission to build a thriving healthcare ecosystem that promotes successful, independent physicians, strengthens the patient-physician relationship, and improves patient satisfaction and healthcare outcomes through quality, compassionate coordinated care.
ApolloMed's partnership with IntraCare is poised to accelerate access to high-quality, value-based care for seniors in three areas. First, ApolloMed's ACO will partner with IntraCare's primary care providers as part of the ACO REACH program, an attribution-based risk-bearing model designed to advance health equity and bring the benefits of accountable care to Medicare beneficiaries in underserved communities. In addition, ApolloMed will deploy its value-based care platform as the exclusive care enablement partner for IntraCare providers participating in the ACO REACH program. Finally, to further IntraCare's mission and growth, ApolloMed will lend IntraCare a $25 million senior secured convertible promissory note maturing in 2028. Guggenheim Securities, LLC acted as financial advisor to IntraCare in connection with the transactions.
Brandon Sim, Co-CEO of ApolloMed, stated, "We have admired IntraCare's demonstrated track record of successfully empowering local independent primary care practices in Texas and Oklahoma, a strategy which is aligned with and complementary to our success in our core markets. With this partnership, we are excited to build upon IntraCare's momentum and partner with their providers in our ACO, continuing to scale our Care Partners business. We also look forward to bringing our Care Enablement platform to these providers and will work closely with IntraCare's leadership team in continuing to expand upon their historical success while exploring additional avenues for collaboration down the road."
Anwar Kazi, CEO of IntraCare, added, "We are thrilled to be partnering with ApolloMed, a company that is aligned with IntraCare in its mission of empowering providers in the successful delivery of value-based care. We believe that joining forces with ApolloMed will enable us to accelerate the growth of our business as we look to continue expanding our affiliate network and owned clinic footprint within our existing geographic presence in Texas and Oklahoma."
About Apollo Medical Holdings, Inc.
ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.
Headquartered in Alhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and entities participating in the Centers for Medicare & Medicaid Services Innovation Center (CMMI) innovation models. For more information, please visit www.apollomed.net.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, such as statements about the Company's operational focus and strategic growth plans and expectations regarding its ability to successfully partner with third parties. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports to the Securities and Exchange Commission ("SEC"), including without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC and any subsequent quarterly reports on Form 10-Q.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
(626) 943-6491
investors@apollomed.net
Carolyne Sohn, The Equity Group
(408) 538-4577
csohn@equityny.com
View original content to download multimedia:
SOURCE Apollo Medical Holdings, Inc. | https://www.wafb.com/prnewswire/2023/07/31/apollo-medical-holdings-inc-announces-partnership-with-intracare-advance-value-based-care-texas-oklahoma/ | 2023-07-31T12:34:44 | 1 | https://www.wafb.com/prnewswire/2023/07/31/apollo-medical-holdings-inc-announces-partnership-with-intracare-advance-value-based-care-texas-oklahoma/ |
Report Outlines Company's Progress Toward Its Environmental, Social, and Governance (ESG) Goals
ST. LOUIS, July 31, 2023 /PRNewswire/ -- Global packaging leader TricorBraun today published its inaugural Sustainability report, outlining its progress toward its Environmental, Social, and Governance (ESG) goals.
"We are pleased to present our first-ever Sustainability Report, which brings to life our commitments to sustainable and ethical practices," said Court Carruthers, president and CEO, TricorBraun. "Our team is guided by the principle that we do things the right way always, and this naturally extends to our environmental, social, and governance (ESG) impacts—including helping our customers with their own ESG goals by offering sustainable packaging options while improving our own environmental footprint."
Key highlights from the report include these 2022 milestones:
- Reduced our carbon footprint and incorporated international operations into our Greenhouse Gas (GHG) Inventory
- Sourced renewable energy to further reduce negative climate impacts
- Piloted our first Zero-Waste program in multiple locations across North America
- Further protected our team members by creating a Warehousing Roundtable which emphasizes dock, forklift, and 5S safety programs
- Supported open communications channels that are accessible for all team members by relaunching the TricorBraun Ethics Hub to include additional languages, international access, and mobile reporting
- Established exclusive agreements to offer sustainable packaging options to customers in the US, Canada, and Europe
"The release of our first Sustainability report is a significant milestone as our team continues to work tirelessly in pursuit of achieving our ESG goals," said Susan Bergethon, SVP & general counsel, and leader of the Company's ESG strategy. "We are pleased with our progress to date, and we look forward to making continued progress toward our intentional ESG goals for the benefit of our team members, our customers, our business—and our planet."
To read the full report and learn more about TricorBraun's ESG goals, visit https://www.tricorbraun.com/about-us/esg-at-tricorbraun/2022-sustainability-report.html.
About TricorBraun
Founded in 1902, TricorBraun is a global packaging leader. We provide innovative solutions across a wide array of customer end markets in plastic, glass, and aluminum containers, closures, dispensers, tubes, and flexibles. Our award-winning Design & Engineering Center provides forward-thinking design, driven by consumer insight and creative solutions. TricorBraun is comprised of more than 2,000 packaging professionals operating from more than 100 locations across the Americas, Europe, Asia, and Australia.
View original content to download multimedia:
SOURCE TricorBraun | https://www.wbay.com/prnewswire/2023/07/31/tricorbraun-issues-inaugural-sustainability-report/ | 2023-07-31T12:34:43 | 0 | https://www.wbay.com/prnewswire/2023/07/31/tricorbraun-issues-inaugural-sustainability-report/ |
HOUSTON, July 31, 2023 /PRNewswire/ -- AutomationEdge, a leading Hyperautomation platform has announced strategic partnership with eAlliance Corp, a cutting-edge Hyperautomation solutions provider.
The partnership will enable eAlliance Corp to provide AutomationEdge solutions such as CogniBot - a conversational AI platform, DocEdge - an intelligent document processing platform, Intelligent Service Desk Ticket Data Analysis, IT Process Automation (ITPA) and RPA. This collaboration will empower AutomationEdge and eAlliance Corp to help customers innovate with automation to move the needle on the top and bottom line.
AutomationEdge, along with its Hyperautomation platform, has also build the ready automation solutions across industries. It will help customers achieve faster Go-To-Market for automation projects with lower cost. It is empowering 250+ customers globally in Healthcare, Banking, Insurance, Financial Services and other industries.
For over 20 years, eAlliance Corp has been delivering technology solutions to businesses worldwide across industries. It has been a trusted advisor to its customer in innovation, strategy and execution of automation solutions. Through this partnership, eAlliance will be able to offer innovative business process automation solutions to customers focusing on key enterprise domains such as finance & accounting, customer service, procurement, human resources, cash applications and more.
About AutomationEdge
AutomationEdge is a leading Hyperautomation platform across the globe with end-to-end automation capabilities. With its platforms working together as one solution, it has enabled seamless process automation for global enterprises.
AutomationEdge has already delivered its innovative solutions to large multinational organizations like American Express, Smart Dubai Government, Wipro, AccentCare, Danone, University of Maryland Medical System, Aspen Pharmacare, Oman LNG, Mashreq Bank, HDFC Bank, and Genpact, to name a few.
For more details, contact sales or request a demo.
About eAlliance Corp
eAlliance Corp is a professional services firm with big company expertise and small company relationships, taking pride in agility and real-time responsiveness. eAlliance Corp is a trusted name in the Hyperautomation industry, offering comprehensive services and solutions to help businesses achieve their automation goals with ease. Founded in 2002 in Chicago, IL, staffed with resources in the US and India possessing vast experience and leadership in business and technology.
For more details, visit website.
For media inquiries, please contact:
Rahul Wandile
Media Relations – AutomationEdge
rahul.wandile@automationedge.com
www.automationedge.com
Follow AutomationEdge on: Twitter, Facebook, LinkedIn, and YouTube
View original content:
SOURCE AutomationEdge | https://www.wafb.com/prnewswire/2023/07/31/automationedge-ealliance-corp-announced-partnership-hyperautomation-solutions/ | 2023-07-31T12:34:45 | 1 | https://www.wafb.com/prnewswire/2023/07/31/automationedge-ealliance-corp-announced-partnership-hyperautomation-solutions/ |
MIAMI, July 31, 2023 /PRNewswire/ -- Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: CUK) today announced that Carnival Corporation (the "Company") intends to commence the marketing of a new senior secured first lien term loan B facility (the "New First Lien Term Loan") with an original principal amount of $1.0 billion, expected to mature in 2027. In conjunction with the New First Lien Term Loan, and subject to market and other conditions, the Company may raise $500 million of other secured debt maturing in 2029 (together with the New First Lien Term Loan, the "Refinancing Transactions"). The Company intends to use the proceeds from the Refinancing Transactions to repay a portion of the borrowings under the Company's existing first-priority senior secured term loan facility maturing in 2025.
After the closing of the Refinancing Transactions, the Company intends to redeem all of the Company's 10.500% second-priority senior secured notes due 2026 and 10.125% second-priority senior secured notes due 2026 (collectively, the "2026 Notes"), saving over $120 million in interest expense on an annualized basis. The $1.2 billion of redemptions will be conditioned on the closing of the Refinancing Transactions. The Company expects to use cash on hand to finance the redemptions. This press release does not constitute a notice of redemption with respect to the 2026 Notes.
The Company's Chief Financial Officer David Bernstein commented: "Given the confidence we have in our business and its cash flow generation, we plan to retire $1.2 billion of our highest cost debt. In connection with this retirement, we plan to extend some of the lowest cost public debt in our portfolio. This is yet another step forward in our deleveraging journey, building on the $1.4 billion we already early retired this year. With this debt repayment, we now expect our year end debt balance to be less than $32.0 billion, an improvement over the November 30, 2023 debt balance of less than $33.0 billion provided in our June guidance."
This press release shall not constitute an offer to sell or the solicitation of an offer to purchase any security and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offering, solicitation or sale would be unlawful.
About Carnival Corporation & plc
Carnival Corporation & plc is the largest global cruise company, and among the largest leisure travel companies, with a portfolio of world-class leading cruise lines - AIDA Cruises, Carnival Cruise Line, Costa Cruises, Cunard, Holland America Line, P&O Cruises (Australia), P&O Cruises (UK), Princess Cruises and Seabourn.
Cautionary Note Concerning Forward-Looking Statements
Carnival Corporation and Carnival plc and their respective subsidiaries are referred to collectively in this press release, as "Carnival Corporation & plc," "our," "us" and "we." Some of the statements, estimates or projections contained in this press release are "forward-looking statements" that involve risks, uncertainties and assumptions with respect to us, including some statements concerning the refinancing transactions described herein, future results, operations, outlooks, plans, goals, reputation, cash flows, liquidity and other events which have not yet occurred. These statements are intended to qualify for the safe harbors from liability provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are statements that could be deemed forward-looking. These statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate and the beliefs and assumptions of our management. We have tried, whenever possible, to identify these statements by using words like "will," "may," "could," "should," "would," "believe," "depends," "expect," "goal," "aspiration," "anticipate," "forecast," "project," "future," "intend," "plan," "estimate," "target," "indicate," "outlook," and similar expressions of future intent or the negative of such terms.
Forward-looking statements include those statements that relate to our outlook and financial position including, but not limited to, statements regarding:
Because forward-looking statements involve risks and uncertainties, there are many factors that could cause our actual results, performance or achievements to differ materially from those expressed or implied by our forward-looking statements. This note contains important cautionary statements of the known factors that we consider could materially affect the accuracy of our forward-looking statements and adversely affect our business, results of operations and financial position. Additionally, many of these risks and uncertainties are currently, and in the future may continue to be, amplified by our substantial debt balance as a result of the pause of our guest cruise operations. There may be additional risks that we consider immaterial or which are unknown. These factors include, but are not limited to, the following:
- events and conditions around the world, including war and other military actions, such as the invasion of Ukraine, inflation, higher fuel prices, higher interest rates and other general concerns impacting the ability or desire of people to travel have led, and may in the future lead, to a decline in demand for cruises, impacting our operating costs and profitability;
- pandemics have in the past and may in the future have a significant negative impact on our financial condition and operations;
- incidents concerning our ships, guests or the cruise industry have in the past and may, in the future, negatively impact the satisfaction of our guests and crew and lead to reputational damage;
- changes in and non-compliance with laws and regulations under which we operate, such as those relating to health, environment, safety and security, data privacy and protection, anti-corruption, economic sanctions, trade protection, labor and employment and tax have in the past and may, in the future, lead to litigation, enforcement actions, fines, penalties and reputational damage;
- factors associated with climate change, including evolving and increasing regulations, increasing global concern about climate change and the shift in climate conscious consumerism and stakeholder scrutiny, and increasing frequency and/or severity of adverse weather conditions could adversely affect our business;
- inability to meet or achieve our sustainability related goals, aspirations, initiatives, and our public statements and disclosures regarding them, may expose us to risks that may adversely impact our business;
- breaches in data security and lapses in data privacy as well as disruptions and other damages to our principal offices, information technology operations and system networks and failure to keep pace with developments in technology may adversely impact our business operations, the satisfaction of our guests and crew and may lead to reputational damage;
- the loss of key team members, our inability to recruit or retain qualified shoreside and shipboard team members and increased labor costs could have an adverse effect on our business and results of operations;
- increases in fuel prices, changes in the types of fuel consumed and availability of fuel supply may adversely impact our scheduled itineraries and costs;
- we rely on supply chain vendors who are integral to the operations of our businesses. These vendors and service providers may be unable to deliver on their commitments, which could negatively impact our business;
- fluctuations in foreign currency exchange rates may adversely impact our financial results;
- overcapacity and competition in the cruise and land-based vacation industry may negatively impact our cruise sales, pricing and destination options;
- inability to implement our shipbuilding programs and ship repairs, maintenance and refurbishments may adversely impact our business operations and the satisfaction of our guests;
- Failure to successfully implement our business strategy following our resumption of guest cruise operations would negatively impact the occupancy levels and pricing of our cruises and could have a material adverse effect on our business. We require a significant amount of cash to service our debt and sustain our operations. Our ability to generate cash depends on many factors, including those beyond our control, and we may not be able to generate cash required to service our debt and sustain our operations; and,
- the risk factors included in Carnival Corporation's and Carnival plc's Annual Report on Form 10-K filed with the SEC on January 27, 2023 and Carnival Corporation's and Carnival plc's Quarterly Reports on Form 10-Q filed with the SEC on March 29, 2023 and June 28, 2023.
The ordering of the risk factors set forth above is not intended to reflect our indication of priority or likelihood.
Forward-looking statements should not be relied upon as a prediction of actual results. Subject to any continuing obligations under applicable law or any relevant stock exchange rules, we expressly disclaim any obligation to disseminate, after the date of this document, any updates or revisions to any such forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which any such statements are based.
Forward-looking and other statements in this document may also address our sustainability progress, plans and goals (including climate change and environmental-related matters). In addition, historical, current and forward-looking sustainability- and climate-related statements may be based on standards and tools for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions and predictions that are subject to change in the future and may not be generally shared.
SOURCE Carnival Corporation & plc
View original content:
SOURCE Carnival Corporation & plc | https://www.kwch.com/prnewswire/2023/07/31/carnival-corporation-amp-plc-announces-anticipated-debt-pre-payment-12b-refinancing-transaction/ | 2023-07-31T12:34:47 | 0 | https://www.kwch.com/prnewswire/2023/07/31/carnival-corporation-amp-plc-announces-anticipated-debt-pre-payment-12b-refinancing-transaction/ |
PARIS, July 31, 2023 /PRNewswire/ -- Yubo, the live social discovery app for Gen Z, has become a member of the Global Internet Forum to Counter Terrorism (GIFCT) to support its mission to prevent terrorist and violent extremist exploitation online through research, technical collaboration, and knowledge sharing.
Through its membership, Yubo will leverage GIFCT's hash-sharing database to identify and remove content shared on Yubo that is associated with United Nations-designated terrorist entities, attacker manifestos, terrorist publications, and other violent extremist groups. GIFCT is an NGO designed to prevent terrorists and violent extremists from exploiting digital platforms.
Since 2017, GIFCT has run a safe and secure industry database of hashes – or "digital fingerprints'' – of known terrorist and violent extremist material, which GIFCT members have identified and removed from their platforms. With users in over 140 countries around the world, Yubo will play a key role in helping GIFCT further scale its international hash-sharing database.
"GIFCT's hash database provides Yubo with a powerful tool to further strengthen our multifaceted approach to content moderation and more effectively identify and eliminate violent extremist content at scale," said Yubo co-founder and CEO Sacha Lazimi. "We look forward to expanding our support of GIFCT through this initiative and working with other member organizations to leverage technology to combat terrorism and enhance safety for all, on- and offline."
GIFCT's hash-sharing database works first by enabling member companies, like Yubo, to identify and "hash" content, such as photos, videos, or PDFs, ensuring a privacy-by-design approach to recording content for reporting or removal without linking to any personally identifiable information. Hashes appear as digital signatures or numerical representations of the original content, which means they cannot be easily reverse engineered to recreate the content.
"The lifecycle of violent extremism is often extended through the dissemination of content online, and the support of member organizations like Yubo is crucial to breaking these cycles," said GIFCT Executive Director Naureen Chowdhury Frink. "We are grateful to our GIFCT member companies for their continued collaboration in our shared mission to prevent terrorists and violent extremists from exploiting digital platforms, and we welcome the important investments Yubo has made for the safety of its community."
Yubo's integration of the GIFCT hash-sharing database follows the platform's support of the Take It Down initiative by the National Center for Missing and Exploited Children (NCMEC) in February. Take It Down is NCMEC's free online service that, like GIFCT, leverages a hash-sharing system to help minors remove their nudes from the internet and combat the online spread of child sexual exploitation.
ABOUT YUBO
Yubo is a live social discovery app making it easy for Gen Z to expand their social circles and hang out online with new friends from around the world. By eliminating likes and follows, we empower young people to show up as their true selves and connect as authentically as they would offline. Safety is a cornerstone of our platform, and we are proud to be the first social app in the world to introduce comprehensive user-age verification tools and real-time video and audio moderation for livestreams. Founded in France in 2015, Yubo is used in more than 140 countries by over 60 million users. Visit us at yubo.live to learn more and follow our journey.
ABOUT GIFCT
GIFCT is a 501(c)(3) non-profit organization and tech-led initiative with over 20 member tech companies offering unique settings for diverse stakeholders to identify and solve the most complex global challenges at the intersection of terrorism and technology. GIFCT's mission is to prevent terrorists and violent extremists from exploiting digital platforms through our vision of a world in which the technology sector marshals its collective creativity and capacity to render terrorists and violent extremists ineffective online. In every aspect of our work, we aim to be transparent, inclusive, and respectful of the fundamental and universal human rights that terrorists and violent extremists seek to undermine.
Media Contact:
Debora Lima, Yubo U.S. Media Director
debora@ext.yubo.live
View original content to download multimedia:
SOURCE Yubo | https://www.kait8.com/prnewswire/2023/07/31/yubo-joins-gifct-combat-spread-violent-extremist-content-online/ | 2023-07-31T12:34:49 | 0 | https://www.kait8.com/prnewswire/2023/07/31/yubo-joins-gifct-combat-spread-violent-extremist-content-online/ |
DUBLIN, Calif., July 31, 2023 /PRNewswire/ -- TriNet Group, Inc. (NYSE: TNET), a leading provider of comprehensive and flexible human capital management (HCM) solutions for small and medium-size businesses (SMBs), today announced its plan to launch a fixed price tender offer (the "Tender Offer") to repurchase approximately $640 million in value of shares of TriNet common stock (the "shares") at a price of $107.00 per share, which is expected to commence on August 1, 2023. In addition, the Company signed a separate agreement on July 30, 2023 (the "Repurchase Agreement") to repurchase a minimum of approximately $360 million in value of shares from affiliates of its largest stockholder, Atairos Group, Inc. (collectively, "Atairos"). Assuming the Tender Offer is fully subscribed, both transactions together will result in the repurchase of approximately $1 billion in shares.
"Today is an exciting day for TriNet as we announce our intention to launch transactions to buy back $1 billion of TriNet stock," said Burton M. Goldfield, TriNet's President and CEO. "For some time, we have believed that TriNet's stock represents significant value, especially in light of our recent financial and operating performance. With our optimism around our long-term outlook, we believe now is a great time to take bold action around our capital structure."
"We have long valued Atairos' share ownership and Board of Directors participation," Goldfield continued. "As a part of these buybacks, Atairos intends to maintain its current approximate pro rata percentage ownership, but has also agreed to sell additional shares if our tender offer is undersubscribed, potentially reducing their ownership to no less than 30%. We welcome their continued ownership and Board participation."
"TriNet is a dynamic growth company with a proven business model and strong corporate cash flows," said Kelly Tuminelli, TriNet's Chief Financial Officer. "Through this action, we are using our financial resources to reduce TriNet's overall weighted average cost of capital. This is in line with our recently announced financial policy, while accreting long term value for all of our shareholders."
The Tender Offer will provide that the Company repurchase for cash up to 5,981,308 shares (representing approximately $640 million in value of shares) at a price of $107.00 per share (the "Purchase Price"), less any applicable withholding taxes and without interest. The Tender Offer is expected to commence on August 1, 2023 and expire at 12:00 midnight, New York City time, at the end of the day on August 28, 2023 (the "Expiration Date"), unless extended or terminated.
The Repurchase Agreement, which was executed on July 30, 2023, provides that TriNet will repurchase for cash a minimum of 3,364,486 shares (representing approximately $360 million in value of shares) from Atairos at the purchase price set forth in the Tender Offer, but not less than $107.00 per share (the "Atairos Commitment Amount"). Atairos beneficially owns 21,450,259 shares as of the date hereof (representing approximately 36% of the Company's outstanding shares as of July 27, 2023) and, assuming the full subscription of the Tender Offer, Atairos will continue to own approximately 36% of the Company's outstanding shares following the repurchase.
If the Tender Offer is not fully subscribed, but at least 3,644,859 shares are properly tendered and not properly withdrawn pursuant to the Tender Offer, Atairos has agreed to increase the number of shares to be sold to the Company under the Repurchase Agreement and will sell an additional number of shares equal to the difference between the number of shares offered to be repurchased pursuant to the Tender Offer and the number of shares actually repurchased in the Tender Offer such that the total share value of both transactions remains $1 billion; provided that such increase does not cause Atairos to beneficially own less than 33% of the Company's outstanding shares immediately following the closing of the Share Repurchase (taking into account the shares purchased in the Tender Offer), which percent may be further reduced to 30% at Atairos' sole discretion. If the Tender Offer is not fully subscribed and fewer than 3,644,859 shares are properly tendered and not properly withdrawn pursuant to the Tender Offer, the Company will repurchase that number of shares properly tendered and not properly withdrawn pursuant to the Tender Offer and, unless Atairos agrees to further reduce its ownership level, the Company will repurchase only the Atairos Commitment Amount from Atairos under the Repurchase Agreement.
The Share Repurchase is expected to close on the 11th business day following the Expiration Date, or September 13, 2023. The Share Repurchase is conditioned upon, among other matters, the completion of the Tender Offer, which, in turn, is subject to certain conditions, including the receipt of financing. These transactions will be made under TriNet's $1 billion stock repurchase program increase announced on July 26, 2023.
Assuming that the conditions to the Tender Offer are satisfied or waived and the Tender Offer is fully subscribed, the Company would purchase 5,981,308 shares pursuant to the Tender Offer and 3,364,486 shares pursuant to the Share Repurchase for an aggregate of 9,345,794 shares, representing approximately 16% of the Company's outstanding shares as of July 27, 2023.
The Tender Offer and the Share Repurchase have been authorized and approved by the Company's Board of Directors, the Finance and Audit Committee of the Board of Directors and the members of the Board of Directors who are independent of Atairos. However, neither the Company nor any member of the Board of Directors has made, or is making, any recommendation to stockholders as to whether they should tender or refrain from tendering their shares. Stockholders must make their own decision as to whether to tender their shares and, if so, how many shares to tender. Stockholders are urged to discuss their decisions with their tax advisor, financial advisor and/or broker.
Certain Information Regarding the Tender Offer
The information in this press release describing the Tender Offer is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell shares in the Tender Offer. TriNet has not yet commenced the Tender Offer described herein, and there can be no assurance that TriNet will commence the Tender Offer on the terms described in this press release. The Tender Offer will be made only pursuant to the Offer to Purchase and the related materials that the Company will file with the SEC, and will distribute to its stockholders, as they may be amended or supplemented, on the commencement date of the Tender Offer. Stockholders should read the Offer to Purchase and related materials carefully and in their entirety because they will contain important information, including the terms and conditions of the Tender Offer. When they are available, stockholders of the Company may obtain a free copy of the Tender Offer statement on Schedule TO, the Offer to Purchase and other documents that the Company will file with the SEC from the SEC's website at www.sec.gov. When they are available, stockholders also will be able to obtain a copy of these documents, without charge, from D.F. King & Co., Inc., toll free at (800) 431-9643. Stockholders are urged to carefully read all of those materials when they become available prior to making any decision with respect to the Tender Offer.
About TriNet
TriNet (NYSE: TNET) provides small and medium-size businesses with full-service industry-specific HR solutions, providing both professional employer organization and human resources information system services. TriNet offers access to human capital expertise, benefits, risk mitigation, compliance, payroll, and R&D tax credit services, all enabled by industry-leading technology. TriNet's suite of products also includes services and software-based solutions to help streamline workflows by connecting HR, benefits, employee engagement, payroll and time & attendance. Rooted in more than 30 years of supporting entrepreneurs and adapting to the ever-changing modern workplace, TriNet empowers SMBs to focus on what matters most-growing their business and enabling their people.
Forward Looking Statements
This press release contains forward-looking statements that are based on TriNet's current expectations. Such statements include TriNet's plan to initiate the Tender Offer and ability to complete the Share Repurchase on the terms and timing described herein, or at all. Such forward-looking statements are subject to certain risks, uncertainties and assumptions, including investor demand, market conditions, customary closing conditions and other factors. There can be no assurance that TriNet will complete the Share Repurchase or initiate the Tender Offer. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those expected. More information about potential risk factors that could affect TriNet and its results is included in TriNet's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2022 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2023 and June 30, 2023. TriNet does not assume any obligation to update the forward-looking information contained in this press release.
View original content to download multimedia:
SOURCE TriNet Group, Inc. | https://www.wbay.com/prnewswire/2023/07/31/trinet-group-inc-announces-intention-launch-combined-1-billion-fixed-price-tender-offer-repurchase-atairos-each-price-107-per-share-common-stock/ | 2023-07-31T12:34:50 | 0 | https://www.wbay.com/prnewswire/2023/07/31/trinet-group-inc-announces-intention-launch-combined-1-billion-fixed-price-tender-offer-repurchase-atairos-each-price-107-per-share-common-stock/ |
Impact "much bigger than a single project"
WAYNESBORO, Ga., July 31, 2023 /PRNewswire/ -- Bechtel, the engineering, procurement, and construction company brought in to complete construction on new Units 3 and 4 at the Vogtle nuclear power plant in Georgia, today issued the following statement from Brendan Bechtel, Bechtel Chairman and CEO, marking the start of commercial operations for Unit 3:
"We are extremely proud of Bechtel's part in achieving this milestone. Our team has been 100 percent committed to Vogtle's completion since being brought in to finish the project.
"Today's start of commercial operations for Vogtle Unit 3 gives the Southeast a major new source of clean, reliable, carbon-free baseload energy. And, as the first new nuclear unit built in the U.S. in more than 30 years, it helps put America back on the map as a leader in the global nuclear industry.
"Bechtel has supported the design and construction of 150 nuclear plants worldwide. We know firsthand how Vogtle Units 3 and 4 go a long way in restoring America's muscle memory in nuclear construction, including the workforce and domestic supply chains required to build America's largest nuclear power plant. Vogtle Unit 3 comes online at a pivotal time when energy security concerns and the need to cut carbon emissions are driving growth in the world's nuclear fleet.
"Plant Vogtle will generate more carbon-free electricity yearly than any other energy facility currently operating in the country. Its completion reinforces that the United States is the responsible partner of choice for new nuclear energy around the world, and maintains U.S. interests in ensuring strong safety, security, and non-proliferation standards. This is why Vogtle's impact is much bigger than a single project.
"Thank you to the thousands of skilled craft professionals, union partners, engineers, project managers, procurement experts, suppliers, subcontractors, and everyone who made this day possible. And thank you to Georgia Power and Southern Nuclear for the opportunity to bring this project over the finish line. We look forward to doing the same with Unit 4 in the coming months."
Background
In 2017, Bechtel was brought in by Georgia Power and Southern Nuclear to take over construction of Vogtle Units 3 and 4, bringing extensive experience supporting the design and construction of 150 nuclear plants worldwide. Vogtle Units 3 and 4 are the first Westinghouse AP1000 units to ever be built in the U.S.
Bechtel has completed more than 76,000 megawatts of new nuclear generation capacity and has designed, built, or performed engineering and/or construction services on more than 80% of nuclear plants in the United States. Today, the company leads efforts in designing and constructing advanced nuclear plants, critical to global efforts to achieve net zero carbon emissions.
Bechtel partnered with North America's Building Trades Unions (NABTU) to build Plant Vogtle Units 3 and 4. At peak, Bechtel and NABTU had a combined 9,000 workers on site.
About Bechtel
Bechtel is a trusted engineering, construction, and project management partner to industry and government. Differentiated by the quality of our people and our relentless drive to deliver the most successful outcomes, we align our capabilities to our customers' objectives to create a lasting positive impact. Since 1898, we have helped customers complete more than 25,000 projects in 160 countries on all seven continents that have created jobs, grown economies, improved the resiliency of the world's infrastructure, increased access to energy, resources, and vital services, and made the world a safer, cleaner place.
Bechtel serves the Energy; Infrastructure; Manufacturing & Technology; Mining & Metals; and Nuclear, Security & Environmental markets. Our services span from initial planning and investment through start-up and operations. www.bechtel.com
Contact:
Amanda Meixel
ammeixel@bechtel.com
M: 1-706-360-5526
P: 1-703-429-6313
View original content to download multimedia:
SOURCE Bechtel | https://www.wafb.com/prnewswire/2023/07/31/bechtel-commercial-operations-vogtle-unit-3-is-an-important-milestone-us-nuclear-industry/ | 2023-07-31T12:34:51 | 0 | https://www.wafb.com/prnewswire/2023/07/31/bechtel-commercial-operations-vogtle-unit-3-is-an-important-milestone-us-nuclear-industry/ |
NORWOOD, Mass., July 31, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the BTIG Virtual Biotechnology Conference, to be held August 7-8, 2023.
BTIG Virtual Biotechnology Conference
Format: Fireside chat and one-on-one investor meetings
Fireside Chat Date: Tuesday, August 8, 2023
Fireside Chat Time: 9:00 a.m. ET
To register for the conference, contact your BTIG sales representative.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. (the "Company" or "Corbus") is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus' internal development pipeline includes CRB-701, a next generation antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
Sean.moran@corbuspharma.com
Bruce Mackle Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
View original content to download multimedia:
SOURCE Corbus Pharmaceuticals | https://www.kwch.com/prnewswire/2023/07/31/corbus-pharmaceuticals-present-btig-virtual-biotechnology-conference/ | 2023-07-31T12:34:54 | 0 | https://www.kwch.com/prnewswire/2023/07/31/corbus-pharmaceuticals-present-btig-virtual-biotechnology-conference/ |
BEIJING, July 31, 2023 /PRNewswire/ -- 36Kr Holdings Inc. ("36Kr" or the "Company") (NASDAQ: KRKR), a prominent brand and a pioneering platform dedicated to serving New Economy participants in China, today announced the launch of its 36Kr Media Lab in Silicon Valley, an initiative to embrace the large language models (LLM) revolution taking place in the content creation industry and optimize the application of artificial intelligence (AI) for the new economy sector.
36Kr Silicon Valley Media Lab's first project leveraging LLM, "Empty Office," will experimentally explore scenarios where AI can think and work as humans, enhancing content production efficiency and reducing costs. Through "Empty Office," 36Kr is also building innovative media solutions that will transform traditional video, graphic and text communications into avant-garde dialogues between customized AI characters and audiences. These network-based dialogues will be naturally and seamlessly driven by real-time data generation, and available anytime, anywhere.
At the same time, 36Kr Silicon Valley Media Lab continues to focus on tailoring its LLM to the new economy sector. By utilizing dedicated financial and business datasets, including enterprises' financial results, news, market dynamics and knowledge repositories, among other resources, to train its LLM to thoroughly understand and analyze business information, 36Kr has developed a model that keenly grasps the business nuances to generate accurate analysis and interpretation. 36Kr Silicon Valley Media Lab constantly maintains its database, serving as the reference foundation to ensure that its fact-based model produces rigorous and up-to-date business and financial analysis.
Furthermore, 36Kr's professionally-training, fine-tuning capability enables its LLM-empowered "Empty Office" to quickly and efficiently create informative content for the new economy sector. For instance, in the case of a business event, such as a new product launch, an AI agent can instantly extract relevant data from the database, automatically perform a comprehensive analysis, and issue reports within just seconds. This top-speed response gives 36Kr's business and financial-focused media platform an unrivaled edge.
Mr. Dagang Feng, Co-chairman and CEO of 36Kr, commented, "The launch of 36Kr Silicon Valley Media Lab is a testament to our AI technology acumen and vision as well as our commitment to extending media's boundaries. By integrating pioneering AI technology into content creation, 36Kr will constantly elevate the efficiency and quality of content production alongside the rapid advancement of the LLM, fostering a superior content ecosystem encompassing business, finance and technology, further turbocharging the evolution of the New Economy. As we adopt and develop more AI tools amid the technology's rapid advancement, we are strategically positioning the Company to break new ground and ultimately drive long-term growth for our business."
About 36Kr Holdings Inc.
36Kr Holdings Inc. is a prominent brand and a pioneering platform dedicated to serving New Economy participants in China with the mission of empowering New Economy participants to achieve more. The Company started its business with high-quality New Economy-focused content offerings, covering a variety of industries in China's New Economy with diverse distribution channels. Leveraging traffic brought by high-quality content, the Company has expanded its offerings to business services, including online advertising services, enterprise value-added services, and subscription services, to address the evolving needs of New Economy companies and upgrading needs of traditional companies. The Company is supported by a comprehensive database and strong data analytics capabilities. Through diverse service offerings and significant brand influence, the Company is well-positioned to continuously capture the high growth potential of China's New Economy.
For more information, please visit: http://ir.36kr.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: the Company's goal and strategies; the Company's future business development, results of operations and financial condition; relevant government policies and regulations relating to our business and industry; the Company's expectations regarding the use of proceeds from this offering; the Company's expectations regarding demand for, and market acceptance of, its services; the Company's ability to maintain and enhance its brand; the Company's ability to provide high-quality content in a timely manner to attract and retain users; the Company's ability to retain and hire quality in-house writers and editors; the Company's ability to maintain cooperation with third-party professional content providers; the Company's ability to maintain relationships with third-party platforms; general economic and business conditions in China; possible disruptions in commercial activities caused by natural or human-induced disasters; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company's filings with the SEC. All information provided in this press release and in the attachments is as of the date of this press release, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.
For investor and media inquiries, please contact:
In China:
36Kr Holdings Inc.
Investor Relations
Tel: +86 (10) 8965-0708
E-mail: ir@36kr.com
The Piacente Group, Inc.
Jenny Cai
Tel: +86 (10) 6508-0677
E-mail: 36Kr@tpg-ir.com
In the United States:
The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
E-mail: 36Kr@tpg-ir.com
View original content:
SOURCE 36Kr Holdings Inc. | https://www.kait8.com/prnewswire/2023/07/31/36kr-launches-silicon-valley-media-lab-empower-content-ecosystem-with-llm-based-ai-technology/ | 2023-07-31T12:34:55 | 1 | https://www.kait8.com/prnewswire/2023/07/31/36kr-launches-silicon-valley-media-lab-empower-content-ecosystem-with-llm-based-ai-technology/ |
HOUSTON, July 31, 2023 /PRNewswire/ -- AutomationEdge, a leading Hyperautomation platform has announced strategic partnership with eAlliance Corp, a cutting-edge Hyperautomation solutions provider.
The partnership will enable eAlliance Corp to provide AutomationEdge solutions such as CogniBot - a conversational AI platform, DocEdge - an intelligent document processing platform, Intelligent Service Desk Ticket Data Analysis, IT Process Automation (ITPA) and RPA. This collaboration will empower AutomationEdge and eAlliance Corp to help customers innovate with automation to move the needle on the top and bottom line.
AutomationEdge, along with its Hyperautomation platform, has also build the ready automation solutions across industries. It will help customers achieve faster Go-To-Market for automation projects with lower cost. It is empowering 250+ customers globally in Healthcare, Banking, Insurance, Financial Services and other industries.
For over 20 years, eAlliance Corp has been delivering technology solutions to businesses worldwide across industries. It has been a trusted advisor to its customer in innovation, strategy and execution of automation solutions. Through this partnership, eAlliance will be able to offer innovative business process automation solutions to customers focusing on key enterprise domains such as finance & accounting, customer service, procurement, human resources, cash applications and more.
About AutomationEdge
AutomationEdge is a leading Hyperautomation platform across the globe with end-to-end automation capabilities. With its platforms working together as one solution, it has enabled seamless process automation for global enterprises.
AutomationEdge has already delivered its innovative solutions to large multinational organizations like American Express, Smart Dubai Government, Wipro, AccentCare, Danone, University of Maryland Medical System, Aspen Pharmacare, Oman LNG, Mashreq Bank, HDFC Bank, and Genpact, to name a few.
For more details, contact sales or request a demo.
About eAlliance Corp
eAlliance Corp is a professional services firm with big company expertise and small company relationships, taking pride in agility and real-time responsiveness. eAlliance Corp is a trusted name in the Hyperautomation industry, offering comprehensive services and solutions to help businesses achieve their automation goals with ease. Founded in 2002 in Chicago, IL, staffed with resources in the US and India possessing vast experience and leadership in business and technology.
For more details, visit website.
For media inquiries, please contact:
Rahul Wandile
Media Relations – AutomationEdge
rahul.wandile@automationedge.com
www.automationedge.com
Follow AutomationEdge on: Twitter, Facebook, LinkedIn, and YouTube
View original content:
SOURCE AutomationEdge | https://www.kait8.com/prnewswire/2023/07/31/automationedge-ealliance-corp-announced-partnership-hyperautomation-solutions/ | 2023-07-31T12:34:56 | 0 | https://www.kait8.com/prnewswire/2023/07/31/automationedge-ealliance-corp-announced-partnership-hyperautomation-solutions/ |
WSGW Morning Team: July 31, 2023 (Monday)
It’s the WSGW Monday Morning Team with YOU and Charlie and Mike – presented by Paint Bull in Saginaw…..
Charlie and Mike and YOU: Charlie’s strange bike encounter on the Dixie Highway (runs 3:43)…..
***********************************************
Charlie and Mike and YOU: You could play XBox with your pizza scented controller!!!!! (runs 2:41)…..
Click for Official Rules and Entry Link
***********************************************
Charlie and Mike and YOU: A new Dungeons and Dragons video game is coming out and D&D player, Mike Percha, has a little perspective (runs 4:56)…..
***********************************************
Charlie and Mike and YOU: A One Hit Wonder song that was covered by a popular artist, too (runs 4:15)…..
***********************************************
Charlie and Mike and Art and YOU: Follow up on a story about the auction of Alan Alda’s dog tags and boots from M*A*S*H (runs
PHOTO: AP Photo/LM Otero
***********************************************
Here is the video and story of Cardi B retaliating against a fan throwing a drink at her on stage…..
***********************************************
OOPS! From Trenton High School in Trenton, Michigan…..
PHOTO: Robin Jankowski-DeDecker
OOPS! On a Road in Massachusetts
PHOTO: Photo courtesy of the Town of Holden/Facebook
***********************************************
Pastry Shop in Lisbon Selling “Pope Cookies” Ahead of His Visit This Week
PHOTO: Reuters
***********************************************
New Rocket Grab Plus Launch for YOU…..
***********************************************
New WSGW OnLine Poll for YOU!
***********************************************
WSGW Broadcasts on Tuesday, August 1, from Day One of the Saginaw County Fair
Click for Link to Saginaw County Fair
***********************************************
Purchase Your Entry today so you can play golf with us!
OR, Win Your Invitation by playing “Closest to the Pin”…..
***********************************************
The WSGW Morning Team with YOU and Charlie and Michael sponsored by
Paint Bull
on Bay Road in Saginaw
Paint Bull has been serving the Great Lakes Bay Region for over 30 years and is excited to continue to build on service offerings to all valued customers!
While Paint Bull continues to provide quality repairs on minor automotive damage at affordable prices, you can now enjoy services such as detailing, paint protection, film installation, and the latest graphene coating applications!
Whether you’re a do-it-yourselfer, a professional detailer, or just want your vehicle to look its best, Paint Bull will help with the quality products and services you need!
Paint Bull, on Bay Road, north of Shattuck, Saginaw
************************************************
Wake Up Song of the Day: Pilot “Magic“. It’s a “One Hit Wonder Monday” song! For our purposes, defined as a singer or group known for only one song to chart on the U.S. Billboard Top 40. Or, even if a second song is on the chart, it is overwhelmed and generally forgotten because of the success of the “One Hit Wonder”. In 1974, this Scottish band released this song from their first album (which was produced by the Alan Parsons Project – which three of the band members would join when Pilot disbanded after just a few years). The two writers of this song, David Paton and Billy Lyall, were briefly substitute members of the Bay City Roller’s before that band named after Bay City, Michigan, had its breakthrough. The song peaked at #5 in America in 1975. Selena Gomez covered the song for the soundtrack of the Disney Channel series “Wizards of Waverly Place”. Her version reached #61 on the chart. Here is a link for Selena singing “Magic“.
Comments, Praise, and Criticisms: [email protected]
Click to like WSGW on Facebook
Click to Return to TheMorning Team | https://www.wsgw.com/wsgw-morning-team-july-31-2023-monday/ | 2023-07-31T12:34:55 | 0 | https://www.wsgw.com/wsgw-morning-team-july-31-2023-monday/ |
New dispensary delivers on brand promise of product quality and variety with convenient locations
TALLAHASSEE, Fla., July 31, 2023 /PRNewswire/ -- Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States, announced the relocation of a medical dispensary in Kissimmee, Fla. located at 2647 E. Irlo Bronson Memorial Hwy. The dispensary will be open 9AM – 8:30PM Monday through Saturday and 11AM – 8PM on Sunday.
"Trulieve is committed to offering our Florida patients a broad selection of convenient locations and top-quality products to choose from, while also providing for best-in-class customer service," said Trulieve's Chief Executive Officer Kim Rivers. "This new location delivers on that commitment and we will continue to seek new opportunities to better serve this community."
Trulieve invites the Kissimmee community to join in celebrating this new dispensary on Friday, August 4 with partner giveaways, music, food trucks, specials discounts and more, starting at 9 AM. Trulieve also offers statewide home delivery, convenient online ordering and in-store pickup. As always, all first-time guests are eligible for a 60% new customer discount at any Florida-based location.
Designed to meet every patient's needs, our portfolio of in-house brands includes Alchemy, Co2lors, Cultivar Collection, Modern Flower, Momenta, Muse, Roll One, Sweet Talk and Trekkers. Customers also have access to beloved brands such as Alien Labs, Bhang, Binske, Black Tuna, Blue River, Connected Cannabis, DeLisioso, Khalifa Kush, Love's Oven, Miami Mango, Old Hippie Stash, O.Pen, Seed Junky and Sunshine Cannabis, all available exclusively at Trulieve in Florida.
For more information, or to learn how to become a registered patient, please visit Trulieve.com and connect on Facebook, Instagram or Twitter.
About Trulieve
Trulieve is an industry leading, vertically integrated cannabis company and multi-state operator in the U.S., with established hubs in the Northeast, Southeast, and Southwest, anchored by leading market positions in Arizona, Florida, and Pennsylvania. Trulieve is poised for accelerated growth and expansion, building scale in retail and distribution in new and existing markets through its hub strategy. By providing innovative, high-quality products across its brand portfolio, Trulieve delivers optimal customer experiences and increases access to cannabis, helping patients and customers to live without limits. Trulieve is listed on the CSE under the symbol TRUL and trades on the OTCQX market under the symbol TCNNF. For more information, please visit Trulieve.com.
Facebook: @Trulieve
Instagram: @Trulieve_
Twitter: @Trulieve
Investor Contact
Christine Hersey, Vice President of Investor Relations
+1 (424) 202-0210
Christine.Hersey@Trulieve.com
Media Contact
Teresa Coulter, VancoreJones Communications
+1 (407) 808-6139
TCoulter@vancorejones.com
View original content to download multimedia:
SOURCE Trulieve Cannabis Corp. | https://www.wbay.com/prnewswire/2023/07/31/trulieve-opening-relocated-medical-marijuana-dispensary-kissimmee-florida/ | 2023-07-31T12:34:56 | 0 | https://www.wbay.com/prnewswire/2023/07/31/trulieve-opening-relocated-medical-marijuana-dispensary-kissimmee-florida/ |
NEW YORK, July 31, 2023 /PRNewswire/ -- BGC Group, Inc. (Nasdaq: BGC) ("BGC"), a leading global brokerage and financial technology company, today announced the addition of a Weather Derivatives Team with the hire of Nicholas and Eric Ernst. Nicholas joins the firm as Managing Director, BGC Weather Derivatives while Eric joins as Weather Broker.
John Abularrage, Co-Global Head of Financial Services Brokerage, commented on today's announcement, "We are excited to welcome Nicholas and Eric to BGC. They bring with them almost three decades of invaluable experience in the weather derivatives and climate risk transfer space. With these new hires, BGC now operates the premier weather and climate derivatives desk in the industry."
Nicholas Ernst brings with him over 20 years of experience in the weather derivatives and risk transfer space. Prior to joining BGC, he served as Managing Director, Weather Markets at ICAP. Additionally, Nicholas spent time in similar roles at OTC Global and Evolutions Markets.
Before joining BGC, Eric Ernst served as a Weather Broker at ICAP. Prior to that, Eric held various roles at Choice Energy and spent three years in the renewable energy sector.
About BGC Group, Inc.
BGC Group, Inc. ("BGC") began trading on Nasdaq at the market opening on July 3, 2023, under the new ticker symbol "BGC", following the corporate conversion of its predecessor BGC Partners, Inc. (formerly Nasdaq: BGCP). BGC is a leading global brokerage and financial technology company. BGC, through its various affiliates, specializes in the brokerage of a broad range of products, including Fixed Income (Rates and Credit), Foreign Exchange, Equities, Energy and Commodities, Shipping, and Futures. BGC, through its various affiliates, also provides a wide variety of services, including trade execution, brokerage, clearing, trade compression, post-trade, information, and other back-office services to a broad range of financial and non-financial institutions. Through its brands, including Fenics®, FMX™, FMX Futures Exchange™, Fenics Markets Xchange™, Fenics Digital™, Fenics UST™, Fenics FX™, Fenics Repo™, Fenics Direct™, Fenics MID™, Fenics Market Data™, Fenics GO™, Fenics PortfolioMatch™, BGC®, BGC Trader™, kACE2™, and Lucera®, BGC offers financial technology solutions, market data, and analytics related to numerous financial instruments and markets. BGC, BGC Group, BGC Partners, BGC Trader, GFI, GFI Ginga, CreditMatch, Fenics, Fenics.com, FMX, Sunrise Brokers, Poten & Partners, RP Martin, kACE2, Capitalab, Swaptioniser, CBID, Caventor, LumeMarkets and Lucera are trademarks/service marks and/or registered trademarks/service marks of BGC and/or its affiliates.
BGC's customers include many of the world's largest banks, broker-dealers, investment banks, trading firms, hedge funds, governments, corporations, and investment firms. BGC's Class A common stock trades on the Nasdaq Global Select Market under the ticker symbol "BGC". BGC is led by Chairman of the Board and Chief Executive Officer Howard W. Lutnick. For more information, please visit http://www.bgcg.com. You can also follow BGC at https://twitter.com/bgcgroupinc, https://www.linkedin.com/company/bgc_group and/or http://ir.bgcg.com.
Discussion of Forward-Looking Statements about BGC
Statements in this document regarding BGC that are not historical facts are "forward-looking statements" that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the effects of the COVID-19 pandemic on the Company's business, results, financial position, liquidity and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, BGC undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see BGC's Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.
Media Contact:
Karen Laureano-Rikardsen
+1 212-829-4975
View original content to download multimedia:
SOURCE BGC Group, Inc. | https://www.wafb.com/prnewswire/2023/07/31/bgc-group-hires-nicholas-eric-ernst-launch-weather-derivatives-desk/ | 2023-07-31T12:34:58 | 0 | https://www.wafb.com/prnewswire/2023/07/31/bgc-group-hires-nicholas-eric-ernst-launch-weather-derivatives-desk/ |
The report highlights emerging trends that will significantly impact the financial services industry over the next decade
NEW YORK, July 31, 2023 /PRNewswire/ -- Deloitte today announced its "2023 Financial Services Industry Predictions" report, which outlines emerging trends across the banking & capital markets, insurance, real estate, and investment management sectors. The report highlights the impact of data and emerging technologies, products and services, and climate change on the future of financial services – and as a result, on society and the economy.
"The reality is that emerging technological changes could be more pervasive and impactful going forward in ways that can be scarcely imagined today," said Jim Eckenrode, managing director, Deloitte Center for Financial Services. Deloitte Services LP. "Financial services will likely play an important role in helping these breakthroughs emerge to the benefit of us all, while simultaneously opening up new avenues of revenue and profit."
Some of Deloitte's predictions for the financial services industry over the next decade:
Generative AI is expected to boost productivity: Generative AI is expected to have a significant impact on the investment banking industry and the financial services industry as a whole, as organizations explore ways to harness the power of the technology to improve productivity. Deloitte predicts the top 14 global investment banks could boost their front-office productivity by an average of 25% by using Generative AI (GAI), thereby earning potentially an additional revenue of $3 million per front-office employee in 2026, from an average of $11.3 million during 2020-22.
Demand for carbon credit offset financing: Deloitte predicts that global consumers will purchase $115 billion of carbon offsets a year by 2030. Carbon credits will likely be embedded in many of the purchasing decisions that consumers make in their day-to-day lives. The surge in demand for these credits could produce new trading networks that offer tailored, localized and niche options for climate change mitigation projects. Banks could be instrumental in developing and supporting the back-end infrastructure that connect brands' payment processes to the carbon credit market. And banks can play an instrumental role in developing and supporting the carbon credit market.
Insurers prepare for driverless vehicles: Deloitte estimates advancements in self-driving technology may eliminate the need for around 380,000 long-haul truck drivers in the next five years. This alone would have a major impact on workers' compensation insurers, with a potential loss of around $3 billion worth of premiums. But widespread adoption of autonomous vehicles could also result in a shift in premiums across multiple insurance lines, including commercial auto, product and professional liability, and cyber coverage.
Office space to fill the affordable housing gap: Deloitte predicts office-to-residential conversions could become profitable within the next five years, estimating that around 14,700 affordable units in central business districts across the country can be added by 2030, assuming approximately 20% of converted square footage can be earmarked for affordable housing.
"As financial services firms grapple with what's on the horizon, they need to think about how the landscape is radically shifting," said Monica O'Reilly, Vice Chair, US Financial Services Industry Leader, Deloitte & Touche LLP. "Market and economic pressures, emerging technologies, and new revenue opportunities will impact tomorrow's business strategies, and financial services firms should prepare for that now."
Additional trends included in the report that are expected to shape the financial services industry:
Democratization of financial advice: Financial advice shouldn't just be for the wealthy anymore — and it doesn't have to be. Financial firms can leverage robo-advisory platforms to bring much-needed financial advice to the global mass market and make it profitable. Deloitte estimates net financial wealth held by the mass retail population segment globally to almost double to $22 trillion by 2030.
Synthetic identity fraud could trigger need for more sophisticated biometric security systems: Synthetic identity fraud—a hoax in which cybercriminals create new identities with some stolen or fabricated data — is the fastest growing financial crime in the United States,i and it shows no sign of abating. Deloitte expects it to generate at least $25 billion in losses by 2030, prompting banks to develop more advanced biometric security systems to weed out would-be perpetrators.
Higher deposit costs expected to challenge banks: Deloitte predicts the average cost of interest-bearing deposits for the U.S. banking industry in 2024 and 2025 to remain elevated at 1.7% and 1.5%, respectively, even as the fed funds rate declines from the recent peak. This may crimp bank profitability in the medium term.
Real-time B2B payments could take off: Deloitte expects real-time payments could tap an addressable market of $12 trillion in check-based business-to-business (B2B) transaction volume globally by 2028. Banks and payment firms could play a pivotal role in helping usher in a new era of more efficient and instant domestic and cross-border value exchange among businesses.
Rise of embedded insurance: Embedded finance, and particularly embedded insurance, is expected to continue to expand. Execution may not be easy for insurers, though, and it could take the rest of the decade for embedded finance to fully shake out.
Increased spending on quantum computing: Spending on quantum-related capabilities will likely grow quickly over the next few years as indicated by the increased capital investments and patent filings for the hardware technology. Globally, the financial services industry's spending on quantum computing capabilities is expected to grow 233x from just US$80 million in 2022 to US$19 billion in 2032, growing at a 10-year CAGR of 72%.
Alternative data in investment management: Deloitte estimates the revenue for alternative data providers, earned from all industries globally with the majority coming from investment management firms, to grow 29x between 2022 and 2030. The new data largely consist of novel types and forms of data such as satellite images, social media posts, geolocation data, credit card transactions, and mobile application data that are starkly different from the traditionally structured financial data.
Funding for climate hardtech: An additional US$2 trillion in private hardtech investment is predicted to be needed to help effectively slow global warming. Most of total climate funding will likely need to come from the private sector — but so far, there isn't enough. Financial services organizations can play a lead role in bridging the funding gap.
About Deloitte
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including nearly 90% of the Fortune 500® and more than 7,000 private companies. Our people come together for the greater good and work across the industry sectors that drive and shape today's marketplace — delivering measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to see challenges as opportunities to transform and thrive, and help lead the way toward a stronger economy and a healthier society. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Building on more than 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte's more than 415,000 people worldwide connect for impact at www.deloitte.com.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
iFedPayments Improvement, "Synthetic identity fraud," accessed June 8, 2023.
View original content to download multimedia:
SOURCE Deloitte | https://www.kwch.com/prnewswire/2023/07/31/deloitte-2023-financial-services-industry-predictions-generative-ai-carbon-offset-financing-driverless-vehicles-office-space-conversion-among-top-trends-transforming-financial-services/ | 2023-07-31T12:35:00 | 1 | https://www.kwch.com/prnewswire/2023/07/31/deloitte-2023-financial-services-industry-predictions-generative-ai-carbon-offset-financing-driverless-vehicles-office-space-conversion-among-top-trends-transforming-financial-services/ |
Impact "much bigger than a single project"
WAYNESBORO, Ga., July 31, 2023 /PRNewswire/ -- Bechtel, the engineering, procurement, and construction company brought in to complete construction on new Units 3 and 4 at the Vogtle nuclear power plant in Georgia, today issued the following statement from Brendan Bechtel, Bechtel Chairman and CEO, marking the start of commercial operations for Unit 3:
"We are extremely proud of Bechtel's part in achieving this milestone. Our team has been 100 percent committed to Vogtle's completion since being brought in to finish the project.
"Today's start of commercial operations for Vogtle Unit 3 gives the Southeast a major new source of clean, reliable, carbon-free baseload energy. And, as the first new nuclear unit built in the U.S. in more than 30 years, it helps put America back on the map as a leader in the global nuclear industry.
"Bechtel has supported the design and construction of 150 nuclear plants worldwide. We know firsthand how Vogtle Units 3 and 4 go a long way in restoring America's muscle memory in nuclear construction, including the workforce and domestic supply chains required to build America's largest nuclear power plant. Vogtle Unit 3 comes online at a pivotal time when energy security concerns and the need to cut carbon emissions are driving growth in the world's nuclear fleet.
"Plant Vogtle will generate more carbon-free electricity yearly than any other energy facility currently operating in the country. Its completion reinforces that the United States is the responsible partner of choice for new nuclear energy around the world, and maintains U.S. interests in ensuring strong safety, security, and non-proliferation standards. This is why Vogtle's impact is much bigger than a single project.
"Thank you to the thousands of skilled craft professionals, union partners, engineers, project managers, procurement experts, suppliers, subcontractors, and everyone who made this day possible. And thank you to Georgia Power and Southern Nuclear for the opportunity to bring this project over the finish line. We look forward to doing the same with Unit 4 in the coming months."
Background
In 2017, Bechtel was brought in by Georgia Power and Southern Nuclear to take over construction of Vogtle Units 3 and 4, bringing extensive experience supporting the design and construction of 150 nuclear plants worldwide. Vogtle Units 3 and 4 are the first Westinghouse AP1000 units to ever be built in the U.S.
Bechtel has completed more than 76,000 megawatts of new nuclear generation capacity and has designed, built, or performed engineering and/or construction services on more than 80% of nuclear plants in the United States. Today, the company leads efforts in designing and constructing advanced nuclear plants, critical to global efforts to achieve net zero carbon emissions.
Bechtel partnered with North America's Building Trades Unions (NABTU) to build Plant Vogtle Units 3 and 4. At peak, Bechtel and NABTU had a combined 9,000 workers on site.
About Bechtel
Bechtel is a trusted engineering, construction, and project management partner to industry and government. Differentiated by the quality of our people and our relentless drive to deliver the most successful outcomes, we align our capabilities to our customers' objectives to create a lasting positive impact. Since 1898, we have helped customers complete more than 25,000 projects in 160 countries on all seven continents that have created jobs, grown economies, improved the resiliency of the world's infrastructure, increased access to energy, resources, and vital services, and made the world a safer, cleaner place.
Bechtel serves the Energy; Infrastructure; Manufacturing & Technology; Mining & Metals; and Nuclear, Security & Environmental markets. Our services span from initial planning and investment through start-up and operations. www.bechtel.com
Contact:
Amanda Meixel
ammeixel@bechtel.com
M: 1-706-360-5526
P: 1-703-429-6313
View original content to download multimedia:
SOURCE Bechtel | https://www.kait8.com/prnewswire/2023/07/31/bechtel-commercial-operations-vogtle-unit-3-is-an-important-milestone-us-nuclear-industry/ | 2023-07-31T12:35:02 | 1 | https://www.kait8.com/prnewswire/2023/07/31/bechtel-commercial-operations-vogtle-unit-3-is-an-important-milestone-us-nuclear-industry/ |
This Launch Marks the Latest Expansion of the Brand's Complexion Offerings as it Doubles Down on The Skincare-Meets-Makeup Hybrid Category
NEW YORK, July 31, 2023 /PRNewswire/ -- TULA Skincare, the leading clinically proven probiotic extract powered skincare brand has announced the expansion of its complexion offerings to include concealer.
After learning that TULA's customers were looking for a skin brightening eye treatment along with a concealer, the brand created a state-of-the-art clean skincare-makeup hybrid that delivers skin-boosting benefits with high-performance medium-to-full coverage.
Available in a 20-shade range, the dermatologist-tested, Radiant Skin Brightening Serum Concealer is infused with TULA's unique Rainbow Seabright™ Elixir. This clinically-proven serum-like formula instantly conceals dark circles and discoloration for longwearing, crease-proof results, while brightening the appearance of skin over time. Additional ingredients include TULA's S6Pro Complex® - a US patent pending super six blend of prebiotics and probiotic extracts to help soothe skin, improve skin smoothness and maintain skin balance, along with eye peptides and tea leaf caffeine to help improve the look of dark circles, skin texture, and eye bags. The Radiant Skin Brightening Serum Concealer can be paired with the brand's Radiant Skin Brightening Serum Skin Tint or Filter Primer Blurring & Moisturizing Primer to help build one's complexion wardrobe, or spot conceal for a no-makeup, makeup look.
"Expanding our complexion category to include a concealer was a natural next step for us, especially knowing the strong desire our customers have had for an eye treatment with brightening benefits." said TULA Skincare CEO, Savannah Sachs. " We are excited to have another offering for our glow getters that will surely be a staple in their skincare and beauty routines."
To mark the launch, TULA will be executing a multi-channel launch campaign across its digital platform, and organic social, paid media, and influencer channels. Efforts will include launching a custom "shade finder" on tula.com to help customers find their perfect match concealer shade, highlighting content speaking to the "no-makeup, makeup" and makeup-skincare hybrid trends across TikTok and Instagram, and partnering with a curated set of influencers and providing them with an early access link exclusively for their followers to purchase the concealer prior to launch. In addition to tula.com, the concealer will launch in Ulta Beauty stores nationwide and online and will be featured in an upcoming issue of the Ulta Beauty Magazine, with in-store complexion events planned in the coming months in multiple doors.
TULA's Radiant Skin Brightening Serum Concealer will be available for purchase on July 31 on tula.com, and will retail for $32.
About TULA Skincare
TULA is a doctor-founded skincare brand built on clinically proven formulas powered by probiotic extracts. We believe that the same types of ingredients which are good for your body are also great for your skin. We focus on being healthy, not perfect and on empowering everyone to feel confident in their skin.
Media Contact: Zoe Jeans at Bux + Bewl Communications: zoe@buxandbewl.com
View original content to download multimedia:
SOURCE TULA Skincare | https://www.wbay.com/prnewswire/2023/07/31/tula-skincare-launches-new-radiant-skin-brightening-serum-concealer/ | 2023-07-31T12:35:03 | 0 | https://www.wbay.com/prnewswire/2023/07/31/tula-skincare-launches-new-radiant-skin-brightening-serum-concealer/ |
- Cash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023
- Announced positive interim data from BHV-7000 EEG biomarker study demonstrating evidence of central nervous system (CNS) target engagement, confirming previously reported preclinical and clinical data, and highlighting the paradigm-changing potential of BHV-7000 in the treatment of epilepsy and mood disorders
- Brain penetrant TYK2/JAK1 inhibitor, BHV-8000, advanced into Phase 1 with projected therapeutic concentrations achieved and well-tolerated profile observed to date
- Advanced targeted extracellular protein degradation platform with potential to support numerous clinical candidates across a broad range of high unmet need indications
- Orphan drug designation (ODD) granted by the European Commission for taldefgrobep alfa a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA)
- Type A meeting planned with FDA regarding troriluzole program in Spinocerebellar Ataxia Type 3 (SCA3) and enrollment in Phase 3 obsessive compulsive disorder (OCD) trial expected to complete at end of 2023
NEW HAVEN, Conn., July 31, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, "In less than a year since our spin-off, the Biohaven team has driven strong and consistent progress across multiple drug development platforms. We were excited to recently report positive interim data from the ongoing EEG biomarker study of our lead Kv7 activator, BHV-7000. As expected, BHV-7000 demonstrated CNS activity consistent with what has been reported in EEG studies with other Kv7 channel activators in development that are clinically effective in treating epilepsy and with other approved anti-seizure medications. Importantly, BHV-7000 demonstrates CNS target engagement but is not associated with the typical CNS adverse events associated with other ASMs, like somnolence and fatigue. We look forward to completing the higher dose groups in this EEG study and initiating Phase 2/3 studies with our once daily, extended-release oral formulation later this year."
Dr. Coric continued, "We also shared a number of equally exciting announcements across our broader pipeline this quarter. We successfully administered the first three doses in the SAD portion of our ongoing SAD/MAD study evaluating BHV-8000, an oral, brain-penetrant, dual TYK2/JAK1 inhibitor. Potential therapeutic concentrations of BHV-8000 were achieved and BHV-8000 was well tolerated with only mild adverse events reported, reinforcing our plans to start a Phase 2 clinical trial with BHV-8000 in Parkinson's disease and potentially other neuroinflammatory diseases in 2024. In addition, we have advanced IND enabling preclinical studies and remain on track to submit an IND with our IgG degrader, BHV-1300, later this year. We also anticipate submitting an IND with our IgA degrader in 2024 as we continue to advance multiple clinical degrader candidates across a wide range of indications. We also shared key updates for our taldefgrobep alfa program (an anti-myostatin) with enrollment completion in our pivotal study in SMA and a planned Phase 2 trial initiation in obesity."
"Finally, I want to reaffirm Biohaven's commitment to the SCA3 patient community in spite of the recent disappointing regulatory decision by the FDA not to review our submitted NDA. Given the seriousness of SCA3 and consistent treatment benefits observed across multiple prespecified outcome measures, including an 80% delay in disease progression over the one-year study period with substantial risk reduction in falls, we believe that full consideration of all available data is warranted for this ultra-rare disease. Biohaven has built its foundation around our patient mission and we plan to continue to work with regulatory agencies to try to advance troriluzole for individuals suffering from SCA3."
Second Quarter 2023 and Recent Business Highlights
- Announced positive interim data from EEG biomarker study with BHV-7000 - In July 2023, the Company provided a preliminary data update from the ongoing electroencephalogram (EEG) biomarker study for the Kv7 Channel Activator platform. Preliminary Phase 1 data confirmed evidence of target engagement in the central nervous system for subjects with projected therapeutic concentrations of BHV-7000 (based on the EC50 from preclinical models), measured by changes from baseline in EEG spectral power that occurred after dosing. These pharmacodynamic (PD) effects were similar to those reported in the literature for anti-seizure medicines (ASMs), including Kv7 activators in development that are clinically effective in treating epilepsy. BHV-7000's PD effects were also differentiated from those reported for other Kv7 activators including, specifically, the absence of increases in EEG spectral power in frequency bands associated with drowsiness and somnolence. Results from the low-dose group validate the preclinical hypothesis, confirm the Phase 1 SAD/MAD clinical data, and provide strong support for Biohaven's plans to initiate pivotal studies with BHV-7000 in focal epilepsy and bipolar disorder in the second half of 2023. The preliminary data highlight BHV-7000's differentiation and potentially favorable clinical profile compared to other ASMs, and the Company expects to present the complete EEG results by the end of the year. Additionally, new pharmacokinetic data from multiple clinical formulations being studied has now confirmed a once daily extended-release oral formulation that will be used in the Phase 2/3 clinical programs.
- Successfully dosed three cohorts with single ascending doses of oral, brain penetrant, dual TYK2/JAK1 agent, BHV-8000 - In July 2023, the Company announced that it successfully dosed three cohorts in the SAD portion of an ongoing SAD/MAD Phase 1 study evaluating brain penetrant TYK2/JAK1 agent, BHV-8000 in healthy volunteers. The ongoing Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and PD of single and multiple ascending doses of BHV-8000 in healthy volunteers. Based on the preliminary data available, projected therapeutic concentrations of BHV-8000 were achieved, and BHV-8000 was well tolerated with only mild adverse events reported. These data provide support for further development of BHV-8000, and the Company anticipates beginning a Phase 2 clinical trial with BHV-8000 in Parkinson's disease and potentially other neuroinflammatory diseases in 2024. The Company had previously reported initiation of dosing with BHV-8000 in the Phase 1 study at Biohaven's R&D Day in May 2023.
- Reported on continued progress observed with Biohaven's first-in-class bispecific IgG degrader, BHV-1300, as compound advances to IND filing in 2H2023 - In July 2023, the Company shared an update on BHV-1300's highly competitive safety, manufacturable and PD profile. The Company is assembling a pipeline of partially de-risked, follow-on IgG degraders as well as antigen-specific degraders providing both optionality and a sustainable output of drug candidates for several years. An IND application for BHV-1300 is on track for submission in 2023 and an IND application for Biohaven's IgA degrader on track for submission in 2024
- Type A meeting planned to comprehensively address FDA's concerns in connection with Troriluzole program in SCA3 - In July 2023, the Company announced that the FDA informed Biohaven it would not review the recently submitted New Drug Application (NDA) for troriluzole for the treatment of spinocerebellar ataxia type 3 (SCA3), an ultra-rare, genetically-defined, neurodegenerative disease associated with progressive disability, frequent falls, loss of ambulation, speech and swallowing impairment, and premature death that is the most common SCA genotype worldwide. The FDA informed Biohaven it would not review the application given that the study's primary endpoint was not met and thus, would not permit a substantive review. Biohaven is committed to working closely with the FDA to bring troriluzole to people with SCA3 as quickly as possible given no therapy is currently approved for this ultra-rare genetic disorder. Biohaven plans to request a Type A meeting to comprehensively address FDA's concerns cited in the refusal to file letter.
- EMA orphan drug designation granted for taldefgrobep alfa for the treatment of SMA: - In July 2023, the Company announced that taldefgrobep alfa received orphan drug designation (ODD) from the European Commission for taldefgrobep for the treatment of SMA. Taldefgrobep previously received Fast-Track and ODD from the FDA. At Biohaven's R&D Day, the Company announced plans to complete randomization of approximately 180 patients in global SMA trial.
Upcoming Milestones:
Biohaven is progressing its product candidates through clinical programs in a number of common and rare disorders. The Company plans to reach significant pipeline milestones in the coming periods. Biohaven expects to:
- Announce Phase 1 EEG study results by year-end 2023: The Company expects to present complete results from its ongoing EEG study with BHV-7000 in healthy volunteers by the end of the year.
- Initiate Phase 2/3 studies with BHV-7000 in the second half of 2023: Biohaven expects to initiate pivotal trials in patients with focal epilepsy and bipolar disorder in the second half of 2023.
- Submit IND with BHV-1300, the Company's lead extracellular degrader: The Company expects to submit an IND with pan-IgG degrader BHV-1300 in the second half of 2023 and expects to initiate Phase 2 studies in 2024.
- Submit IND with selective Gd-IgA1 degrader: The Company expects to submit an IND with a Gd-IgA1 degrader indicated for IgA nephropathy in the first half of 2024.
- Initiate Phase 2 study with BHV-8000: The Company commenced Phase 1 studies with BHV-8000, an oral, brain-penetrant, dual TYK2/JAK1 inhibitor for neuroinflammatory disorders, in the first half of 2023 and expects to initiate a Phase 2 study in Parkinson's disease in 2024.
- Submit IND with BHV-2100 in chronic pain: The Company expects to submit an IND with BHV-2100, a selective TRPM3 antagonist in the Company's ion channel platform, in the second half of 2023.
- Complete enrollment in Phase 3 study of troriluzole in OCD in 2023: Two Phase 3 randomized, double-blind, placebo-controlled studies of troriluzole in OCD are expected to enroll up to 700 patients (in each trial) across nearly 200 global study sites. The Company anticipates completing enrollment in at least one Phase 3 trial by year-end 2023.
- Complete enrollment in Phase 3 clinical study of taldefgrobep alfa in SMA: The Company expects to complete enrollment in the study of taldefgrobep in SMA in the second half of 2023.
- Continue advancements across multiple neuroscience and immunoscience indications: The Company's preclinical pipeline includes a platform of bispecific degraders of extracellular proteins directed against IgG, IgA and other targets, TRPM3 and Kv7 family of ion channels, and other undisclosed targets, including those with disease-modifying potential.
Capital Position:
Cash, cash equivalents and marketable securities as of June 30, 2023 was $349.0 million, including $13.9 million of restricted cash, and excluding $40.4 million of cash payable to Biohaven Pharmaceutical Holding Company Ltd. (the Former Parent), compared to $467.9 million, including $2.5 million of restricted cash, and excluding $35.2 million of cash payable to the Former Parent, as of December 31, 20221.
Second Quarter 2023 Financial Highlights:
Research and Development (R&D) Expenses: R&D expenses, including non-cash share-based compensation costs, were $79.5 million for the three months ended June 30, 2023, compared to $177.1 million for the three months ended June 30, 2022. Non-cash share-based compensation expense was $2.5 million for the three months ended June 30, 2023, a decrease of $10.3 million as compared to the same period in 2022. Non-cash share-based compensation expense was higher in the second quarter of 2022 primarily because expense allocated from the Former Parent equity plan, prior to the spin-off, was based on equity awards with higher grant date fair values.
General and Administrative (G&A) Expenses: General and administrative expenses were $14.5 million for the three months ended June 30, 2023, compared to $20.0 million for the three months ended June 30, 2022. The decrease of $5.5 million was primarily due to decreased non-cash share-based compensation costs. Non-cash share-based compensation expense was $2.2 million for the three months ended June 30, 2023, a decrease of $5.8 million as compared to the same period in 2022. Non-cash share-based compensation expense was higher in the second quarter of 2022 primarily because expense allocated from the Former Parent equity plan, prior to the spin-off, was based on equity awards with higher grant date fair values.
Other Income (Expense), Net: Other income (expense), net was a net income of $5.8 million for the three months ended June 30, 2023, compared to net expense of $0.1 million for the three months ended June 30, 2022. The increase of $5.9 million was primarily due to an increase in net investment income and an increase of $1.7 million in other income related to our transition services provided to the Former Parent, which is largely non-recurring.
Net Loss: Biohaven reported a net loss for the three months ended June 30, 2023, of $90.3 million, or $1.32 per share, compared to $203.3 million, or $5.16 per share, for the same period in 2022. Non-GAAP adjusted net loss for the three months ended June 30, 2023 was $85.7 million, or $1.25 per share, compared to $182.5 million, or $4.63 per share for the same period in 2022. These non-GAAP adjusted net loss and non-GAAP adjusted net loss per share measures, more fully described below under "Non-GAAP Financial Measures," exclude non-cash share-based compensation charges. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below. For periods prior to Biohaven's spin-off from the Former Parent on October 3, 2022 (the "Spin-Off"), net loss per share and non-GAAP adjusted net loss per share were calculated based on the 39,375,944 common shares of Biohaven distributed to the Former Parent shareholders at the time of the distribution, including common shares issued in connection with the Former Parent share options that were settled on October 3, 2022 and common shares issued in connection with the Former Parent restricted share units that vested on October 3, 2022. The same number of shares is being utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off.
Non-GAAP Financial Measures
This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States (GAAP), and also certain non-GAAP financial measures. In particular, Biohaven has provided non-GAAP adjusted net loss and adjusted net loss per share, which are adjusted to exclude non-cash share-based compensation, which is substantially dependent on changes in the market price of common shares. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. However, Biohaven believes the presentation of non-GAAP adjusted net loss and adjusted net loss per share, when viewed in conjunction with GAAP results, provides investors with a more meaningful understanding of ongoing operating performance and can assist investors in comparing Biohaven's performance between periods.
In addition, these non-GAAP financial measures are among those indicators Biohaven uses as a basis for evaluating performance, and planning and forecasting future periods. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between these non-GAAP measures and the most directly comparable GAAP measures is provided later in this news release.
About Biohaven
Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases. Biohaven's experienced management team brings with it a track record of delivering new drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia. The company is advancing a pipeline of therapies for diseases, many of which have limited or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia, myostatin inhibition for neuromuscular diseases and metabolic disorders, and brain-penetrant TYK2/JAK1 inhibition for neuroinflammatory disorders. Biohaven's portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and targeted extracellular protein degradation platform technology (MoDE™) with potential application in neurological disorders, cancer, and autoimmune diseases.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates; the potential for Biohaven's product candidates to be first in class therapies; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this new release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
MoDEs is a trademark of Biohaven Therapeutics Ltd.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
+1 (312) 961-2502
View original content to download multimedia:
SOURCE Biohaven Ltd. | https://www.wafb.com/prnewswire/2023/07/31/biohaven-reports-second-quarter-2023-financial-results-recent-business-developments/ | 2023-07-31T12:35:04 | 1 | https://www.wafb.com/prnewswire/2023/07/31/biohaven-reports-second-quarter-2023-financial-results-recent-business-developments/ |
SAN FRANCISCO, July 31, 2023 /PRNewswire/ -- Today, Blitz Insurance, a specialty insurance carrier, partners with Ascend to modernize payment experiences for insurance brokers selling in specialty markets. With this partnership, Blitz Insurance will open new customer segments by offering both direct bill and premium financing into their payments workflow.
"When we looked into the market for a solution, Ascend was the right choice. Ascend meets our needs for a better payments experience for our partners while reducing everyone's operational expenses," said Brandon Murphy, Chief Distribution Officer of Blitz Insurance. "We will now have the ability to not only expand to direct bill and a premium finance option but also simplify the movement of money between us and our partners."
With Ascend, Blitz Insurance is now able to provide a direct bill in addition to their existing agency bill workflow - allowing brokers to decide what billing method works best for them. By utilizing Ascend, Blitz Insurance not only grows their footprint of appointed brokers but also gains administrative efficiency by automating what would otherwise have been a large operational undertaking.
Ascend automatically attributes incoming payments to policies in real time, speeding up the reconciliation process. By modernizing the payments experience and speeding up the reconciliation of incoming premiums, Blitz Insurance can offer a best-in-class experience to its brokers and agents.
"We find that across the insurance ecosystem - companies want to provide a seamless payment workflow for their customers and their teams," said Andrew Wynn, co-CEO of Ascend. "Ascend is built so brokers and carriers can offer this experience without shouldering the administrative resources and costs needed to support these operations."
About Ascend
Ascend is the first insurance payments platform that automates financial operations from collections and financing to carrier and commission payables. Founded by two-time insurtech entrepreneurs Andrew Wynn and Praveen Chekuri, Ascend helps insurance brokers, MGAs, and carriers improve their bottom lines by eliminating expensive and labor-intensive payment workflows. To learn more, please visit LinkedIn, Twitter or check out https://www.useascend.com/.
About Blitz Insurance
Blitz is a tech-driven insurer revolutionizing the $60B specialty market catering to SME segment. By leveraging industry knowledge and cutting-edge technology, we deliver a simpler, smarter, and faster coverage experience.
The company is led by a veteran team of insurance and technology experts and has been funded with $25M from its founder & CEO, a Forbes-listed serial entrepreneur in the real estate and insurance industries.
Contact:
Mike Nguyen
press@useascend.com
View original content to download multimedia:
SOURCE Ascend | https://www.wafb.com/prnewswire/2023/07/31/blitz-insurance-partners-with-ascend-expand-payment-financing-offerings/ | 2023-07-31T12:35:05 | 1 | https://www.wafb.com/prnewswire/2023/07/31/blitz-insurance-partners-with-ascend-expand-payment-financing-offerings/ |
Partnership Expands Access to Seizure First Aid Trainings for School Personnel
BOWIE, Md., July 31, 2023 /PRNewswire/ -- The Epilepsy Foundation today announced a five-year collaboration with Vector Solutions, the leading provider of training and software solutions for K-12 and higher education institutions, to offer the Epilepsy Foundation's Seizure Recognition & First Aid Certification training in the Vector Safety and Compliance Course Library. This agreement will provide an easy and convenient way for educators and school personnel, who are already contracted with Vector, to take the seizure first aid training to better serve their students.
There are 470,000 children living with epilepsy in the U.S. According to the Centers for Disease Control and Prevention (CDC), the opportunity for academic success is increased when students with chronic health conditions have a safe and supportive learning environment.
"Our collaboration with Vector will give school personnel — who are required by state laws to take seizure first aid training — a place to do so easily and effectively through a familiar learning portal," said Brandy Fureman, Ph.D., chief outcomes officer, Epilepsy Foundation. "In addition, it will expand access to our seizure first aid training to school systems around the country using Vector's platform. Our end goal is to have a seizure safe nation where everyone who has a seizure feels safe, no matter where they are. This partnership is a stepstone toward that goal."
In 2018, Kentucky led the charge to pass the nation's first-ever law requiring school personnel to complete seizure recognition and first aid training. Since then, the Epilepsy Foundation, family advocates and partner organizations have been working to pass similar Seizure Safe Schools legislation nationwide. The model Seizure Safe Schools legislation has five components, one of which requires all school personnel, including school nurses and teachers, to complete training so that they can recognize and respond appropriately and efficiently to students experiencing seizures. To date, almost half of the states have passed some form of Seizure Safe Schools legislation.
For years, the Epilepsy Foundation has partnered with the CDC to build nationwide programs to ensure school personnel, first responders, seniors, caregivers, and the public are better trained to recognize seizures and administer first aid. The Epilepsy Foundation's seizure first aid trainings provide information to increase knowledge, skills, and confidence in recognizing seizures and safely administering seizure first aid.
"We are excited to collaborate with the Epilepsy Foundation to deliver its trainings through our online learning management system," said, Rob Buelow, General Manager of Education at Vector Solutions. "The safety and well-being of students is paramount and educators must be properly equipped to address the unique needs of all students. Through this partnership, K-12 and higher education staff across the nation will be empowered to serve their students and ensure their health and safety."
For more information about the Epilepsy Foundation's seizure first aid trainings, visit epilepsy.com/firstaid. The trainings will be available in the Vector platform later this summer and school administrators who have a current subscription will receive notification when the trainings are live.
About Epilepsy
According to the World Health Organization, epilepsy is the most common serious brain disorder worldwide with no age, racial, social class, national or geographic boundaries. The U.S. Centers for Disease Control & Prevention estimates that 3.4 million people in the United States are affected by epilepsy. Epilepsy is the underlying tendency of the brain to produce seizures which are sudden abnormal bursts of electrical energy that disrupt brain functions.
About the Epilepsy Foundation
With a network of partners throughout the United States, the Epilepsy Foundation is leading the fight to overcome the challenges of living with epilepsy. The Foundation connects people to treatment, support, and resources; leads advocacy efforts; funds innovative research and the training of specialists; and educates the public about epilepsy and seizure first aid. For more than five decades, the Epilepsy Foundation has shone a light on epilepsy to promote awareness and understanding, and to advocate for laws that matter to people with epilepsy, while also funding epilepsy research and supporting epilepsy investigators and specialists in their early careers. In partnership with the CDC, the Epilepsy Foundation has helped to improve access to care for people with epilepsy, expanded its digital reach and online resources in homes across the country, and trained more than 600,000 people in seizure recognition and first aid. The Epilepsy Foundation continues to focus on serving the epilepsy community through advocacy, education, direct services and research for new therapies. To learn more visit epilepsy.com or call 1.800.332.1000. Follow us on Facebook and Twitter.
About Vector Solutions for K-12 Education
Vector Solutions for K-12 Education is a leading provider of training, software and professional development solutions committed to creating safer, smarter and better school environments. Trusted by more than 5,000 K-12 districts in the United States, Vector's award-winning suite of products save administrators time, improve compliance, and streamline administrative processes. Vector trainings on imperative topics like safety and compliance; inclusive instruction; mental health and well-being; diversity, equity and inclusion; and cybersecurity enable students and teachers alike to make schools safer, more inclusive, and more effective places to work and learn. For more information about Vector Solutions for K-12 Education, visit www.vectorsolutions.com/k12.
View original content to download multimedia:
SOURCE Epilepsy Foundation | https://www.kwch.com/prnewswire/2023/07/31/epilepsy-foundation-partners-with-vector-solutions-offer-seizure-first-aid-trainings-educators/ | 2023-07-31T12:35:07 | 0 | https://www.kwch.com/prnewswire/2023/07/31/epilepsy-foundation-partners-with-vector-solutions-offer-seizure-first-aid-trainings-educators/ |
NEW YORK, July 31, 2023 /PRNewswire/ -- BGC Group, Inc. (Nasdaq: BGC) ("BGC"), a leading global brokerage and financial technology company, today announced the addition of a Weather Derivatives Team with the hire of Nicholas and Eric Ernst. Nicholas joins the firm as Managing Director, BGC Weather Derivatives while Eric joins as Weather Broker.
John Abularrage, Co-Global Head of Financial Services Brokerage, commented on today's announcement, "We are excited to welcome Nicholas and Eric to BGC. They bring with them almost three decades of invaluable experience in the weather derivatives and climate risk transfer space. With these new hires, BGC now operates the premier weather and climate derivatives desk in the industry."
Nicholas Ernst brings with him over 20 years of experience in the weather derivatives and risk transfer space. Prior to joining BGC, he served as Managing Director, Weather Markets at ICAP. Additionally, Nicholas spent time in similar roles at OTC Global and Evolutions Markets.
Before joining BGC, Eric Ernst served as a Weather Broker at ICAP. Prior to that, Eric held various roles at Choice Energy and spent three years in the renewable energy sector.
About BGC Group, Inc.
BGC Group, Inc. ("BGC") began trading on Nasdaq at the market opening on July 3, 2023, under the new ticker symbol "BGC", following the corporate conversion of its predecessor BGC Partners, Inc. (formerly Nasdaq: BGCP). BGC is a leading global brokerage and financial technology company. BGC, through its various affiliates, specializes in the brokerage of a broad range of products, including Fixed Income (Rates and Credit), Foreign Exchange, Equities, Energy and Commodities, Shipping, and Futures. BGC, through its various affiliates, also provides a wide variety of services, including trade execution, brokerage, clearing, trade compression, post-trade, information, and other back-office services to a broad range of financial and non-financial institutions. Through its brands, including Fenics®, FMX™, FMX Futures Exchange™, Fenics Markets Xchange™, Fenics Digital™, Fenics UST™, Fenics FX™, Fenics Repo™, Fenics Direct™, Fenics MID™, Fenics Market Data™, Fenics GO™, Fenics PortfolioMatch™, BGC®, BGC Trader™, kACE2™, and Lucera®, BGC offers financial technology solutions, market data, and analytics related to numerous financial instruments and markets. BGC, BGC Group, BGC Partners, BGC Trader, GFI, GFI Ginga, CreditMatch, Fenics, Fenics.com, FMX, Sunrise Brokers, Poten & Partners, RP Martin, kACE2, Capitalab, Swaptioniser, CBID, Caventor, LumeMarkets and Lucera are trademarks/service marks and/or registered trademarks/service marks of BGC and/or its affiliates.
BGC's customers include many of the world's largest banks, broker-dealers, investment banks, trading firms, hedge funds, governments, corporations, and investment firms. BGC's Class A common stock trades on the Nasdaq Global Select Market under the ticker symbol "BGC". BGC is led by Chairman of the Board and Chief Executive Officer Howard W. Lutnick. For more information, please visit http://www.bgcg.com. You can also follow BGC at https://twitter.com/bgcgroupinc, https://www.linkedin.com/company/bgc_group and/or http://ir.bgcg.com.
Discussion of Forward-Looking Statements about BGC
Statements in this document regarding BGC that are not historical facts are "forward-looking statements" that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the effects of the COVID-19 pandemic on the Company's business, results, financial position, liquidity and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, BGC undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see BGC's Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.
Media Contact:
Karen Laureano-Rikardsen
+1 212-829-4975
View original content to download multimedia:
SOURCE BGC Group, Inc. | https://www.kait8.com/prnewswire/2023/07/31/bgc-group-hires-nicholas-eric-ernst-launch-weather-derivatives-desk/ | 2023-07-31T12:35:08 | 0 | https://www.kait8.com/prnewswire/2023/07/31/bgc-group-hires-nicholas-eric-ernst-launch-weather-derivatives-desk/ |
Launch demonstrates companies' commitment to bringing complex generic medicines to the market to help increase patient access
PITTSBURGH and WOODBURY, Minn., July 31, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, and Kindeva Drug Delivery L.P. today announced the launch of Breyna™ (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the first generic version of AstraZeneca's Symbicort® with an Abbreviated New Drug Application (ANDA) approved by the U.S. Food and Drug Administration (FDA). Breyna, a drug-device combination product, is indicated for certain patients with asthma or chronic obstructive pulmonary disease (COPD) and will be immediately available in both 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths.
Viatris Head of North America Jose Cotarelo said: "We are excited to bring Breyna to the U.S. market for the many Americans living with asthma and COPD. This launch represents years of hard work breaking down barriers to access and builds upon our past successes of bringing other complex products to market as we continue to move up the value chain. Being the first to bring an FDA-approved generic version of Symbicort to patients is a true example of how access is the cornerstone of our mission to empower people worldwide to live healthier at every stage of life."
The indications for Breyna include asthma in patients six years of age and older, and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD, including chronic bronchitis and/or emphysema. Breyna is not indicated for the relief of acute bronchospasm. The 160 mcg/4.5 mcg is the only strength indicated for the treatment of COPD. COPD is a term used to describe a certain kind of chronic lung disease and is characterized by breathlessness; it affects more than 16 million Americans. Asthma causes swelling of the airways resulting in difficulty breathing, and approximately 25 million Americans have the chronic condition.
Milton Boyer, CEO of Kindeva Drug Delivery, added: "The launch of Breyna represents a significant milestone as it is the first FDA-approved generic version of Symbicort in the U.S., one of the most prescribed complex drug-device combination products to treat asthma and COPD. We are pleased for Viatris as well as the many Kindeva colleagues who have worked tirelessly to leverage our complex drug-delivery expertise for this important respiratory product — supporting a persistent need to continue bringing more quality medicines for asthma and COPD to patients."
To further expand access to Breyna, Viatris has established a copay program offered for eligible commercially-insured patients, which may help reduce out-of-pocket expenses on prescriptions to as little as $20 per 30-day supply. The program offers $30/month or up to $360 per year with 12 refills annually. The program will be available in August.
About Breyna
Breyna is indicated for the treatment of asthma in patients 6 years and older not adequately controlled on a long-term asthma-control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta2-adrenergic agonists (LABA). Breyna 160 mcg/4.5 mcg dosage is indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and Breyna 160 mcg/4.5 mcg is also indicated to reduce exacerbations of COPD. Breyna is NOT indicated for the relief of acute bronchospasm.
Important Safety Information
Breyna is contraindicated in the primary treatment of status asthmaticus or other acute episode of asthma or COPD where intensive measures are required, and in hypersensitivity to any of the ingredients in Breyna. Use of long-acting beta2-adrenergic agonists (LABA) as monotherapy (without inhaled corticosteroids [ICS]) for asthma is associated with an increased risk of asthma-related death. Available data from controlled clinial trials also suggest that use of LABA as monotherapy increases the risk of asthma-related hospitalization in pediatric and adolescent patients. These findings are considered a class effect of LABA. When LABA are used in fixed dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to ICS alone. Breyna is NOT a rescue medication and does NOT replace fast-acting inhalers to treat acute symptoms. Breyna should not be initiated in patients during rapidly deteriorating episodes of asthma or COPD. Patients who are receiving Breyna should not use additional formoterol or other LABA for any reason. Localized infections of the mouth and pharynx with Candida albicans has occurred in patients treated with Breyna. Patients should rinse the mouth after inhalation of Breyna. Lower respiratory tract infections, including pneumonia, have been reported following the administration of ICS. Due to possible immunosuppression, potential worsening of infections could occur. A more serious or even fatal course of chickenpox or measles can occur in susceptible patients. It is possible that systemic corticosteroid effects such as hypercorticism and adrenal suppression may occur, particularly at higher doses. Particular care is needed for patients who are transferred from systemically active corticosteroids to ICS. Deaths due to adrenal insufficiency have occurred in asthmatic patients during and after transfer from systemic corticosteroids to less systemically available ICS. Caution should be exercised when considering administration of Breyna in patients on long-term ketoconazole and other known potent CYP3A4 inhibitors. As with other inhaled medications, paradoxical bronchospasm may occur with Breyna. Immediate hypersensitivity reactions may occur, as demonstrated by cases of urticaria, angioedema, rash, and bronchospasm. Excessive beta-adrenergic stimulation has been associated with central nervous system and cardiovascular effects. Breyna should be used with caution in patients with cardiovascular disorders especially coronary insufficiency, cardiac arrhythmias, and hypertension. Long-term use of ICS may result in a decrease in bone mineral density (BMD Assessment of BMD is recommended prior to initiating Breyna and periodically thereafter. ICS may result in a reduction in growth velocity when administered to pediatric patients. Glaucoma, increased intracolular pressure, and cataracts have been reported following the administration of ICS, including budesonide, a component of Breyna. Close monitoring for glaucoma and cataracts is warranted in patients with a change in vision or history of increased intraocular pressure. In rare cases, patients on ICS may present with systemic eosinophilic conditions. Breyna should be used with caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, ketoacidosis, and in patients who are unusually responsive to sympathomimetic amines. The most common adverse reactions ≥3% reported in asthma clinical trials included nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, influenza, back pain, nasal congestion, stomach discomfort, vomiting, and oral candidiasis. The most common adverse reactions ≥3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis, and upper respiratory tract infection. Breyna should be administered with caution to patients being treated with MAO inhibitors or tricyclic antidepressants, or within 2 weeks of discontinuation of such agents. Beta-blockers may not only block the pulmonary effect of beta-agonists, such as formoterol, but may produce severe bronchospasm in patients with asthma. ECG changes and/or hypokalemia associated with nonpotassium-sparing diuretics may worsen with concomitant beta-agonists. Use caution with the coadministration of Breyna.
About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, and a variety of over-the-counter consumer products. With more than 38,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.
About Kindeva Drug Delivery
Kindeva Drug Delivery is a global contract development manufacturing organization focused on drug-device combination products. Kindeva Drug Delivery develops and manufactures products across a broad range of complex drug-delivery formats, including injectables (autoinjector, intradermal, microneedle), pulmonary & nasal, and transdermal patches. Its service offering spans early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva Drug Delivery serves a global client base from its nine manufacturing and research and development facilities located in the U.S. and U.K. For more information, please visit www.kindevadd.com.
Forward-Looking Statements
This press release includes statements that constitute "forward-looking statements." These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward looking statements may include statements that the launch of Breyna demonstrates the companies' commitment to bringing complex generic medicines to the market to help increase patient access; Breyna will be immediately available in both 80 mcg/4.5 mcg and 160 mcg/4.5 mcg dosage strengths; this launch represents years of hard work breaking down barriers to access and builds upon our past successes of bringing other complex products to market as we continue to move up the value chain; to further expand access to Breyna, Viatris has established a copay program offered for eligible commercially-insured patients, which may help reduce out-of-pocket expenses on prescriptions to as little as $20 per 30-day supply; and, the program will be available in August. Factors that could cause or contribute to such differences include, but are not limited to: the possibility that the Company may be unable to realize the intended benefits of, or achieve the intended goals or outlooks with respect to, its strategic initiatives; the possibility that the Company may be unable to achieve expected benefits, synergies and operating efficiencies in connection with acquisitions, divestitures, or its global restructuring program, within the expected timeframe or at all; impairment charges or other losses related to the divestiture or sale of businesses or assets; the Company's failure to achieve expected or targeted future financial and operating performance and results; the potential impact of public health outbreaks, epidemics and pandemics, including the ongoing challenges and uncertainties posed by COVID-19; actions and decisions of healthcare and pharmaceutical regulators; changes in healthcare and pharmaceutical laws and regulations in the U.S. and abroad; any regulatory, legal or other impediments to Viatris' ability to bring new products to market, including but not limited to "at-risk" launches; Viatris' or its partners' ability to develop, manufacture, and commercialize products; the scope, timing and outcome of any ongoing legal proceedings, and the impact of any such proceedings; any significant breach of data security or data privacy or disruptions to our information technology systems; risks associated with international operations; the ability to protect intellectual property and preserve intellectual property rights; changes in third-party relationships; the effect of any changes in Viatris' or its partners' customer and supplier relationships and customer purchasing patterns; the impacts of competition; changes in the economic and financial conditions of Viatris or its partners; uncertainties and matters beyond the control of management, including general economic conditions, inflation and exchange rates; failure to execute stock repurchases consistent with current expectations; stock price volatility; and the other risks described in Viatris' filings with the Securities and Exchange Commission (SEC). Viatris routinely uses its website as a means of disclosing material information to the public in a broad, non-exclusionary manner for purposes of the SEC's Regulation Fair Disclosure (Reg FD). Viatris undertakes no obligation to update these statements for revisions or changes after the date of this release other than as required by law.
View original content to download multimedia:
SOURCE Viatris Inc. | https://www.wbay.com/prnewswire/2023/07/31/viatris-announces-launch-breyna-budesonide-formoterol-fumarate-dihydrate-inhalation-aerosol-first-fda-approved-generic-version-symbicort-people-with-asthma-chronic-obstructive-pulmonary-disease-partnership-with-kindeva/ | 2023-07-31T12:35:09 | 0 | https://www.wbay.com/prnewswire/2023/07/31/viatris-announces-launch-breyna-budesonide-formoterol-fumarate-dihydrate-inhalation-aerosol-first-fda-approved-generic-version-symbicort-people-with-asthma-chronic-obstructive-pulmonary-disease-partnership-with-kindeva/ |
SAN JOSE, Calif., July 31, 2023 /PRNewswire/ -- Broadcom Inc. (NASDAQ: AVGO), a Delaware corporation headquartered in San Jose, CA, and a global technology leader that designs, develops and supplies semiconductor and infrastructure software solutions, today announced it will report its third quarter fiscal year 2023 financial results and business outlook on Thursday, August 31, 2023 after the close of the market. Broadcom's management will host a conference call at 2:00 p.m. Pacific Time on the same day to discuss these results and business outlook.
Date: Thursday, August 31, 2023
Time: 2:00 PM (PT); 5:00 PM (ET)
To Listen via Telephone: Preregistration is required by the conference call operator. Please preregister at https://register.vevent.com/register/BIab1222c9ed364122895c0b8a81ef898b. Upon registering, you will be emailed a link to the dial-in number and unique PIN.
To Listen via Internet: The conference call can be accessed live online in the Investors section of the Broadcom website at https://investors.broadcom.com.
Replay: An audio replay of the conference call can be accessed for one year through the Investors section of Broadcom's website at https://investors.broadcom.com.
About Broadcom Inc.
Broadcom Inc. (NASDAQ: AVGO), a Delaware corporation headquartered in San Jose, CA, is a global technology leader that designs, develops and supplies a broad range of semiconductor and infrastructure software solutions. Broadcom's category-leading product portfolio serves critical markets including data center, networking, enterprise software, broadband, wireless, storage and industrial. Our solutions include data center networking and storage, enterprise, mainframe and cyber security software focused on automation, monitoring and security, smartphone components, telecoms and factory automation. For more information, go to https://investors.broadcom.com.
Contact:
Broadcom Inc.
Ji Yoo
Investor Relations
408-433-8000
investor.relations@broadcom.com
(AVGO-Q)
View original content:
SOURCE Broadcom Inc. | https://www.wafb.com/prnewswire/2023/07/31/broadcom-inc-announce-third-quarter-fiscal-year-2023-financial-results-thursday-august-31-2023/ | 2023-07-31T12:35:12 | 0 | https://www.wafb.com/prnewswire/2023/07/31/broadcom-inc-announce-third-quarter-fiscal-year-2023-financial-results-thursday-august-31-2023/ |
First-of-Its-Kind Solution Helps Ensure Medicines Prescribed to Patients are Safe, Effective, and Appropriate, Tackling Growing Public Health Challenge Posed by Suboptimal Medication Use
FeelBetter's Pharmaco-Clinical Intelligence Aids in Proactively Identifying and Managing Polypharmacy-Related Risks, Reducing Preventable Deterioration and Hospitalizations
BOSTON and TEL AVIV, Israel , July 31, 2023 /PRNewswire/ -- FeelBetter, the leading provider of medication management technology and pioneer of Pharmaco-Clinical Intelligence, today announced that it has raised $5.9 million in funding. Firstime Ventures and Shoni Health Ventures led the funding round with participation from Random Forest VC, The Group Ventures, and existing FeelBetter investor Triventures, bringing the Company's total funding to $8 million.
A growing public health concern for senior patients, many of whom have multiple chronic conditions, the simultaneous use of multiple medications paves the way for poor health outcomes, increased use of health services, and rising care costs. In the US alone, every year, suboptimal medication management results in 275,000 deaths and more than $528B in avoidable costs.
Launched in 2018, FeelBetter is tackling the challenges associated with suboptimal medication management among polypharmacy patients. Led by an interdisciplinary team of clinicians, clinical pharmacists, and technologists, FeelBetter has pioneered a new category of technology called Pharmaco-Clinical Intelligence. It combines novel pharmacology and clinical capabilities and is changing the polypharmacy paradigm on both an individual and population health level. A comprehensive solution powered by AI and machine learning capabilities, FeelBetter's Pharmaco-Clinical Intelligence drives proactive, personalized medication management, helping healthcare professionals ensure that their patients' medication regimens are safe, effective, and appropriate.
"FeelBetter's purpose-built technology makes it possible to deliver a more personalized, whole-patient approach to medication management – one that goes beyond a single illness, diagnosis, or point in time, and comprehensively focuses on each individual's care journey," said Liat Primor, FeelBetter's CEO and Co-Founder. "At a time when investors are especially selective about the types of bets they are taking, this round and vote of confidence from the world-class teams at Fristime Ventures, Shoni Health Ventures, Random Forest VC, Triventures, and The Venture Group, as well as angel investors, validates the need for and potential of our Pharmaco-Clinical Intelligence as a solution for the growing, global health challenge posed by suboptimal medication management."
Yoram Hordan, FeelBetter's CTO, COO, and Co-Founder, added: "The funding will enable us to expand our reach, further refine our solution, and empower more healthcare providers to deliver personalized, proactive care. Our Pharmaco-Clinical Intelligence, developed collaboratively by clinical and pharmacology experts alongside technology and machine learning specialists, seamlessly matches a patient's specific clinical and pharmacology data with their sequence of health events. This unlocks unparalleled accuracy in detecting at-risk patients both individually and population wide and enables new levels of precision in disease management and prevention."
Recognizing that a range of diverse factors can influence a senior patient's health status, FeelBetter's Pharmaco-Clinical Intelligence synthesizes and analyzes healthcare data from multiple sources to pinpoint patients at high risk of deterioration and preventable hospitalization due to suboptimal medication management. The SaaS solution also proactively suggests immediate and actionable interventions to reduce polypharmacy risks, and aids healthcare providers in monitoring patients' progress and measuring the impact of clinical interventions. Additionally, by using FeelBetter, provider organizations can more effectively and efficiently allocate resources to better serve patients, and minimize preventable, costly use of healthcare services.
"FeelBetter's algorithm has been trained on two decades of longitudinal clinical, pharmacy, claims, and lab data from hundreds of thousands of patients to find patterns in the complex connections and relationships between disparate data sources," said Michael Kerbis, Founding Partner, Random Forest VC. "When taken together, these patterns can capture the full picture of a patient's health journey, enabling FeelBetter to predict which individuals are at the greatest risk of adverse events related to suboptimal medication regimens and recommend timely clinical interventions to drive better health outcomes."
Eran Lerer, CEO and Managing Partner, Shoni Health Ventures, said: "From risk stratifying patients to preventing adverse events so patients can safely stay in their communities, FeelBetter offers a proven, end-to-end solution for the suboptimal medication management problem. It's a groundbreaking tool that is poised to change how the medical community approaches polypharmacy, and we're thrilled to take part in this important transformation."
Keren Kopilov, Partner, Firstime Ventures, added: "By incorporating the expertise of physicians and clinical pharmacists, as well as leveraging data from all relevant sources, FeelBetter provides a solution that is uniquely comprehensive. It intuitively fits into clinical workflows and enables optimized medication management at unparalleled speed and scale. We look forward to leveraging our expertise to support FeelBetter's mission and continued growth as it meets the tremendous opportunities ahead."
About FeelBetter
FeelBetter is the pioneer of Pharmaco-Clinical Intelligence, changing the polypharmacy paradigm on both an individual and population health level with a comprehensive solution designed to tackle the challenges associated with suboptimal medication management. Powered by AI and machine learning capabilities, FeelBetter's Pharmaco-Clinical Intelligence drives personalized medication management, helping healthcare professionals ensure that their patients' medication regimens are safe, effective, and appropriate. The technology pinpoints patients at high risk of deterioration and preventable hospitalization due to suboptimal medication management, and proactively suggests immediate and actionable interventions to reduce these risks. Provider organizations use FeelBetter to monitor their patients' progress and more proactively deliver the right follow-up care, as well as to efficiently allocate resources and minimize preventable, costly use of healthcare services.
Led by an interdisciplinary team of clinicians, clinical pharmacists, and technologists, FeelBetter is headquartered in Boston and Tel Aviv, Israel. Investors include Firstime Ventures, Shoni Health Ventures, Triventures, Random Forest VC, The Group Ventures, and GoodCompany Ventures. To learn more, visit feelbetter.healthcare.
Media Contact
Nicole Pariser
nicole@i-feelbetter.com
View original content to download multimedia:
SOURCE FeelBetter | https://www.kwch.com/prnewswire/2023/07/31/feelbetter-raises-59m-optimize-personalize-medication-management-polypharmacy-patients/ | 2023-07-31T12:35:13 | 0 | https://www.kwch.com/prnewswire/2023/07/31/feelbetter-raises-59m-optimize-personalize-medication-management-polypharmacy-patients/ |
- Cash, cash equivalents, and marketable securities totaled $349.0 million as of June 30, 2023
- Announced positive interim data from BHV-7000 EEG biomarker study demonstrating evidence of central nervous system (CNS) target engagement, confirming previously reported preclinical and clinical data, and highlighting the paradigm-changing potential of BHV-7000 in the treatment of epilepsy and mood disorders
- Brain penetrant TYK2/JAK1 inhibitor, BHV-8000, advanced into Phase 1 with projected therapeutic concentrations achieved and well-tolerated profile observed to date
- Advanced targeted extracellular protein degradation platform with potential to support numerous clinical candidates across a broad range of high unmet need indications
- Orphan drug designation (ODD) granted by the European Commission for taldefgrobep alfa a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA)
- Type A meeting planned with FDA regarding troriluzole program in Spinocerebellar Ataxia Type 3 (SCA3) and enrollment in Phase 3 obsessive compulsive disorder (OCD) trial expected to complete at end of 2023
NEW HAVEN, Conn., July 31, 2023 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.
Vlad Coric, M.D., Chairman and Chief Executive Officer of Biohaven, commented, "In less than a year since our spin-off, the Biohaven team has driven strong and consistent progress across multiple drug development platforms. We were excited to recently report positive interim data from the ongoing EEG biomarker study of our lead Kv7 activator, BHV-7000. As expected, BHV-7000 demonstrated CNS activity consistent with what has been reported in EEG studies with other Kv7 channel activators in development that are clinically effective in treating epilepsy and with other approved anti-seizure medications. Importantly, BHV-7000 demonstrates CNS target engagement but is not associated with the typical CNS adverse events associated with other ASMs, like somnolence and fatigue. We look forward to completing the higher dose groups in this EEG study and initiating Phase 2/3 studies with our once daily, extended-release oral formulation later this year."
Dr. Coric continued, "We also shared a number of equally exciting announcements across our broader pipeline this quarter. We successfully administered the first three doses in the SAD portion of our ongoing SAD/MAD study evaluating BHV-8000, an oral, brain-penetrant, dual TYK2/JAK1 inhibitor. Potential therapeutic concentrations of BHV-8000 were achieved and BHV-8000 was well tolerated with only mild adverse events reported, reinforcing our plans to start a Phase 2 clinical trial with BHV-8000 in Parkinson's disease and potentially other neuroinflammatory diseases in 2024. In addition, we have advanced IND enabling preclinical studies and remain on track to submit an IND with our IgG degrader, BHV-1300, later this year. We also anticipate submitting an IND with our IgA degrader in 2024 as we continue to advance multiple clinical degrader candidates across a wide range of indications. We also shared key updates for our taldefgrobep alfa program (an anti-myostatin) with enrollment completion in our pivotal study in SMA and a planned Phase 2 trial initiation in obesity."
"Finally, I want to reaffirm Biohaven's commitment to the SCA3 patient community in spite of the recent disappointing regulatory decision by the FDA not to review our submitted NDA. Given the seriousness of SCA3 and consistent treatment benefits observed across multiple prespecified outcome measures, including an 80% delay in disease progression over the one-year study period with substantial risk reduction in falls, we believe that full consideration of all available data is warranted for this ultra-rare disease. Biohaven has built its foundation around our patient mission and we plan to continue to work with regulatory agencies to try to advance troriluzole for individuals suffering from SCA3."
Second Quarter 2023 and Recent Business Highlights
- Announced positive interim data from EEG biomarker study with BHV-7000 - In July 2023, the Company provided a preliminary data update from the ongoing electroencephalogram (EEG) biomarker study for the Kv7 Channel Activator platform. Preliminary Phase 1 data confirmed evidence of target engagement in the central nervous system for subjects with projected therapeutic concentrations of BHV-7000 (based on the EC50 from preclinical models), measured by changes from baseline in EEG spectral power that occurred after dosing. These pharmacodynamic (PD) effects were similar to those reported in the literature for anti-seizure medicines (ASMs), including Kv7 activators in development that are clinically effective in treating epilepsy. BHV-7000's PD effects were also differentiated from those reported for other Kv7 activators including, specifically, the absence of increases in EEG spectral power in frequency bands associated with drowsiness and somnolence. Results from the low-dose group validate the preclinical hypothesis, confirm the Phase 1 SAD/MAD clinical data, and provide strong support for Biohaven's plans to initiate pivotal studies with BHV-7000 in focal epilepsy and bipolar disorder in the second half of 2023. The preliminary data highlight BHV-7000's differentiation and potentially favorable clinical profile compared to other ASMs, and the Company expects to present the complete EEG results by the end of the year. Additionally, new pharmacokinetic data from multiple clinical formulations being studied has now confirmed a once daily extended-release oral formulation that will be used in the Phase 2/3 clinical programs.
- Successfully dosed three cohorts with single ascending doses of oral, brain penetrant, dual TYK2/JAK1 agent, BHV-8000 - In July 2023, the Company announced that it successfully dosed three cohorts in the SAD portion of an ongoing SAD/MAD Phase 1 study evaluating brain penetrant TYK2/JAK1 agent, BHV-8000 in healthy volunteers. The ongoing Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and PD of single and multiple ascending doses of BHV-8000 in healthy volunteers. Based on the preliminary data available, projected therapeutic concentrations of BHV-8000 were achieved, and BHV-8000 was well tolerated with only mild adverse events reported. These data provide support for further development of BHV-8000, and the Company anticipates beginning a Phase 2 clinical trial with BHV-8000 in Parkinson's disease and potentially other neuroinflammatory diseases in 2024. The Company had previously reported initiation of dosing with BHV-8000 in the Phase 1 study at Biohaven's R&D Day in May 2023.
- Reported on continued progress observed with Biohaven's first-in-class bispecific IgG degrader, BHV-1300, as compound advances to IND filing in 2H2023 - In July 2023, the Company shared an update on BHV-1300's highly competitive safety, manufacturable and PD profile. The Company is assembling a pipeline of partially de-risked, follow-on IgG degraders as well as antigen-specific degraders providing both optionality and a sustainable output of drug candidates for several years. An IND application for BHV-1300 is on track for submission in 2023 and an IND application for Biohaven's IgA degrader on track for submission in 2024
- Type A meeting planned to comprehensively address FDA's concerns in connection with Troriluzole program in SCA3 - In July 2023, the Company announced that the FDA informed Biohaven it would not review the recently submitted New Drug Application (NDA) for troriluzole for the treatment of spinocerebellar ataxia type 3 (SCA3), an ultra-rare, genetically-defined, neurodegenerative disease associated with progressive disability, frequent falls, loss of ambulation, speech and swallowing impairment, and premature death that is the most common SCA genotype worldwide. The FDA informed Biohaven it would not review the application given that the study's primary endpoint was not met and thus, would not permit a substantive review. Biohaven is committed to working closely with the FDA to bring troriluzole to people with SCA3 as quickly as possible given no therapy is currently approved for this ultra-rare genetic disorder. Biohaven plans to request a Type A meeting to comprehensively address FDA's concerns cited in the refusal to file letter.
- EMA orphan drug designation granted for taldefgrobep alfa for the treatment of SMA: - In July 2023, the Company announced that taldefgrobep alfa received orphan drug designation (ODD) from the European Commission for taldefgrobep for the treatment of SMA. Taldefgrobep previously received Fast-Track and ODD from the FDA. At Biohaven's R&D Day, the Company announced plans to complete randomization of approximately 180 patients in global SMA trial.
Upcoming Milestones:
Biohaven is progressing its product candidates through clinical programs in a number of common and rare disorders. The Company plans to reach significant pipeline milestones in the coming periods. Biohaven expects to:
- Announce Phase 1 EEG study results by year-end 2023: The Company expects to present complete results from its ongoing EEG study with BHV-7000 in healthy volunteers by the end of the year.
- Initiate Phase 2/3 studies with BHV-7000 in the second half of 2023: Biohaven expects to initiate pivotal trials in patients with focal epilepsy and bipolar disorder in the second half of 2023.
- Submit IND with BHV-1300, the Company's lead extracellular degrader: The Company expects to submit an IND with pan-IgG degrader BHV-1300 in the second half of 2023 and expects to initiate Phase 2 studies in 2024.
- Submit IND with selective Gd-IgA1 degrader: The Company expects to submit an IND with a Gd-IgA1 degrader indicated for IgA nephropathy in the first half of 2024.
- Initiate Phase 2 study with BHV-8000: The Company commenced Phase 1 studies with BHV-8000, an oral, brain-penetrant, dual TYK2/JAK1 inhibitor for neuroinflammatory disorders, in the first half of 2023 and expects to initiate a Phase 2 study in Parkinson's disease in 2024.
- Submit IND with BHV-2100 in chronic pain: The Company expects to submit an IND with BHV-2100, a selective TRPM3 antagonist in the Company's ion channel platform, in the second half of 2023.
- Complete enrollment in Phase 3 study of troriluzole in OCD in 2023: Two Phase 3 randomized, double-blind, placebo-controlled studies of troriluzole in OCD are expected to enroll up to 700 patients (in each trial) across nearly 200 global study sites. The Company anticipates completing enrollment in at least one Phase 3 trial by year-end 2023.
- Complete enrollment in Phase 3 clinical study of taldefgrobep alfa in SMA: The Company expects to complete enrollment in the study of taldefgrobep in SMA in the second half of 2023.
- Continue advancements across multiple neuroscience and immunoscience indications: The Company's preclinical pipeline includes a platform of bispecific degraders of extracellular proteins directed against IgG, IgA and other targets, TRPM3 and Kv7 family of ion channels, and other undisclosed targets, including those with disease-modifying potential.
Capital Position:
Cash, cash equivalents and marketable securities as of June 30, 2023 was $349.0 million, including $13.9 million of restricted cash, and excluding $40.4 million of cash payable to Biohaven Pharmaceutical Holding Company Ltd. (the Former Parent), compared to $467.9 million, including $2.5 million of restricted cash, and excluding $35.2 million of cash payable to the Former Parent, as of December 31, 20221.
Second Quarter 2023 Financial Highlights:
Research and Development (R&D) Expenses: R&D expenses, including non-cash share-based compensation costs, were $79.5 million for the three months ended June 30, 2023, compared to $177.1 million for the three months ended June 30, 2022. Non-cash share-based compensation expense was $2.5 million for the three months ended June 30, 2023, a decrease of $10.3 million as compared to the same period in 2022. Non-cash share-based compensation expense was higher in the second quarter of 2022 primarily because expense allocated from the Former Parent equity plan, prior to the spin-off, was based on equity awards with higher grant date fair values.
General and Administrative (G&A) Expenses: General and administrative expenses were $14.5 million for the three months ended June 30, 2023, compared to $20.0 million for the three months ended June 30, 2022. The decrease of $5.5 million was primarily due to decreased non-cash share-based compensation costs. Non-cash share-based compensation expense was $2.2 million for the three months ended June 30, 2023, a decrease of $5.8 million as compared to the same period in 2022. Non-cash share-based compensation expense was higher in the second quarter of 2022 primarily because expense allocated from the Former Parent equity plan, prior to the spin-off, was based on equity awards with higher grant date fair values.
Other Income (Expense), Net: Other income (expense), net was a net income of $5.8 million for the three months ended June 30, 2023, compared to net expense of $0.1 million for the three months ended June 30, 2022. The increase of $5.9 million was primarily due to an increase in net investment income and an increase of $1.7 million in other income related to our transition services provided to the Former Parent, which is largely non-recurring.
Net Loss: Biohaven reported a net loss for the three months ended June 30, 2023, of $90.3 million, or $1.32 per share, compared to $203.3 million, or $5.16 per share, for the same period in 2022. Non-GAAP adjusted net loss for the three months ended June 30, 2023 was $85.7 million, or $1.25 per share, compared to $182.5 million, or $4.63 per share for the same period in 2022. These non-GAAP adjusted net loss and non-GAAP adjusted net loss per share measures, more fully described below under "Non-GAAP Financial Measures," exclude non-cash share-based compensation charges. A reconciliation of the GAAP financial results to non-GAAP financial results is included in the tables below. For periods prior to Biohaven's spin-off from the Former Parent on October 3, 2022 (the "Spin-Off"), net loss per share and non-GAAP adjusted net loss per share were calculated based on the 39,375,944 common shares of Biohaven distributed to the Former Parent shareholders at the time of the distribution, including common shares issued in connection with the Former Parent share options that were settled on October 3, 2022 and common shares issued in connection with the Former Parent restricted share units that vested on October 3, 2022. The same number of shares is being utilized for the calculation of basic and diluted earnings per share for all periods presented prior to the Spin-Off.
Non-GAAP Financial Measures
This press release includes financial results prepared in accordance with accounting principles generally accepted in the United States (GAAP), and also certain non-GAAP financial measures. In particular, Biohaven has provided non-GAAP adjusted net loss and adjusted net loss per share, which are adjusted to exclude non-cash share-based compensation, which is substantially dependent on changes in the market price of common shares. Non-GAAP financial measures are not an alternative for financial measures prepared in accordance with GAAP. However, Biohaven believes the presentation of non-GAAP adjusted net loss and adjusted net loss per share, when viewed in conjunction with GAAP results, provides investors with a more meaningful understanding of ongoing operating performance and can assist investors in comparing Biohaven's performance between periods.
In addition, these non-GAAP financial measures are among those indicators Biohaven uses as a basis for evaluating performance, and planning and forecasting future periods. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP financial measures. A reconciliation between these non-GAAP measures and the most directly comparable GAAP measures is provided later in this news release.
About Biohaven
Biohaven is a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases. Biohaven's experienced management team brings with it a track record of delivering new drug approvals for products for diseases such as migraine, depression, bipolar and schizophrenia. The company is advancing a pipeline of therapies for diseases, many of which have limited or no treatment options, leveraging its proven drug development capabilities and proprietary platforms, including Kv7 ion channel modulation for epilepsy and neuronal hyperexcitability, glutamate modulation for obsessive-compulsive disorder and spinocerebellar ataxia, myostatin inhibition for neuromuscular diseases and metabolic disorders, and brain-penetrant TYK2/JAK1 inhibition for neuroinflammatory disorders. Biohaven's portfolio of early- and late-stage product candidates also includes discovery research programs focused on TRPM3 channel activation for neuropathic pain, CD-38 antibody recruiting, bispecific molecules for multiple myeloma, antibody drug conjugates (ADCs), and targeted extracellular protein degradation platform technology (MoDE™) with potential application in neurological disorders, cancer, and autoimmune diseases.
Forward-looking Statements
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including "continue", "plan", "will", "believe", "may", "expect", "anticipate" and similar expressions, is intended to identify forward-looking statements. Investors are cautioned that any forward-looking statements, including statements regarding the future development, timing and potential marketing approval and commercialization of development candidates, are not guarantees of future performance or results and involve substantial risks and uncertainties. Actual results, developments and events may differ materially from those in the forward-looking statements as a result of various factors including: the expected timing, commencement and outcomes of Biohaven's planned and ongoing clinical trials; the timing of planned interactions and filings with the FDA; the timing and outcome of expected regulatory filings; complying with applicable U.S. regulatory requirements; the potential commercialization of Biohaven's product candidates; the potential for Biohaven's product candidates to be first in class therapies; and the effectiveness and safety of Biohaven's product candidates. Additional important factors to be considered in connection with forward-looking statements are described in Biohaven's filings with the Securities and Exchange Commission, including within the sections titled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". The forward-looking statements are made as of the date of this new release, and Biohaven does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
MoDEs is a trademark of Biohaven Therapeutics Ltd.
Investor Contact:
Jennifer Porcelli
Vice President, Investor Relations
jennifer.porcelli@biohavenpharma.com
+1 (201) 248-0741
Media Contact:
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
+1 (312) 961-2502
View original content to download multimedia:
SOURCE Biohaven Ltd. | https://www.kait8.com/prnewswire/2023/07/31/biohaven-reports-second-quarter-2023-financial-results-recent-business-developments/ | 2023-07-31T12:35:15 | 0 | https://www.kait8.com/prnewswire/2023/07/31/biohaven-reports-second-quarter-2023-financial-results-recent-business-developments/ |
SAN FRANCISCO, July 31, 2023 /PRNewswire/ -- Today, Blitz Insurance, a specialty insurance carrier, partners with Ascend to modernize payment experiences for insurance brokers selling in specialty markets. With this partnership, Blitz Insurance will open new customer segments by offering both direct bill and premium financing into their payments workflow.
"When we looked into the market for a solution, Ascend was the right choice. Ascend meets our needs for a better payments experience for our partners while reducing everyone's operational expenses," said Brandon Murphy, Chief Distribution Officer of Blitz Insurance. "We will now have the ability to not only expand to direct bill and a premium finance option but also simplify the movement of money between us and our partners."
With Ascend, Blitz Insurance is now able to provide a direct bill in addition to their existing agency bill workflow - allowing brokers to decide what billing method works best for them. By utilizing Ascend, Blitz Insurance not only grows their footprint of appointed brokers but also gains administrative efficiency by automating what would otherwise have been a large operational undertaking.
Ascend automatically attributes incoming payments to policies in real time, speeding up the reconciliation process. By modernizing the payments experience and speeding up the reconciliation of incoming premiums, Blitz Insurance can offer a best-in-class experience to its brokers and agents.
"We find that across the insurance ecosystem - companies want to provide a seamless payment workflow for their customers and their teams," said Andrew Wynn, co-CEO of Ascend. "Ascend is built so brokers and carriers can offer this experience without shouldering the administrative resources and costs needed to support these operations."
About Ascend
Ascend is the first insurance payments platform that automates financial operations from collections and financing to carrier and commission payables. Founded by two-time insurtech entrepreneurs Andrew Wynn and Praveen Chekuri, Ascend helps insurance brokers, MGAs, and carriers improve their bottom lines by eliminating expensive and labor-intensive payment workflows. To learn more, please visit LinkedIn, Twitter or check out https://www.useascend.com/.
About Blitz Insurance
Blitz is a tech-driven insurer revolutionizing the $60B specialty market catering to SME segment. By leveraging industry knowledge and cutting-edge technology, we deliver a simpler, smarter, and faster coverage experience.
The company is led by a veteran team of insurance and technology experts and has been funded with $25M from its founder & CEO, a Forbes-listed serial entrepreneur in the real estate and insurance industries.
Contact:
Mike Nguyen
press@useascend.com
View original content to download multimedia:
SOURCE Ascend | https://www.kait8.com/prnewswire/2023/07/31/blitz-insurance-partners-with-ascend-expand-payment-financing-offerings/ | 2023-07-31T12:35:16 | 0 | https://www.kait8.com/prnewswire/2023/07/31/blitz-insurance-partners-with-ascend-expand-payment-financing-offerings/ |
New nuclear unit now serving customers with clean, reliable energy 24/7
ATLANTA, July 31, 2023 /PRNewswire/ -- Georgia Power declared today that Plant Vogtle Unit 3 has entered commercial operation and is now serving customers and the State of Georgia. The new unit represents a long-term investment in the state's clean energy future and will provide reliable, emissions-free energy to customers for decades to come.
"The Plant Vogtle 3 & 4 nuclear expansion is another incredible example of how Georgia Power is building a reliable and resilient energy future for our state," said Kim Greene, chairman, president and CEO of Georgia Power. "It is important that we make these kinds of long-term investments and see them through so we can continue providing clean, safe, reliable and affordable energy to our 2.7 million customers. Today's achievement is a testament to our commitment to doing just that, and it marks the first day of the next 60 to 80 years that Vogtle Unit 3 will serve our customers with clean, reliable energy."
Vogtle Unit 3 is the first newly-constructed nuclear unit in the U.S. in over 30 years and can power an estimated 500,000 homes and businesses. Once all four units are online, the Plant Vogtle site will be the largest generator of clean energy in the nation and support continued growth in Georgia as more industries, businesses and families come to the state.
"Today is a historic day for the State of Georgia, Southern Company, and the entire energy sector, as we continue transforming the way we power the lives of millions of Americans," said Chris Womack, president and CEO of Southern Company. "With Unit 3 completed, and Unit 4 in the final stages of construction and testing, this project shows just how new nuclear can and will play a critical role in achieving a clean energy future for the United States. Bringing this unit safely into service is a credit to the hard work and dedication of our teams at Southern Company and the thousands of additional workers who have helped build that future at this site, as well as all of the partners who have helped make this day a reality."
Nuclear energy is the only zero-emission baseload energy source available today, offering high reliability, and efficient operations around the clock. Nuclear energy currently provides approximately 25% of Georgia Power's overall energy mix, including the existing units at Plant Vogtle and Georgia's other nuclear facility at Plant Hatch in Baxley, Georgia.
"The Vogtle expansion is an American energy success story and would not be possible without the support of strong public and private partners like our partners at North America's Building Trades Unions," said Tom Fanning, chairman of the Board of Directors for Southern Company. "We continue to appreciate their support and those who have stood with us at the local, state and federal levels to complete this new clean energy source to serve electric customers. Providing leadership in our industry and a commitment to safety and quality are in Southern Company's DNA. Today's milestone at the Vogtle expansion site underscores this legacy, and I couldn't be prouder of the dedication our teams have shown in seeing Unit 3 through to completion."
The final stages of construction and testing continue at Vogtle Unit 4, with the unit projected to be placed in service during the late fourth quarter 2023 or the first quarter of 2024. The unit completed hot functional testing in May, in significantly less time than Unit 3 as the team continues leveraging best practices and learnings from the earlier unit. The Vogtle site has also received nuclear fuel for Unit 4, with a total of 157 fuel assemblies necessary for the safe and reliable startup of the unit.
Also, last week, Georgia Power announced the receipt of the 103(g) finding from the Nuclear Regulatory Commission (NRC) for Vogtle Unit 4. This finding was confirmed in an official letter received by Southern Nuclear and signifies that the new unit has been constructed and will be operated in conformance with the Combined License and NRC regulations. No further NRC findings are necessary in order for Southern Nuclear to load fuel or begin the startup sequence for the new unit.
The new Vogtle units are an essential part of Georgia Power's commitment to delivering clean, safe, reliable and affordable energy to its 2.7 million customers. Southern Nuclear will operate the new units on behalf of the co-owners: Georgia Power, Oglethorpe Power, MEAG Power and Dalton Utilities.
About Georgia Power
Georgia Power is the largest electric subsidiary of Southern Company (NYSE: SO), America's premier energy company. Value, Reliability, Customer Service and Stewardship are the cornerstones of the company's promise to 2.7 million customers in all but four of Georgia's 159 counties. Committed to delivering clean, safe, reliable and affordable energy, Georgia Power maintains a diverse, innovative generation mix that includes nuclear, coal and natural gas, as well as renewables such as solar, hydroelectric and wind. Georgia Power focuses on delivering world-class service to its customers every day and the company is recognized by J.D. Power as an industry leader in customer satisfaction. For more information, visit www.GeorgiaPower.com and connect with the company on Facebook (Facebook.com/GeorgiaPower), Twitter (Twitter.com/GeorgiaPower) and Instagram (Instagram.com/ga_power).
Cautionary Note Regarding Forward-Looking Statements
Certain information contained in this release is forward-looking information based on current expectations and plans that involve risks and uncertainties. Forward-looking information includes, among other things, statements concerning the projected in-service date for Plant Vogtle Unit 4 and the future operations of Plant Vogtle Units 3 and 4. Georgia Power cautions that there are certain factors that can cause actual results to differ materially from the forward-looking information that has been provided. The reader is cautioned not to put undue reliance on this forward-looking information, which is not a guarantee of future performance and is subject to a number of uncertainties and other factors, many of which are outside the control of Georgia Power; accordingly, there can be no assurance that such suggested results will be realized. The following factors, in addition to those discussed in Georgia Power's Annual Report on Form 10-K for the year ended December 31, 2022, and subsequent securities filings, could cause actual results to differ materially from management expectations as suggested by such forward-looking information: the ability to control costs and avoid cost and schedule overruns during the development, construction, and operation of facilities or other projects, including Plant Vogtle Unit 4, which includes components based on new technology that only within the last few years began initial operation in the global nuclear industry at this scale, due to current and/or future challenges which include, but are not limited to, changes in labor costs, availability and productivity, challenges with the management of contractors or vendors, subcontractor performance, adverse weather conditions, shortages, delays, increased costs, or inconsistent quality of equipment, materials, and labor, contractor or supplier delay, the impacts of inflation, delays due to judicial or regulatory action, nonperformance under construction, operating, or other agreements, operational readiness, including specialized operator training and required site safety programs, engineering or design problems or any remediation related thereto, design and other licensing-based compliance matters, challenges with start-up activities, including major equipment failure, or system integration, and/or operational performance, continued challenges related to the COVID-19 pandemic or future pandemic health events, continued public and policymaker support for projects, environmental and geological conditions, delays or increased costs to interconnect facilities to transmission grids, and increased financing costs as a result of changes in market interest rates or as a result of project delays; the ability to overcome or mitigate the current challenges, or challenges yet to be identified, at Plant Vogtle Unit 4, that could further impact the cost and schedule for the project; legal proceedings and regulatory approvals and actions related to construction projects, such as Plant Vogtle Unit 4, including Georgia Public Service Commission approvals and U.S. Nuclear Regulatory Commission ("NRC") actions; under certain specified circumstances, a decision by holders of more than 10% of the ownership interests of Plant Vogtle Unit 3 and 4 not to proceed with construction; the notices of tender by Oglethorpe Power Corporation and the City of Dalton of a portion of their ownership interests in Plant Vogtle Units 3 and 4 to Georgia Power, including related litigation; the ability to construct facilities in accordance with the requirements of permits and licenses (including satisfaction of NRC requirements), to satisfy any environmental performance standards and the requirements of tax credits and other incentives, and to integrate facilities into the Southern Company system upon completion of construction; the inherent risks involved in operating and constructing nuclear generating facilities; the ability of counterparties of Georgia Power to make payments as and when due and to perform as required; the direct or indirect effect on Georgia Power's business resulting from cyber intrusion or physical attack and the threat of cyber and physical attacks; catastrophic events such as fires, earthquakes, explosions, floods, tornadoes, hurricanes and other storms, droughts, pandemic health events, political unrest, wars or other similar occurrences; the potential effects of the continued COVID-19 pandemic; and the direct or indirect effects on Georgia Power's business resulting from incidents affecting the U.S. electric grid or operation of generating or storage resources. Georgia Power expressly disclaim any obligation to update any forward–looking information.
View original content to download multimedia:
SOURCE Georgia Power | https://www.wbay.com/prnewswire/2023/07/31/vogtle-unit-3-goes-into-operation/ | 2023-07-31T12:35:16 | 0 | https://www.wbay.com/prnewswire/2023/07/31/vogtle-unit-3-goes-into-operation/ |
MIAMI, July 31, 2023 /PRNewswire/ -- Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: CUK) today announced that Carnival Corporation (the "Company") intends to commence the marketing of a new senior secured first lien term loan B facility (the "New First Lien Term Loan") with an original principal amount of $1.0 billion, expected to mature in 2027. In conjunction with the New First Lien Term Loan, and subject to market and other conditions, the Company may raise $500 million of other secured debt maturing in 2029 (together with the New First Lien Term Loan, the "Refinancing Transactions"). The Company intends to use the proceeds from the Refinancing Transactions to repay a portion of the borrowings under the Company's existing first-priority senior secured term loan facility maturing in 2025.
After the closing of the Refinancing Transactions, the Company intends to redeem all of the Company's 10.500% second-priority senior secured notes due 2026 and 10.125% second-priority senior secured notes due 2026 (collectively, the "2026 Notes"), saving over $120 million in interest expense on an annualized basis. The $1.2 billion of redemptions will be conditioned on the closing of the Refinancing Transactions. The Company expects to use cash on hand to finance the redemptions. This press release does not constitute a notice of redemption with respect to the 2026 Notes.
The Company's Chief Financial Officer David Bernstein commented: "Given the confidence we have in our business and its cash flow generation, we plan to retire $1.2 billion of our highest cost debt. In connection with this retirement, we plan to extend some of the lowest cost public debt in our portfolio. This is yet another step forward in our deleveraging journey, building on the $1.4 billion we already early retired this year. With this debt repayment, we now expect our year end debt balance to be less than $32.0 billion, an improvement over the November 30, 2023 debt balance of less than $33.0 billion provided in our June guidance."
This press release shall not constitute an offer to sell or the solicitation of an offer to purchase any security and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offering, solicitation or sale would be unlawful.
About Carnival Corporation & plc
Carnival Corporation & plc is the largest global cruise company, and among the largest leisure travel companies, with a portfolio of world-class leading cruise lines - AIDA Cruises, Carnival Cruise Line, Costa Cruises, Cunard, Holland America Line, P&O Cruises (Australia), P&O Cruises (UK), Princess Cruises and Seabourn.
Cautionary Note Concerning Forward-Looking Statements
Carnival Corporation and Carnival plc and their respective subsidiaries are referred to collectively in this press release, as "Carnival Corporation & plc," "our," "us" and "we." Some of the statements, estimates or projections contained in this press release are "forward-looking statements" that involve risks, uncertainties and assumptions with respect to us, including some statements concerning the refinancing transactions described herein, future results, operations, outlooks, plans, goals, reputation, cash flows, liquidity and other events which have not yet occurred. These statements are intended to qualify for the safe harbors from liability provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are statements that could be deemed forward-looking. These statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate and the beliefs and assumptions of our management. We have tried, whenever possible, to identify these statements by using words like "will," "may," "could," "should," "would," "believe," "depends," "expect," "goal," "aspiration," "anticipate," "forecast," "project," "future," "intend," "plan," "estimate," "target," "indicate," "outlook," and similar expressions of future intent or the negative of such terms.
Forward-looking statements include those statements that relate to our outlook and financial position including, but not limited to, statements regarding:
Because forward-looking statements involve risks and uncertainties, there are many factors that could cause our actual results, performance or achievements to differ materially from those expressed or implied by our forward-looking statements. This note contains important cautionary statements of the known factors that we consider could materially affect the accuracy of our forward-looking statements and adversely affect our business, results of operations and financial position. Additionally, many of these risks and uncertainties are currently, and in the future may continue to be, amplified by our substantial debt balance as a result of the pause of our guest cruise operations. There may be additional risks that we consider immaterial or which are unknown. These factors include, but are not limited to, the following:
- events and conditions around the world, including war and other military actions, such as the invasion of Ukraine, inflation, higher fuel prices, higher interest rates and other general concerns impacting the ability or desire of people to travel have led, and may in the future lead, to a decline in demand for cruises, impacting our operating costs and profitability;
- pandemics have in the past and may in the future have a significant negative impact on our financial condition and operations;
- incidents concerning our ships, guests or the cruise industry have in the past and may, in the future, negatively impact the satisfaction of our guests and crew and lead to reputational damage;
- changes in and non-compliance with laws and regulations under which we operate, such as those relating to health, environment, safety and security, data privacy and protection, anti-corruption, economic sanctions, trade protection, labor and employment and tax have in the past and may, in the future, lead to litigation, enforcement actions, fines, penalties and reputational damage;
- factors associated with climate change, including evolving and increasing regulations, increasing global concern about climate change and the shift in climate conscious consumerism and stakeholder scrutiny, and increasing frequency and/or severity of adverse weather conditions could adversely affect our business;
- inability to meet or achieve our sustainability related goals, aspirations, initiatives, and our public statements and disclosures regarding them, may expose us to risks that may adversely impact our business;
- breaches in data security and lapses in data privacy as well as disruptions and other damages to our principal offices, information technology operations and system networks and failure to keep pace with developments in technology may adversely impact our business operations, the satisfaction of our guests and crew and may lead to reputational damage;
- the loss of key team members, our inability to recruit or retain qualified shoreside and shipboard team members and increased labor costs could have an adverse effect on our business and results of operations;
- increases in fuel prices, changes in the types of fuel consumed and availability of fuel supply may adversely impact our scheduled itineraries and costs;
- we rely on supply chain vendors who are integral to the operations of our businesses. These vendors and service providers may be unable to deliver on their commitments, which could negatively impact our business;
- fluctuations in foreign currency exchange rates may adversely impact our financial results;
- overcapacity and competition in the cruise and land-based vacation industry may negatively impact our cruise sales, pricing and destination options;
- inability to implement our shipbuilding programs and ship repairs, maintenance and refurbishments may adversely impact our business operations and the satisfaction of our guests;
- Failure to successfully implement our business strategy following our resumption of guest cruise operations would negatively impact the occupancy levels and pricing of our cruises and could have a material adverse effect on our business. We require a significant amount of cash to service our debt and sustain our operations. Our ability to generate cash depends on many factors, including those beyond our control, and we may not be able to generate cash required to service our debt and sustain our operations; and,
- the risk factors included in Carnival Corporation's and Carnival plc's Annual Report on Form 10-K filed with the SEC on January 27, 2023 and Carnival Corporation's and Carnival plc's Quarterly Reports on Form 10-Q filed with the SEC on March 29, 2023 and June 28, 2023.
The ordering of the risk factors set forth above is not intended to reflect our indication of priority or likelihood.
Forward-looking statements should not be relied upon as a prediction of actual results. Subject to any continuing obligations under applicable law or any relevant stock exchange rules, we expressly disclaim any obligation to disseminate, after the date of this document, any updates or revisions to any such forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which any such statements are based.
Forward-looking and other statements in this document may also address our sustainability progress, plans and goals (including climate change and environmental-related matters). In addition, historical, current and forward-looking sustainability- and climate-related statements may be based on standards and tools for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions and predictions that are subject to change in the future and may not be generally shared.
SOURCE Carnival Corporation & plc
View original content:
SOURCE Carnival Corporation & plc | https://www.wafb.com/prnewswire/2023/07/31/carnival-corporation-amp-plc-announces-anticipated-debt-pre-payment-12b-refinancing-transaction/ | 2023-07-31T12:35:18 | 0 | https://www.wafb.com/prnewswire/2023/07/31/carnival-corporation-amp-plc-announces-anticipated-debt-pre-payment-12b-refinancing-transaction/ |
FREIT Board Committed to Protecting Value for All Stockholders
Highlights Kushner's Transaction Record with FREIT and Ongoing Litigation with Kushner
HACKENSACK, N.J., July 31, 2023 /PRNewswire/ -- First Real Estate Investment Trust of New Jersey, Inc. ("FREIT" or the "Company") (OTCM: FREVS) today announced that its Board of Directors has unanimously adopted a stockholder rights plan (the "Rights Plan") following evaluation and consultation with the Company's legal and financial advisors.
The Rights Plan is similar to plans adopted by other publicly traded companies incorporated in Maryland and is intended to protect the long-term interests of FREIT stockholders and to enable them to realize the full potential value of their investment. The Rights Plan has a three-year duration and the rights will be exercisable only if any person (or any persons acting as a group) acquires 10% or more of FREIT common stock. This ownership limitation better aligns FREIT with the ownership limitation of other REITs.
The Rights Plan does not preclude the Board from considering an offer that recognizes the full value of the Company. Rather, the Rights Plan will reduce the likelihood that any entity, person or group gains control of FREIT without paying an appropriate control premium. Importantly, the Rights Plan provides the Board with adequate time to fully assess its options following its receipt of an unsolicited, non-binding expression of interest from K Corp Acquisitions LLC, a Kushner company, to acquire FREIT.
While the Board will always evaluate credible proposals to maximize stockholder value, it is mindful that Charles Kushner has proven not to be a bona fide counterparty in a prior potential transaction with FREIT. As such, the Board believes any definitive agreement with Charles Kushner would carry significant, atypical closing and additional litigation risk.
The Rights Plan will benefit FREIT stockholders by providing the Company with enough time to pursue a final outcome in the previously announced ongoing litigation with Sinatra LLC, a Kushner company, related to Kushner's abandonment of a January 2020 definitive agreement to acquire certain of FREIT's assets. Following the outcome of the litigation, the Board will have greater flexibility to consider a value-maximizing transaction.
Additional Details of the Rights Plan
In connection with the adoption of the Rights Plan, the Board of Directors declared a dividend distribution of one preferred stock purchase right for each outstanding share of FREIT common stock to stockholders of record as of the close of business on August 11, 2023. Initially, these rights will not be exercisable and will trade with the shares of FREIT common stock.
The Rights Plan provides several recognized stockholder protections, such as the following:
- Under the Rights Plan, the rights generally will become exercisable if a person or group becomes an "acquiring person" by acquiring 10% or more of the common stock of FREIT (which includes stock subject to a derivative transaction or an acquired derivative security) or if a person commences a tender offer that could result in that person becoming an "acquiring person".
- If a person becomes an "acquiring person," each holder of a right (other than the acquiring person) would be entitled to purchase, at the then-current exercise price, such number of shares of common stock (or, subject to the terms of the Rights Plan, shares of preferred stock that are equivalent to shares of FREIT common stock) at a 50% discount. If FREIT is acquired in a merger or other business combination transaction after any such event, each holder of a right would then be entitled to purchase, at the then-current exercise price, shares of the acquiring company's common stock at a 50% discount. The Board, at its option, may exchange on a cashless basis, each right (other than rights owned by the acquiring person that have become null and void) in whole or in part, at an exchange ratio of one share of FREIT common stock per outstanding right, subject to adjustment.
- The Rights will expire in three years on July 31, 2026, unless the rights have been previously redeemed or exchanged by the Board of Directors in accordance with the terms of the Rights Plan.
Under the Rights Plan, any person, entity or group that currently owns more than the triggering percentage may continue to own its shares of FREIT common stock but may not acquire any additional shares of common stock, or form a group with another owner of FREIT common stock, without triggering the Rights Plan.
Additional details about the Rights Plan will be contained in a Current Report on Form 8-K to be filed by FREIT with the Securities and Exchange Commission.
Advisors
Goldman Sachs & Co. LLC is acting as financial advisor to FREIT and Goodwin Procter LLP and Miles & Stockbridge P.C. are acting as legal counsel.
About FREIT
First Real Estate Investment Trust of New Jersey, Inc. is a publicly traded (over-the-counter – symbol FREVS) REIT organized in 1961. Its portfolio of residential and commercial properties are located in New Jersey and New York, with the largest concentration in northern New Jersey. For more information, visit: www.freitnj.com.
Forward-Looking Statements
This Company release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These forward-looking statements can be identified by the use of words such as "expect," "plan," "will," "estimate," "project," "intend," "believe," "guidance," "approximately," "anticipate," "may," "should," "seek" or the negative of these words and phrases or similar words or phrases that are predictions of or indicate future events or trends and that do not relate to historical matters. You can also identify forward-looking statements by discussions of strategy, plans or intentions of management. These forward-looking statements are subject to known and unknown risks and uncertainties that you should not rely on as predictions of future events. Forward-looking statements depend on assumptions, data and/or methods which may be incorrect or imprecise and we may not be able to realize them. The following risks and uncertainties, among others, could cause actual results to differ materially from those currently anticipated due to a number of factors, which include, but are not limited to: industry and economic conditions; the Company's ability to satisfy the conditions to closing and complete the proposed transaction; the Company's dependence upon its external manager to conduct its business and achieve its investment objectives; unknown liabilities acquired in connection with acquired properties or interests in real estate-related entities; general risks affecting the real estate industry and local real estate markets (including, without limitation, the market value of the Company's properties, potential illiquidity of the Company's remaining real estate investments, condemnations, and potential damage from natural disasters); the financial performance of the Company's tenants; the impact of any financial, accounting, legal or regulatory issues or litigation that may affect the Trust and its major tenants; volatility and uncertainty in the financial markets, including potential fluctuations in the consumer price index; risks associated with the Company's failure to maintain status as a REIT under the Internal Revenue Code of 1986, as amended; and other additional risks discussed in the Company's annual report on Form 10-K for the fiscal year ended October 31, 2022. The Company expressly disclaims any responsibility to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Media & Investor Contact
Scott Bisang / Nick Lamplough / Jack Kelleher
Collected Strategies
FREIT-IR@collectedstrategies.com
View original content to download multimedia:
SOURCE First Real Estate Investment Trust of New Jersey | https://www.kwch.com/prnewswire/2023/07/31/first-real-estate-investment-trust-new-jersey-inc-adopts-stockholder-rights-plan/ | 2023-07-31T12:35:20 | 0 | https://www.kwch.com/prnewswire/2023/07/31/first-real-estate-investment-trust-new-jersey-inc-adopts-stockholder-rights-plan/ |
BEIJING, July 31, 2023 /PRNewswire/ -- WiMi Hologram Cloud Inc. (NASDAQ: WIMI) ("WiMi" or the "Company"), a leading global Hologram Augmented Reality ("AR") Technology provider, today announced that an algorithm of nonlinear optical holography was developed. This is an algorithm that uses nonlinear optical effects to reconstruct a holographic image of an object. The laser beam is modulated using nonlinear optical materials to encode information about the object under test into an optical interference pattern, and then this interference pattern is recorded and processed using holography. In this process, the optical interference pattern has spatial and temporal features of high complexity, which can be used to realize nonlinear interactions between photons through the use of nonlinear optical effects (e.g., optical phase conjugation effects) to achieve the three-dimensional reconstruction of the object. It utilizes the nonlinear properties of light in optics to realize the processing and conversion of optical signals, and has the advantages of high resolution, no damage, and fast reconstruction.
This algorithm developed by WiMi is to use the characteristics of nonlinear optical materials to realize the self-modulation of light waves, self-frequency conversion and other processing, through holographic technology recorded light field information can provide richer optical information, to achieve better holographic image reconstruction effect. The laser beam and the reference beam are first constructed, and they are interfered with through the nonlinear crystal. In the interference region, the modulation of parameters such as refractive index, absorption, and refraction angle of the material that will be self-modulated is generated, and to obtain the hologram, the phase modulation of the signal beam is required. During the propagation of the laser wave in the material, the frequency of the wave changes due to the presence of nonlinear effects, forming a new non-planar wave called a differential frequency wave. The differential frequency wave is then recorded by holographic technology, and the corresponding data processing and reconstruction are carried out to obtain the hologram image of the original information. Finally, the desired image is obtained by processing the hologram.
Compared with traditional holographic algorithms, this technology can realize a variety of nonlinear optical effects, eliminate interference fringes and noise in traditional holographic technology, improve image clarity and signal-to-noise ratio, and obtain higher holographic imaging quality and resolution. It can also realize real-time imaging by adjusting the control factors such as laser power and material parameters, and can realize image modulation and enhancement by controlling different optical parameters, which improves the flexibility and applicability, and has higher practical value of application.
With the rapid development of computer technology and optical technology, WiMi's algorithm will also be continuously improved and enhanced, and its scope of application will be further expanded. It is foreseeable that the holographic algorithm will play an important role in the fields of medical imaging, education, entertainment, etc. At the same time, it will be one of the directions of future development of optical technology, which can provide important technical support for scientific research and industrial manufacturing.
About WIMI Hologram Cloud
WIMI Hologram Cloud, Inc. (NASDAQ:WIMI) is a holographic cloud comprehensive technical solution provider that focuses on professional areas including holographic AR automotive HUD software, 3D holographic pulse LiDAR, head-mounted light field holographic equipment, holographic semiconductor, holographic cloud software, holographic car navigation and others. Its services and holographic AR technologies include holographic AR automotive application, 3D holographic pulse LiDAR technology, holographic vision semiconductor technology, holographic software development, holographic AR advertising technology, holographic AR entertainment technology, holographic ARSDK payment, interactive holographic communication and other holographic AR technologies.
Safe Harbor Statements
This press release contains "forward-looking statements" within the Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar statements. Statements that are not historical facts, including statements about the Company's beliefs and expectations, are forward-looking statements. Among other things, the business outlook and quotations from management in this press release and the Company's strategic and operational plans contain forward−looking statements. The Company may also make written or oral forward−looking statements in its periodic reports to the US Securities and Exchange Commission ("SEC") on Forms 20−F and 6−K, in its annual report to shareholders, in press releases, and other written materials, and in oral statements made by its officers, directors or employees to third parties. Forward-looking statements involve inherent risks and uncertainties. Several factors could cause actual results to differ materially from those contained in any forward−looking statement, including but not limited to the following: the Company's goals and strategies; the Company's future business development, financial condition, and results of operations; the expected growth of the AR holographic industry; and the Company's expectations regarding demand for and market acceptance of its products and services.
Further information regarding these and other risks is included in the Company's annual report on Form 20-F and the current report on Form 6-K and other documents filed with the SEC. All information provided in this press release is as of the date of this press release. The Company does not undertake any obligation to update any forward-looking statement except as required under applicable laws.
View original content:
SOURCE WiMi Hologram Cloud Inc. | https://www.wbay.com/prnewswire/2023/07/31/wimi-hologram-cloud-developed-algorithm-nonlinear-optical-holography/ | 2023-07-31T12:35:22 | 1 | https://www.wbay.com/prnewswire/2023/07/31/wimi-hologram-cloud-developed-algorithm-nonlinear-optical-holography/ |
MIAMI, July 31, 2023 /PRNewswire/ -- Carnival Corporation & plc (NYSE/LSE: CCL; NYSE: CUK) today announced that Carnival Corporation (the "Company") intends to commence the marketing of a new senior secured first lien term loan B facility (the "New First Lien Term Loan") with an original principal amount of $1.0 billion, expected to mature in 2027. In conjunction with the New First Lien Term Loan, and subject to market and other conditions, the Company may raise $500 million of other secured debt maturing in 2029 (together with the New First Lien Term Loan, the "Refinancing Transactions"). The Company intends to use the proceeds from the Refinancing Transactions to repay a portion of the borrowings under the Company's existing first-priority senior secured term loan facility maturing in 2025.
After the closing of the Refinancing Transactions, the Company intends to redeem all of the Company's 10.500% second-priority senior secured notes due 2026 and 10.125% second-priority senior secured notes due 2026 (collectively, the "2026 Notes"), saving over $120 million in interest expense on an annualized basis. The $1.2 billion of redemptions will be conditioned on the closing of the Refinancing Transactions. The Company expects to use cash on hand to finance the redemptions. This press release does not constitute a notice of redemption with respect to the 2026 Notes.
The Company's Chief Financial Officer David Bernstein commented: "Given the confidence we have in our business and its cash flow generation, we plan to retire $1.2 billion of our highest cost debt. In connection with this retirement, we plan to extend some of the lowest cost public debt in our portfolio. This is yet another step forward in our deleveraging journey, building on the $1.4 billion we already early retired this year. With this debt repayment, we now expect our year end debt balance to be less than $32.0 billion, an improvement over the November 30, 2023 debt balance of less than $33.0 billion provided in our June guidance."
This press release shall not constitute an offer to sell or the solicitation of an offer to purchase any security and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such offering, solicitation or sale would be unlawful.
About Carnival Corporation & plc
Carnival Corporation & plc is the largest global cruise company, and among the largest leisure travel companies, with a portfolio of world-class leading cruise lines - AIDA Cruises, Carnival Cruise Line, Costa Cruises, Cunard, Holland America Line, P&O Cruises (Australia), P&O Cruises (UK), Princess Cruises and Seabourn.
Cautionary Note Concerning Forward-Looking Statements
Carnival Corporation and Carnival plc and their respective subsidiaries are referred to collectively in this press release, as "Carnival Corporation & plc," "our," "us" and "we." Some of the statements, estimates or projections contained in this press release are "forward-looking statements" that involve risks, uncertainties and assumptions with respect to us, including some statements concerning the refinancing transactions described herein, future results, operations, outlooks, plans, goals, reputation, cash flows, liquidity and other events which have not yet occurred. These statements are intended to qualify for the safe harbors from liability provided by Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are statements that could be deemed forward-looking. These statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate and the beliefs and assumptions of our management. We have tried, whenever possible, to identify these statements by using words like "will," "may," "could," "should," "would," "believe," "depends," "expect," "goal," "aspiration," "anticipate," "forecast," "project," "future," "intend," "plan," "estimate," "target," "indicate," "outlook," and similar expressions of future intent or the negative of such terms.
Forward-looking statements include those statements that relate to our outlook and financial position including, but not limited to, statements regarding:
Because forward-looking statements involve risks and uncertainties, there are many factors that could cause our actual results, performance or achievements to differ materially from those expressed or implied by our forward-looking statements. This note contains important cautionary statements of the known factors that we consider could materially affect the accuracy of our forward-looking statements and adversely affect our business, results of operations and financial position. Additionally, many of these risks and uncertainties are currently, and in the future may continue to be, amplified by our substantial debt balance as a result of the pause of our guest cruise operations. There may be additional risks that we consider immaterial or which are unknown. These factors include, but are not limited to, the following:
- events and conditions around the world, including war and other military actions, such as the invasion of Ukraine, inflation, higher fuel prices, higher interest rates and other general concerns impacting the ability or desire of people to travel have led, and may in the future lead, to a decline in demand for cruises, impacting our operating costs and profitability;
- pandemics have in the past and may in the future have a significant negative impact on our financial condition and operations;
- incidents concerning our ships, guests or the cruise industry have in the past and may, in the future, negatively impact the satisfaction of our guests and crew and lead to reputational damage;
- changes in and non-compliance with laws and regulations under which we operate, such as those relating to health, environment, safety and security, data privacy and protection, anti-corruption, economic sanctions, trade protection, labor and employment and tax have in the past and may, in the future, lead to litigation, enforcement actions, fines, penalties and reputational damage;
- factors associated with climate change, including evolving and increasing regulations, increasing global concern about climate change and the shift in climate conscious consumerism and stakeholder scrutiny, and increasing frequency and/or severity of adverse weather conditions could adversely affect our business;
- inability to meet or achieve our sustainability related goals, aspirations, initiatives, and our public statements and disclosures regarding them, may expose us to risks that may adversely impact our business;
- breaches in data security and lapses in data privacy as well as disruptions and other damages to our principal offices, information technology operations and system networks and failure to keep pace with developments in technology may adversely impact our business operations, the satisfaction of our guests and crew and may lead to reputational damage;
- the loss of key team members, our inability to recruit or retain qualified shoreside and shipboard team members and increased labor costs could have an adverse effect on our business and results of operations;
- increases in fuel prices, changes in the types of fuel consumed and availability of fuel supply may adversely impact our scheduled itineraries and costs;
- we rely on supply chain vendors who are integral to the operations of our businesses. These vendors and service providers may be unable to deliver on their commitments, which could negatively impact our business;
- fluctuations in foreign currency exchange rates may adversely impact our financial results;
- overcapacity and competition in the cruise and land-based vacation industry may negatively impact our cruise sales, pricing and destination options;
- inability to implement our shipbuilding programs and ship repairs, maintenance and refurbishments may adversely impact our business operations and the satisfaction of our guests;
- Failure to successfully implement our business strategy following our resumption of guest cruise operations would negatively impact the occupancy levels and pricing of our cruises and could have a material adverse effect on our business. We require a significant amount of cash to service our debt and sustain our operations. Our ability to generate cash depends on many factors, including those beyond our control, and we may not be able to generate cash required to service our debt and sustain our operations; and,
- the risk factors included in Carnival Corporation's and Carnival plc's Annual Report on Form 10-K filed with the SEC on January 27, 2023 and Carnival Corporation's and Carnival plc's Quarterly Reports on Form 10-Q filed with the SEC on March 29, 2023 and June 28, 2023.
The ordering of the risk factors set forth above is not intended to reflect our indication of priority or likelihood.
Forward-looking statements should not be relied upon as a prediction of actual results. Subject to any continuing obligations under applicable law or any relevant stock exchange rules, we expressly disclaim any obligation to disseminate, after the date of this document, any updates or revisions to any such forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which any such statements are based.
Forward-looking and other statements in this document may also address our sustainability progress, plans and goals (including climate change and environmental-related matters). In addition, historical, current and forward-looking sustainability- and climate-related statements may be based on standards and tools for measuring progress that are still developing, internal controls and processes that continue to evolve, and assumptions and predictions that are subject to change in the future and may not be generally shared.
SOURCE Carnival Corporation & plc
View original content:
SOURCE Carnival Corporation & plc | https://www.kait8.com/prnewswire/2023/07/31/carnival-corporation-amp-plc-announces-anticipated-debt-pre-payment-12b-refinancing-transaction/ | 2023-07-31T12:35:22 | 0 | https://www.kait8.com/prnewswire/2023/07/31/carnival-corporation-amp-plc-announces-anticipated-debt-pre-payment-12b-refinancing-transaction/ |
NORWOOD, Mass., July 31, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the BTIG Virtual Biotechnology Conference, to be held August 7-8, 2023.
BTIG Virtual Biotechnology Conference
Format: Fireside chat and one-on-one investor meetings
Fireside Chat Date: Tuesday, August 8, 2023
Fireside Chat Time: 9:00 a.m. ET
To register for the conference, contact your BTIG sales representative.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. (the "Company" or "Corbus") is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus' internal development pipeline includes CRB-701, a next generation antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
Sean.moran@corbuspharma.com
Bruce Mackle Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
View original content to download multimedia:
SOURCE Corbus Pharmaceuticals | https://www.wafb.com/prnewswire/2023/07/31/corbus-pharmaceuticals-present-btig-virtual-biotechnology-conference/ | 2023-07-31T12:35:25 | 1 | https://www.wafb.com/prnewswire/2023/07/31/corbus-pharmaceuticals-present-btig-virtual-biotechnology-conference/ |
The report highlights emerging trends that will significantly impact the financial services industry over the next decade
NEW YORK, July 31, 2023 /PRNewswire/ -- Deloitte today announced its "2023 Financial Services Industry Predictions" report, which outlines emerging trends across the banking & capital markets, insurance, real estate, and investment management sectors. The report highlights the impact of data and emerging technologies, products and services, and climate change on the future of financial services – and as a result, on society and the economy.
"The reality is that emerging technological changes could be more pervasive and impactful going forward in ways that can be scarcely imagined today," said Jim Eckenrode, managing director, Deloitte Center for Financial Services. Deloitte Services LP. "Financial services will likely play an important role in helping these breakthroughs emerge to the benefit of us all, while simultaneously opening up new avenues of revenue and profit."
Some of Deloitte's predictions for the financial services industry over the next decade:
Generative AI is expected to boost productivity: Generative AI is expected to have a significant impact on the investment banking industry and the financial services industry as a whole, as organizations explore ways to harness the power of the technology to improve productivity. Deloitte predicts the top 14 global investment banks could boost their front-office productivity by an average of 25% by using Generative AI (GAI), thereby earning potentially an additional revenue of $3 million per front-office employee in 2026, from an average of $11.3 million during 2020-22.
Demand for carbon credit offset financing: Deloitte predicts that global consumers will purchase $115 billion of carbon offsets a year by 2030. Carbon credits will likely be embedded in many of the purchasing decisions that consumers make in their day-to-day lives. The surge in demand for these credits could produce new trading networks that offer tailored, localized and niche options for climate change mitigation projects. Banks could be instrumental in developing and supporting the back-end infrastructure that connect brands' payment processes to the carbon credit market. And banks can play an instrumental role in developing and supporting the carbon credit market.
Insurers prepare for driverless vehicles: Deloitte estimates advancements in self-driving technology may eliminate the need for around 380,000 long-haul truck drivers in the next five years. This alone would have a major impact on workers' compensation insurers, with a potential loss of around $3 billion worth of premiums. But widespread adoption of autonomous vehicles could also result in a shift in premiums across multiple insurance lines, including commercial auto, product and professional liability, and cyber coverage.
Office space to fill the affordable housing gap: Deloitte predicts office-to-residential conversions could become profitable within the next five years, estimating that around 14,700 affordable units in central business districts across the country can be added by 2030, assuming approximately 20% of converted square footage can be earmarked for affordable housing.
"As financial services firms grapple with what's on the horizon, they need to think about how the landscape is radically shifting," said Monica O'Reilly, Vice Chair, US Financial Services Industry Leader, Deloitte & Touche LLP. "Market and economic pressures, emerging technologies, and new revenue opportunities will impact tomorrow's business strategies, and financial services firms should prepare for that now."
Additional trends included in the report that are expected to shape the financial services industry:
Democratization of financial advice: Financial advice shouldn't just be for the wealthy anymore — and it doesn't have to be. Financial firms can leverage robo-advisory platforms to bring much-needed financial advice to the global mass market and make it profitable. Deloitte estimates net financial wealth held by the mass retail population segment globally to almost double to $22 trillion by 2030.
Synthetic identity fraud could trigger need for more sophisticated biometric security systems: Synthetic identity fraud—a hoax in which cybercriminals create new identities with some stolen or fabricated data — is the fastest growing financial crime in the United States,i and it shows no sign of abating. Deloitte expects it to generate at least $25 billion in losses by 2030, prompting banks to develop more advanced biometric security systems to weed out would-be perpetrators.
Higher deposit costs expected to challenge banks: Deloitte predicts the average cost of interest-bearing deposits for the U.S. banking industry in 2024 and 2025 to remain elevated at 1.7% and 1.5%, respectively, even as the fed funds rate declines from the recent peak. This may crimp bank profitability in the medium term.
Real-time B2B payments could take off: Deloitte expects real-time payments could tap an addressable market of $12 trillion in check-based business-to-business (B2B) transaction volume globally by 2028. Banks and payment firms could play a pivotal role in helping usher in a new era of more efficient and instant domestic and cross-border value exchange among businesses.
Rise of embedded insurance: Embedded finance, and particularly embedded insurance, is expected to continue to expand. Execution may not be easy for insurers, though, and it could take the rest of the decade for embedded finance to fully shake out.
Increased spending on quantum computing: Spending on quantum-related capabilities will likely grow quickly over the next few years as indicated by the increased capital investments and patent filings for the hardware technology. Globally, the financial services industry's spending on quantum computing capabilities is expected to grow 233x from just US$80 million in 2022 to US$19 billion in 2032, growing at a 10-year CAGR of 72%.
Alternative data in investment management: Deloitte estimates the revenue for alternative data providers, earned from all industries globally with the majority coming from investment management firms, to grow 29x between 2022 and 2030. The new data largely consist of novel types and forms of data such as satellite images, social media posts, geolocation data, credit card transactions, and mobile application data that are starkly different from the traditionally structured financial data.
Funding for climate hardtech: An additional US$2 trillion in private hardtech investment is predicted to be needed to help effectively slow global warming. Most of total climate funding will likely need to come from the private sector — but so far, there isn't enough. Financial services organizations can play a lead role in bridging the funding gap.
About Deloitte
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including nearly 90% of the Fortune 500® and more than 7,000 private companies. Our people come together for the greater good and work across the industry sectors that drive and shape today's marketplace — delivering measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to see challenges as opportunities to transform and thrive, and help lead the way toward a stronger economy and a healthier society. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Building on more than 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte's more than 415,000 people worldwide connect for impact at www.deloitte.com.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
iFedPayments Improvement, "Synthetic identity fraud," accessed June 8, 2023.
View original content to download multimedia:
SOURCE Deloitte | https://www.wafb.com/prnewswire/2023/07/31/deloitte-2023-financial-services-industry-predictions-generative-ai-carbon-offset-financing-driverless-vehicles-office-space-conversion-among-top-trends-transforming-financial-services/ | 2023-07-31T12:35:25 | 1 | https://www.wafb.com/prnewswire/2023/07/31/deloitte-2023-financial-services-industry-predictions-generative-ai-carbon-offset-financing-driverless-vehicles-office-space-conversion-among-top-trends-transforming-financial-services/ |
New video spot, "Dear Kitten: Modern Technology" finds Grey Cat and Orange Kitten all grown up and dealing with the digital age.
ST. LOUIS, July 31, 2023 /PRNewswire/ -- Dear reader, are you ready for adorable internet feline nostalgia? Friskies, the popular cat food and treat brand, has launched the revival of the playful 'Dear Kitten' series, which took the internet by storm when it was first released nearly 10 years ago. In partnership with BuzzFeed, the new installment, titled 'Dear Kitten: Modern Technology,' takes a humorous look at how technology has evolved over the years through the eyes of the original wise and experienced narrator, Grey Cat, while highlighting the special bond between humans and their feline companions.
Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9185151-purina-friskies-buzzfeed-dear-kitten-campaign-video/
In 'Modern Technology,' Grey Cat, voiced again by Ze Frank, shares valuable insights with Orange Kitten, now referred to as Orange Cat, as they navigate the rapidly changing landscape of modern devices. The video takes viewers on a comical journey, showcasing the entertaining and often perplexing situations cats experience when faced with today's advanced technology – including another daring encounter with Vacuum.
"It's been nearly a decade since you've heard from me, which I'm sure has been tough for you," said Grey Cat. "Although I am now older, I am also even wiser – like a furry sensei. I've witnessed advancements in technology that have both fascinated and bewildered me, so, it is once again my duty to get Orange Cat (and you, my feline friends) up to speed on the facts about this great big, weird world. Buckle up."
The original 'Dear Kitten' series, which captivated audiences with its witty storytelling, amassed hundreds of millions of views and resonated with pet lovers worldwide. The collaboration between Friskies and BuzzFeed provided an opportunity to once again create engaging and entertaining content that celebrates the unique bond between humans and their pets.
"Friskies is all about providing your cat with variety to feed their playfulness and curiosity, and with 'Dear Kitten', we brought that same playful spirit to life for cat lovers," said Kelly Roberts, Purina Brand Manager. "As we approach the 10-year anniversary of the original series, it felt like the perfect time to check-in to see what life is like today for our favorite feline duo and welcome a new generation of cat lovers into the 'Dear Kitten' family."
The 'Modern Technology' video was officially released on July 27, 2023, on BuzzFeed. The next video installment, titled 'Day in the Life of an Influencer' will be released later this Summer. To stay updated on the series visit BuzzFeed's official channels or follow Friskies on social media.
About Nestlé Purina PetCare
Nestlé Purina PetCare creates richer lives for pets and the people who love them. Founded in 1894, Purina has helped dogs and cats live longer, healthier lives by offering scientifically based nutritional innovations. Purina manufactures some of the world's most trusted and popular pet care products, including Purina ONE, Pro Plan, Friskies and Tidy Cats. Our more than 10,000 U.S. associates take pride in our trusted pet food, treat and litter brands that feed 46 million dogs and 68 million cats every year. More than 500 Purina scientists, veterinarians, and pet care experts ensure our commitment to unsurpassed quality and nutrition.
Purina promotes responsible pet care through our scientific research, our products and our support for pet-related organizations. Over the past five years, Purina has contributed more than $150 million towards organizations that bring, and keep, people and pets together, as well as those that help our communities and environment thrive.
Purina is part of Nestlé, a global leader in Nutrition, Health and Wellness. For more information, visit purina.com or subscribe here to get the latest Purina news.
About BuzzFeed, Inc.
BuzzFeed, Inc. is home to the best of the internet. Across food, news, pop culture and commerce, our brands drive conversation and inspire what audiences watch, read, buy, and obsess over next. Born on the internet in 2006, BuzzFeed, Inc. is committed to making it better: providing trusted, quality, brand-safe news and entertainment to hundreds of millions of people; making content on the internet more inclusive, empathetic, and creative; and inspiring our audience to live better lives.
View original content:
SOURCE Friskies® | https://www.kwch.com/prnewswire/2023/07/31/friskies-buzzfeed-reboot-dear-kitten-hit-video-series-after-nearly-decade/ | 2023-07-31T12:35:26 | 0 | https://www.kwch.com/prnewswire/2023/07/31/friskies-buzzfeed-reboot-dear-kitten-hit-video-series-after-nearly-decade/ |
GUANGZHOU, China, July 31, 2023 /PRNewswire/ -- Yatsen Holding Limited ("Yatsen" or the "Company") (NYSE: YSG), a leading China-based beauty group, today announced that it has published its 2022 Environmental, Social and Governance ("ESG") report, outlining the Company's progress and performance in key ESG areas.
The report provides a comprehensive review of Yatsen's ESG initiatives and developments, including corporate governance, research and development, employee rights protection, human capital development, environmental sustainability and social responsibility, among others.
To view the report in full, please visit the ESG section on the Yatsen Investor Relations website. Alternatively, please click here for the English version and here for the Chinese version of the 2022 report.
About Yatsen Holding Limited
Yatsen Holding Limited (NYSE: YSG) is a leading China-based beauty group with the mission of creating an exciting new journey of beauty discovery for consumers around the world. Founded in 2016, the Company has launched and acquired numerous color cosmetics and skincare brands, including Perfect Diary, Little Ondine, Abby's Choice, Galénic, DR.WU (its mainland China business), Eve Lom, Pink Bear and EANTiM. The Company's flagship brand, Perfect Diary, is one of the leading color cosmetics brands in China in terms of retail sales value. The Company primarily reaches and engages with customers directly, both online and offline, with an expansive presence across all major e-commerce, social and content platforms in China.
For more information, please visit http://ir.yatsenglobal.com/.
For investor and media inquiries, please contact:
In China:
Yatsen Holding Limited
Investor Relations
E-mail: ir@yatsenglobal.com
The Piacente Group, Inc
Hui Fan
Tel: +86-10-6508-0677
E-mail: yatsen@thepiacentegroup.com
In the United States:
The Piacente Group, Inc.
Brandi Piacente
Tel: +1-212-481-2050
E-mail: yatsen@thepiacentegroup.com
View original content:
SOURCE Yatsen Holding Limited | https://www.wbay.com/prnewswire/2023/07/31/yatsen-issues-2022-esg-report/ | 2023-07-31T12:35:28 | 0 | https://www.wbay.com/prnewswire/2023/07/31/yatsen-issues-2022-esg-report/ |
NORWOOD, Mass., July 31, 2023 /PRNewswire/ -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a precision oncology company, today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the BTIG Virtual Biotechnology Conference, to be held August 7-8, 2023.
BTIG Virtual Biotechnology Conference
Format: Fireside chat and one-on-one investor meetings
Fireside Chat Date: Tuesday, August 8, 2023
Fireside Chat Time: 9:00 a.m. ET
To register for the conference, contact your BTIG sales representative.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. (the "Company" or "Corbus") is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus' internal development pipeline includes CRB-701, a next generation antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGFβ expressed on cancer cells. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, "expect," "anticipate," "intend," "plan," "believe," "estimate," "potential," "predict," "project," "should," "would" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
INVESTOR CONTACT:
Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
Sean.moran@corbuspharma.com
Bruce Mackle Managing Director
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
View original content to download multimedia:
SOURCE Corbus Pharmaceuticals | https://www.kait8.com/prnewswire/2023/07/31/corbus-pharmaceuticals-present-btig-virtual-biotechnology-conference/ | 2023-07-31T12:35:29 | 0 | https://www.kait8.com/prnewswire/2023/07/31/corbus-pharmaceuticals-present-btig-virtual-biotechnology-conference/ |
Partnership Expands Access to Seizure First Aid Trainings for School Personnel
BOWIE, Md., July 31, 2023 /PRNewswire/ -- The Epilepsy Foundation today announced a five-year collaboration with Vector Solutions, the leading provider of training and software solutions for K-12 and higher education institutions, to offer the Epilepsy Foundation's Seizure Recognition & First Aid Certification training in the Vector Safety and Compliance Course Library. This agreement will provide an easy and convenient way for educators and school personnel, who are already contracted with Vector, to take the seizure first aid training to better serve their students.
There are 470,000 children living with epilepsy in the U.S. According to the Centers for Disease Control and Prevention (CDC), the opportunity for academic success is increased when students with chronic health conditions have a safe and supportive learning environment.
"Our collaboration with Vector will give school personnel — who are required by state laws to take seizure first aid training — a place to do so easily and effectively through a familiar learning portal," said Brandy Fureman, Ph.D., chief outcomes officer, Epilepsy Foundation. "In addition, it will expand access to our seizure first aid training to school systems around the country using Vector's platform. Our end goal is to have a seizure safe nation where everyone who has a seizure feels safe, no matter where they are. This partnership is a stepstone toward that goal."
In 2018, Kentucky led the charge to pass the nation's first-ever law requiring school personnel to complete seizure recognition and first aid training. Since then, the Epilepsy Foundation, family advocates and partner organizations have been working to pass similar Seizure Safe Schools legislation nationwide. The model Seizure Safe Schools legislation has five components, one of which requires all school personnel, including school nurses and teachers, to complete training so that they can recognize and respond appropriately and efficiently to students experiencing seizures. To date, almost half of the states have passed some form of Seizure Safe Schools legislation.
For years, the Epilepsy Foundation has partnered with the CDC to build nationwide programs to ensure school personnel, first responders, seniors, caregivers, and the public are better trained to recognize seizures and administer first aid. The Epilepsy Foundation's seizure first aid trainings provide information to increase knowledge, skills, and confidence in recognizing seizures and safely administering seizure first aid.
"We are excited to collaborate with the Epilepsy Foundation to deliver its trainings through our online learning management system," said, Rob Buelow, General Manager of Education at Vector Solutions. "The safety and well-being of students is paramount and educators must be properly equipped to address the unique needs of all students. Through this partnership, K-12 and higher education staff across the nation will be empowered to serve their students and ensure their health and safety."
For more information about the Epilepsy Foundation's seizure first aid trainings, visit epilepsy.com/firstaid. The trainings will be available in the Vector platform later this summer and school administrators who have a current subscription will receive notification when the trainings are live.
About Epilepsy
According to the World Health Organization, epilepsy is the most common serious brain disorder worldwide with no age, racial, social class, national or geographic boundaries. The U.S. Centers for Disease Control & Prevention estimates that 3.4 million people in the United States are affected by epilepsy. Epilepsy is the underlying tendency of the brain to produce seizures which are sudden abnormal bursts of electrical energy that disrupt brain functions.
About the Epilepsy Foundation
With a network of partners throughout the United States, the Epilepsy Foundation is leading the fight to overcome the challenges of living with epilepsy. The Foundation connects people to treatment, support, and resources; leads advocacy efforts; funds innovative research and the training of specialists; and educates the public about epilepsy and seizure first aid. For more than five decades, the Epilepsy Foundation has shone a light on epilepsy to promote awareness and understanding, and to advocate for laws that matter to people with epilepsy, while also funding epilepsy research and supporting epilepsy investigators and specialists in their early careers. In partnership with the CDC, the Epilepsy Foundation has helped to improve access to care for people with epilepsy, expanded its digital reach and online resources in homes across the country, and trained more than 600,000 people in seizure recognition and first aid. The Epilepsy Foundation continues to focus on serving the epilepsy community through advocacy, education, direct services and research for new therapies. To learn more visit epilepsy.com or call 1.800.332.1000. Follow us on Facebook and Twitter.
About Vector Solutions for K-12 Education
Vector Solutions for K-12 Education is a leading provider of training, software and professional development solutions committed to creating safer, smarter and better school environments. Trusted by more than 5,000 K-12 districts in the United States, Vector's award-winning suite of products save administrators time, improve compliance, and streamline administrative processes. Vector trainings on imperative topics like safety and compliance; inclusive instruction; mental health and well-being; diversity, equity and inclusion; and cybersecurity enable students and teachers alike to make schools safer, more inclusive, and more effective places to work and learn. For more information about Vector Solutions for K-12 Education, visit www.vectorsolutions.com/k12.
View original content to download multimedia:
SOURCE Epilepsy Foundation | https://www.wafb.com/prnewswire/2023/07/31/epilepsy-foundation-partners-with-vector-solutions-offer-seizure-first-aid-trainings-educators/ | 2023-07-31T12:35:32 | 1 | https://www.wafb.com/prnewswire/2023/07/31/epilepsy-foundation-partners-with-vector-solutions-offer-seizure-first-aid-trainings-educators/ |
Success of the Global Premier Fertility Platform Leading to Additional Growth and Expansion
IRVINE, Calif., July 31, 2023 /PRNewswire/ -- Global Premier Fertility, a world-class fertility network that builds, leads, and manages fertility clinics and adjacent businesses announced the closing of a syndicated round of capital from existing investors and a new institutional funding partner, for an undisclosed amount.
The funding will provide Global Premier Fertility the ability to continue its key strategic initiatives for current platform growth and expansion, along with the recruitment of Reproductive Endocrinologists needed for immediate opportunities.
"We're very excited about the success of the platform and the opportunity for growth by expanding our core business through our partnerships with fertility centers and major health systems," said Kolin Ozonian, Founder and CEO of Global Premier Fertility. "As the need for high-quality fertility care continues to grow, we're positioned to address the fertility market demands by leveraging our unique partnership model with the best fertility specialists in the country to provide unrivaled, highly-personalized care."
Global Premier Fertility also recently held its first annual Science and Operations Summit in a private setting in Laguna Beach, CA. The scientific team covered the past, present and future of fertility and embryology science, highlighting the exciting advancements arriving to fertility laboratories in the near future. Ferring Pharmaceuticals also held an interactive session of their proprietary fertility patient experience map, providing keen insights to the challenges patients navigate through their fertility journey.
"Our first annual summit was a great success, notably was the robust discussion and collaboration of best practices regarding patient care and experience, not only from our Global Premier Fertility physicians and team members, but also with the physicians who attended from outside of the Global Premier Fertility network," said Rob Doll, President of Global Premier Fertility. "The summit further highlights the differentiating aspects of what separates Global Premier Fertility from other networks in the fertility industry."
For more information about Global Premier Fertility, please visit https://globalpremierfertility.com/.
About Global Premier Fertility:
Global Premier Fertility offers a unique partnership model through an innovative platform that builds, leads and manages fertility centers, providing physicians the resources needed to lead day-to-day operations while working alongside an experienced fertility leadership team to execute the vision of the practice. The Global Premier Fertility family of Partner Centers improves patient outcomes by providing a seamless patient experience through an innovative, comprehensive suite of services, delivering personalized fertility care from the nation's top specialists.
View original content to download multimedia:
SOURCE Albatross Capital Partners | https://www.kwch.com/prnewswire/2023/07/31/global-premier-fertility-closes-syndicated-round-funding-holds-its-first-annual-science-operations-summit/ | 2023-07-31T12:35:33 | 0 | https://www.kwch.com/prnewswire/2023/07/31/global-premier-fertility-closes-syndicated-round-funding-holds-its-first-annual-science-operations-summit/ |
The report highlights emerging trends that will significantly impact the financial services industry over the next decade
NEW YORK, July 31, 2023 /PRNewswire/ -- Deloitte today announced its "2023 Financial Services Industry Predictions" report, which outlines emerging trends across the banking & capital markets, insurance, real estate, and investment management sectors. The report highlights the impact of data and emerging technologies, products and services, and climate change on the future of financial services – and as a result, on society and the economy.
"The reality is that emerging technological changes could be more pervasive and impactful going forward in ways that can be scarcely imagined today," said Jim Eckenrode, managing director, Deloitte Center for Financial Services. Deloitte Services LP. "Financial services will likely play an important role in helping these breakthroughs emerge to the benefit of us all, while simultaneously opening up new avenues of revenue and profit."
Some of Deloitte's predictions for the financial services industry over the next decade:
Generative AI is expected to boost productivity: Generative AI is expected to have a significant impact on the investment banking industry and the financial services industry as a whole, as organizations explore ways to harness the power of the technology to improve productivity. Deloitte predicts the top 14 global investment banks could boost their front-office productivity by an average of 25% by using Generative AI (GAI), thereby earning potentially an additional revenue of $3 million per front-office employee in 2026, from an average of $11.3 million during 2020-22.
Demand for carbon credit offset financing: Deloitte predicts that global consumers will purchase $115 billion of carbon offsets a year by 2030. Carbon credits will likely be embedded in many of the purchasing decisions that consumers make in their day-to-day lives. The surge in demand for these credits could produce new trading networks that offer tailored, localized and niche options for climate change mitigation projects. Banks could be instrumental in developing and supporting the back-end infrastructure that connect brands' payment processes to the carbon credit market. And banks can play an instrumental role in developing and supporting the carbon credit market.
Insurers prepare for driverless vehicles: Deloitte estimates advancements in self-driving technology may eliminate the need for around 380,000 long-haul truck drivers in the next five years. This alone would have a major impact on workers' compensation insurers, with a potential loss of around $3 billion worth of premiums. But widespread adoption of autonomous vehicles could also result in a shift in premiums across multiple insurance lines, including commercial auto, product and professional liability, and cyber coverage.
Office space to fill the affordable housing gap: Deloitte predicts office-to-residential conversions could become profitable within the next five years, estimating that around 14,700 affordable units in central business districts across the country can be added by 2030, assuming approximately 20% of converted square footage can be earmarked for affordable housing.
"As financial services firms grapple with what's on the horizon, they need to think about how the landscape is radically shifting," said Monica O'Reilly, Vice Chair, US Financial Services Industry Leader, Deloitte & Touche LLP. "Market and economic pressures, emerging technologies, and new revenue opportunities will impact tomorrow's business strategies, and financial services firms should prepare for that now."
Additional trends included in the report that are expected to shape the financial services industry:
Democratization of financial advice: Financial advice shouldn't just be for the wealthy anymore — and it doesn't have to be. Financial firms can leverage robo-advisory platforms to bring much-needed financial advice to the global mass market and make it profitable. Deloitte estimates net financial wealth held by the mass retail population segment globally to almost double to $22 trillion by 2030.
Synthetic identity fraud could trigger need for more sophisticated biometric security systems: Synthetic identity fraud—a hoax in which cybercriminals create new identities with some stolen or fabricated data — is the fastest growing financial crime in the United States,i and it shows no sign of abating. Deloitte expects it to generate at least $25 billion in losses by 2030, prompting banks to develop more advanced biometric security systems to weed out would-be perpetrators.
Higher deposit costs expected to challenge banks: Deloitte predicts the average cost of interest-bearing deposits for the U.S. banking industry in 2024 and 2025 to remain elevated at 1.7% and 1.5%, respectively, even as the fed funds rate declines from the recent peak. This may crimp bank profitability in the medium term.
Real-time B2B payments could take off: Deloitte expects real-time payments could tap an addressable market of $12 trillion in check-based business-to-business (B2B) transaction volume globally by 2028. Banks and payment firms could play a pivotal role in helping usher in a new era of more efficient and instant domestic and cross-border value exchange among businesses.
Rise of embedded insurance: Embedded finance, and particularly embedded insurance, is expected to continue to expand. Execution may not be easy for insurers, though, and it could take the rest of the decade for embedded finance to fully shake out.
Increased spending on quantum computing: Spending on quantum-related capabilities will likely grow quickly over the next few years as indicated by the increased capital investments and patent filings for the hardware technology. Globally, the financial services industry's spending on quantum computing capabilities is expected to grow 233x from just US$80 million in 2022 to US$19 billion in 2032, growing at a 10-year CAGR of 72%.
Alternative data in investment management: Deloitte estimates the revenue for alternative data providers, earned from all industries globally with the majority coming from investment management firms, to grow 29x between 2022 and 2030. The new data largely consist of novel types and forms of data such as satellite images, social media posts, geolocation data, credit card transactions, and mobile application data that are starkly different from the traditionally structured financial data.
Funding for climate hardtech: An additional US$2 trillion in private hardtech investment is predicted to be needed to help effectively slow global warming. Most of total climate funding will likely need to come from the private sector — but so far, there isn't enough. Financial services organizations can play a lead role in bridging the funding gap.
About Deloitte
Deloitte provides industry-leading audit, consulting, tax and advisory services to many of the world's most admired brands, including nearly 90% of the Fortune 500® and more than 7,000 private companies. Our people come together for the greater good and work across the industry sectors that drive and shape today's marketplace — delivering measurable and lasting results that help reinforce public trust in our capital markets, inspire clients to see challenges as opportunities to transform and thrive, and help lead the way toward a stronger economy and a healthier society. Deloitte is proud to be part of the largest global professional services network serving our clients in the markets that are most important to them. Building on more than 175 years of service, our network of member firms spans more than 150 countries and territories. Learn how Deloitte's more than 415,000 people worldwide connect for impact at www.deloitte.com.
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee ("DTTL"), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as "Deloitte Global") does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the "Deloitte" name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.
iFedPayments Improvement, "Synthetic identity fraud," accessed June 8, 2023.
View original content to download multimedia:
SOURCE Deloitte | https://www.kait8.com/prnewswire/2023/07/31/deloitte-2023-financial-services-industry-predictions-generative-ai-carbon-offset-financing-driverless-vehicles-office-space-conversion-among-top-trends-transforming-financial-services/ | 2023-07-31T12:35:35 | 1 | https://www.kait8.com/prnewswire/2023/07/31/deloitte-2023-financial-services-industry-predictions-generative-ai-carbon-offset-financing-driverless-vehicles-office-space-conversion-among-top-trends-transforming-financial-services/ |
Leveraging artificial intelligence, Mumbai-based IT services firm Yodaplus is catalyzing industry transformations, from nutraceuticals to retail, by streamlining business operations and boosting decision-making capabilities.
MUMBAI, India, July 31, 2023 /PRNewswire/ -- Yodaplus, a Mumbai-based IT services firm, is at the forefront of empowering organizations worldwide with advanced technological capabilities. Today, the company sheds light on the evolving global landscape of Artificial Intelligence (AI) and its growing adoption within its service portfolio.
With its wide range of services and deep industry knowledge, Yodaplus has been a game changer – enabling organizations to focus on their core operations and achieve sustainable growth. And now, by integrating AI into services, Yodaplus helps businesses navigate the complex digital transformation landscape more efficiently, creating a competitive edge.
AI continues to transform business operations globally, powering automation, analytics, decision-making, and enhancing user experiences. This ultimately delivers safer and more effective products to meet the growing global demand.
Yodaplus is known for its expansive roster of clients - from development banks and blockchain companies to EdTech startups and HRMS providers. With such a diverse clientele, embracing AI is more necessary than a choice, and Yodaplus has promptly addressed this need.
"As we navigate the digital age, the integration of AI into our service offerings has become an undeniable necessity," commented Vishrut Srivastava, MD, Yodaplus. "AI is here to stay, poised to make our lives more efficient and free mankind from the burden of mundane tasks. At Yodaplus, we are committed to embracing AI to drive growth and innovation for our clients while we continue to explore new horizons in this transformative technological landscape."
In line with this commitment, Yodaplus has developed an AI engine transforming the global nutraceutical supply chain. Addressing the complexities of generating differentiated nutraceutical label claims necessitates a well-mapped global database and the application of AI. To solve this problem, Yodaplus developed an AI-driven smart labels function via the NutrifyGenie AI engine.
NutrifyGenie uses sophisticated algorithms that facilitate simplified and precise decision-making, authenticating label claim validation and enabling real-time regulatory compliance. This feature provides users with pre-made labels, including correct dosage values for nutraceutical products, significantly expediting product development.
Enabling companies to effortlessly commercialize their innovations in essential markets fulfills the continuously increasing demand for nutraceutical products. As the nutraceutical industry continues to grow, Yodaplus's AI engine will play a crucial role in accelerating the new product development process and helping businesses bring innovative and differentiated products to market faster than ever before.
Not just that, the company has also recently deployed advanced invoice parsing for a retail giant. This smart solution facilitates operations by accurately extracting and collating relevant information from invoices, thus automating a previously laborious task. Furthermore, Yodaplus uses sophisticated AI tools to assist an asset management client in conducting comprehensive financial records analysis, rendering them outstanding financial decision-making capabilities.
About Yodaplus
An ever-evolving, highly specialized technology solutions company, Yodaplus offers an array of services designed to address the unique needs of businesses globally, extending beyond its Mumbai base to the US, UK, UAE, and Singapore. The company's mission, steered by MD Vishrut Srivastava, is dedicated to providing top-tier IT services and aims to propel businesses toward unprecedented growth and success. With this commitment, Yodaplus becomes your duly trusted tech partner.
For more information about Yodaplus, please visit www.yodaplus.com.
Press Contact:
Amit Pareek
Senior Marketing Manager
amitp@yodaplus.com
Photo: https://mma.prnewswire.com/media/2163861/Vishrut_Srivatava_MD_Yodaplus.jpg
Logo: https://mma.prnewswire.com/media/2144978/4185052/Yodaplus_Logo.jpg
View original content:
SOURCE Yodaplus Technologies | https://www.wbay.com/prnewswire/2023/07/31/yodaplus-shaping-future-industries-with-powerful-ai-integration/ | 2023-07-31T12:35:35 | 0 | https://www.wbay.com/prnewswire/2023/07/31/yodaplus-shaping-future-industries-with-powerful-ai-integration/ |
Partnership Expands Access to Seizure First Aid Trainings for School Personnel
BOWIE, Md., July 31, 2023 /PRNewswire/ -- The Epilepsy Foundation today announced a five-year collaboration with Vector Solutions, the leading provider of training and software solutions for K-12 and higher education institutions, to offer the Epilepsy Foundation's Seizure Recognition & First Aid Certification training in the Vector Safety and Compliance Course Library. This agreement will provide an easy and convenient way for educators and school personnel, who are already contracted with Vector, to take the seizure first aid training to better serve their students.
There are 470,000 children living with epilepsy in the U.S. According to the Centers for Disease Control and Prevention (CDC), the opportunity for academic success is increased when students with chronic health conditions have a safe and supportive learning environment.
"Our collaboration with Vector will give school personnel — who are required by state laws to take seizure first aid training — a place to do so easily and effectively through a familiar learning portal," said Brandy Fureman, Ph.D., chief outcomes officer, Epilepsy Foundation. "In addition, it will expand access to our seizure first aid training to school systems around the country using Vector's platform. Our end goal is to have a seizure safe nation where everyone who has a seizure feels safe, no matter where they are. This partnership is a stepstone toward that goal."
In 2018, Kentucky led the charge to pass the nation's first-ever law requiring school personnel to complete seizure recognition and first aid training. Since then, the Epilepsy Foundation, family advocates and partner organizations have been working to pass similar Seizure Safe Schools legislation nationwide. The model Seizure Safe Schools legislation has five components, one of which requires all school personnel, including school nurses and teachers, to complete training so that they can recognize and respond appropriately and efficiently to students experiencing seizures. To date, almost half of the states have passed some form of Seizure Safe Schools legislation.
For years, the Epilepsy Foundation has partnered with the CDC to build nationwide programs to ensure school personnel, first responders, seniors, caregivers, and the public are better trained to recognize seizures and administer first aid. The Epilepsy Foundation's seizure first aid trainings provide information to increase knowledge, skills, and confidence in recognizing seizures and safely administering seizure first aid.
"We are excited to collaborate with the Epilepsy Foundation to deliver its trainings through our online learning management system," said, Rob Buelow, General Manager of Education at Vector Solutions. "The safety and well-being of students is paramount and educators must be properly equipped to address the unique needs of all students. Through this partnership, K-12 and higher education staff across the nation will be empowered to serve their students and ensure their health and safety."
For more information about the Epilepsy Foundation's seizure first aid trainings, visit epilepsy.com/firstaid. The trainings will be available in the Vector platform later this summer and school administrators who have a current subscription will receive notification when the trainings are live.
About Epilepsy
According to the World Health Organization, epilepsy is the most common serious brain disorder worldwide with no age, racial, social class, national or geographic boundaries. The U.S. Centers for Disease Control & Prevention estimates that 3.4 million people in the United States are affected by epilepsy. Epilepsy is the underlying tendency of the brain to produce seizures which are sudden abnormal bursts of electrical energy that disrupt brain functions.
About the Epilepsy Foundation
With a network of partners throughout the United States, the Epilepsy Foundation is leading the fight to overcome the challenges of living with epilepsy. The Foundation connects people to treatment, support, and resources; leads advocacy efforts; funds innovative research and the training of specialists; and educates the public about epilepsy and seizure first aid. For more than five decades, the Epilepsy Foundation has shone a light on epilepsy to promote awareness and understanding, and to advocate for laws that matter to people with epilepsy, while also funding epilepsy research and supporting epilepsy investigators and specialists in their early careers. In partnership with the CDC, the Epilepsy Foundation has helped to improve access to care for people with epilepsy, expanded its digital reach and online resources in homes across the country, and trained more than 600,000 people in seizure recognition and first aid. The Epilepsy Foundation continues to focus on serving the epilepsy community through advocacy, education, direct services and research for new therapies. To learn more visit epilepsy.com or call 1.800.332.1000. Follow us on Facebook and Twitter.
About Vector Solutions for K-12 Education
Vector Solutions for K-12 Education is a leading provider of training, software and professional development solutions committed to creating safer, smarter and better school environments. Trusted by more than 5,000 K-12 districts in the United States, Vector's award-winning suite of products save administrators time, improve compliance, and streamline administrative processes. Vector trainings on imperative topics like safety and compliance; inclusive instruction; mental health and well-being; diversity, equity and inclusion; and cybersecurity enable students and teachers alike to make schools safer, more inclusive, and more effective places to work and learn. For more information about Vector Solutions for K-12 Education, visit www.vectorsolutions.com/k12.
View original content to download multimedia:
SOURCE Epilepsy Foundation | https://www.kait8.com/prnewswire/2023/07/31/epilepsy-foundation-partners-with-vector-solutions-offer-seizure-first-aid-trainings-educators/ | 2023-07-31T12:35:36 | 1 | https://www.kait8.com/prnewswire/2023/07/31/epilepsy-foundation-partners-with-vector-solutions-offer-seizure-first-aid-trainings-educators/ |
First-of-Its-Kind Solution Helps Ensure Medicines Prescribed to Patients are Safe, Effective, and Appropriate, Tackling Growing Public Health Challenge Posed by Suboptimal Medication Use
FeelBetter's Pharmaco-Clinical Intelligence Aids in Proactively Identifying and Managing Polypharmacy-Related Risks, Reducing Preventable Deterioration and Hospitalizations
BOSTON and TEL AVIV, Israel , July 31, 2023 /PRNewswire/ -- FeelBetter, the leading provider of medication management technology and pioneer of Pharmaco-Clinical Intelligence, today announced that it has raised $5.9 million in funding. Firstime Ventures and Shoni Health Ventures led the funding round with participation from Random Forest VC, The Group Ventures, and existing FeelBetter investor Triventures, bringing the Company's total funding to $8 million.
A growing public health concern for senior patients, many of whom have multiple chronic conditions, the simultaneous use of multiple medications paves the way for poor health outcomes, increased use of health services, and rising care costs. In the US alone, every year, suboptimal medication management results in 275,000 deaths and more than $528B in avoidable costs.
Launched in 2018, FeelBetter is tackling the challenges associated with suboptimal medication management among polypharmacy patients. Led by an interdisciplinary team of clinicians, clinical pharmacists, and technologists, FeelBetter has pioneered a new category of technology called Pharmaco-Clinical Intelligence. It combines novel pharmacology and clinical capabilities and is changing the polypharmacy paradigm on both an individual and population health level. A comprehensive solution powered by AI and machine learning capabilities, FeelBetter's Pharmaco-Clinical Intelligence drives proactive, personalized medication management, helping healthcare professionals ensure that their patients' medication regimens are safe, effective, and appropriate.
"FeelBetter's purpose-built technology makes it possible to deliver a more personalized, whole-patient approach to medication management – one that goes beyond a single illness, diagnosis, or point in time, and comprehensively focuses on each individual's care journey," said Liat Primor, FeelBetter's CEO and Co-Founder. "At a time when investors are especially selective about the types of bets they are taking, this round and vote of confidence from the world-class teams at Fristime Ventures, Shoni Health Ventures, Random Forest VC, Triventures, and The Venture Group, as well as angel investors, validates the need for and potential of our Pharmaco-Clinical Intelligence as a solution for the growing, global health challenge posed by suboptimal medication management."
Yoram Hordan, FeelBetter's CTO, COO, and Co-Founder, added: "The funding will enable us to expand our reach, further refine our solution, and empower more healthcare providers to deliver personalized, proactive care. Our Pharmaco-Clinical Intelligence, developed collaboratively by clinical and pharmacology experts alongside technology and machine learning specialists, seamlessly matches a patient's specific clinical and pharmacology data with their sequence of health events. This unlocks unparalleled accuracy in detecting at-risk patients both individually and population wide and enables new levels of precision in disease management and prevention."
Recognizing that a range of diverse factors can influence a senior patient's health status, FeelBetter's Pharmaco-Clinical Intelligence synthesizes and analyzes healthcare data from multiple sources to pinpoint patients at high risk of deterioration and preventable hospitalization due to suboptimal medication management. The SaaS solution also proactively suggests immediate and actionable interventions to reduce polypharmacy risks, and aids healthcare providers in monitoring patients' progress and measuring the impact of clinical interventions. Additionally, by using FeelBetter, provider organizations can more effectively and efficiently allocate resources to better serve patients, and minimize preventable, costly use of healthcare services.
"FeelBetter's algorithm has been trained on two decades of longitudinal clinical, pharmacy, claims, and lab data from hundreds of thousands of patients to find patterns in the complex connections and relationships between disparate data sources," said Michael Kerbis, Founding Partner, Random Forest VC. "When taken together, these patterns can capture the full picture of a patient's health journey, enabling FeelBetter to predict which individuals are at the greatest risk of adverse events related to suboptimal medication regimens and recommend timely clinical interventions to drive better health outcomes."
Eran Lerer, CEO and Managing Partner, Shoni Health Ventures, said: "From risk stratifying patients to preventing adverse events so patients can safely stay in their communities, FeelBetter offers a proven, end-to-end solution for the suboptimal medication management problem. It's a groundbreaking tool that is poised to change how the medical community approaches polypharmacy, and we're thrilled to take part in this important transformation."
Keren Kopilov, Partner, Firstime Ventures, added: "By incorporating the expertise of physicians and clinical pharmacists, as well as leveraging data from all relevant sources, FeelBetter provides a solution that is uniquely comprehensive. It intuitively fits into clinical workflows and enables optimized medication management at unparalleled speed and scale. We look forward to leveraging our expertise to support FeelBetter's mission and continued growth as it meets the tremendous opportunities ahead."
About FeelBetter
FeelBetter is the pioneer of Pharmaco-Clinical Intelligence, changing the polypharmacy paradigm on both an individual and population health level with a comprehensive solution designed to tackle the challenges associated with suboptimal medication management. Powered by AI and machine learning capabilities, FeelBetter's Pharmaco-Clinical Intelligence drives personalized medication management, helping healthcare professionals ensure that their patients' medication regimens are safe, effective, and appropriate. The technology pinpoints patients at high risk of deterioration and preventable hospitalization due to suboptimal medication management, and proactively suggests immediate and actionable interventions to reduce these risks. Provider organizations use FeelBetter to monitor their patients' progress and more proactively deliver the right follow-up care, as well as to efficiently allocate resources and minimize preventable, costly use of healthcare services.
Led by an interdisciplinary team of clinicians, clinical pharmacists, and technologists, FeelBetter is headquartered in Boston and Tel Aviv, Israel. Investors include Firstime Ventures, Shoni Health Ventures, Triventures, Random Forest VC, The Group Ventures, and GoodCompany Ventures. To learn more, visit feelbetter.healthcare.
Media Contact
Nicole Pariser
nicole@i-feelbetter.com
View original content to download multimedia:
SOURCE FeelBetter | https://www.wafb.com/prnewswire/2023/07/31/feelbetter-raises-59m-optimize-personalize-medication-management-polypharmacy-patients/ | 2023-07-31T12:35:38 | 1 | https://www.wafb.com/prnewswire/2023/07/31/feelbetter-raises-59m-optimize-personalize-medication-management-polypharmacy-patients/ |
Global wellness company introduces revolutionary Derma Fusion Technology to target enhanced weight management
FRISCO, Texas, July 31, 2023 /PRNewswire/ -- With many revolutionary wearable nutrition formulas already part of the impressive Le-Vel Brands product lineup, DFT DUO ELITE is the latest addition designed to elevate weight management support.
"To say this is our strongest, most creative formula is an understatement. The intent behind this product is a left/right approach to help it circulate faster, in a more efficient manner and is engineered for healthy weight management." - Le-Vel CEO, Jason Camper
DFT DUO ELITE is the largest, most powerful Derma Fusion Technology (DFT) ever created, made to heighten weight management results. Using the original DFT DUO and ELITE DFT as inspiration, this is a strengthened version formulated with an expanded footprint & higher concentrations of ingredients that support fat burning while retaining lean muscle.
DUO ELITE is the final step of a simple, three-part morning routine. Begin the THRIVE ELITE Experience by taking two ELITE Lifestyle Capsules with water in the morning. 20-40 minutes later, drink the ELITE Lifestyle Mix. Lastly, apply your DFT DUO ELITE to both the right & left side of your body and leave on for 24 hours. Use daily for maximum benefits.
Reviews are flowing in from customers already:
"This thing packs a serious punch. I love that Le-Vel is always evolving with the customer's needs. We asked for more power and they delivered." - Mikey O.
"Wow, the appetite support and extra energy even on Day 2 is AMAZING!" - Tiffany V.
For more information about DFT DUO ELITE, go to: www.le-vel.com/Products/THRIVE/DuoEliteDFT
Meaningful weight loss requires healthy lifestyle choices, diet and exercise, and good nutritional intake.
Founded in 2012 by Jason Camper and Paul Gravette, Le-Vel formulates and sells health and wellness products and skincare. Le-Vel's products include the THRIVE Experience and THRIVE ELITE Experience. Le-Vel has over 10 million Customer and Brand Promoter accounts and currently ships within North America, Southeast Asia, Australia, New Zealand, and the UK.
To learn more about Le-Vel, visit: www.le-vel.com
Le-Vel Instagram - https://www.instagram.com/le_velofficial/
Le-Vel Facebook - https://www.facebook.com/LevelBrands
Media Contact: Liz Reuth liz.reuth@le-vel.com
View original content to download multimedia:
SOURCE Le-Vel Brands | https://www.kwch.com/prnewswire/2023/07/31/go-bigger-le-vel-launches-largest-most-powerful-wearable-nutrition-ever-made/ | 2023-07-31T12:35:40 | 0 | https://www.kwch.com/prnewswire/2023/07/31/go-bigger-le-vel-launches-largest-most-powerful-wearable-nutrition-ever-made/ |
GUANGZHOU, China, July 31, 2023 /PRNewswire/ -- Against the backdrop of sustainable development around the globe, excellent ESG (environmental, social and governance) performance is a new measure for the quality and sustainable prospect of an enterprise. In the future, driven by the "dual carbon" strategic goal, ESG indicators will be new focus for domestic consumer goods companies.
Recently, the fast-growing beauty group YSG released its Environmental, Social and Governance Report of 2022 (hereinafter referred to as the ESG Report). This is the second consecutive year for the Company to release the ESG Report, which thoroughly demonstrates the actions and achievements of YSG in practicing the ESG framework in multiple dimensions in the past year.
YSG's good ESG performance has won the recognition of an authoritative third party institute— in December 2022, the world's largest index company, Morgan Stanley Capital International, MSCI, upgraded the rating of YSG to A, which is an internationally recognized leading level. The rating report shows that YSG is an industry leader in the management of packaging materials and wastes, and is committed to reducing the impact of packaging materials through green packaging, lightweight packaging and recycling, etc.
Expanding "Carbon Footprint" Assessment Category, Embarking on Sustainable Path of Beauty Products
Under the guidance of "dual carbon" national strategy, the beauty industry is actively participating in sustainable development and green growth. Domestic beauty enterprises rise to implement the ESG goals. With the long-term vision of "health and beauty explorer in the era of new technology", YSG has been adhering to low-carbon development, and has always been practicing its commitment to environmental friendliness.
Following Perfect Diary's core product "Rouge Intense Velet Slim Lipstick" launched in 2021, YSG has continued to expand the scope of categories covered by carbon footprint verification. The ESG report shows that in 2022, the Company conducted carbon footprint assessment on Perfect Diary's ace products, "Weightless Velvet Lip Stain" and "Translucent Blurring Loose Powder (Anti-dullness Version)". Through this process, YSG can ascertain the carbon emissions of products in the whole life cycle, identify the potential for emission reduction at each stage, and continue to upgrade its products in the future to reduce the impact on the environment.
In addition, YSG also focuses on issues such as suppliers' carbon emissions and energy management in order to realize low-carbon and sustainable development of the entire supply chain. The Company encourages suppliers to take the initiative to meet the challenge of carbon emission reduction and to seize the opportunity to set feasible and challenging carbon emission reduction goals, so as to work together with YSG to continuously reduce the total amount of carbon emissions of the supply chain. By the end of 2022, all seven core suppliers of YSG have implemented carbon emission management.
At the same time, the consumption of packaging materials, possible pollutions and other issues have drawn more concern; plastic reduction, lightweight packaging, recycling has become the direction advocated by the government and expected by consumers. In 2022, Yatsen's brands, including Perfect Diary, Pink Bear, and Little Ondine, adjusted the weight and size of their product cartons, switched from offset-printed cardboard boxes to watermarked ones, and adopted eco-friendly kraft paper materials, reducing paper consumption by 25%;at the same time, plastic films have been removed for all paper boxes, further reducing the use of plastic packaging materials. Galénic's plastic packaging in China is 100% replaced by degradable bio-based paper plastics. EVE LOM's product packaging achieved 100% recyclability (obtaining The Green Dot logo).
Committed to Scientific Research and Innovation, Laying Solid Foundation for Brand R&D
In the past year, the cosmetic industry has been speeding into the era of detailed brand building with quality as the focus, and the attention paid to R&D by domestic beauty brands has risen significantly, as the beauty industry has entered a new stage of competing for "internal strength". According to the ESG report, YSG attaches great importance to product innovation and R&D, and has invested RMB 127 million in R&D in 2022, accounting for 3.4% of its total revenue. The R&D expense ratio continues to rank among the top in the world.
With the support of the Open Lab R&D system, YSG has formed cooperation with many renowned research institutions, universities and colleges and hospitals home and abroad, identifying, studying and transferring for commercial applications worldwide— all for quality beauty products. Multiple types of achievements of technology-supported cosmetics have been made. Perfect Diary cooperated with the Key Laboratory of Molecular Nanostructure and Nanotechnology of Chinese Academy of Sciences and developed the SmartLOCK, which is used in the Translucent Blurring Loose Powder for its high efficiency in keeping look fresh with antioxidant capacity.
What is more noteworthy is that YSG understands that R&D innovation is the way to long-term development of an enterprise, drives category innovation, which in turn brings R&D breakthrough. In 2022 June, YSG R&D Center officially obtained the Laboratory Accreditation Certificate issued by China National Accreditation Service for Conformity Assessment (CNAS), which marks that the Center's product testing capabilities, equipment and devices have reached national approved standards. In November of the same year, the Company established the Sun Yat-sen University-Yatsen Group (YSG) Skin Health Precise Research Joint Laboratory,which has now built two major platforms, namely, the Chinese Skin Aging Research Platform for Chinese and the Bio-Fermentation Research Platform of Sun Yat-sen University.
Shouldering Public Welfare, Setting Benchmark for Sustainable Development
As young listed beauty enterprise, YSG spares no effort on public welfare while promoting its own development, deepening its enterprise and brand value. The Company explores actively the new path of beauty, aiming to discover female beauty, guard natural beauty and pass on the beauty of goodwill. The on-going "Create a beautiful life" and other training programs have witnessed YSG's endeavour in public welfare.
Since the establishment of the Company, YSG has been committed to involving more people to enjoy beauty as part of its corporate social responsibility practice. In 2020, YSG, with the goal of "helping women to discover and create beauty", joined hands with the China Women's Development Foundation to launch "Creating a beautiful life" public welfare training program. A total of RMB 2 million has been invested in the program in three years. As of March 2023, 5 training sessions have been completed, empowering 202 women to start their own business/employment in the field of beauty through the learning of beauty skills, quality enhancement, in-person visits and practice, industry exchanges, and mentor support.
At the same time, the Company is also expanding the depth and breadth of public welfare practices, actively contributing to social welfare such as education and research, child care, rural revitalization, public welfare for the disabled, shouldering a sense of social responsibility and mission, insisting on giving back real benefits to the society, and spreading the beauty of goodwill even farther.
Promoting high-quality development is the core in YSG's transformation process and the fundamental guideline for the Company's ESG practices. Mr. Huang Jinfeng, Founder, Chairman and CEO of YSG, said, "2022 is a year for YSG to deepen its transformation and reform in a comprehensive manner. Good ESG governance is an important driving force to promote the sustainable development of enterprises. In the future, YSG will focus on three aspects of optimization: continue to give full play to the value of ESG to create new momentum for development; continue to improve the green management to create sustainable products; and promote more public welfare programs to give full play to their own strengths and social influence, and actively give back to the society."
On the road of sustainable and high-quality development, YSG will continue to enhance its professional ability, improve itself through reformation, apply new technology and new thinking to the field of beauty, drive product upgrading with innovation, provide high-quality and innovative products to global consumers, and bring new vitality and confidence to the beauty industry.
View original content to download multimedia:
SOURCE Yatsen Global | https://www.wbay.com/prnewswire/2023/07/31/ysg-releases-its-second-esg-report-setting-benchmark-industry/ | 2023-07-31T12:35:42 | 0 | https://www.wbay.com/prnewswire/2023/07/31/ysg-releases-its-second-esg-report-setting-benchmark-industry/ |
First-of-Its-Kind Solution Helps Ensure Medicines Prescribed to Patients are Safe, Effective, and Appropriate, Tackling Growing Public Health Challenge Posed by Suboptimal Medication Use
FeelBetter's Pharmaco-Clinical Intelligence Aids in Proactively Identifying and Managing Polypharmacy-Related Risks, Reducing Preventable Deterioration and Hospitalizations
BOSTON and TEL AVIV, Israel , July 31, 2023 /PRNewswire/ -- FeelBetter, the leading provider of medication management technology and pioneer of Pharmaco-Clinical Intelligence, today announced that it has raised $5.9 million in funding. Firstime Ventures and Shoni Health Ventures led the funding round with participation from Random Forest VC, The Group Ventures, and existing FeelBetter investor Triventures, bringing the Company's total funding to $8 million.
A growing public health concern for senior patients, many of whom have multiple chronic conditions, the simultaneous use of multiple medications paves the way for poor health outcomes, increased use of health services, and rising care costs. In the US alone, every year, suboptimal medication management results in 275,000 deaths and more than $528B in avoidable costs.
Launched in 2018, FeelBetter is tackling the challenges associated with suboptimal medication management among polypharmacy patients. Led by an interdisciplinary team of clinicians, clinical pharmacists, and technologists, FeelBetter has pioneered a new category of technology called Pharmaco-Clinical Intelligence. It combines novel pharmacology and clinical capabilities and is changing the polypharmacy paradigm on both an individual and population health level. A comprehensive solution powered by AI and machine learning capabilities, FeelBetter's Pharmaco-Clinical Intelligence drives proactive, personalized medication management, helping healthcare professionals ensure that their patients' medication regimens are safe, effective, and appropriate.
"FeelBetter's purpose-built technology makes it possible to deliver a more personalized, whole-patient approach to medication management – one that goes beyond a single illness, diagnosis, or point in time, and comprehensively focuses on each individual's care journey," said Liat Primor, FeelBetter's CEO and Co-Founder. "At a time when investors are especially selective about the types of bets they are taking, this round and vote of confidence from the world-class teams at Fristime Ventures, Shoni Health Ventures, Random Forest VC, Triventures, and The Venture Group, as well as angel investors, validates the need for and potential of our Pharmaco-Clinical Intelligence as a solution for the growing, global health challenge posed by suboptimal medication management."
Yoram Hordan, FeelBetter's CTO, COO, and Co-Founder, added: "The funding will enable us to expand our reach, further refine our solution, and empower more healthcare providers to deliver personalized, proactive care. Our Pharmaco-Clinical Intelligence, developed collaboratively by clinical and pharmacology experts alongside technology and machine learning specialists, seamlessly matches a patient's specific clinical and pharmacology data with their sequence of health events. This unlocks unparalleled accuracy in detecting at-risk patients both individually and population wide and enables new levels of precision in disease management and prevention."
Recognizing that a range of diverse factors can influence a senior patient's health status, FeelBetter's Pharmaco-Clinical Intelligence synthesizes and analyzes healthcare data from multiple sources to pinpoint patients at high risk of deterioration and preventable hospitalization due to suboptimal medication management. The SaaS solution also proactively suggests immediate and actionable interventions to reduce polypharmacy risks, and aids healthcare providers in monitoring patients' progress and measuring the impact of clinical interventions. Additionally, by using FeelBetter, provider organizations can more effectively and efficiently allocate resources to better serve patients, and minimize preventable, costly use of healthcare services.
"FeelBetter's algorithm has been trained on two decades of longitudinal clinical, pharmacy, claims, and lab data from hundreds of thousands of patients to find patterns in the complex connections and relationships between disparate data sources," said Michael Kerbis, Founding Partner, Random Forest VC. "When taken together, these patterns can capture the full picture of a patient's health journey, enabling FeelBetter to predict which individuals are at the greatest risk of adverse events related to suboptimal medication regimens and recommend timely clinical interventions to drive better health outcomes."
Eran Lerer, CEO and Managing Partner, Shoni Health Ventures, said: "From risk stratifying patients to preventing adverse events so patients can safely stay in their communities, FeelBetter offers a proven, end-to-end solution for the suboptimal medication management problem. It's a groundbreaking tool that is poised to change how the medical community approaches polypharmacy, and we're thrilled to take part in this important transformation."
Keren Kopilov, Partner, Firstime Ventures, added: "By incorporating the expertise of physicians and clinical pharmacists, as well as leveraging data from all relevant sources, FeelBetter provides a solution that is uniquely comprehensive. It intuitively fits into clinical workflows and enables optimized medication management at unparalleled speed and scale. We look forward to leveraging our expertise to support FeelBetter's mission and continued growth as it meets the tremendous opportunities ahead."
About FeelBetter
FeelBetter is the pioneer of Pharmaco-Clinical Intelligence, changing the polypharmacy paradigm on both an individual and population health level with a comprehensive solution designed to tackle the challenges associated with suboptimal medication management. Powered by AI and machine learning capabilities, FeelBetter's Pharmaco-Clinical Intelligence drives personalized medication management, helping healthcare professionals ensure that their patients' medication regimens are safe, effective, and appropriate. The technology pinpoints patients at high risk of deterioration and preventable hospitalization due to suboptimal medication management, and proactively suggests immediate and actionable interventions to reduce these risks. Provider organizations use FeelBetter to monitor their patients' progress and more proactively deliver the right follow-up care, as well as to efficiently allocate resources and minimize preventable, costly use of healthcare services.
Led by an interdisciplinary team of clinicians, clinical pharmacists, and technologists, FeelBetter is headquartered in Boston and Tel Aviv, Israel. Investors include Firstime Ventures, Shoni Health Ventures, Triventures, Random Forest VC, The Group Ventures, and GoodCompany Ventures. To learn more, visit feelbetter.healthcare.
Media Contact
Nicole Pariser
nicole@i-feelbetter.com
View original content to download multimedia:
SOURCE FeelBetter | https://www.kait8.com/prnewswire/2023/07/31/feelbetter-raises-59m-optimize-personalize-medication-management-polypharmacy-patients/ | 2023-07-31T12:35:42 | 0 | https://www.kait8.com/prnewswire/2023/07/31/feelbetter-raises-59m-optimize-personalize-medication-management-polypharmacy-patients/ |
FREIT Board Committed to Protecting Value for All Stockholders
Highlights Kushner's Transaction Record with FREIT and Ongoing Litigation with Kushner
HACKENSACK, N.J., July 31, 2023 /PRNewswire/ -- First Real Estate Investment Trust of New Jersey, Inc. ("FREIT" or the "Company") (OTCM: FREVS) today announced that its Board of Directors has unanimously adopted a stockholder rights plan (the "Rights Plan") following evaluation and consultation with the Company's legal and financial advisors.
The Rights Plan is similar to plans adopted by other publicly traded companies incorporated in Maryland and is intended to protect the long-term interests of FREIT stockholders and to enable them to realize the full potential value of their investment. The Rights Plan has a three-year duration and the rights will be exercisable only if any person (or any persons acting as a group) acquires 10% or more of FREIT common stock. This ownership limitation better aligns FREIT with the ownership limitation of other REITs.
The Rights Plan does not preclude the Board from considering an offer that recognizes the full value of the Company. Rather, the Rights Plan will reduce the likelihood that any entity, person or group gains control of FREIT without paying an appropriate control premium. Importantly, the Rights Plan provides the Board with adequate time to fully assess its options following its receipt of an unsolicited, non-binding expression of interest from K Corp Acquisitions LLC, a Kushner company, to acquire FREIT.
While the Board will always evaluate credible proposals to maximize stockholder value, it is mindful that Charles Kushner has proven not to be a bona fide counterparty in a prior potential transaction with FREIT. As such, the Board believes any definitive agreement with Charles Kushner would carry significant, atypical closing and additional litigation risk.
The Rights Plan will benefit FREIT stockholders by providing the Company with enough time to pursue a final outcome in the previously announced ongoing litigation with Sinatra LLC, a Kushner company, related to Kushner's abandonment of a January 2020 definitive agreement to acquire certain of FREIT's assets. Following the outcome of the litigation, the Board will have greater flexibility to consider a value-maximizing transaction.
Additional Details of the Rights Plan
In connection with the adoption of the Rights Plan, the Board of Directors declared a dividend distribution of one preferred stock purchase right for each outstanding share of FREIT common stock to stockholders of record as of the close of business on August 11, 2023. Initially, these rights will not be exercisable and will trade with the shares of FREIT common stock.
The Rights Plan provides several recognized stockholder protections, such as the following:
- Under the Rights Plan, the rights generally will become exercisable if a person or group becomes an "acquiring person" by acquiring 10% or more of the common stock of FREIT (which includes stock subject to a derivative transaction or an acquired derivative security) or if a person commences a tender offer that could result in that person becoming an "acquiring person".
- If a person becomes an "acquiring person," each holder of a right (other than the acquiring person) would be entitled to purchase, at the then-current exercise price, such number of shares of common stock (or, subject to the terms of the Rights Plan, shares of preferred stock that are equivalent to shares of FREIT common stock) at a 50% discount. If FREIT is acquired in a merger or other business combination transaction after any such event, each holder of a right would then be entitled to purchase, at the then-current exercise price, shares of the acquiring company's common stock at a 50% discount. The Board, at its option, may exchange on a cashless basis, each right (other than rights owned by the acquiring person that have become null and void) in whole or in part, at an exchange ratio of one share of FREIT common stock per outstanding right, subject to adjustment.
- The Rights will expire in three years on July 31, 2026, unless the rights have been previously redeemed or exchanged by the Board of Directors in accordance with the terms of the Rights Plan.
Under the Rights Plan, any person, entity or group that currently owns more than the triggering percentage may continue to own its shares of FREIT common stock but may not acquire any additional shares of common stock, or form a group with another owner of FREIT common stock, without triggering the Rights Plan.
Additional details about the Rights Plan will be contained in a Current Report on Form 8-K to be filed by FREIT with the Securities and Exchange Commission.
Advisors
Goldman Sachs & Co. LLC is acting as financial advisor to FREIT and Goodwin Procter LLP and Miles & Stockbridge P.C. are acting as legal counsel.
About FREIT
First Real Estate Investment Trust of New Jersey, Inc. is a publicly traded (over-the-counter – symbol FREVS) REIT organized in 1961. Its portfolio of residential and commercial properties are located in New Jersey and New York, with the largest concentration in northern New Jersey. For more information, visit: www.freitnj.com.
Forward-Looking Statements
This Company release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These forward-looking statements can be identified by the use of words such as "expect," "plan," "will," "estimate," "project," "intend," "believe," "guidance," "approximately," "anticipate," "may," "should," "seek" or the negative of these words and phrases or similar words or phrases that are predictions of or indicate future events or trends and that do not relate to historical matters. You can also identify forward-looking statements by discussions of strategy, plans or intentions of management. These forward-looking statements are subject to known and unknown risks and uncertainties that you should not rely on as predictions of future events. Forward-looking statements depend on assumptions, data and/or methods which may be incorrect or imprecise and we may not be able to realize them. The following risks and uncertainties, among others, could cause actual results to differ materially from those currently anticipated due to a number of factors, which include, but are not limited to: industry and economic conditions; the Company's ability to satisfy the conditions to closing and complete the proposed transaction; the Company's dependence upon its external manager to conduct its business and achieve its investment objectives; unknown liabilities acquired in connection with acquired properties or interests in real estate-related entities; general risks affecting the real estate industry and local real estate markets (including, without limitation, the market value of the Company's properties, potential illiquidity of the Company's remaining real estate investments, condemnations, and potential damage from natural disasters); the financial performance of the Company's tenants; the impact of any financial, accounting, legal or regulatory issues or litigation that may affect the Trust and its major tenants; volatility and uncertainty in the financial markets, including potential fluctuations in the consumer price index; risks associated with the Company's failure to maintain status as a REIT under the Internal Revenue Code of 1986, as amended; and other additional risks discussed in the Company's annual report on Form 10-K for the fiscal year ended October 31, 2022. The Company expressly disclaims any responsibility to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Media & Investor Contact
Scott Bisang / Nick Lamplough / Jack Kelleher
Collected Strategies
FREIT-IR@collectedstrategies.com
View original content to download multimedia:
SOURCE First Real Estate Investment Trust of New Jersey | https://www.wafb.com/prnewswire/2023/07/31/first-real-estate-investment-trust-new-jersey-inc-adopts-stockholder-rights-plan/ | 2023-07-31T12:35:44 | 1 | https://www.wafb.com/prnewswire/2023/07/31/first-real-estate-investment-trust-new-jersey-inc-adopts-stockholder-rights-plan/ |
New video spot, "Dear Kitten: Modern Technology" finds Grey Cat and Orange Kitten all grown up and dealing with the digital age.
ST. LOUIS, July 31, 2023 /PRNewswire/ -- Dear reader, are you ready for adorable internet feline nostalgia? Friskies, the popular cat food and treat brand, has launched the revival of the playful 'Dear Kitten' series, which took the internet by storm when it was first released nearly 10 years ago. In partnership with BuzzFeed, the new installment, titled 'Dear Kitten: Modern Technology,' takes a humorous look at how technology has evolved over the years through the eyes of the original wise and experienced narrator, Grey Cat, while highlighting the special bond between humans and their feline companions.
Experience the full interactive Multichannel News Release here: https://www.multivu.com/players/English/9185151-purina-friskies-buzzfeed-dear-kitten-campaign-video/
In 'Modern Technology,' Grey Cat, voiced again by Ze Frank, shares valuable insights with Orange Kitten, now referred to as Orange Cat, as they navigate the rapidly changing landscape of modern devices. The video takes viewers on a comical journey, showcasing the entertaining and often perplexing situations cats experience when faced with today's advanced technology – including another daring encounter with Vacuum.
"It's been nearly a decade since you've heard from me, which I'm sure has been tough for you," said Grey Cat. "Although I am now older, I am also even wiser – like a furry sensei. I've witnessed advancements in technology that have both fascinated and bewildered me, so, it is once again my duty to get Orange Cat (and you, my feline friends) up to speed on the facts about this great big, weird world. Buckle up."
The original 'Dear Kitten' series, which captivated audiences with its witty storytelling, amassed hundreds of millions of views and resonated with pet lovers worldwide. The collaboration between Friskies and BuzzFeed provided an opportunity to once again create engaging and entertaining content that celebrates the unique bond between humans and their pets.
"Friskies is all about providing your cat with variety to feed their playfulness and curiosity, and with 'Dear Kitten', we brought that same playful spirit to life for cat lovers," said Kelly Roberts, Purina Brand Manager. "As we approach the 10-year anniversary of the original series, it felt like the perfect time to check-in to see what life is like today for our favorite feline duo and welcome a new generation of cat lovers into the 'Dear Kitten' family."
The 'Modern Technology' video was officially released on July 27, 2023, on BuzzFeed. The next video installment, titled 'Day in the Life of an Influencer' will be released later this Summer. To stay updated on the series visit BuzzFeed's official channels or follow Friskies on social media.
About Nestlé Purina PetCare
Nestlé Purina PetCare creates richer lives for pets and the people who love them. Founded in 1894, Purina has helped dogs and cats live longer, healthier lives by offering scientifically based nutritional innovations. Purina manufactures some of the world's most trusted and popular pet care products, including Purina ONE, Pro Plan, Friskies and Tidy Cats. Our more than 10,000 U.S. associates take pride in our trusted pet food, treat and litter brands that feed 46 million dogs and 68 million cats every year. More than 500 Purina scientists, veterinarians, and pet care experts ensure our commitment to unsurpassed quality and nutrition.
Purina promotes responsible pet care through our scientific research, our products and our support for pet-related organizations. Over the past five years, Purina has contributed more than $150 million towards organizations that bring, and keep, people and pets together, as well as those that help our communities and environment thrive.
Purina is part of Nestlé, a global leader in Nutrition, Health and Wellness. For more information, visit purina.com or subscribe here to get the latest Purina news.
About BuzzFeed, Inc.
BuzzFeed, Inc. is home to the best of the internet. Across food, news, pop culture and commerce, our brands drive conversation and inspire what audiences watch, read, buy, and obsess over next. Born on the internet in 2006, BuzzFeed, Inc. is committed to making it better: providing trusted, quality, brand-safe news and entertainment to hundreds of millions of people; making content on the internet more inclusive, empathetic, and creative; and inspiring our audience to live better lives.
View original content:
SOURCE Friskies® | https://www.wafb.com/prnewswire/2023/07/31/friskies-buzzfeed-reboot-dear-kitten-hit-video-series-after-nearly-decade/ | 2023-07-31T12:35:45 | 0 | https://www.wafb.com/prnewswire/2023/07/31/friskies-buzzfeed-reboot-dear-kitten-hit-video-series-after-nearly-decade/ |
LA ROMANA, Dominican Republic, July 31, 2023 /PRNewswire/ -- The international known company Hilton Hotels & Resorts opens its doors to its Hilton Garden Inn La Romana hotel project in the Dominican Republic, in collaboration with a group of important investors under the company Riverhome Capital S.A.S., whose main shareholder is the prominent Dominican former major league player, Edwin Encarnación; together with the vision of the lawyer Guillermo Estrella Ramia and the Minister of Tourism, David Collado.
The inauguration was led by Luis Abinader Corona, president of the Dominican Republic and who expressed that "This hotel has something very special, opening up the beach and the sector of La Caleta of La Romana, which for a long time was closed to the province and its visitors. Since private investment must always be accompanied by public infrastructure, we are working on creating them, so we are all part of this development of La Romana."
With an investment of 25 million united states dollars and the creation of more than 300 direct jobs, it is considered as a hotel option for the growing flows of tourists that the area is currently receiving. Located a short distance from other points of relevance, such as La Romana Airport 18 minutes away, Casa de Campo 12 minutes away and Central Romana just a few blocks away.
The new hotel facility has a privileged location on a 5,000 square meters property, located on the coast of the municipal district of La Caleta, La Romana province. With a capacity of 130 rooms, distributed in five of the seven floors of the building, it also counts with swimming pools, two bars, a restaurant, gym, event, meeting and multipurpose rooms, and outdoor areas, ideal for social and corporate celebrations.
The hotel responds to the interest of Edwin Encarnación to invest in the development of his province of origin, who expressed that "from the moment this project was presented to me, I knew that I had to be part and be the one to assume this. I joined the development of this hotel, with the only requirement that most of the workers came from here, from my town La Romana, and we achieved this."
View original content to download multimedia:
SOURCE Grupo De Valle | https://www.kwch.com/prnewswire/2023/07/31/hilton-garden-inn-la-romana-dominican-republic-celebrates-its-opening/ | 2023-07-31T12:35:46 | 0 | https://www.kwch.com/prnewswire/2023/07/31/hilton-garden-inn-la-romana-dominican-republic-celebrates-its-opening/ |
PARIS, July 31, 2023 /PRNewswire/ -- Yubo, the live social discovery app for Gen Z, has become a member of the Global Internet Forum to Counter Terrorism (GIFCT) to support its mission to prevent terrorist and violent extremist exploitation online through research, technical collaboration, and knowledge sharing.
Through its membership, Yubo will leverage GIFCT's hash-sharing database to identify and remove content shared on Yubo that is associated with United Nations-designated terrorist entities, attacker manifestos, terrorist publications, and other violent extremist groups. GIFCT is an NGO designed to prevent terrorists and violent extremists from exploiting digital platforms.
Since 2017, GIFCT has run a safe and secure industry database of hashes – or "digital fingerprints'' – of known terrorist and violent extremist material, which GIFCT members have identified and removed from their platforms. With users in over 140 countries around the world, Yubo will play a key role in helping GIFCT further scale its international hash-sharing database.
"GIFCT's hash database provides Yubo with a powerful tool to further strengthen our multifaceted approach to content moderation and more effectively identify and eliminate violent extremist content at scale," said Yubo co-founder and CEO Sacha Lazimi. "We look forward to expanding our support of GIFCT through this initiative and working with other member organizations to leverage technology to combat terrorism and enhance safety for all, on- and offline."
GIFCT's hash-sharing database works first by enabling member companies, like Yubo, to identify and "hash" content, such as photos, videos, or PDFs, ensuring a privacy-by-design approach to recording content for reporting or removal without linking to any personally identifiable information. Hashes appear as digital signatures or numerical representations of the original content, which means they cannot be easily reverse engineered to recreate the content.
"The lifecycle of violent extremism is often extended through the dissemination of content online, and the support of member organizations like Yubo is crucial to breaking these cycles," said GIFCT Executive Director Naureen Chowdhury Frink. "We are grateful to our GIFCT member companies for their continued collaboration in our shared mission to prevent terrorists and violent extremists from exploiting digital platforms, and we welcome the important investments Yubo has made for the safety of its community."
Yubo's integration of the GIFCT hash-sharing database follows the platform's support of the Take It Down initiative by the National Center for Missing and Exploited Children (NCMEC) in February. Take It Down is NCMEC's free online service that, like GIFCT, leverages a hash-sharing system to help minors remove their nudes from the internet and combat the online spread of child sexual exploitation.
ABOUT YUBO
Yubo is a live social discovery app making it easy for Gen Z to expand their social circles and hang out online with new friends from around the world. By eliminating likes and follows, we empower young people to show up as their true selves and connect as authentically as they would offline. Safety is a cornerstone of our platform, and we are proud to be the first social app in the world to introduce comprehensive user-age verification tools and real-time video and audio moderation for livestreams. Founded in France in 2015, Yubo is used in more than 140 countries by over 60 million users. Visit us at yubo.live to learn more and follow our journey.
ABOUT GIFCT
GIFCT is a 501(c)(3) non-profit organization and tech-led initiative with over 20 member tech companies offering unique settings for diverse stakeholders to identify and solve the most complex global challenges at the intersection of terrorism and technology. GIFCT's mission is to prevent terrorists and violent extremists from exploiting digital platforms through our vision of a world in which the technology sector marshals its collective creativity and capacity to render terrorists and violent extremists ineffective online. In every aspect of our work, we aim to be transparent, inclusive, and respectful of the fundamental and universal human rights that terrorists and violent extremists seek to undermine.
Media Contact:
Debora Lima, Yubo U.S. Media Director
debora@ext.yubo.live
View original content to download multimedia:
SOURCE Yubo | https://www.wbay.com/prnewswire/2023/07/31/yubo-joins-gifct-combat-spread-violent-extremist-content-online/ | 2023-07-31T12:35:48 | 0 | https://www.wbay.com/prnewswire/2023/07/31/yubo-joins-gifct-combat-spread-violent-extremist-content-online/ |
Success of the Global Premier Fertility Platform Leading to Additional Growth and Expansion
IRVINE, Calif., July 31, 2023 /PRNewswire/ -- Global Premier Fertility, a world-class fertility network that builds, leads, and manages fertility clinics and adjacent businesses announced the closing of a syndicated round of capital from existing investors and a new institutional funding partner, for an undisclosed amount.
The funding will provide Global Premier Fertility the ability to continue its key strategic initiatives for current platform growth and expansion, along with the recruitment of Reproductive Endocrinologists needed for immediate opportunities.
"We're very excited about the success of the platform and the opportunity for growth by expanding our core business through our partnerships with fertility centers and major health systems," said Kolin Ozonian, Founder and CEO of Global Premier Fertility. "As the need for high-quality fertility care continues to grow, we're positioned to address the fertility market demands by leveraging our unique partnership model with the best fertility specialists in the country to provide unrivaled, highly-personalized care."
Global Premier Fertility also recently held its first annual Science and Operations Summit in a private setting in Laguna Beach, CA. The scientific team covered the past, present and future of fertility and embryology science, highlighting the exciting advancements arriving to fertility laboratories in the near future. Ferring Pharmaceuticals also held an interactive session of their proprietary fertility patient experience map, providing keen insights to the challenges patients navigate through their fertility journey.
"Our first annual summit was a great success, notably was the robust discussion and collaboration of best practices regarding patient care and experience, not only from our Global Premier Fertility physicians and team members, but also with the physicians who attended from outside of the Global Premier Fertility network," said Rob Doll, President of Global Premier Fertility. "The summit further highlights the differentiating aspects of what separates Global Premier Fertility from other networks in the fertility industry."
For more information about Global Premier Fertility, please visit https://globalpremierfertility.com/.
About Global Premier Fertility:
Global Premier Fertility offers a unique partnership model through an innovative platform that builds, leads and manages fertility centers, providing physicians the resources needed to lead day-to-day operations while working alongside an experienced fertility leadership team to execute the vision of the practice. The Global Premier Fertility family of Partner Centers improves patient outcomes by providing a seamless patient experience through an innovative, comprehensive suite of services, delivering personalized fertility care from the nation's top specialists.
View original content to download multimedia:
SOURCE Albatross Capital Partners | https://www.kait8.com/prnewswire/2023/07/31/global-premier-fertility-closes-syndicated-round-funding-holds-its-first-annual-science-operations-summit/ | 2023-07-31T12:35:49 | 0 | https://www.kait8.com/prnewswire/2023/07/31/global-premier-fertility-closes-syndicated-round-funding-holds-its-first-annual-science-operations-summit/ |
Success of the Global Premier Fertility Platform Leading to Additional Growth and Expansion
IRVINE, Calif., July 31, 2023 /PRNewswire/ -- Global Premier Fertility, a world-class fertility network that builds, leads, and manages fertility clinics and adjacent businesses announced the closing of a syndicated round of capital from existing investors and a new institutional funding partner, for an undisclosed amount.
The funding will provide Global Premier Fertility the ability to continue its key strategic initiatives for current platform growth and expansion, along with the recruitment of Reproductive Endocrinologists needed for immediate opportunities.
"We're very excited about the success of the platform and the opportunity for growth by expanding our core business through our partnerships with fertility centers and major health systems," said Kolin Ozonian, Founder and CEO of Global Premier Fertility. "As the need for high-quality fertility care continues to grow, we're positioned to address the fertility market demands by leveraging our unique partnership model with the best fertility specialists in the country to provide unrivaled, highly-personalized care."
Global Premier Fertility also recently held its first annual Science and Operations Summit in a private setting in Laguna Beach, CA. The scientific team covered the past, present and future of fertility and embryology science, highlighting the exciting advancements arriving to fertility laboratories in the near future. Ferring Pharmaceuticals also held an interactive session of their proprietary fertility patient experience map, providing keen insights to the challenges patients navigate through their fertility journey.
"Our first annual summit was a great success, notably was the robust discussion and collaboration of best practices regarding patient care and experience, not only from our Global Premier Fertility physicians and team members, but also with the physicians who attended from outside of the Global Premier Fertility network," said Rob Doll, President of Global Premier Fertility. "The summit further highlights the differentiating aspects of what separates Global Premier Fertility from other networks in the fertility industry."
For more information about Global Premier Fertility, please visit https://globalpremierfertility.com/.
About Global Premier Fertility:
Global Premier Fertility offers a unique partnership model through an innovative platform that builds, leads and manages fertility centers, providing physicians the resources needed to lead day-to-day operations while working alongside an experienced fertility leadership team to execute the vision of the practice. The Global Premier Fertility family of Partner Centers improves patient outcomes by providing a seamless patient experience through an innovative, comprehensive suite of services, delivering personalized fertility care from the nation's top specialists.
View original content to download multimedia:
SOURCE Albatross Capital Partners | https://www.wafb.com/prnewswire/2023/07/31/global-premier-fertility-closes-syndicated-round-funding-holds-its-first-annual-science-operations-summit/ | 2023-07-31T12:35:52 | 0 | https://www.wafb.com/prnewswire/2023/07/31/global-premier-fertility-closes-syndicated-round-funding-holds-its-first-annual-science-operations-summit/ |
- CARDIO-TTRansform is the largest, most comprehensive ATTR-CM study with more than 1,400 patients enrolled
- Eplontersen is currently under U.S. FDA review for ATTRv-polyneuropathy, with ATTR-CM representing a second, larger potential patient population
CARLSBAD, Calif., July 31, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment in the Phase 3 CARDIO-TTRansform cardiovascular outcomes study of eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a large and growing patient population at risk of life-threatening cardiovascular (CV) events. The study enrolled more than 1,400 patients.
Eplontersen is an investigational antisense medicine designed to inhibit the production of transthyretin and slow the progression of cardiomyopathy for people living with hereditary or wild-type ATTR-CM.
"CARDIO-TTRansform is the largest and most comprehensive ATTR-CM study ever conducted. The evaluation of eplontersen in this broad, diverse patient population will enable robust and clinically meaningful analysis of the composite endpoint of CV mortality and recurrent CV events," said Eugene Schneider, M.D., executive vice president and chief clinical development officer for Ionis. "It will also allow us to gather data from important patient subsets, including patients with or without stabilizer therapy and those with or without hereditary disease within the evolving ATTR-CM landscape. We look forward to reporting results as early as the first half of 2025."
As part of a global development and commercialization agreement, Ionis and AstraZeneca are seeking regulatory approval for eplontersen for the treatment of transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) in the U.S. and plan to seek regulatory approval in Europe and other parts of the world. The U.S. Food and Drug Administration accepted the New Drug Application for eplontersen for the treatment of ATTRv-PN with a PDUFA action date of Dec. 22, 2023. Eplontersen was granted Orphan Drug Designation in the U.S.
For more information on the CARDIO-TTRansform study, please visit www.clinicaltrials.gov (NCT04136171).
About the CARDIO-TTRansform Study
CARDIO-TTRansform is a global, double-blind, randomized, placebo-controlled Phase 3 cardiovascular outcome study in more than 1,400 patients with ATTR cardiomyopathy (ATTR-CM). It is designed to compare eplontersen to placebo in patients with both wild-type ATTRwt-CM and hereditary ATTRv-CM who are either naïve to treatment or on a currently available standard of care. The primary composite endpoint is cardiovascular (CV) mortality and recurrent CV clinical events comparing the two study arms up to week 140. Secondary endpoints include the change from baseline in the 6-minute walk test (6MWT) and the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at week 121, as well as the rates of CV mortality, CV clinical events and all-cause mortality at week 140.
About Eplontersen
Eplontersen is an investigational LIgand-Conjugated Antisense (LICA) medicine designed to inhibit the production of TTR protein. Eplontersen is being developed as a monthly self-administered subcutaneous injection to treat all types of ATTR. ATTR amyloidosis is a systemic, progressive and fatal disease in which patients experience multiple overlapping clinical manifestations caused by the inappropriate formation and aggregation of TTR amyloid deposits in various tissues and organs, including peripheral nerves, heart, intestinal tract, eyes, kidneys, central nervous system, thyroid and bone marrow. The progressive accumulation of TTR amyloid deposits in these tissues and organs leads to organ failure and eventually death.
About Transthyretin-mediated Amyloid Cardiomyopathy (ATTR-CM)
Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed and potentially fatal disease. It is caused by the accumulation of misfolded TTR protein in the cardiac muscle. Patients experience ongoing debilitating heart damage resulting in progressive heart failure, which results in death within three to five years from disease onset. ATTR-CM includes both the genetic and wild-type form of the disease. Worldwide, there are an estimated 300,000 – 500,0001,2 patients with ATTR-CM.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
Ionis' Forward-looking Statements
This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of eplontersen, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2022, and the most recent Form 10-Q quarterly filing, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.
1 Mohamed-Salem L, et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol. 2018 Nov 1;270:192-196. doi: 10.1016/j.ijcard.2018.06.006.
2 Cuscaden C, et al. Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation. J Nucl Cardiol. 2020 May 8. doi: 10.1007/s12350-020-02152-x.
View original content to download multimedia:
SOURCE Ionis Pharmaceuticals, Inc. | https://www.kwch.com/prnewswire/2023/07/31/ionis-completes-enrollment-landmark-phase-3-cardio-ttransform-study-patients-with-ttr-mediated-amyloid-cardiomyopathy/ | 2023-07-31T12:35:53 | 1 | https://www.kwch.com/prnewswire/2023/07/31/ionis-completes-enrollment-landmark-phase-3-cardio-ttransform-study-patients-with-ttr-mediated-amyloid-cardiomyopathy/ |
Global wellness company introduces revolutionary Derma Fusion Technology to target enhanced weight management
FRISCO, Texas, July 31, 2023 /PRNewswire/ -- With many revolutionary wearable nutrition formulas already part of the impressive Le-Vel Brands product lineup, DFT DUO ELITE is the latest addition designed to elevate weight management support.
"To say this is our strongest, most creative formula is an understatement. The intent behind this product is a left/right approach to help it circulate faster, in a more efficient manner and is engineered for healthy weight management." - Le-Vel CEO, Jason Camper
DFT DUO ELITE is the largest, most powerful Derma Fusion Technology (DFT) ever created, made to heighten weight management results. Using the original DFT DUO and ELITE DFT as inspiration, this is a strengthened version formulated with an expanded footprint & higher concentrations of ingredients that support fat burning while retaining lean muscle.
DUO ELITE is the final step of a simple, three-part morning routine. Begin the THRIVE ELITE Experience by taking two ELITE Lifestyle Capsules with water in the morning. 20-40 minutes later, drink the ELITE Lifestyle Mix. Lastly, apply your DFT DUO ELITE to both the right & left side of your body and leave on for 24 hours. Use daily for maximum benefits.
Reviews are flowing in from customers already:
"This thing packs a serious punch. I love that Le-Vel is always evolving with the customer's needs. We asked for more power and they delivered." - Mikey O.
"Wow, the appetite support and extra energy even on Day 2 is AMAZING!" - Tiffany V.
For more information about DFT DUO ELITE, go to: www.le-vel.com/Products/THRIVE/DuoEliteDFT
Meaningful weight loss requires healthy lifestyle choices, diet and exercise, and good nutritional intake.
Founded in 2012 by Jason Camper and Paul Gravette, Le-Vel formulates and sells health and wellness products and skincare. Le-Vel's products include the THRIVE Experience and THRIVE ELITE Experience. Le-Vel has over 10 million Customer and Brand Promoter accounts and currently ships within North America, Southeast Asia, Australia, New Zealand, and the UK.
To learn more about Le-Vel, visit: www.le-vel.com
Le-Vel Instagram - https://www.instagram.com/le_velofficial/
Le-Vel Facebook - https://www.facebook.com/LevelBrands
Media Contact: Liz Reuth liz.reuth@le-vel.com
View original content to download multimedia:
SOURCE Le-Vel Brands | https://www.kait8.com/prnewswire/2023/07/31/go-bigger-le-vel-launches-largest-most-powerful-wearable-nutrition-ever-made/ | 2023-07-31T12:35:55 | 1 | https://www.kait8.com/prnewswire/2023/07/31/go-bigger-le-vel-launches-largest-most-powerful-wearable-nutrition-ever-made/ |
The cutting-edge platform empowers B2B SaaS start-ups to reduce churn, increase upsell, and boost NRR
WILMINGTON, Del., July 31, 2023 /PRNewswire/ -- ZapScale, a new-age customer success platform, is making waves in the industry by offering an unrivalled one-day onboarding experience along with the ability to track 150 customer data points for a comprehensive 360-degree view of customer health. This ground-breaking feature sets ZapScale apart from its competitors.
The secret behind ZapScale's lightning-fast onboarding lies in its comprehensive toolkit. With a robust framework of 40 pre-built KPI-based health frameworks, 60 pre-designed playbooks to automate CS ops, and seamless native integrations with all popular tools, ZapScale empowers businesses to gain complete visibility over customer data. With deep customer health insights, ZapScale's customers have seen an improvement in retention and increase in upsell opportunities.
Manasij Ganguli, Founder and CEO of ZapScale, shares his personal motivation for creating this game-changing platform: "ZapScale was born out of my passion to empower B2B SaaS start-ups with an efficient and effective CS platform. Having faced numerous customer success challenges in my previous start-up, which I successfully sold in 2019, I realized the critical need for a solution that could streamline, optimize, and accelerate CS operations.
For small to mid-sized businesses that have limited time and resources, implementing a CS platform has historically been a daunting task, taking weeks, if not months, to set up essential elements like customer health, playbooks, and integrations. ZapScale has addressed this challenge by offering a user-friendly and efficient implementation process, eliminating waste of time and resources. Now, businesses can seamlessly focus on their customers right from day 1."
ZapScale eliminates the traditional barriers and time-consuming processes associated with implementing CS platforms using key in-built features that facilitate custom mapping, support custom fields, and require no unique key to integrate applications, ensuring a tailored yet quick integration experience.
ZapScale is swiftly gaining traction in the market, with 30+ global companies already using the customer success platform. Starting at $249 per month, with a one-month free trial, ZapScale is helping businesses significantly improve their customer success initiatives.
For more information about ZapScale and to schedule a demo, visit www.zapscale.com.
Contact:
Nikita Kalra
Marketing Head, ZapScale
nikita@zapscale.com
Logo: https://mma.prnewswire.com/media/2097823/ZS_Logo.jpg
View original content:
SOURCE ZapScale | https://www.wbay.com/prnewswire/2023/07/31/zapscale-sets-new-industry-standard-with-easiest-customer-success-platform-one-day-onboarding/ | 2023-07-31T12:35:54 | 0 | https://www.wbay.com/prnewswire/2023/07/31/zapscale-sets-new-industry-standard-with-easiest-customer-success-platform-one-day-onboarding/ |
LA ROMANA, Dominican Republic, July 31, 2023 /PRNewswire/ -- The international known company Hilton Hotels & Resorts opens its doors to its Hilton Garden Inn La Romana hotel project in the Dominican Republic, in collaboration with a group of important investors under the company Riverhome Capital S.A.S., whose main shareholder is the prominent Dominican former major league player, Edwin Encarnación; together with the vision of the lawyer Guillermo Estrella Ramia and the Minister of Tourism, David Collado.
The inauguration was led by Luis Abinader Corona, president of the Dominican Republic and who expressed that "This hotel has something very special, opening up the beach and the sector of La Caleta of La Romana, which for a long time was closed to the province and its visitors. Since private investment must always be accompanied by public infrastructure, we are working on creating them, so we are all part of this development of La Romana."
With an investment of 25 million united states dollars and the creation of more than 300 direct jobs, it is considered as a hotel option for the growing flows of tourists that the area is currently receiving. Located a short distance from other points of relevance, such as La Romana Airport 18 minutes away, Casa de Campo 12 minutes away and Central Romana just a few blocks away.
The new hotel facility has a privileged location on a 5,000 square meters property, located on the coast of the municipal district of La Caleta, La Romana province. With a capacity of 130 rooms, distributed in five of the seven floors of the building, it also counts with swimming pools, two bars, a restaurant, gym, event, meeting and multipurpose rooms, and outdoor areas, ideal for social and corporate celebrations.
The hotel responds to the interest of Edwin Encarnación to invest in the development of his province of origin, who expressed that "from the moment this project was presented to me, I knew that I had to be part and be the one to assume this. I joined the development of this hotel, with the only requirement that most of the workers came from here, from my town La Romana, and we achieved this."
View original content to download multimedia:
SOURCE Grupo De Valle | https://www.kait8.com/prnewswire/2023/07/31/hilton-garden-inn-la-romana-dominican-republic-celebrates-its-opening/ | 2023-07-31T12:35:56 | 0 | https://www.kait8.com/prnewswire/2023/07/31/hilton-garden-inn-la-romana-dominican-republic-celebrates-its-opening/ |
Global wellness company introduces revolutionary Derma Fusion Technology to target enhanced weight management
FRISCO, Texas, July 31, 2023 /PRNewswire/ -- With many revolutionary wearable nutrition formulas already part of the impressive Le-Vel Brands product lineup, DFT DUO ELITE is the latest addition designed to elevate weight management support.
"To say this is our strongest, most creative formula is an understatement. The intent behind this product is a left/right approach to help it circulate faster, in a more efficient manner and is engineered for healthy weight management." - Le-Vel CEO, Jason Camper
DFT DUO ELITE is the largest, most powerful Derma Fusion Technology (DFT) ever created, made to heighten weight management results. Using the original DFT DUO and ELITE DFT as inspiration, this is a strengthened version formulated with an expanded footprint & higher concentrations of ingredients that support fat burning while retaining lean muscle.
DUO ELITE is the final step of a simple, three-part morning routine. Begin the THRIVE ELITE Experience by taking two ELITE Lifestyle Capsules with water in the morning. 20-40 minutes later, drink the ELITE Lifestyle Mix. Lastly, apply your DFT DUO ELITE to both the right & left side of your body and leave on for 24 hours. Use daily for maximum benefits.
Reviews are flowing in from customers already:
"This thing packs a serious punch. I love that Le-Vel is always evolving with the customer's needs. We asked for more power and they delivered." - Mikey O.
"Wow, the appetite support and extra energy even on Day 2 is AMAZING!" - Tiffany V.
For more information about DFT DUO ELITE, go to: www.le-vel.com/Products/THRIVE/DuoEliteDFT
Meaningful weight loss requires healthy lifestyle choices, diet and exercise, and good nutritional intake.
Founded in 2012 by Jason Camper and Paul Gravette, Le-Vel formulates and sells health and wellness products and skincare. Le-Vel's products include the THRIVE Experience and THRIVE ELITE Experience. Le-Vel has over 10 million Customer and Brand Promoter accounts and currently ships within North America, Southeast Asia, Australia, New Zealand, and the UK.
To learn more about Le-Vel, visit: www.le-vel.com
Le-Vel Instagram - https://www.instagram.com/le_velofficial/
Le-Vel Facebook - https://www.facebook.com/LevelBrands
Media Contact: Liz Reuth liz.reuth@le-vel.com
View original content to download multimedia:
SOURCE Le-Vel Brands | https://www.wafb.com/prnewswire/2023/07/31/go-bigger-le-vel-launches-largest-most-powerful-wearable-nutrition-ever-made/ | 2023-07-31T12:35:58 | 1 | https://www.wafb.com/prnewswire/2023/07/31/go-bigger-le-vel-launches-largest-most-powerful-wearable-nutrition-ever-made/ |
Leading Fertility Clinic Network Extends Offering of TMRW's Automated Platform for the Safe Management & Storage of Frozen Eggs & Embryos to More Clinics Across the United States
NEW YORK, July 31, 2023 /PRNewswire/ -- Ivy Fertility, a globally-recognized innovator in advanced reproductive technology, in-vitro fertilization (IVF), and third-party reproduction, announced today that it will expand its partnership with TMRW Life Sciences, a fertility technology company. TMRW is automating the IVF lab with the world's first and only automated platform for the safe management and storage of frozen eggs and embryos – a process that since the dawn of the industry has been run completely manually. TMRW's technology is currently available at two Ivy Network clinics. With this expanded partnership, TMRW's on-site and off-site specimen management platform will be available for full adoption at all of Ivy Fertility's 13 clinics across the United States.
Ivy Fertility's San Diego Fertility Center was one of the first clinics in the United States to adopt TMRW's platform and Utah Fertility Center went live this month. TMRW's platform reduces potential points of failure by 94% compared with manual systems, providing new levels of safety, efficiency and transparency for Ivy Fertility's clinics. The partnership demonstrates Ivy Fertility's continued commitment to delivering personalized fertility services using advanced technology by making state-of-the-art solutions available to all of their clinics.
"Providing enhanced security and peace of mind to our patients is one of our core values," said Lisa Van Dolah, Ivy Fertility's CEO. "With our TMRW partnership, we're able to offer patients and our practice even greater security and that is paramount as we continue to grow."
The network's clinicians will now have the opportunity to modernize their specimen management and storage practices with TMRW's digital tools onsite and, in addition, by transferring patient specimens offsite to and from TMRW Cryobanks. The technology upgrade provides clinics with new levels of safety, standardization and scalability, and it helps reduce the risk of specimen mix-up, error, and loss.
"After years of working together with San Diego Fertility Center, and more recently with Utah Fertility Center, we're thrilled to expand our partnership to support the potential for full adoption of both on-site and off-site specimen management across the Ivy Fertility network," said Louis Villalba, CEO of TMRW.
TMRW is now the storage platform used by clinics that see nearly 20% of all patients in the United States. The future of fertility is automated and, together with its clinic partners, TMRW is rapidly becoming the standard of care.
About Ivy Fertility
Ivy Fertility is globally recognized as pioneers and innovators in the field of advanced reproductive technologies, in vitro fertilization, third-party reproduction, andrology, and fertility research. The Ivy Fertility network includes Virginia Fertility & IVF, Fertility Associates of Memphis, Fertility Centers of Orange County, IVF Fertility Center, Los Angeles Reproductive Center, Nevada Center for Reproductive Medicine, Nevada Fertility Center, Pacific Northwest Fertility, Reproductive Partners Medical Group, San Diego Fertility Center, and Utah Fertility Center. By developing new procedures, achieving scientific breakthroughs, and teaching the latest techniques, Ivy Fertility upholds its commitment to successful outcomes. It continually contributes to the development of the entire fertility community. The Ivy team is passionate about its family-building mission and works tirelessly each day to help patients become parents.
For more information, visit ivyfertility.com.
TMRW Life Sciences
Founded in 2018, TMRW Life Sciences, Inc., is a fertility technology company that automates the management and storage of frozen eggs and embryos. For the first time, frozen specimens can be digitally identified and tracked, safely managed with automated robotics, and remotely monitored around the clock. TMRW's next-generation technology platforms set a new standard of care, reducing potential points of failure by 94% compared to manual systems. TMRW delivers peace of mind by helping reduce the risk of specimen mix-up, damage, or loss. Named Fast Company's #1 Most Innovative Biotech company in 2022, TMRW has been adopted by leading clinics across the United States and will soon be available in the UK and Europe.
For more information, visit tmrwlifesciences.com.
View original content:
SOURCE TMRW Life Sciences | https://www.kwch.com/prnewswire/2023/07/31/ivy-fertility-network-expands-partnership-with-tmrw-life-sciences-demand-grows-fertility-clinic-lab-automation/ | 2023-07-31T12:35:59 | 1 | https://www.kwch.com/prnewswire/2023/07/31/ivy-fertility-network-expands-partnership-with-tmrw-life-sciences-demand-grows-fertility-clinic-lab-automation/ |
- CARDIO-TTRansform is the largest, most comprehensive ATTR-CM study with more than 1,400 patients enrolled
- Eplontersen is currently under U.S. FDA review for ATTRv-polyneuropathy, with ATTR-CM representing a second, larger potential patient population
CARLSBAD, Calif., July 31, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment in the Phase 3 CARDIO-TTRansform cardiovascular outcomes study of eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a large and growing patient population at risk of life-threatening cardiovascular (CV) events. The study enrolled more than 1,400 patients.
Eplontersen is an investigational antisense medicine designed to inhibit the production of transthyretin and slow the progression of cardiomyopathy for people living with hereditary or wild-type ATTR-CM.
"CARDIO-TTRansform is the largest and most comprehensive ATTR-CM study ever conducted. The evaluation of eplontersen in this broad, diverse patient population will enable robust and clinically meaningful analysis of the composite endpoint of CV mortality and recurrent CV events," said Eugene Schneider, M.D., executive vice president and chief clinical development officer for Ionis. "It will also allow us to gather data from important patient subsets, including patients with or without stabilizer therapy and those with or without hereditary disease within the evolving ATTR-CM landscape. We look forward to reporting results as early as the first half of 2025."
As part of a global development and commercialization agreement, Ionis and AstraZeneca are seeking regulatory approval for eplontersen for the treatment of transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) in the U.S. and plan to seek regulatory approval in Europe and other parts of the world. The U.S. Food and Drug Administration accepted the New Drug Application for eplontersen for the treatment of ATTRv-PN with a PDUFA action date of Dec. 22, 2023. Eplontersen was granted Orphan Drug Designation in the U.S.
For more information on the CARDIO-TTRansform study, please visit www.clinicaltrials.gov (NCT04136171).
About the CARDIO-TTRansform Study
CARDIO-TTRansform is a global, double-blind, randomized, placebo-controlled Phase 3 cardiovascular outcome study in more than 1,400 patients with ATTR cardiomyopathy (ATTR-CM). It is designed to compare eplontersen to placebo in patients with both wild-type ATTRwt-CM and hereditary ATTRv-CM who are either naïve to treatment or on a currently available standard of care. The primary composite endpoint is cardiovascular (CV) mortality and recurrent CV clinical events comparing the two study arms up to week 140. Secondary endpoints include the change from baseline in the 6-minute walk test (6MWT) and the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at week 121, as well as the rates of CV mortality, CV clinical events and all-cause mortality at week 140.
About Eplontersen
Eplontersen is an investigational LIgand-Conjugated Antisense (LICA) medicine designed to inhibit the production of TTR protein. Eplontersen is being developed as a monthly self-administered subcutaneous injection to treat all types of ATTR. ATTR amyloidosis is a systemic, progressive and fatal disease in which patients experience multiple overlapping clinical manifestations caused by the inappropriate formation and aggregation of TTR amyloid deposits in various tissues and organs, including peripheral nerves, heart, intestinal tract, eyes, kidneys, central nervous system, thyroid and bone marrow. The progressive accumulation of TTR amyloid deposits in these tissues and organs leads to organ failure and eventually death.
About Transthyretin-mediated Amyloid Cardiomyopathy (ATTR-CM)
Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed and potentially fatal disease. It is caused by the accumulation of misfolded TTR protein in the cardiac muscle. Patients experience ongoing debilitating heart damage resulting in progressive heart failure, which results in death within three to five years from disease onset. ATTR-CM includes both the genetic and wild-type form of the disease. Worldwide, there are an estimated 300,000 – 500,0001,2 patients with ATTR-CM.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
Ionis' Forward-looking Statements
This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of eplontersen, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2022, and the most recent Form 10-Q quarterly filing, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.
1 Mohamed-Salem L, et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol. 2018 Nov 1;270:192-196. doi: 10.1016/j.ijcard.2018.06.006.
2 Cuscaden C, et al. Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation. J Nucl Cardiol. 2020 May 8. doi: 10.1007/s12350-020-02152-x.
View original content to download multimedia:
SOURCE Ionis Pharmaceuticals, Inc. | https://www.kait8.com/prnewswire/2023/07/31/ionis-completes-enrollment-landmark-phase-3-cardio-ttransform-study-patients-with-ttr-mediated-amyloid-cardiomyopathy/ | 2023-07-31T12:36:02 | 0 | https://www.kait8.com/prnewswire/2023/07/31/ionis-completes-enrollment-landmark-phase-3-cardio-ttransform-study-patients-with-ttr-mediated-amyloid-cardiomyopathy/ |
LA ROMANA, Dominican Republic, July 31, 2023 /PRNewswire/ -- The international known company Hilton Hotels & Resorts opens its doors to its Hilton Garden Inn La Romana hotel project in the Dominican Republic, in collaboration with a group of important investors under the company Riverhome Capital S.A.S., whose main shareholder is the prominent Dominican former major league player, Edwin Encarnación; together with the vision of the lawyer Guillermo Estrella Ramia and the Minister of Tourism, David Collado.
The inauguration was led by Luis Abinader Corona, president of the Dominican Republic and who expressed that "This hotel has something very special, opening up the beach and the sector of La Caleta of La Romana, which for a long time was closed to the province and its visitors. Since private investment must always be accompanied by public infrastructure, we are working on creating them, so we are all part of this development of La Romana."
With an investment of 25 million united states dollars and the creation of more than 300 direct jobs, it is considered as a hotel option for the growing flows of tourists that the area is currently receiving. Located a short distance from other points of relevance, such as La Romana Airport 18 minutes away, Casa de Campo 12 minutes away and Central Romana just a few blocks away.
The new hotel facility has a privileged location on a 5,000 square meters property, located on the coast of the municipal district of La Caleta, La Romana province. With a capacity of 130 rooms, distributed in five of the seven floors of the building, it also counts with swimming pools, two bars, a restaurant, gym, event, meeting and multipurpose rooms, and outdoor areas, ideal for social and corporate celebrations.
The hotel responds to the interest of Edwin Encarnación to invest in the development of his province of origin, who expressed that "from the moment this project was presented to me, I knew that I had to be part and be the one to assume this. I joined the development of this hotel, with the only requirement that most of the workers came from here, from my town La Romana, and we achieved this."
View original content to download multimedia:
SOURCE Grupo De Valle | https://www.wafb.com/prnewswire/2023/07/31/hilton-garden-inn-la-romana-dominican-republic-celebrates-its-opening/ | 2023-07-31T12:36:04 | 0 | https://www.wafb.com/prnewswire/2023/07/31/hilton-garden-inn-la-romana-dominican-republic-celebrates-its-opening/ |
- CARDIO-TTRansform is the largest, most comprehensive ATTR-CM study with more than 1,400 patients enrolled
- Eplontersen is currently under U.S. FDA review for ATTRv-polyneuropathy, with ATTR-CM representing a second, larger potential patient population
CARLSBAD, Calif., July 31, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment in the Phase 3 CARDIO-TTRansform cardiovascular outcomes study of eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a large and growing patient population at risk of life-threatening cardiovascular (CV) events. The study enrolled more than 1,400 patients.
Eplontersen is an investigational antisense medicine designed to inhibit the production of transthyretin and slow the progression of cardiomyopathy for people living with hereditary or wild-type ATTR-CM.
"CARDIO-TTRansform is the largest and most comprehensive ATTR-CM study ever conducted. The evaluation of eplontersen in this broad, diverse patient population will enable robust and clinically meaningful analysis of the composite endpoint of CV mortality and recurrent CV events," said Eugene Schneider, M.D., executive vice president and chief clinical development officer for Ionis. "It will also allow us to gather data from important patient subsets, including patients with or without stabilizer therapy and those with or without hereditary disease within the evolving ATTR-CM landscape. We look forward to reporting results as early as the first half of 2025."
As part of a global development and commercialization agreement, Ionis and AstraZeneca are seeking regulatory approval for eplontersen for the treatment of transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) in the U.S. and plan to seek regulatory approval in Europe and other parts of the world. The U.S. Food and Drug Administration accepted the New Drug Application for eplontersen for the treatment of ATTRv-PN with a PDUFA action date of Dec. 22, 2023. Eplontersen was granted Orphan Drug Designation in the U.S.
For more information on the CARDIO-TTRansform study, please visit www.clinicaltrials.gov (NCT04136171).
About the CARDIO-TTRansform Study
CARDIO-TTRansform is a global, double-blind, randomized, placebo-controlled Phase 3 cardiovascular outcome study in more than 1,400 patients with ATTR cardiomyopathy (ATTR-CM). It is designed to compare eplontersen to placebo in patients with both wild-type ATTRwt-CM and hereditary ATTRv-CM who are either naïve to treatment or on a currently available standard of care. The primary composite endpoint is cardiovascular (CV) mortality and recurrent CV clinical events comparing the two study arms up to week 140. Secondary endpoints include the change from baseline in the 6-minute walk test (6MWT) and the Kansas City Cardiomyopathy Questionnaire (KCCQ) scores at week 121, as well as the rates of CV mortality, CV clinical events and all-cause mortality at week 140.
About Eplontersen
Eplontersen is an investigational LIgand-Conjugated Antisense (LICA) medicine designed to inhibit the production of TTR protein. Eplontersen is being developed as a monthly self-administered subcutaneous injection to treat all types of ATTR. ATTR amyloidosis is a systemic, progressive and fatal disease in which patients experience multiple overlapping clinical manifestations caused by the inappropriate formation and aggregation of TTR amyloid deposits in various tissues and organs, including peripheral nerves, heart, intestinal tract, eyes, kidneys, central nervous system, thyroid and bone marrow. The progressive accumulation of TTR amyloid deposits in these tissues and organs leads to organ failure and eventually death.
About Transthyretin-mediated Amyloid Cardiomyopathy (ATTR-CM)
Transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) is an underdiagnosed and potentially fatal disease. It is caused by the accumulation of misfolded TTR protein in the cardiac muscle. Patients experience ongoing debilitating heart damage resulting in progressive heart failure, which results in death within three to five years from disease onset. ATTR-CM includes both the genetic and wild-type form of the disease. Worldwide, there are an estimated 300,000 – 500,0001,2 patients with ATTR-CM.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.
To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.
Ionis' Forward-looking Statements
This press release includes forward-looking statements regarding Ionis' business and the therapeutic and commercial potential of eplontersen, Ionis' technologies and other products in development. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties including those related to our commercial products and the medicines in our pipeline, and particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended Dec. 31, 2022, and the most recent Form 10-Q quarterly filing, which are on file with the Securities and Exchange Commission. Copies of these and other documents are available from the Company.
In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" all refer to Ionis Pharmaceuticals and its subsidiaries.
Ionis Pharmaceuticals® is a registered trademark of Ionis Pharmaceuticals, Inc.
1 Mohamed-Salem L, et al. Prevalence of wild type ATTR assessed as myocardial uptake in bone scan in the elderly population. Int J Cardiol. 2018 Nov 1;270:192-196. doi: 10.1016/j.ijcard.2018.06.006.
2 Cuscaden C, et al. Estimation of prevalence of transthyretin (ATTR) cardiac amyloidosis in an Australian subpopulation using bone scans with echocardiography and clinical correlation. J Nucl Cardiol. 2020 May 8. doi: 10.1007/s12350-020-02152-x.
View original content to download multimedia:
SOURCE Ionis Pharmaceuticals, Inc. | https://www.wafb.com/prnewswire/2023/07/31/ionis-completes-enrollment-landmark-phase-3-cardio-ttransform-study-patients-with-ttr-mediated-amyloid-cardiomyopathy/ | 2023-07-31T12:36:05 | 0 | https://www.wafb.com/prnewswire/2023/07/31/ionis-completes-enrollment-landmark-phase-3-cardio-ttransform-study-patients-with-ttr-mediated-amyloid-cardiomyopathy/ |
IXL's teaching and learning platform will be used district wide to close knowledge gaps, improve academic achievement and provide equitable educational experiences
LEXINGTON, Ky., July 31, 2023 /PRNewswire/ -- IXL, the personalized learning platform used by more than 14 million students, has announced a new partnership with Fayette County Public Schools (FCPS) in Kentucky. As part of the collaboration, the state's second-largest K-12 school system will now use IXL's award-winning platform district-wide to boost academic achievement in math, English language arts, science, social studies and Spanish. IXL is used by nearly 40 percent of all K-12 students in Kentucky, accounting for more than 283,000 learners.
Fayette County Public Schools strives to provide a world-class education
and positive learning environment to more than 40,000 students from the Lexington area. FCPS began using IXL to support its special education and English language learner communities, and recently expanded its implementation district-wide after successfully piloting the platform.
The district highly values IXL Analytics because it provides educators with data that allows them to track student achievement across schools and identify any gaps in knowledge. This information can then be used to quickly intervene and provide students with the support they need to succeed.
FCPS also appreciates IXL's comprehensive curriculum and instructional resources because they give educators the flexibility to create personalized learning pathways for students. These pathways allow students to learn at their own pace and in their own way, which helps them grow independently. Additionally, IXL provides FCPS with custom math skill plans that are aligned to the district's scope and sequence, as well as test preparation for Kentucky's Summative Assessment. These plans reinforce standards-aligned instruction, which helps students master the concepts they need to know to succeed.
"IXL is an immersive learning tool that helps students master content at school, on-the-go and at home. Insights provided by IXL help teachers track growth and target recommendations for next steps, and research shows that students who use IXL perform better on state assessments," said Brooke Stinson, Director of Assessment, Fayette County Public Schools. "We are excited for this partnership and to provide this resource for all of our students."
"We are delighted to continue our partnership with Fayette County Public Schools. By using IXL's platform district-wide, educators will be able to more effectively track student progress, close achievement gaps and empower all students to reach their full potential," said Paul Mishkin, CEO of IXL Learning. "We are proud to be an important resource to our partners, and we look forward to working with FCPS' team so that all of its learners have even more opportunities to succeed."
Recover learning and boost achievement with IXL's award-winning platform
IXL gives school districts everything that they need to make a bigger positive impact on learning. The all-inclusive platform provides thousands of curriculum and instructional resources, actionable analytics and a state-of-the-art assessment suite. In addition to helping schools and students succeed academically, IXL can even uncover hidden obstacles to learning, develop students' intrinsic motivation to learn and more.
IXL's state-of-the-art assessment suite
IXL's assessment suite works in concert with its curriculum to give educators and students real-time insight into performance, pinpoint gaps in knowledge and provide specific next steps that help recover learning. IXL's adaptive assessment, the Real-Time Diagnostic, accurately measures students' grade-level proficiency and growth in key math and ELA strands, helping educators understand exactly what learners know and what they can do to improve. Additionally, IXL's universal screener flags at-risk students in as little as 20 minutes to help educators plan district-wide math interventions.
Comprehensive curriculum for deeper learning
Teachers use IXL's comprehensive curriculum to provide students with tailored support and ensure that they master essential concepts. More than 10,000 rigorous, mastery-based skills deeply engage students, build a strong foundation of knowledge and prepare learners for higher-level thinking. Based on students' previous work in the curriculum, IXL generates personalized recommendations in real time that guide learners to the skills that will help them grow the fastest. Additionally, IXL's skill plans simplify lesson planning by providing teachers with skills that match their state standards and textbooks. IXL also provides test preparation skill plans and personalized study plans for the SAT and ACT.
Instructional resources and classroom engagement tools
IXL's built-in instructional resources include nearly 2,400 math and English language arts video tutorials, corrective feedback, educational games for young learners and step-by-step lessons that support students when they're working independently. Classroom engagement tools, like Group Jams and Leaderboards, make classroom learning engaging and create collaborative learning opportunities.
Actionable analytics for districts, schools, classrooms and individual learners
IXL Analytics is an essential daily tool that allows teachers to easily identify trouble spots, monitor performance on skills, deliver data-driven instruction and use limited class time more effectively. Administrators can use IXL District Analytics and IXL School Analytics to track student progress and teacher engagement, enabling them to improve IXL's impact on their school or district.
About Fayette County Public Schools
Fayette County Public Schools serves over 40,000 students from the Lexington metro area, with the goal of providing a world-class education for every child. The mission of Fayette County Public Schools is to create a collaborative community that ensures all students achieve at high levels and graduate prepared to excel in a global society.
About IXL Learning
Currently used by 14 million students and in 95 of the top 100 U.S. school districts, IXL is an all-inclusive educational platform that provides a comprehensive PK-12 curriculum and instructional resources, actionable analytics and a state-of-the-art assessment suite. IXL's end-to-end teaching and learning solution supports personalized instruction in math, English language arts, science, social studies and Spanish. With more than 130 billion questions asked and answered around the world, IXL is helping schools and parents successfully boost student achievement. The IXL Learning family of products also includes Rosetta Stone, TPT, SpanishDictionary.com, inglés.com, Wyzant, Vocabulary.com, ABCya, Education.com and Emmersion. To learn more about IXL, visit www.ixl.com, facebook.com/IXL and twitter.com/IXLLearning.
Press Contact
Eric Bates
IXL Learning
press@ixl.com
View original content to download multimedia:
SOURCE IXL Learning | https://www.kwch.com/prnewswire/2023/07/31/ixl-fayette-county-public-schools-partner-boost-academic-achievement-personalize-learning-all-students/ | 2023-07-31T12:36:06 | 0 | https://www.kwch.com/prnewswire/2023/07/31/ixl-fayette-county-public-schools-partner-boost-academic-achievement-personalize-learning-all-students/ |
Leading Fertility Clinic Network Extends Offering of TMRW's Automated Platform for the Safe Management & Storage of Frozen Eggs & Embryos to More Clinics Across the United States
NEW YORK, July 31, 2023 /PRNewswire/ -- Ivy Fertility, a globally-recognized innovator in advanced reproductive technology, in-vitro fertilization (IVF), and third-party reproduction, announced today that it will expand its partnership with TMRW Life Sciences, a fertility technology company. TMRW is automating the IVF lab with the world's first and only automated platform for the safe management and storage of frozen eggs and embryos – a process that since the dawn of the industry has been run completely manually. TMRW's technology is currently available at two Ivy Network clinics. With this expanded partnership, TMRW's on-site and off-site specimen management platform will be available for full adoption at all of Ivy Fertility's 13 clinics across the United States.
Ivy Fertility's San Diego Fertility Center was one of the first clinics in the United States to adopt TMRW's platform and Utah Fertility Center went live this month. TMRW's platform reduces potential points of failure by 94% compared with manual systems, providing new levels of safety, efficiency and transparency for Ivy Fertility's clinics. The partnership demonstrates Ivy Fertility's continued commitment to delivering personalized fertility services using advanced technology by making state-of-the-art solutions available to all of their clinics.
"Providing enhanced security and peace of mind to our patients is one of our core values," said Lisa Van Dolah, Ivy Fertility's CEO. "With our TMRW partnership, we're able to offer patients and our practice even greater security and that is paramount as we continue to grow."
The network's clinicians will now have the opportunity to modernize their specimen management and storage practices with TMRW's digital tools onsite and, in addition, by transferring patient specimens offsite to and from TMRW Cryobanks. The technology upgrade provides clinics with new levels of safety, standardization and scalability, and it helps reduce the risk of specimen mix-up, error, and loss.
"After years of working together with San Diego Fertility Center, and more recently with Utah Fertility Center, we're thrilled to expand our partnership to support the potential for full adoption of both on-site and off-site specimen management across the Ivy Fertility network," said Louis Villalba, CEO of TMRW.
TMRW is now the storage platform used by clinics that see nearly 20% of all patients in the United States. The future of fertility is automated and, together with its clinic partners, TMRW is rapidly becoming the standard of care.
About Ivy Fertility
Ivy Fertility is globally recognized as pioneers and innovators in the field of advanced reproductive technologies, in vitro fertilization, third-party reproduction, andrology, and fertility research. The Ivy Fertility network includes Virginia Fertility & IVF, Fertility Associates of Memphis, Fertility Centers of Orange County, IVF Fertility Center, Los Angeles Reproductive Center, Nevada Center for Reproductive Medicine, Nevada Fertility Center, Pacific Northwest Fertility, Reproductive Partners Medical Group, San Diego Fertility Center, and Utah Fertility Center. By developing new procedures, achieving scientific breakthroughs, and teaching the latest techniques, Ivy Fertility upholds its commitment to successful outcomes. It continually contributes to the development of the entire fertility community. The Ivy team is passionate about its family-building mission and works tirelessly each day to help patients become parents.
For more information, visit ivyfertility.com.
TMRW Life Sciences
Founded in 2018, TMRW Life Sciences, Inc., is a fertility technology company that automates the management and storage of frozen eggs and embryos. For the first time, frozen specimens can be digitally identified and tracked, safely managed with automated robotics, and remotely monitored around the clock. TMRW's next-generation technology platforms set a new standard of care, reducing potential points of failure by 94% compared to manual systems. TMRW delivers peace of mind by helping reduce the risk of specimen mix-up, damage, or loss. Named Fast Company's #1 Most Innovative Biotech company in 2022, TMRW has been adopted by leading clinics across the United States and will soon be available in the UK and Europe.
For more information, visit tmrwlifesciences.com.
View original content:
SOURCE TMRW Life Sciences | https://www.kait8.com/prnewswire/2023/07/31/ivy-fertility-network-expands-partnership-with-tmrw-life-sciences-demand-grows-fertility-clinic-lab-automation/ | 2023-07-31T12:36:09 | 1 | https://www.kait8.com/prnewswire/2023/07/31/ivy-fertility-network-expands-partnership-with-tmrw-life-sciences-demand-grows-fertility-clinic-lab-automation/ |
Leading Fertility Clinic Network Extends Offering of TMRW's Automated Platform for the Safe Management & Storage of Frozen Eggs & Embryos to More Clinics Across the United States
NEW YORK, July 31, 2023 /PRNewswire/ -- Ivy Fertility, a globally-recognized innovator in advanced reproductive technology, in-vitro fertilization (IVF), and third-party reproduction, announced today that it will expand its partnership with TMRW Life Sciences, a fertility technology company. TMRW is automating the IVF lab with the world's first and only automated platform for the safe management and storage of frozen eggs and embryos – a process that since the dawn of the industry has been run completely manually. TMRW's technology is currently available at two Ivy Network clinics. With this expanded partnership, TMRW's on-site and off-site specimen management platform will be available for full adoption at all of Ivy Fertility's 13 clinics across the United States.
Ivy Fertility's San Diego Fertility Center was one of the first clinics in the United States to adopt TMRW's platform and Utah Fertility Center went live this month. TMRW's platform reduces potential points of failure by 94% compared with manual systems, providing new levels of safety, efficiency and transparency for Ivy Fertility's clinics. The partnership demonstrates Ivy Fertility's continued commitment to delivering personalized fertility services using advanced technology by making state-of-the-art solutions available to all of their clinics.
"Providing enhanced security and peace of mind to our patients is one of our core values," said Lisa Van Dolah, Ivy Fertility's CEO. "With our TMRW partnership, we're able to offer patients and our practice even greater security and that is paramount as we continue to grow."
The network's clinicians will now have the opportunity to modernize their specimen management and storage practices with TMRW's digital tools onsite and, in addition, by transferring patient specimens offsite to and from TMRW Cryobanks. The technology upgrade provides clinics with new levels of safety, standardization and scalability, and it helps reduce the risk of specimen mix-up, error, and loss.
"After years of working together with San Diego Fertility Center, and more recently with Utah Fertility Center, we're thrilled to expand our partnership to support the potential for full adoption of both on-site and off-site specimen management across the Ivy Fertility network," said Louis Villalba, CEO of TMRW.
TMRW is now the storage platform used by clinics that see nearly 20% of all patients in the United States. The future of fertility is automated and, together with its clinic partners, TMRW is rapidly becoming the standard of care.
About Ivy Fertility
Ivy Fertility is globally recognized as pioneers and innovators in the field of advanced reproductive technologies, in vitro fertilization, third-party reproduction, andrology, and fertility research. The Ivy Fertility network includes Virginia Fertility & IVF, Fertility Associates of Memphis, Fertility Centers of Orange County, IVF Fertility Center, Los Angeles Reproductive Center, Nevada Center for Reproductive Medicine, Nevada Fertility Center, Pacific Northwest Fertility, Reproductive Partners Medical Group, San Diego Fertility Center, and Utah Fertility Center. By developing new procedures, achieving scientific breakthroughs, and teaching the latest techniques, Ivy Fertility upholds its commitment to successful outcomes. It continually contributes to the development of the entire fertility community. The Ivy team is passionate about its family-building mission and works tirelessly each day to help patients become parents.
For more information, visit ivyfertility.com.
TMRW Life Sciences
Founded in 2018, TMRW Life Sciences, Inc., is a fertility technology company that automates the management and storage of frozen eggs and embryos. For the first time, frozen specimens can be digitally identified and tracked, safely managed with automated robotics, and remotely monitored around the clock. TMRW's next-generation technology platforms set a new standard of care, reducing potential points of failure by 94% compared to manual systems. TMRW delivers peace of mind by helping reduce the risk of specimen mix-up, damage, or loss. Named Fast Company's #1 Most Innovative Biotech company in 2022, TMRW has been adopted by leading clinics across the United States and will soon be available in the UK and Europe.
For more information, visit tmrwlifesciences.com.
View original content:
SOURCE TMRW Life Sciences | https://www.wafb.com/prnewswire/2023/07/31/ivy-fertility-network-expands-partnership-with-tmrw-life-sciences-demand-grows-fertility-clinic-lab-automation/ | 2023-07-31T12:36:12 | 0 | https://www.wafb.com/prnewswire/2023/07/31/ivy-fertility-network-expands-partnership-with-tmrw-life-sciences-demand-grows-fertility-clinic-lab-automation/ |
Initial agreement to include 10 battery-electric and three hydrogen fuel cell electric Class 8 trucks
PHOENIX and LOWELL, Ark., July 31, 2023 /PRNewswire/ -- Nikola Corporation (Nasdaq: NKLA), a global leader in zero-emissions transportation and energy supply and infrastructure solutions, via the HYLA brand, and J.B. Hunt Transport Services Inc. (Nasdaq: JBHT), one of the largest supply chain solutions providers in North America, today announced an agreement in which subsidiary J.B. Hunt Transport Inc. will purchase 13 Nikola zero-emission Class 8 trucks as the transportation company focuses on its sustainability efforts and reducing the intensity of its carbon emissions.
"It's important for us to be at the forefront of new technologies and innovative solutions that have the potential to change the way we move freight," said Nick Hobbs, chief operating officer and president of contract services at J.B. Hunt. "These zero-emission trucks from Nikola advance our progress towards achieving our ambitious goal to reduce carbon emission intensity through viable solutions."
The initial truck order will include 10 battery-electric and three hydrogen fuel cell electric vehicles, with delivery of the first vehicles expected in August 2023. These trucks will be strategically located at facilities servicing J.B. Hunt's key routes, including in the greater Los Angeles and Phoenix areas. Nikola's hydrogen arm, HYLA, will supply the hydrogen and fueling infrastructure.
"We are thrilled that the industry leader for supply-chain solutions has chosen our Nikola Class 8 battery-electric and hydrogen fuel cell electric trucks to use for their operations," said Nikola CEO Michael Lohscheller. "Their purchase and use of these zero-emissions trucks are a testament to the hard work of our engineering, development and manufacturing teams, who created a robust, highly advanced truck lineup, as well as our HYLA hydrogen infrastructure solutions, which are designed to benefit companies such as J.B. Hunt."
J.B. Hunt is committed to helping drive the industry toward a low-carbon future and reducing its environmental impact. In November 2022, the company set an ambitious goal to reduce carbon emission intensity 32% by 2034 (with a 2019 baseline). Incorporating alternative powered equipment into its fleet is one of three key focus areas in reaching the goal.
J.B. Hunt continually evaluates opportunities to utilize emerging technologies in exhaust-free vehicles. In the fourth quarter of 2022, the company took delivery of its first company-owned Class 8 electric vehicle. In 2017, J.B. Hunt was one of the first companies to place an order for an all-electric heavy-duty Class 8 truck and began incorporating electric vehicles into operations in 2023. In addition to electric vehicles, J.B. Hunt is helping reduce carbon emissions through intermodal conversion. Over the past decade, J.B. Hunt's intermodal service has helped avoid an estimated 30 million metric tons of CO2e emissions from over-the-road truck transportation.
ABOUT NIKOLA CORPORATION
Nikola Corporation is globally transforming the transportation industry. As a designer and manufacturer of zero-emission battery-electric and hydrogen-electric vehicles, electric vehicle drivetrains, vehicle components, energy storage systems, and hydrogen station infrastructure, via the HYLA brand, Nikola is driven to revolutionize the economic and environmental impact of commerce as we know it today. Founded in 2015, Nikola Corporation is headquartered in Phoenix, Arizona. For more information, visit www.nikolamotor.com , Facebook @nikolamotorcompany, Instagram @nikolamotorcompany, YouTube @nikolamotorcompany, LinkedIn @nikolamotorcompany or Twitter @nikolamotor.
ABOUT J.B. HUNT
J.B. Hunt Transport Services Inc. is on a mission to create the most efficient transportation network in North America. The company's industry-leading solutions and mode-neutral approach generate value for customers by eliminating waste, reducing costs and enhancing supply chain visibility. Powered by one of the largest company-owned fleets in the country with more than 162,000 pieces of trailing equipment and nearly one million accessible trucks through its J.B. Hunt 360°® digital freight marketplace, J.B. Hunt can meet the unique shipping needs of any business, from first mile to final delivery, and every shipment in-between. Through disciplined investments in its people, technology and capacity, J.B. Hunt is delivering exceptional value and service that enable long-term growth for the company and its stakeholders.
J.B. Hunt Transport Services Inc. is a Fortune 500 company, an S&P 500 company and a component of the Dow Jones Transportation Average. Its stock trades on NASDAQ under the ticker symbol JBHT. J.B. Hunt Transport Inc. is a wholly owned subsidiary of JBHT. The company's services include intermodal, dedicated, refrigerated, truckload, less-than-truckload, flatbed, single source, last mile, transload and more. For more information, visit www.jbhunt.com.
FORWARD LOOKING STATEMENTS
This press release contains certain forward-looking statements within the meaning of federal securities laws with respect to Nikola Corporation (Nikola"), including statements relating to the truck order, expected delivery timing and expected benefits of Nikola's zero-emissions trucks; Nikola's expectations regarding the production of hydrogen fuel cell electric trucks; and Nikola's ability to provide sufficient volumes of hydrogen to support hydrogen fuel cell electric vehicle demand. These forward-looking statements generally are identified by words such as "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," and similar expressions. Forward-looking statements are predictions, projections, and other statements about future events based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: design and manufacturing changes and delays, including global shortages in parts and materials; general economic, financial, legal, regulatory, political and business conditions and changes in domestic and foreign markets; demand for and customer acceptance of Nikola's trucks; the terms of the agreement; the risk of cancellation of orders; risks associated with development and testing of fuel-cell power modules and hydrogen storage systems; risks related to the rollout of Nikola's business and milestones and the timing of expected business milestones; Nikola's availability of and need for capital; and the factors, risks and uncertainties regarding Nikola's business described in the "Risk Factors" section of Nikola's quarterly report on Form 10-Q for the quarter ended March 31, 2023 filed with the SEC, in addition to Nikola's subsequent filings with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, Nikola assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
View original content to download multimedia:
SOURCE Nikola Corporation | https://www.kwch.com/prnewswire/2023/07/31/jb-hunt-purchase-13-zero-emission-nikola-trucks/ | 2023-07-31T12:36:13 | 1 | https://www.kwch.com/prnewswire/2023/07/31/jb-hunt-purchase-13-zero-emission-nikola-trucks/ |
Initial agreement to include 10 battery-electric and three hydrogen fuel cell electric Class 8 trucks
PHOENIX and LOWELL, Ark., July 31, 2023 /PRNewswire/ -- Nikola Corporation (Nasdaq: NKLA), a global leader in zero-emissions transportation and energy supply and infrastructure solutions, via the HYLA brand, and J.B. Hunt Transport Services Inc. (Nasdaq: JBHT), one of the largest supply chain solutions providers in North America, today announced an agreement in which subsidiary J.B. Hunt Transport Inc. will purchase 13 Nikola zero-emission Class 8 trucks as the transportation company focuses on its sustainability efforts and reducing the intensity of its carbon emissions.
"It's important for us to be at the forefront of new technologies and innovative solutions that have the potential to change the way we move freight," said Nick Hobbs, chief operating officer and president of contract services at J.B. Hunt. "These zero-emission trucks from Nikola advance our progress towards achieving our ambitious goal to reduce carbon emission intensity through viable solutions."
The initial truck order will include 10 battery-electric and three hydrogen fuel cell electric vehicles, with delivery of the first vehicles expected in August 2023. These trucks will be strategically located at facilities servicing J.B. Hunt's key routes, including in the greater Los Angeles and Phoenix areas. Nikola's hydrogen arm, HYLA, will supply the hydrogen and fueling infrastructure.
"We are thrilled that the industry leader for supply-chain solutions has chosen our Nikola Class 8 battery-electric and hydrogen fuel cell electric trucks to use for their operations," said Nikola CEO Michael Lohscheller. "Their purchase and use of these zero-emissions trucks are a testament to the hard work of our engineering, development and manufacturing teams, who created a robust, highly advanced truck lineup, as well as our HYLA hydrogen infrastructure solutions, which are designed to benefit companies such as J.B. Hunt."
J.B. Hunt is committed to helping drive the industry toward a low-carbon future and reducing its environmental impact. In November 2022, the company set an ambitious goal to reduce carbon emission intensity 32% by 2034 (with a 2019 baseline). Incorporating alternative powered equipment into its fleet is one of three key focus areas in reaching the goal.
J.B. Hunt continually evaluates opportunities to utilize emerging technologies in exhaust-free vehicles. In the fourth quarter of 2022, the company took delivery of its first company-owned Class 8 electric vehicle. In 2017, J.B. Hunt was one of the first companies to place an order for an all-electric heavy-duty Class 8 truck and began incorporating electric vehicles into operations in 2023. In addition to electric vehicles, J.B. Hunt is helping reduce carbon emissions through intermodal conversion. Over the past decade, J.B. Hunt's intermodal service has helped avoid an estimated 30 million metric tons of CO2e emissions from over-the-road truck transportation.
ABOUT NIKOLA CORPORATION
Nikola Corporation is globally transforming the transportation industry. As a designer and manufacturer of zero-emission battery-electric and hydrogen-electric vehicles, electric vehicle drivetrains, vehicle components, energy storage systems, and hydrogen station infrastructure, via the HYLA brand, Nikola is driven to revolutionize the economic and environmental impact of commerce as we know it today. Founded in 2015, Nikola Corporation is headquartered in Phoenix, Arizona. For more information, visit www.nikolamotor.com , Facebook @nikolamotorcompany, Instagram @nikolamotorcompany, YouTube @nikolamotorcompany, LinkedIn @nikolamotorcompany or Twitter @nikolamotor.
ABOUT J.B. HUNT
J.B. Hunt Transport Services Inc. is on a mission to create the most efficient transportation network in North America. The company's industry-leading solutions and mode-neutral approach generate value for customers by eliminating waste, reducing costs and enhancing supply chain visibility. Powered by one of the largest company-owned fleets in the country with more than 162,000 pieces of trailing equipment and nearly one million accessible trucks through its J.B. Hunt 360°® digital freight marketplace, J.B. Hunt can meet the unique shipping needs of any business, from first mile to final delivery, and every shipment in-between. Through disciplined investments in its people, technology and capacity, J.B. Hunt is delivering exceptional value and service that enable long-term growth for the company and its stakeholders.
J.B. Hunt Transport Services Inc. is a Fortune 500 company, an S&P 500 company and a component of the Dow Jones Transportation Average. Its stock trades on NASDAQ under the ticker symbol JBHT. J.B. Hunt Transport Inc. is a wholly owned subsidiary of JBHT. The company's services include intermodal, dedicated, refrigerated, truckload, less-than-truckload, flatbed, single source, last mile, transload and more. For more information, visit www.jbhunt.com.
FORWARD LOOKING STATEMENTS
This press release contains certain forward-looking statements within the meaning of federal securities laws with respect to Nikola Corporation (Nikola"), including statements relating to the truck order, expected delivery timing and expected benefits of Nikola's zero-emissions trucks; Nikola's expectations regarding the production of hydrogen fuel cell electric trucks; and Nikola's ability to provide sufficient volumes of hydrogen to support hydrogen fuel cell electric vehicle demand. These forward-looking statements generally are identified by words such as "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," and similar expressions. Forward-looking statements are predictions, projections, and other statements about future events based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: design and manufacturing changes and delays, including global shortages in parts and materials; general economic, financial, legal, regulatory, political and business conditions and changes in domestic and foreign markets; demand for and customer acceptance of Nikola's trucks; the terms of the agreement; the risk of cancellation of orders; risks associated with development and testing of fuel-cell power modules and hydrogen storage systems; risks related to the rollout of Nikola's business and milestones and the timing of expected business milestones; Nikola's availability of and need for capital; and the factors, risks and uncertainties regarding Nikola's business described in the "Risk Factors" section of Nikola's quarterly report on Form 10-Q for the quarter ended March 31, 2023 filed with the SEC, in addition to Nikola's subsequent filings with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, Nikola assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
View original content to download multimedia:
SOURCE Nikola Corporation | https://www.kait8.com/prnewswire/2023/07/31/jb-hunt-purchase-13-zero-emission-nikola-trucks/ | 2023-07-31T12:36:15 | 1 | https://www.kait8.com/prnewswire/2023/07/31/jb-hunt-purchase-13-zero-emission-nikola-trucks/ |
Juggernaut and Mr. Highman will continue as substantial shareholders of Bobbie. The acquisition positions the combined company as the third largest fully integrated infant and toddler brand in the U.S., creating a more resilient industry for American families
WASHINGTON, July 31, 2023 /PRNewswire/ -- Juggernaut Capital Partners, a leading middle market private equity investor primarily in the consumer and healthcare sectors, is pleased to announce the sale of Nature's One, the pediatric nutrition company founded by Jay Highman which set the bar for quality and innovation in formula over decades. Joining forces with Bobbie Baby, Inc., the nation's fastest growing infant formula company, the combined business will be the first of its kind in pediatric nutrition.
"Nature's One is a true pioneer in the pediatric nutrition space. Juggernaut partnered with founder, Jay Highman, to accelerate product development and vertical integration initiatives. Over the past five years, the company completed the first FDA-approved clinical feeding study of an organic infant formula and designed and constructed the first newly built infant formula facility in the U.S. in 35 years," said John Shulman, Founder and Managing Partner at Juggernaut. "It has been a pleasure to partner with Jay and his team. We believe the combination with Bobbie cements the organization as a continued disruptor and a next-generation industry leader. We are proud to continue as a meaningful shareholder in the go-forward company."
Founded in 1997, Nature's One introduced the first organic baby formula to the U.S. market. Recognized for its dedication to purity and quality, all of the company's formulas have received the Clean Label Project's Purity Award and have tested best in class for purity and nutrition when compared to popular baby formulas sold in the U.S. Nature's One operates the only independent, FDA audited organic infant nutrition facility in the U.S.
Nature's One was advised by CG / Sawaya Partners (operating under Canaccord Genuity) and Morgan Lewis & Bockius LLP. Bobbie was advised by Perella Weinberg Partners LP and Goodwin Procter LLP.
About Juggernaut Capital Partners:
Juggernaut Capital Partners is a leading private equity firm focusing on lower middle market companies, primarily in the consumer and healthcare sectors. Juggernaut is currently investing out of Juggernaut Capital Partners V, L.P. For more information on Juggernaut Capital Partners, please visit www.juggernautcap.com.
About Nature's One:
Founded in 1997, Nature's One introduced the first organic formula, Baby's Only® Organic in the United States. Nature's One has dedicated 25 years to the research, development, and sourcing of pure ingredients. Recognized as the first and highest-ranked formulas for purity and nutritional superiority by the Clean Label Project, Baby's Only Formulas are preferred by parents who want to offer their child a "Better Start…for Life™." Baby's Only Formulas are sold nationally at Whole Foods, Target, Walmart, Sam's Club, and many fine natural food retailers, as well online at www.naturesone.com.
About Bobbie:
Bobbie is the mission-driven organic pediatric nutrition company that exists to build a parenting culture of confidence, not comparison. Founded in 2018, Bobbie hit the market with its flagship European-inspired formula in 2021 as the first direct-to-consumer, subscription-based infant formula in the U.S. Today, it's proud to be the only mom-founded and led infant formula brand in the world, and the fastest-growing in the U.S. since the 1980's. Bobbie is focused on providing purposefully sourced, USDA Organic products made with simple ingredients – crafted right here in America, for American families. For more information, visit www.hibobbie.com.
View original content:
SOURCE Juggernaut Capital Partners | https://www.kait8.com/prnewswire/2023/07/31/juggernaut-capital-partners-natures-one-founder-jay-highman-have-sold-natures-one-bobbie-baby-inc/ | 2023-07-31T12:36:16 | 0 | https://www.kait8.com/prnewswire/2023/07/31/juggernaut-capital-partners-natures-one-founder-jay-highman-have-sold-natures-one-bobbie-baby-inc/ |
IXL's teaching and learning platform will be used district wide to close knowledge gaps, improve academic achievement and provide equitable educational experiences
LEXINGTON, Ky., July 31, 2023 /PRNewswire/ -- IXL, the personalized learning platform used by more than 14 million students, has announced a new partnership with Fayette County Public Schools (FCPS) in Kentucky. As part of the collaboration, the state's second-largest K-12 school system will now use IXL's award-winning platform district-wide to boost academic achievement in math, English language arts, science, social studies and Spanish. IXL is used by nearly 40 percent of all K-12 students in Kentucky, accounting for more than 283,000 learners.
Fayette County Public Schools strives to provide a world-class education
and positive learning environment to more than 40,000 students from the Lexington area. FCPS began using IXL to support its special education and English language learner communities, and recently expanded its implementation district-wide after successfully piloting the platform.
The district highly values IXL Analytics because it provides educators with data that allows them to track student achievement across schools and identify any gaps in knowledge. This information can then be used to quickly intervene and provide students with the support they need to succeed.
FCPS also appreciates IXL's comprehensive curriculum and instructional resources because they give educators the flexibility to create personalized learning pathways for students. These pathways allow students to learn at their own pace and in their own way, which helps them grow independently. Additionally, IXL provides FCPS with custom math skill plans that are aligned to the district's scope and sequence, as well as test preparation for Kentucky's Summative Assessment. These plans reinforce standards-aligned instruction, which helps students master the concepts they need to know to succeed.
"IXL is an immersive learning tool that helps students master content at school, on-the-go and at home. Insights provided by IXL help teachers track growth and target recommendations for next steps, and research shows that students who use IXL perform better on state assessments," said Brooke Stinson, Director of Assessment, Fayette County Public Schools. "We are excited for this partnership and to provide this resource for all of our students."
"We are delighted to continue our partnership with Fayette County Public Schools. By using IXL's platform district-wide, educators will be able to more effectively track student progress, close achievement gaps and empower all students to reach their full potential," said Paul Mishkin, CEO of IXL Learning. "We are proud to be an important resource to our partners, and we look forward to working with FCPS' team so that all of its learners have even more opportunities to succeed."
Recover learning and boost achievement with IXL's award-winning platform
IXL gives school districts everything that they need to make a bigger positive impact on learning. The all-inclusive platform provides thousands of curriculum and instructional resources, actionable analytics and a state-of-the-art assessment suite. In addition to helping schools and students succeed academically, IXL can even uncover hidden obstacles to learning, develop students' intrinsic motivation to learn and more.
IXL's state-of-the-art assessment suite
IXL's assessment suite works in concert with its curriculum to give educators and students real-time insight into performance, pinpoint gaps in knowledge and provide specific next steps that help recover learning. IXL's adaptive assessment, the Real-Time Diagnostic, accurately measures students' grade-level proficiency and growth in key math and ELA strands, helping educators understand exactly what learners know and what they can do to improve. Additionally, IXL's universal screener flags at-risk students in as little as 20 minutes to help educators plan district-wide math interventions.
Comprehensive curriculum for deeper learning
Teachers use IXL's comprehensive curriculum to provide students with tailored support and ensure that they master essential concepts. More than 10,000 rigorous, mastery-based skills deeply engage students, build a strong foundation of knowledge and prepare learners for higher-level thinking. Based on students' previous work in the curriculum, IXL generates personalized recommendations in real time that guide learners to the skills that will help them grow the fastest. Additionally, IXL's skill plans simplify lesson planning by providing teachers with skills that match their state standards and textbooks. IXL also provides test preparation skill plans and personalized study plans for the SAT and ACT.
Instructional resources and classroom engagement tools
IXL's built-in instructional resources include nearly 2,400 math and English language arts video tutorials, corrective feedback, educational games for young learners and step-by-step lessons that support students when they're working independently. Classroom engagement tools, like Group Jams and Leaderboards, make classroom learning engaging and create collaborative learning opportunities.
Actionable analytics for districts, schools, classrooms and individual learners
IXL Analytics is an essential daily tool that allows teachers to easily identify trouble spots, monitor performance on skills, deliver data-driven instruction and use limited class time more effectively. Administrators can use IXL District Analytics and IXL School Analytics to track student progress and teacher engagement, enabling them to improve IXL's impact on their school or district.
About Fayette County Public Schools
Fayette County Public Schools serves over 40,000 students from the Lexington metro area, with the goal of providing a world-class education for every child. The mission of Fayette County Public Schools is to create a collaborative community that ensures all students achieve at high levels and graduate prepared to excel in a global society.
About IXL Learning
Currently used by 14 million students and in 95 of the top 100 U.S. school districts, IXL is an all-inclusive educational platform that provides a comprehensive PK-12 curriculum and instructional resources, actionable analytics and a state-of-the-art assessment suite. IXL's end-to-end teaching and learning solution supports personalized instruction in math, English language arts, science, social studies and Spanish. With more than 130 billion questions asked and answered around the world, IXL is helping schools and parents successfully boost student achievement. The IXL Learning family of products also includes Rosetta Stone, TPT, SpanishDictionary.com, inglés.com, Wyzant, Vocabulary.com, ABCya, Education.com and Emmersion. To learn more about IXL, visit www.ixl.com, facebook.com/IXL and twitter.com/IXLLearning.
Press Contact
Eric Bates
IXL Learning
press@ixl.com
View original content to download multimedia:
SOURCE IXL Learning | https://www.wafb.com/prnewswire/2023/07/31/ixl-fayette-county-public-schools-partner-boost-academic-achievement-personalize-learning-all-students/ | 2023-07-31T12:36:18 | 0 | https://www.wafb.com/prnewswire/2023/07/31/ixl-fayette-county-public-schools-partner-boost-academic-achievement-personalize-learning-all-students/ |
Juggernaut and Mr. Highman will continue as substantial shareholders of Bobbie. The acquisition positions the combined company as the third largest fully integrated infant and toddler brand in the U.S., creating a more resilient industry for American families
WASHINGTON, July 31, 2023 /PRNewswire/ -- Juggernaut Capital Partners, a leading middle market private equity investor primarily in the consumer and healthcare sectors, is pleased to announce the sale of Nature's One, the pediatric nutrition company founded by Jay Highman which set the bar for quality and innovation in formula over decades. Joining forces with Bobbie Baby, Inc., the nation's fastest growing infant formula company, the combined business will be the first of its kind in pediatric nutrition.
"Nature's One is a true pioneer in the pediatric nutrition space. Juggernaut partnered with founder, Jay Highman, to accelerate product development and vertical integration initiatives. Over the past five years, the company completed the first FDA-approved clinical feeding study of an organic infant formula and designed and constructed the first newly built infant formula facility in the U.S. in 35 years," said John Shulman, Founder and Managing Partner at Juggernaut. "It has been a pleasure to partner with Jay and his team. We believe the combination with Bobbie cements the organization as a continued disruptor and a next-generation industry leader. We are proud to continue as a meaningful shareholder in the go-forward company."
Founded in 1997, Nature's One introduced the first organic baby formula to the U.S. market. Recognized for its dedication to purity and quality, all of the company's formulas have received the Clean Label Project's Purity Award and have tested best in class for purity and nutrition when compared to popular baby formulas sold in the U.S. Nature's One operates the only independent, FDA audited organic infant nutrition facility in the U.S.
Nature's One was advised by CG / Sawaya Partners (operating under Canaccord Genuity) and Morgan Lewis & Bockius LLP. Bobbie was advised by Perella Weinberg Partners LP and Goodwin Procter LLP.
About Juggernaut Capital Partners:
Juggernaut Capital Partners is a leading private equity firm focusing on lower middle market companies, primarily in the consumer and healthcare sectors. Juggernaut is currently investing out of Juggernaut Capital Partners V, L.P. For more information on Juggernaut Capital Partners, please visit www.juggernautcap.com.
About Nature's One:
Founded in 1997, Nature's One introduced the first organic formula, Baby's Only® Organic in the United States. Nature's One has dedicated 25 years to the research, development, and sourcing of pure ingredients. Recognized as the first and highest-ranked formulas for purity and nutritional superiority by the Clean Label Project, Baby's Only Formulas are preferred by parents who want to offer their child a "Better Start…for Life™." Baby's Only Formulas are sold nationally at Whole Foods, Target, Walmart, Sam's Club, and many fine natural food retailers, as well online at www.naturesone.com.
About Bobbie:
Bobbie is the mission-driven organic pediatric nutrition company that exists to build a parenting culture of confidence, not comparison. Founded in 2018, Bobbie hit the market with its flagship European-inspired formula in 2021 as the first direct-to-consumer, subscription-based infant formula in the U.S. Today, it's proud to be the only mom-founded and led infant formula brand in the world, and the fastest-growing in the U.S. since the 1980's. Bobbie is focused on providing purposefully sourced, USDA Organic products made with simple ingredients – crafted right here in America, for American families. For more information, visit www.hibobbie.com.
View original content:
SOURCE Juggernaut Capital Partners | https://www.kwch.com/prnewswire/2023/07/31/juggernaut-capital-partners-natures-one-founder-jay-highman-have-sold-natures-one-bobbie-baby-inc/ | 2023-07-31T12:36:19 | 1 | https://www.kwch.com/prnewswire/2023/07/31/juggernaut-capital-partners-natures-one-founder-jay-highman-have-sold-natures-one-bobbie-baby-inc/ |
BURLINGTON, N.C., July 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 14, 2023, in New York City, beginning at 1:00 p.m. ET and is expected to conclude by approximately 4:00 p.m. ET.
This event will highlight Labcorp's go-forward strategy from Labcorp Chairman & CEO Adam Schechter, followed by business overviews and a longer-term financial outlook. Presentations will be followed by a Q&A session.
A live webcast of the event will be available through the Labcorp Investor Relations website beginning at 1:00 p.m. ET. A replay of the webcast and supporting materials will be available after the conclusion of the event.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
View original content to download multimedia:
SOURCE Labcorp | https://www.kait8.com/prnewswire/2023/07/31/labcorp-host-investor-day-september-14-2023/ | 2023-07-31T12:36:22 | 1 | https://www.kait8.com/prnewswire/2023/07/31/labcorp-host-investor-day-september-14-2023/ |
Initial agreement to include 10 battery-electric and three hydrogen fuel cell electric Class 8 trucks
PHOENIX and LOWELL, Ark., July 31, 2023 /PRNewswire/ -- Nikola Corporation (Nasdaq: NKLA), a global leader in zero-emissions transportation and energy supply and infrastructure solutions, via the HYLA brand, and J.B. Hunt Transport Services Inc. (Nasdaq: JBHT), one of the largest supply chain solutions providers in North America, today announced an agreement in which subsidiary J.B. Hunt Transport Inc. will purchase 13 Nikola zero-emission Class 8 trucks as the transportation company focuses on its sustainability efforts and reducing the intensity of its carbon emissions.
"It's important for us to be at the forefront of new technologies and innovative solutions that have the potential to change the way we move freight," said Nick Hobbs, chief operating officer and president of contract services at J.B. Hunt. "These zero-emission trucks from Nikola advance our progress towards achieving our ambitious goal to reduce carbon emission intensity through viable solutions."
The initial truck order will include 10 battery-electric and three hydrogen fuel cell electric vehicles, with delivery of the first vehicles expected in August 2023. These trucks will be strategically located at facilities servicing J.B. Hunt's key routes, including in the greater Los Angeles and Phoenix areas. Nikola's hydrogen arm, HYLA, will supply the hydrogen and fueling infrastructure.
"We are thrilled that the industry leader for supply-chain solutions has chosen our Nikola Class 8 battery-electric and hydrogen fuel cell electric trucks to use for their operations," said Nikola CEO Michael Lohscheller. "Their purchase and use of these zero-emissions trucks are a testament to the hard work of our engineering, development and manufacturing teams, who created a robust, highly advanced truck lineup, as well as our HYLA hydrogen infrastructure solutions, which are designed to benefit companies such as J.B. Hunt."
J.B. Hunt is committed to helping drive the industry toward a low-carbon future and reducing its environmental impact. In November 2022, the company set an ambitious goal to reduce carbon emission intensity 32% by 2034 (with a 2019 baseline). Incorporating alternative powered equipment into its fleet is one of three key focus areas in reaching the goal.
J.B. Hunt continually evaluates opportunities to utilize emerging technologies in exhaust-free vehicles. In the fourth quarter of 2022, the company took delivery of its first company-owned Class 8 electric vehicle. In 2017, J.B. Hunt was one of the first companies to place an order for an all-electric heavy-duty Class 8 truck and began incorporating electric vehicles into operations in 2023. In addition to electric vehicles, J.B. Hunt is helping reduce carbon emissions through intermodal conversion. Over the past decade, J.B. Hunt's intermodal service has helped avoid an estimated 30 million metric tons of CO2e emissions from over-the-road truck transportation.
ABOUT NIKOLA CORPORATION
Nikola Corporation is globally transforming the transportation industry. As a designer and manufacturer of zero-emission battery-electric and hydrogen-electric vehicles, electric vehicle drivetrains, vehicle components, energy storage systems, and hydrogen station infrastructure, via the HYLA brand, Nikola is driven to revolutionize the economic and environmental impact of commerce as we know it today. Founded in 2015, Nikola Corporation is headquartered in Phoenix, Arizona. For more information, visit www.nikolamotor.com , Facebook @nikolamotorcompany, Instagram @nikolamotorcompany, YouTube @nikolamotorcompany, LinkedIn @nikolamotorcompany or Twitter @nikolamotor.
ABOUT J.B. HUNT
J.B. Hunt Transport Services Inc. is on a mission to create the most efficient transportation network in North America. The company's industry-leading solutions and mode-neutral approach generate value for customers by eliminating waste, reducing costs and enhancing supply chain visibility. Powered by one of the largest company-owned fleets in the country with more than 162,000 pieces of trailing equipment and nearly one million accessible trucks through its J.B. Hunt 360°® digital freight marketplace, J.B. Hunt can meet the unique shipping needs of any business, from first mile to final delivery, and every shipment in-between. Through disciplined investments in its people, technology and capacity, J.B. Hunt is delivering exceptional value and service that enable long-term growth for the company and its stakeholders.
J.B. Hunt Transport Services Inc. is a Fortune 500 company, an S&P 500 company and a component of the Dow Jones Transportation Average. Its stock trades on NASDAQ under the ticker symbol JBHT. J.B. Hunt Transport Inc. is a wholly owned subsidiary of JBHT. The company's services include intermodal, dedicated, refrigerated, truckload, less-than-truckload, flatbed, single source, last mile, transload and more. For more information, visit www.jbhunt.com.
FORWARD LOOKING STATEMENTS
This press release contains certain forward-looking statements within the meaning of federal securities laws with respect to Nikola Corporation (Nikola"), including statements relating to the truck order, expected delivery timing and expected benefits of Nikola's zero-emissions trucks; Nikola's expectations regarding the production of hydrogen fuel cell electric trucks; and Nikola's ability to provide sufficient volumes of hydrogen to support hydrogen fuel cell electric vehicle demand. These forward-looking statements generally are identified by words such as "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," and similar expressions. Forward-looking statements are predictions, projections, and other statements about future events based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: design and manufacturing changes and delays, including global shortages in parts and materials; general economic, financial, legal, regulatory, political and business conditions and changes in domestic and foreign markets; demand for and customer acceptance of Nikola's trucks; the terms of the agreement; the risk of cancellation of orders; risks associated with development and testing of fuel-cell power modules and hydrogen storage systems; risks related to the rollout of Nikola's business and milestones and the timing of expected business milestones; Nikola's availability of and need for capital; and the factors, risks and uncertainties regarding Nikola's business described in the "Risk Factors" section of Nikola's quarterly report on Form 10-Q for the quarter ended March 31, 2023 filed with the SEC, in addition to Nikola's subsequent filings with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, Nikola assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
View original content to download multimedia:
SOURCE Nikola Corporation | https://www.wafb.com/prnewswire/2023/07/31/jb-hunt-purchase-13-zero-emission-nikola-trucks/ | 2023-07-31T12:36:25 | 0 | https://www.wafb.com/prnewswire/2023/07/31/jb-hunt-purchase-13-zero-emission-nikola-trucks/ |
BURLINGTON, N.C., July 31, 2023 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced it will host an Investor Day on Thursday, September 14, 2023, in New York City, beginning at 1:00 p.m. ET and is expected to conclude by approximately 4:00 p.m. ET.
This event will highlight Labcorp's go-forward strategy from Labcorp Chairman & CEO Adam Schechter, followed by business overviews and a longer-term financial outlook. Presentations will be followed by a Q&A session.
A live webcast of the event will be available through the Labcorp Investor Relations website beginning at 1:00 p.m. ET. A replay of the webcast and supporting materials will be available after the conclusion of the event.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 60,000 employees serve clients in over 100 countries, worked on over 80% of the new drugs approved by the FDA in 2022 and performed more than 600 million tests for patients around the world. Learn more about us at www.Labcorp.com or follow us on LinkedIn and Twitter @Labcorp.
View original content to download multimedia:
SOURCE Labcorp | https://www.kwch.com/prnewswire/2023/07/31/labcorp-host-investor-day-september-14-2023/ | 2023-07-31T12:36:26 | 0 | https://www.kwch.com/prnewswire/2023/07/31/labcorp-host-investor-day-september-14-2023/ |
Adult Males are Slightly More Likely to Live with Parents Than Their Female Counterparts
58% of Gen Z Consumers Live with Family Members
SAN FRANCISCO, July 31, 2023 /PRNewswire/ -- LendingClub Corporation (NYSE: LC), the parent company of LendingClub Bank, America's leading digital marketplace bank, today released findings from the 24th edition of the Reality Check: Paycheck-To-Paycheck research series, conducted in partnership with PYMNTS. The Household Finances Deep Dive Edition examines the impact of household composition on consumers' ability to manage expenses and put aside savings. The series draws on insights from a survey of 4,602 U.S. consumers conducted from June 5 to June 16, as well as analysis of other economic data.
The Paycheck-to-Paycheck Landscape
In June 2023, 61% of U.S. consumers lived paycheck to paycheck, unchanged from June 2022 — as is the share of those struggling to pay bills (at 21%) — even though more middle-income consumers cited living paycheck to paycheck in June 2023 than last year. Among consumers earning $50,000 to $100,000, 65% lived paycheck to paycheck as of June 2023, compared to 60% in June 2022. Meanwhile, the shares of high-income consumers — those earning more than $100,000 annually — and low-income consumers — those earning less than $50,000 annually — living paycheck to paycheck in June 2023 sit at 45% and 77%, respectively, relatively unchanged from June 2022.
This stability in the financial situation of U.S. households indicates that consumers continue to adapt to inflationary pressures, finding ways to manage their spending and live within their means.
Household Composition Determines Financial Lifestyle
Consumers living with only a partner or spouse are likely to face less financial hardship, while those with dependents and those living with friends or housemates are more likely to live paycheck to paycheck.
The research finds that 86% of consumers live with one or more people, and one-third of paycheck-to-paycheck consumers live in households of four or more people. Consumers not living paycheck to paycheck are most likely to reside in two-person households, at 41%. Meanwhile, 49% of millennials and 55% of bridge millennials live in households of four or more people, making them the age groups most likely to reside in the largest households.
There is also a direct correlation among household size, stage of life and financial lifestyle. As household size increases, the ratio of income earners to non-earners typically falls, attributable to households with dependent children. When looking at the share of paycheck-to-paycheck consumers who live in a two-member household, the data finds that 54% do so — 7 percentage points below the sample average. Meanwhile, at 66%, consumers with children under the age of 18 are 12% more likely to live paycheck to paycheck than those without children, at 59%. Among consumers living with friends or housemates, 77% live paycheck to paycheck — the most likely to do so. This suggests that those sharing expenses with a partner or spouse fare better, that is until they have children or even parents to support.
"As household size increases, the ratio of income earners to household members typically falls, creating a higher likelihood of financial distress," said Alia Dudum, LendingClub's Money Expert. "The relationship between household income and household composition explains why many families tend to struggle financially and why millennials and bridge millennials, many of whom are in their peak child-rearing years, tend to remain financially vulnerable."
Economic Considerations Top Reason to Stay in the Family Household
Economics are the main driver for consumers to live with family longer, with 43% wanting to save money and 30% unable to afford housing independently. Besides economic reasons, consumers remain at home to maintain family ties (24%), for transitional reasons (23%), and to provide care (22%).
At one-fifth (20%), adult males are slightly more likely to live with parents than their female counterparts (18%), a phenomenon that grows significantly among those financially struggling (26% of males compared to 18% of females). At 58%, Gen Z is the generation most likely to stay with family members, with 50% citing economic reasons. Members of Gen Z living with three or more people — often familial settings — spent 22% of their income on housing, compared to 30% of those living alone or with a partner.
That said, consumers living with family members to offset expenses are not planning extended stays. For example, one-third of those consumers expect to move out in the coming year, particularly millennials and bridge millennials.
Financial Transparency Determined by Relationship Status
Financial transparency within shared households is paramount to ensure bills are paid and expenses are covered, but the transparency level depends on who consumers live with. Couples living together share financial information 87% of the time and have a joint bank account 76% of the time. Parents are also likely to discuss finances with the children residing in their household, with 45% of parents sharing financial information with their children and 34% granting them access to a shared account. Bill splitting is the most common financial interaction for consumers living with friends or housemates, at 74%. Additionally, borrowing money from other household members is a financial option many use to make ends meet, with consumers mostly engaging in this practice with parents or siblings, at 47%, and friends and housemates, at 44%.
Families and couples maintain outstanding credit card balances that are significantly higher, on average, than those of consumers who live alone. Consumers with children under the age of 18 average 50% more credit card debt than those who live alone. Families represent the lion's share of credit card spending, holding average balances of $6,300 for consumers living with a partner and $7,200 for those living with children under 18. Living with a partner or children also significantly increases a consumer's likelihood of having an auto loan or mortgage.
"With today's inflationary pressures, sharing household finances has become not only common but crucial," continued Dudum. "The increasing complexity of modern lifestyles and the rising cost of living have necessitated a shift in the way consumers approach household finances. One person solely bearing the burden of managing all financial matters has become a minority practice. Instead, couples, families, and even roommates increasingly jointly navigate their economic realities, and it's a trend that is here to stay."
To view the full report, visit: https://www.pymnts.com/study/reality-check-paycheck-to-paycheck-inflation-household-spending-shared-expenses/
Methodology
New Reality Check: The Paycheck-to-Paycheck Report — The Household Finances Deep Dive Edition is based on a census-balanced survey of 4,602 U.S. consumers conducted from June 5 to June 16, as well as analysis of other economic data. The data in this report is not intended to be a representation of LendingClub's core member base. The Paycheck-to-Paycheck series expands on existing data published by government agencies, such as the Federal Reserve System and the Bureau of Labor Statistics, to provide a deep look into the core elements of American consumers' financial wellness: income, savings, debt and spending choices. Our sample was balanced to match the U.S. adult population in a set of key demographic variables: 51% of respondents identified as female, 33% were college-educated and 38% declared incomes of more than $100,000 per year.
About LendingClub
LendingClub Corporation (NYSE: LC) is the parent company of LendingClub Bank, National Association, Member FDIC. LendingClub Bank is the leading digital marketplace bank in the U.S., where members can access a broad range of financial products and services designed to help them pay less when borrowing and earn more when saving. Based on more than 150 billion cells of data and over $85 billion in loans, our advanced credit decisioning and machine-learning models are used across the customer lifecycle to expand seamless access to credit for our members while generating compelling risk-adjusted returns for our loan investors. Since 2007, more than 4.7 million members have joined the Club to help reach their financial goals. For more information about LendingClub, visit https://www.lendingclub.com.
Contact:
For Investors: IR@lendingclub.com
Media Contact: Press@lendingclub.com
PYMNTS Contact: information@PYMNTS.com
View original content to download multimedia:
SOURCE LendingClub Corporation | https://www.kait8.com/prnewswire/2023/07/31/lendingclub-pymnts-research-shows-86-consumers-live-with-one-or-more-people-yet-those-living-with-only-partners-or-spouses-reap-financial-benefits/ | 2023-07-31T12:36:29 | 0 | https://www.kait8.com/prnewswire/2023/07/31/lendingclub-pymnts-research-shows-86-consumers-live-with-one-or-more-people-yet-those-living-with-only-partners-or-spouses-reap-financial-benefits/ |
Juggernaut and Mr. Highman will continue as substantial shareholders of Bobbie. The acquisition positions the combined company as the third largest fully integrated infant and toddler brand in the U.S., creating a more resilient industry for American families
WASHINGTON, July 31, 2023 /PRNewswire/ -- Juggernaut Capital Partners, a leading middle market private equity investor primarily in the consumer and healthcare sectors, is pleased to announce the sale of Nature's One, the pediatric nutrition company founded by Jay Highman which set the bar for quality and innovation in formula over decades. Joining forces with Bobbie Baby, Inc., the nation's fastest growing infant formula company, the combined business will be the first of its kind in pediatric nutrition.
"Nature's One is a true pioneer in the pediatric nutrition space. Juggernaut partnered with founder, Jay Highman, to accelerate product development and vertical integration initiatives. Over the past five years, the company completed the first FDA-approved clinical feeding study of an organic infant formula and designed and constructed the first newly built infant formula facility in the U.S. in 35 years," said John Shulman, Founder and Managing Partner at Juggernaut. "It has been a pleasure to partner with Jay and his team. We believe the combination with Bobbie cements the organization as a continued disruptor and a next-generation industry leader. We are proud to continue as a meaningful shareholder in the go-forward company."
Founded in 1997, Nature's One introduced the first organic baby formula to the U.S. market. Recognized for its dedication to purity and quality, all of the company's formulas have received the Clean Label Project's Purity Award and have tested best in class for purity and nutrition when compared to popular baby formulas sold in the U.S. Nature's One operates the only independent, FDA audited organic infant nutrition facility in the U.S.
Nature's One was advised by CG / Sawaya Partners (operating under Canaccord Genuity) and Morgan Lewis & Bockius LLP. Bobbie was advised by Perella Weinberg Partners LP and Goodwin Procter LLP.
About Juggernaut Capital Partners:
Juggernaut Capital Partners is a leading private equity firm focusing on lower middle market companies, primarily in the consumer and healthcare sectors. Juggernaut is currently investing out of Juggernaut Capital Partners V, L.P. For more information on Juggernaut Capital Partners, please visit www.juggernautcap.com.
About Nature's One:
Founded in 1997, Nature's One introduced the first organic formula, Baby's Only® Organic in the United States. Nature's One has dedicated 25 years to the research, development, and sourcing of pure ingredients. Recognized as the first and highest-ranked formulas for purity and nutritional superiority by the Clean Label Project, Baby's Only Formulas are preferred by parents who want to offer their child a "Better Start…for Life™." Baby's Only Formulas are sold nationally at Whole Foods, Target, Walmart, Sam's Club, and many fine natural food retailers, as well online at www.naturesone.com.
About Bobbie:
Bobbie is the mission-driven organic pediatric nutrition company that exists to build a parenting culture of confidence, not comparison. Founded in 2018, Bobbie hit the market with its flagship European-inspired formula in 2021 as the first direct-to-consumer, subscription-based infant formula in the U.S. Today, it's proud to be the only mom-founded and led infant formula brand in the world, and the fastest-growing in the U.S. since the 1980's. Bobbie is focused on providing purposefully sourced, USDA Organic products made with simple ingredients – crafted right here in America, for American families. For more information, visit www.hibobbie.com.
View original content:
SOURCE Juggernaut Capital Partners | https://www.wafb.com/prnewswire/2023/07/31/juggernaut-capital-partners-natures-one-founder-jay-highman-have-sold-natures-one-bobbie-baby-inc/ | 2023-07-31T12:36:32 | 1 | https://www.wafb.com/prnewswire/2023/07/31/juggernaut-capital-partners-natures-one-founder-jay-highman-have-sold-natures-one-bobbie-baby-inc/ |
Adult Males are Slightly More Likely to Live with Parents Than Their Female Counterparts
58% of Gen Z Consumers Live with Family Members
SAN FRANCISCO, July 31, 2023 /PRNewswire/ -- LendingClub Corporation (NYSE: LC), the parent company of LendingClub Bank, America's leading digital marketplace bank, today released findings from the 24th edition of the Reality Check: Paycheck-To-Paycheck research series, conducted in partnership with PYMNTS. The Household Finances Deep Dive Edition examines the impact of household composition on consumers' ability to manage expenses and put aside savings. The series draws on insights from a survey of 4,602 U.S. consumers conducted from June 5 to June 16, as well as analysis of other economic data.
The Paycheck-to-Paycheck Landscape
In June 2023, 61% of U.S. consumers lived paycheck to paycheck, unchanged from June 2022 — as is the share of those struggling to pay bills (at 21%) — even though more middle-income consumers cited living paycheck to paycheck in June 2023 than last year. Among consumers earning $50,000 to $100,000, 65% lived paycheck to paycheck as of June 2023, compared to 60% in June 2022. Meanwhile, the shares of high-income consumers — those earning more than $100,000 annually — and low-income consumers — those earning less than $50,000 annually — living paycheck to paycheck in June 2023 sit at 45% and 77%, respectively, relatively unchanged from June 2022.
This stability in the financial situation of U.S. households indicates that consumers continue to adapt to inflationary pressures, finding ways to manage their spending and live within their means.
Household Composition Determines Financial Lifestyle
Consumers living with only a partner or spouse are likely to face less financial hardship, while those with dependents and those living with friends or housemates are more likely to live paycheck to paycheck.
The research finds that 86% of consumers live with one or more people, and one-third of paycheck-to-paycheck consumers live in households of four or more people. Consumers not living paycheck to paycheck are most likely to reside in two-person households, at 41%. Meanwhile, 49% of millennials and 55% of bridge millennials live in households of four or more people, making them the age groups most likely to reside in the largest households.
There is also a direct correlation among household size, stage of life and financial lifestyle. As household size increases, the ratio of income earners to non-earners typically falls, attributable to households with dependent children. When looking at the share of paycheck-to-paycheck consumers who live in a two-member household, the data finds that 54% do so — 7 percentage points below the sample average. Meanwhile, at 66%, consumers with children under the age of 18 are 12% more likely to live paycheck to paycheck than those without children, at 59%. Among consumers living with friends or housemates, 77% live paycheck to paycheck — the most likely to do so. This suggests that those sharing expenses with a partner or spouse fare better, that is until they have children or even parents to support.
"As household size increases, the ratio of income earners to household members typically falls, creating a higher likelihood of financial distress," said Alia Dudum, LendingClub's Money Expert. "The relationship between household income and household composition explains why many families tend to struggle financially and why millennials and bridge millennials, many of whom are in their peak child-rearing years, tend to remain financially vulnerable."
Economic Considerations Top Reason to Stay in the Family Household
Economics are the main driver for consumers to live with family longer, with 43% wanting to save money and 30% unable to afford housing independently. Besides economic reasons, consumers remain at home to maintain family ties (24%), for transitional reasons (23%), and to provide care (22%).
At one-fifth (20%), adult males are slightly more likely to live with parents than their female counterparts (18%), a phenomenon that grows significantly among those financially struggling (26% of males compared to 18% of females). At 58%, Gen Z is the generation most likely to stay with family members, with 50% citing economic reasons. Members of Gen Z living with three or more people — often familial settings — spent 22% of their income on housing, compared to 30% of those living alone or with a partner.
That said, consumers living with family members to offset expenses are not planning extended stays. For example, one-third of those consumers expect to move out in the coming year, particularly millennials and bridge millennials.
Financial Transparency Determined by Relationship Status
Financial transparency within shared households is paramount to ensure bills are paid and expenses are covered, but the transparency level depends on who consumers live with. Couples living together share financial information 87% of the time and have a joint bank account 76% of the time. Parents are also likely to discuss finances with the children residing in their household, with 45% of parents sharing financial information with their children and 34% granting them access to a shared account. Bill splitting is the most common financial interaction for consumers living with friends or housemates, at 74%. Additionally, borrowing money from other household members is a financial option many use to make ends meet, with consumers mostly engaging in this practice with parents or siblings, at 47%, and friends and housemates, at 44%.
Families and couples maintain outstanding credit card balances that are significantly higher, on average, than those of consumers who live alone. Consumers with children under the age of 18 average 50% more credit card debt than those who live alone. Families represent the lion's share of credit card spending, holding average balances of $6,300 for consumers living with a partner and $7,200 for those living with children under 18. Living with a partner or children also significantly increases a consumer's likelihood of having an auto loan or mortgage.
"With today's inflationary pressures, sharing household finances has become not only common but crucial," continued Dudum. "The increasing complexity of modern lifestyles and the rising cost of living have necessitated a shift in the way consumers approach household finances. One person solely bearing the burden of managing all financial matters has become a minority practice. Instead, couples, families, and even roommates increasingly jointly navigate their economic realities, and it's a trend that is here to stay."
To view the full report, visit: https://www.pymnts.com/study/reality-check-paycheck-to-paycheck-inflation-household-spending-shared-expenses/
Methodology
New Reality Check: The Paycheck-to-Paycheck Report — The Household Finances Deep Dive Edition is based on a census-balanced survey of 4,602 U.S. consumers conducted from June 5 to June 16, as well as analysis of other economic data. The data in this report is not intended to be a representation of LendingClub's core member base. The Paycheck-to-Paycheck series expands on existing data published by government agencies, such as the Federal Reserve System and the Bureau of Labor Statistics, to provide a deep look into the core elements of American consumers' financial wellness: income, savings, debt and spending choices. Our sample was balanced to match the U.S. adult population in a set of key demographic variables: 51% of respondents identified as female, 33% were college-educated and 38% declared incomes of more than $100,000 per year.
About LendingClub
LendingClub Corporation (NYSE: LC) is the parent company of LendingClub Bank, National Association, Member FDIC. LendingClub Bank is the leading digital marketplace bank in the U.S., where members can access a broad range of financial products and services designed to help them pay less when borrowing and earn more when saving. Based on more than 150 billion cells of data and over $85 billion in loans, our advanced credit decisioning and machine-learning models are used across the customer lifecycle to expand seamless access to credit for our members while generating compelling risk-adjusted returns for our loan investors. Since 2007, more than 4.7 million members have joined the Club to help reach their financial goals. For more information about LendingClub, visit https://www.lendingclub.com.
Contact:
For Investors: IR@lendingclub.com
Media Contact: Press@lendingclub.com
PYMNTS Contact: information@PYMNTS.com
View original content to download multimedia:
SOURCE LendingClub Corporation | https://www.kwch.com/prnewswire/2023/07/31/lendingclub-pymnts-research-shows-86-consumers-live-with-one-or-more-people-yet-those-living-with-only-partners-or-spouses-reap-financial-benefits/ | 2023-07-31T12:36:32 | 1 | https://www.kwch.com/prnewswire/2023/07/31/lendingclub-pymnts-research-shows-86-consumers-live-with-one-or-more-people-yet-those-living-with-only-partners-or-spouses-reap-financial-benefits/ |
HOUSTON, July 31, 2023 /PRNewswire/ -- McDermott has been awarded a project management consultancy (PMC) and engineering, procurement, and construction management (EPCM) contract for the Naphtha Cracker Expansion (Phase II) polypropylene expansion and new ethylene derivative unit project from Indian Oil Corporation Limited (IOCL). The project is located at the Panipat Refinery and Petrochemical Complex, located 62 miles (100 kilometers) from New Delhi, India.
The project will increase the ethylene production capacity of the naphtha cracker unit (NCU) by approximately 20 percent. The additional ethylene and propylene production will act as feed for downstream polymer units. The polymer products will be used for the manufacture of household and industrial items, including containers, automobile parts, furniture, and heavy-duty films.
"McDermott is currently executing four other projects for IOCL, including the maleic anhydride (MAH) unit at the same site, allowing us to leverage our local resources and expertise while realizing synergies," said Vaseem Khan, Senior Vice President, Global Operations. "Furthermore, the project supports the growing demand for ethylene and propylene which will reduce imports and accelerate economic development in the area."
McDermott will provide comprehensive EPCM services and overall project management for the duration of the project, which will be executed from its Center of Excellence in Gurugram, India.
About McDermott
McDermott is a premier, fully-integrated provider of engineering and construction solutions to the energy industry. Our customers trust our technology-driven approach engineered to responsibly harness and transform global energy resources into the products the world needs. From concept to commissioning, McDermott's innovative expertise and capabilities advance the next generation of global energy infrastructure—empowering a brighter, more sustainable future for us all. Operating in over 54 countries, McDermott's locally-focused and globally-integrated resources include more than 30,000 employees, a diversified fleet of specialty marine construction vessels and fabrication facilities around the world. To learn more, visit www.mcdermott.com.
Forward-Looking Statements
McDermott cautions that statements in this press release which are forward-looking, and provide other than historical information, involve risks, contingencies and uncertainties. These forward-looking statements include, among other things, statements about the expected scope and execution of the project discussed in this press release. Although we believe that the expectations reflected in those forward-looking statements are reasonable, we can give no assurance that those expectations will prove to have been correct. Those statements are made by using various underlying assumptions and are subject to numerous risks, contingencies and uncertainties, including, among others: adverse changes in the markets in which we operate or credit or capital markets; our inability to successfully execute on contracts in backlog; changes in project design or schedules; the availability of qualified personnel; changes in the terms, scope or timing of contracts, contract cancellations, change orders and other modifications and actions by our customers and other business counterparties; changes in industry norms; actions by lenders, other creditors, customers and other business counterparties of McDermott; and adverse outcomes in legal or other dispute resolution proceedings. If one or more of these risks materialize, or if underlying assumptions prove incorrect, actual results may vary materially from those expected. You should not place undue reliance on forward-looking statements. This communication reflects the views of McDermott's management as of the date hereof. Except to the extent required by applicable law, McDermott undertakes no obligation to update or revise any forward-looking statement.
Contacts:
Global Media Relations
Reba Reid
Senior Director, Global Communications and Marketing
+1 281 588 5636
RReid@McDermott.com
Business Line Media Relations
Barbara Knight
Senior Director, Business Line Communications and Marketing
+971 56 403 2903
BBKnight@McDermott.com
View original content to download multimedia:
SOURCE McDermott International, Ltd | https://www.kait8.com/prnewswire/2023/07/31/mcdermott-selected-petrochemical-expansion-project-by-iocl/ | 2023-07-31T12:36:36 | 0 | https://www.kait8.com/prnewswire/2023/07/31/mcdermott-selected-petrochemical-expansion-project-by-iocl/ |